TW202300174A - 與191p4d12蛋白結合之抗體藥物共軛物(adc) - Google Patents
與191p4d12蛋白結合之抗體藥物共軛物(adc) Download PDFInfo
- Publication number
- TW202300174A TW202300174A TW111117461A TW111117461A TW202300174A TW 202300174 A TW202300174 A TW 202300174A TW 111117461 A TW111117461 A TW 111117461A TW 111117461 A TW111117461 A TW 111117461A TW 202300174 A TW202300174 A TW 202300174A
- Authority
- TW
- Taiwan
- Prior art keywords
- antibody
- cancer
- amino acid
- alkyl
- alkynyl
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title claims abstract description 168
- 229940049595 antibody-drug conjugate Drugs 0.000 title claims abstract description 168
- 108090000623 proteins and genes Proteins 0.000 title abstract description 124
- 102000004169 proteins and genes Human genes 0.000 title abstract description 112
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 187
- 201000011510 cancer Diseases 0.000 claims abstract description 104
- 238000011282 treatment Methods 0.000 claims abstract description 77
- 239000000203 mixture Substances 0.000 claims abstract description 57
- 241000282414 Homo sapiens Species 0.000 claims description 144
- 238000000034 method Methods 0.000 claims description 102
- 230000027455 binding Effects 0.000 claims description 86
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 75
- 239000000427 antigen Substances 0.000 claims description 65
- 108091007433 antigens Proteins 0.000 claims description 64
- 102000036639 antigens Human genes 0.000 claims description 64
- 239000012634 fragment Substances 0.000 claims description 45
- 229940127089 cytotoxic agent Drugs 0.000 claims description 42
- 239000002246 antineoplastic agent Substances 0.000 claims description 29
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 27
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 27
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 26
- 201000002528 pancreatic cancer Diseases 0.000 claims description 26
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 26
- 206010005003 Bladder cancer Diseases 0.000 claims description 24
- 208000020816 lung neoplasm Diseases 0.000 claims description 24
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 24
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 22
- 201000005202 lung cancer Diseases 0.000 claims description 22
- 206010006187 Breast cancer Diseases 0.000 claims description 21
- 208000026310 Breast neoplasm Diseases 0.000 claims description 21
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 18
- 230000005855 radiation Effects 0.000 claims description 12
- 230000004927 fusion Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 150000001412 amines Chemical class 0.000 claims description 6
- 108010093470 monomethyl auristatin E Proteins 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 39
- 230000014509 gene expression Effects 0.000 abstract description 16
- 239000003814 drug Substances 0.000 description 132
- 210000004027 cell Anatomy 0.000 description 122
- 229940079593 drug Drugs 0.000 description 114
- 235000018102 proteins Nutrition 0.000 description 107
- -1 2-pentyl Chemical group 0.000 description 80
- 150000001875 compounds Chemical class 0.000 description 58
- 108010044540 auristatin Proteins 0.000 description 57
- 235000001014 amino acid Nutrition 0.000 description 49
- 125000000623 heterocyclic group Chemical group 0.000 description 46
- 125000005647 linker group Chemical group 0.000 description 45
- 229940024606 amino acid Drugs 0.000 description 44
- 125000003118 aryl group Chemical group 0.000 description 42
- 238000011579 SCID mouse model Methods 0.000 description 39
- 150000001413 amino acids Chemical class 0.000 description 39
- 108090000765 processed proteins & peptides Proteins 0.000 description 32
- 125000000304 alkynyl group Chemical group 0.000 description 31
- 125000006850 spacer group Chemical group 0.000 description 31
- 230000001472 cytotoxic effect Effects 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 29
- 150000003839 salts Chemical class 0.000 description 29
- 230000004614 tumor growth Effects 0.000 description 29
- 231100000433 cytotoxic Toxicity 0.000 description 28
- 125000001424 substituent group Chemical group 0.000 description 28
- 125000003342 alkenyl group Chemical group 0.000 description 27
- 239000003795 chemical substances by application Substances 0.000 description 27
- 239000002254 cytotoxic agent Substances 0.000 description 27
- 230000000694 effects Effects 0.000 description 26
- 125000000217 alkyl group Chemical group 0.000 description 25
- 238000006467 substitution reaction Methods 0.000 description 25
- 238000002512 chemotherapy Methods 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 24
- 241001529936 Murinae Species 0.000 description 23
- 229910052799 carbon Inorganic materials 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 23
- 229910052736 halogen Inorganic materials 0.000 description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 22
- 201000010099 disease Diseases 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 239000000126 substance Substances 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 20
- 125000004432 carbon atom Chemical group C* 0.000 description 20
- 239000000562 conjugate Substances 0.000 description 20
- 230000034994 death Effects 0.000 description 18
- 231100000517 death Toxicity 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 125000002947 alkylene group Chemical group 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 231100000599 cytotoxic agent Toxicity 0.000 description 16
- 150000007523 nucleic acids Chemical group 0.000 description 16
- 238000002560 therapeutic procedure Methods 0.000 description 16
- 239000003053 toxin Substances 0.000 description 16
- 231100000765 toxin Toxicity 0.000 description 16
- 108700012359 toxins Proteins 0.000 description 16
- 241000880493 Leptailurus serval Species 0.000 description 15
- 210000000056 organ Anatomy 0.000 description 15
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 14
- 239000002585 base Substances 0.000 description 14
- 230000002163 immunogen Effects 0.000 description 14
- 238000001959 radiotherapy Methods 0.000 description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 13
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 13
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 13
- 241000700159 Rattus Species 0.000 description 13
- 238000013459 approach Methods 0.000 description 13
- 230000000875 corresponding effect Effects 0.000 description 13
- 230000012010 growth Effects 0.000 description 13
- 125000002950 monocyclic group Chemical group 0.000 description 13
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 13
- 239000012453 solvate Substances 0.000 description 13
- 206010009944 Colon cancer Diseases 0.000 description 12
- 241000282326 Felis catus Species 0.000 description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- 241000699660 Mus musculus Species 0.000 description 12
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 12
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 12
- 206010061535 Ovarian neoplasm Diseases 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 230000004071 biological effect Effects 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 125000004093 cyano group Chemical group *C#N 0.000 description 12
- 239000000824 cytostatic agent Substances 0.000 description 12
- 210000004602 germ cell Anatomy 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 238000011160 research Methods 0.000 description 12
- 229940124597 therapeutic agent Drugs 0.000 description 12
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- 125000004450 alkenylene group Chemical group 0.000 description 11
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 11
- 229930195731 calicheamicin Natural products 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 230000021615 conjugation Effects 0.000 description 11
- 230000001085 cytostatic effect Effects 0.000 description 11
- 230000003013 cytotoxicity Effects 0.000 description 11
- 231100000135 cytotoxicity Toxicity 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 229910052717 sulfur Inorganic materials 0.000 description 11
- 238000001356 surgical procedure Methods 0.000 description 11
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 10
- 102000035195 Peptidases Human genes 0.000 description 10
- 108091005804 Peptidases Proteins 0.000 description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 10
- 210000000481 breast Anatomy 0.000 description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 238000011068 loading method Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000007920 subcutaneous administration Methods 0.000 description 10
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 206010033128 Ovarian cancer Diseases 0.000 description 9
- 206010060862 Prostate cancer Diseases 0.000 description 9
- 239000004365 Protease Substances 0.000 description 9
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 9
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 9
- 125000004419 alkynylene group Chemical group 0.000 description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 150000001721 carbon Chemical group 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 9
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 9
- 108010050848 glycylleucine Proteins 0.000 description 9
- 108010015792 glycyllysine Proteins 0.000 description 9
- 108010037850 glycylvaline Proteins 0.000 description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000011830 transgenic mouse model Methods 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 8
- 239000004606 Fillers/Extenders Substances 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 8
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 8
- 238000009175 antibody therapy Methods 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 8
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 208000029742 colonic neoplasm Diseases 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 229930188854 dolastatin Natural products 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 235000018977 lysine Nutrition 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 108010024654 phenylalanyl-prolyl-alanine Proteins 0.000 description 8
- 230000002285 radioactive effect Effects 0.000 description 8
- 125000006413 ring segment Chemical group 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 150000003384 small molecules Chemical class 0.000 description 8
- AXKGIPZJYUNAIW-UHFFFAOYSA-N (4-aminophenyl)methanol Chemical compound NC1=CC=C(CO)C=C1 AXKGIPZJYUNAIW-UHFFFAOYSA-N 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 7
- 229930012538 Paclitaxel Natural products 0.000 description 7
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 7
- 102000004243 Tubulin Human genes 0.000 description 7
- 108090000704 Tubulin Proteins 0.000 description 7
- 108010005233 alanylglutamic acid Proteins 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 125000004452 carbocyclyl group Chemical group 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000010253 intravenous injection Methods 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 229960001592 paclitaxel Drugs 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 108010070643 prolylglutamic acid Proteins 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 7
- 125000003396 thiol group Chemical group [H]S* 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- QWPXBEHQFHACTK-KZVYIGENSA-N (10e,12e)-86-chloro-12,14,4-trihydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-15,16-dihydro-14h-7-aza-1(6,4)-oxazina-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-6-one Chemical compound CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-KZVYIGENSA-N 0.000 description 6
- XWFWAXPOLRTDFZ-FXQIFTODSA-N Ala-Pro-Ser Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O XWFWAXPOLRTDFZ-FXQIFTODSA-N 0.000 description 6
- SNDBKTFJWVEVPO-WHFBIAKZSA-N Asp-Gly-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SNDBKTFJWVEVPO-WHFBIAKZSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 6
- OSCLNNWLKKIQJM-WDSKDSINSA-N Gln-Ser-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O OSCLNNWLKKIQJM-WDSKDSINSA-N 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 6
- GOMUXSCOIWIJFP-GUBZILKMSA-N Pro-Ser-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GOMUXSCOIWIJFP-GUBZILKMSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 108010039491 Ricin Proteins 0.000 description 6
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 231100000504 carcinogenesis Toxicity 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 125000004434 sulfur atom Chemical group 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 108010080629 tryptophan-leucine Proteins 0.000 description 6
- BRPMXFSTKXXNHF-IUCAKERBSA-N (2s)-1-[2-[[(2s)-pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H]1NCCC1 BRPMXFSTKXXNHF-IUCAKERBSA-N 0.000 description 5
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 5
- SLKLLQWZQHXYSV-CIUDSAMLSA-N Asn-Ala-Lys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O SLKLLQWZQHXYSV-CIUDSAMLSA-N 0.000 description 5
- NRVQLLDIJJEIIZ-VZFHVOOUSA-N Cys-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CS)N)O NRVQLLDIJJEIIZ-VZFHVOOUSA-N 0.000 description 5
- CYTSBCIIEHUPDU-ACZMJKKPSA-N Gln-Asp-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O CYTSBCIIEHUPDU-ACZMJKKPSA-N 0.000 description 5
- WRNAXCVRSBBKGS-BQBZGAKWSA-N Glu-Gly-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O WRNAXCVRSBBKGS-BQBZGAKWSA-N 0.000 description 5
- RAUDKMVXNOWDLS-WDSKDSINSA-N Glu-Gly-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O RAUDKMVXNOWDLS-WDSKDSINSA-N 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- OYQUOLRTJHWVSQ-SRVKXCTJSA-N Leu-His-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O OYQUOLRTJHWVSQ-SRVKXCTJSA-N 0.000 description 5
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 5
- FDBTVENULFNTAL-XQQFMLRXSA-N Leu-Val-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N FDBTVENULFNTAL-XQQFMLRXSA-N 0.000 description 5
- QWPXBEHQFHACTK-UHFFFAOYSA-N Maytansinol Natural products CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-UHFFFAOYSA-N 0.000 description 5
- YLDSJJOGQNEQJK-AVGNSLFASA-N Met-Pro-Leu Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O YLDSJJOGQNEQJK-AVGNSLFASA-N 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 5
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- JLLJTMHNXQTMCK-UBHSHLNASA-N Phe-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 JLLJTMHNXQTMCK-UBHSHLNASA-N 0.000 description 5
- MCWHYUWXVNRXFV-RWMBFGLXSA-N Pro-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 MCWHYUWXVNRXFV-RWMBFGLXSA-N 0.000 description 5
- PRKWBYCXBBSLSK-GUBZILKMSA-N Pro-Ser-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O PRKWBYCXBBSLSK-GUBZILKMSA-N 0.000 description 5
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 5
- KCNSGAMPBPYUAI-CIUDSAMLSA-N Ser-Leu-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O KCNSGAMPBPYUAI-CIUDSAMLSA-N 0.000 description 5
- BEGDZYNDCNEGJZ-XVKPBYJWSA-N Val-Gly-Gln Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O BEGDZYNDCNEGJZ-XVKPBYJWSA-N 0.000 description 5
- UMPVMAYCLYMYGA-ONGXEEELSA-N Val-Leu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O UMPVMAYCLYMYGA-ONGXEEELSA-N 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 5
- 108010078114 alanyl-tryptophyl-alanine Proteins 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 5
- 230000001640 apoptogenic effect Effects 0.000 description 5
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000001588 bifunctional effect Effects 0.000 description 5
- 150000001720 carbohydrates Chemical group 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 108010074027 glycyl-seryl-phenylalanine Proteins 0.000 description 5
- 108010089804 glycyl-threonine Proteins 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 230000016784 immunoglobulin production Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108010077112 prolyl-proline Proteins 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 230000005740 tumor formation Effects 0.000 description 5
- 108010015385 valyl-prolyl-proline Proteins 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 description 4
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical group SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 4
- 108010066676 Abrin Proteins 0.000 description 4
- UHMQKOBNPRAZGB-CIUDSAMLSA-N Ala-Glu-Met Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCSC)C(=O)O)N UHMQKOBNPRAZGB-CIUDSAMLSA-N 0.000 description 4
- BEMGNWZECGIJOI-WDSKDSINSA-N Ala-Gly-Glu Chemical compound [H]N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O BEMGNWZECGIJOI-WDSKDSINSA-N 0.000 description 4
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 4
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 4
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 4
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 4
- 108010053187 Diphtheria Toxin Proteins 0.000 description 4
- 102000016607 Diphtheria Toxin Human genes 0.000 description 4
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 4
- PABFFPWEJMEVEC-JGVFFNPUSA-N Gly-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)CN)C(=O)O PABFFPWEJMEVEC-JGVFFNPUSA-N 0.000 description 4
- XVYKMNXXJXQKME-XEGUGMAKSA-N Gly-Ile-Tyr Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XVYKMNXXJXQKME-XEGUGMAKSA-N 0.000 description 4
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 108010065920 Insulin Lispro Proteins 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 4
- WGNOPSQMIQERPK-UHFFFAOYSA-N Leu-Asn-Pro Natural products CC(C)CC(N)C(=O)NC(CC(=O)N)C(=O)N1CCCC1C(=O)O WGNOPSQMIQERPK-UHFFFAOYSA-N 0.000 description 4
- AXZGZMGRBDQTEY-SRVKXCTJSA-N Leu-Gln-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O AXZGZMGRBDQTEY-SRVKXCTJSA-N 0.000 description 4
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 4
- 241000282567 Macaca fascicularis Species 0.000 description 4
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 4
- KLYYKKGCPOGDPE-OEAJRASXSA-N Phe-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O KLYYKKGCPOGDPE-OEAJRASXSA-N 0.000 description 4
- JLMZKEQFMVORMA-SRVKXCTJSA-N Pro-Pro-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 JLMZKEQFMVORMA-SRVKXCTJSA-N 0.000 description 4
- SBVPYBFMIGDIDX-SRVKXCTJSA-N Pro-Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@H]2NCCC2)CCC1 SBVPYBFMIGDIDX-SRVKXCTJSA-N 0.000 description 4
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 4
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 4
- XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 description 4
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 4
- UBTNVMGPMYDYIU-HJPIBITLSA-N Ser-Tyr-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UBTNVMGPMYDYIU-HJPIBITLSA-N 0.000 description 4
- 241000187747 Streptomyces Species 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 4
- SGAOHNPSEPVAFP-ZDLURKLDSA-N Thr-Ser-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SGAOHNPSEPVAFP-ZDLURKLDSA-N 0.000 description 4
- QOIKZODVIPOPDD-AVGNSLFASA-N Tyr-Cys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOIKZODVIPOPDD-AVGNSLFASA-N 0.000 description 4
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- QHDXUYOYTPWCSK-RCOVLWMOSA-N Val-Asp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N QHDXUYOYTPWCSK-RCOVLWMOSA-N 0.000 description 4
- KRAHMIJVUPUOTQ-DCAQKATOSA-N Val-Ser-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KRAHMIJVUPUOTQ-DCAQKATOSA-N 0.000 description 4
- 229940122803 Vinca alkaloid Drugs 0.000 description 4
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 4
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 229940034982 antineoplastic agent Drugs 0.000 description 4
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000000973 chemotherapeutic effect Effects 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 230000001268 conjugating effect Effects 0.000 description 4
- 238000002784 cytotoxicity assay Methods 0.000 description 4
- 231100000263 cytotoxicity test Toxicity 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 4
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 4
- 108010079413 glycyl-prolyl-glutamic acid Proteins 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 208000037819 metastatic cancer Diseases 0.000 description 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 4
- 108010034507 methionyltryptophan Proteins 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000011275 oncology therapy Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000009097 single-agent therapy Methods 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 229960001052 streptozocin Drugs 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 229960001603 tamoxifen Drugs 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- 108010003137 tyrosyltyrosine Proteins 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- 229960004528 vincristine Drugs 0.000 description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- PKOHVHWNGUHYRE-ZFWWWQNUSA-N (2s)-1-[2-[[(2s)-2-amino-3-(1h-indol-3-yl)propanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound O=C([C@H](CC=1C2=CC=CC=C2NC=1)N)NCC(=O)N1CCC[C@H]1C(O)=O PKOHVHWNGUHYRE-ZFWWWQNUSA-N 0.000 description 3
- IESDGNYHXIOKRW-YXMSTPNBSA-N (2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-YXMSTPNBSA-N 0.000 description 3
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 3
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical group CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
- WDIYWDJLXOCGRW-ACZMJKKPSA-N Ala-Asp-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WDIYWDJLXOCGRW-ACZMJKKPSA-N 0.000 description 3
- BLGHHPHXVJWCNK-GUBZILKMSA-N Ala-Gln-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BLGHHPHXVJWCNK-GUBZILKMSA-N 0.000 description 3
- CCDFBRZVTDDJNM-GUBZILKMSA-N Ala-Leu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O CCDFBRZVTDDJNM-GUBZILKMSA-N 0.000 description 3
- MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 3
- ZCUFMRIQCPNOHZ-NRPADANISA-N Ala-Val-Gln Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N ZCUFMRIQCPNOHZ-NRPADANISA-N 0.000 description 3
- OZNSCVPYWZRQPY-CIUDSAMLSA-N Arg-Asp-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O OZNSCVPYWZRQPY-CIUDSAMLSA-N 0.000 description 3
- LVMUGODRNHFGRA-AVGNSLFASA-N Arg-Leu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O LVMUGODRNHFGRA-AVGNSLFASA-N 0.000 description 3
- QTAIIXQCOPUNBQ-QXEWZRGKSA-N Arg-Val-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O QTAIIXQCOPUNBQ-QXEWZRGKSA-N 0.000 description 3
- ULBHWNVWSCJLCO-NHCYSSNCSA-N Arg-Val-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N ULBHWNVWSCJLCO-NHCYSSNCSA-N 0.000 description 3
- SUMJNGAMIQSNGX-TUAOUCFPSA-N Arg-Val-Pro Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N1CCC[C@@H]1C(O)=O SUMJNGAMIQSNGX-TUAOUCFPSA-N 0.000 description 3
- KNENKKKUYGEZIO-FXQIFTODSA-N Asn-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N KNENKKKUYGEZIO-FXQIFTODSA-N 0.000 description 3
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 3
- YNQIDCRRTWGHJD-ZLUOBGJFSA-N Asp-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(O)=O YNQIDCRRTWGHJD-ZLUOBGJFSA-N 0.000 description 3
- HSWYMWGDMPLTTH-FXQIFTODSA-N Asp-Glu-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HSWYMWGDMPLTTH-FXQIFTODSA-N 0.000 description 3
- AHWRSSLYSGLBGD-CIUDSAMLSA-N Asp-Pro-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AHWRSSLYSGLBGD-CIUDSAMLSA-N 0.000 description 3
- VNXQRBXEQXLERQ-CIUDSAMLSA-N Asp-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N VNXQRBXEQXLERQ-CIUDSAMLSA-N 0.000 description 3
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 3
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 3
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 3
- ZXCAQANTQWBICD-DCAQKATOSA-N Cys-Lys-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N ZXCAQANTQWBICD-DCAQKATOSA-N 0.000 description 3
- JEKIARHEWURQRJ-BZSNNMDCSA-N Cys-Phe-Tyr Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)NC(=O)[C@H](CS)N JEKIARHEWURQRJ-BZSNNMDCSA-N 0.000 description 3
- 239000012626 DNA minor groove binder Substances 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010016626 Dipeptides Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 3
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 3
- FGYPOQPQTUNESW-IUCAKERBSA-N Gln-Gly-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)N FGYPOQPQTUNESW-IUCAKERBSA-N 0.000 description 3
- WLRYGVYQFXRJDA-DCAQKATOSA-N Gln-Pro-Pro Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 WLRYGVYQFXRJDA-DCAQKATOSA-N 0.000 description 3
- ITYRYNUZHPNCIK-GUBZILKMSA-N Glu-Ala-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O ITYRYNUZHPNCIK-GUBZILKMSA-N 0.000 description 3
- RSUVOPBMWMTVDI-XEGUGMAKSA-N Glu-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C)C(O)=O)=CNC2=C1 RSUVOPBMWMTVDI-XEGUGMAKSA-N 0.000 description 3
- PAQUJCSYVIBPLC-AVGNSLFASA-N Glu-Asp-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PAQUJCSYVIBPLC-AVGNSLFASA-N 0.000 description 3
- FLQAKQOBSPFGKG-CIUDSAMLSA-N Glu-Cys-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CCCN=C(N)N FLQAKQOBSPFGKG-CIUDSAMLSA-N 0.000 description 3
- HNVFSTLPVJWIDV-CIUDSAMLSA-N Glu-Glu-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HNVFSTLPVJWIDV-CIUDSAMLSA-N 0.000 description 3
- HVYWQYLBVXMXSV-GUBZILKMSA-N Glu-Leu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O HVYWQYLBVXMXSV-GUBZILKMSA-N 0.000 description 3
- IRXNJYPKBVERCW-DCAQKATOSA-N Glu-Leu-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IRXNJYPKBVERCW-DCAQKATOSA-N 0.000 description 3
- ALMBZBOCGSVSAI-ACZMJKKPSA-N Glu-Ser-Asn Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)O)N ALMBZBOCGSVSAI-ACZMJKKPSA-N 0.000 description 3
- DMYACXMQUABZIQ-NRPADANISA-N Glu-Ser-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O DMYACXMQUABZIQ-NRPADANISA-N 0.000 description 3
- MIWJDJAMMKHUAR-ZVZYQTTQSA-N Glu-Trp-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)O)N MIWJDJAMMKHUAR-ZVZYQTTQSA-N 0.000 description 3
- MFYLRRCYBBJYPI-JYJNAYRXSA-N Glu-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O MFYLRRCYBBJYPI-JYJNAYRXSA-N 0.000 description 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 3
- BIRKKBCSAIHDDF-WDSKDSINSA-N Gly-Glu-Cys Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O BIRKKBCSAIHDDF-WDSKDSINSA-N 0.000 description 3
- HFXJIZNEXNIZIJ-BQBZGAKWSA-N Gly-Glu-Gln Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HFXJIZNEXNIZIJ-BQBZGAKWSA-N 0.000 description 3
- CUYLIWAAAYJKJH-RYUDHWBXSA-N Gly-Glu-Tyr Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CUYLIWAAAYJKJH-RYUDHWBXSA-N 0.000 description 3
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 3
- YIFUFYZELCMPJP-YUMQZZPRSA-N Gly-Leu-Cys Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(O)=O YIFUFYZELCMPJP-YUMQZZPRSA-N 0.000 description 3
- LHYJCVCQPWRMKZ-WEDXCCLWSA-N Gly-Leu-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LHYJCVCQPWRMKZ-WEDXCCLWSA-N 0.000 description 3
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 3
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 3
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 3
- JSLVAHYTAJJEQH-QWRGUYRKSA-N Gly-Ser-Phe Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JSLVAHYTAJJEQH-QWRGUYRKSA-N 0.000 description 3
- FFJQHWKSGAWSTJ-BFHQHQDPSA-N Gly-Thr-Ala Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O FFJQHWKSGAWSTJ-BFHQHQDPSA-N 0.000 description 3
- TVTZEOHWHUVYCG-KYNKHSRBSA-N Gly-Thr-Thr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O TVTZEOHWHUVYCG-KYNKHSRBSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- WMKXFMUJRCEGRP-SRVKXCTJSA-N His-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N WMKXFMUJRCEGRP-SRVKXCTJSA-N 0.000 description 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 3
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical group C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 3
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 3
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- LZDNBBYBDGBADK-UHFFFAOYSA-N L-valyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-UHFFFAOYSA-N 0.000 description 3
- HXWALXSAVBLTPK-NUTKFTJISA-N Leu-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(C)C)N HXWALXSAVBLTPK-NUTKFTJISA-N 0.000 description 3
- HBJZFCIVFIBNSV-DCAQKATOSA-N Leu-Arg-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(O)=O HBJZFCIVFIBNSV-DCAQKATOSA-N 0.000 description 3
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 3
- GPICTNQYKHHHTH-GUBZILKMSA-N Leu-Gln-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O GPICTNQYKHHHTH-GUBZILKMSA-N 0.000 description 3
- NEEOBPIXKWSBRF-IUCAKERBSA-N Leu-Glu-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O NEEOBPIXKWSBRF-IUCAKERBSA-N 0.000 description 3
- QJUWBDPGGYVRHY-YUMQZZPRSA-N Leu-Gly-Cys Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N QJUWBDPGGYVRHY-YUMQZZPRSA-N 0.000 description 3
- HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 3
- HYMLKESRWLZDBR-WEDXCCLWSA-N Leu-Gly-Thr Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O HYMLKESRWLZDBR-WEDXCCLWSA-N 0.000 description 3
- SGIIOQQGLUUMDQ-IHRRRGAJSA-N Leu-His-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N SGIIOQQGLUUMDQ-IHRRRGAJSA-N 0.000 description 3
- FOBUGKUBUJOWAD-IHPCNDPISA-N Leu-Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FOBUGKUBUJOWAD-IHPCNDPISA-N 0.000 description 3
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 3
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 3
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 3
- MPGHETGWWWUHPY-CIUDSAMLSA-N Lys-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN MPGHETGWWWUHPY-CIUDSAMLSA-N 0.000 description 3
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 3
- YPLVCBKEPJPBDQ-MELADBBJSA-N Lys-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N YPLVCBKEPJPBDQ-MELADBBJSA-N 0.000 description 3
- WQDKIVRHTQYJSN-DCAQKATOSA-N Lys-Ser-Arg Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N WQDKIVRHTQYJSN-DCAQKATOSA-N 0.000 description 3
- IEVXCWPVBYCJRZ-IXOXFDKPSA-N Lys-Thr-His Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 IEVXCWPVBYCJRZ-IXOXFDKPSA-N 0.000 description 3
- DLCAXBGXGOVUCD-PPCPHDFISA-N Lys-Thr-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DLCAXBGXGOVUCD-PPCPHDFISA-N 0.000 description 3
- RQILLQOQXLZTCK-KBPBESRZSA-N Lys-Tyr-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O RQILLQOQXLZTCK-KBPBESRZSA-N 0.000 description 3
- UGCIQUYEJIEHKX-GVXVVHGQSA-N Lys-Val-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O UGCIQUYEJIEHKX-GVXVVHGQSA-N 0.000 description 3
- FBQMBZLJHOQAIH-GUBZILKMSA-N Met-Asp-Met Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O FBQMBZLJHOQAIH-GUBZILKMSA-N 0.000 description 3
- FVKRQMQQFGBXHV-QXEWZRGKSA-N Met-Asp-Val Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O FVKRQMQQFGBXHV-QXEWZRGKSA-N 0.000 description 3
- SJDQOYTYNGZZJX-SRVKXCTJSA-N Met-Glu-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O SJDQOYTYNGZZJX-SRVKXCTJSA-N 0.000 description 3
- 244000302512 Momordica charantia Species 0.000 description 3
- 235000009811 Momordica charantia Nutrition 0.000 description 3
- 108010079364 N-glycylalanine Proteins 0.000 description 3
- 108010066427 N-valyltryptophan Proteins 0.000 description 3
- KXUZHWXENMYOHC-QEJZJMRPSA-N Phe-Leu-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O KXUZHWXENMYOHC-QEJZJMRPSA-N 0.000 description 3
- MSHZERMPZKCODG-ACRUOGEOSA-N Phe-Leu-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 MSHZERMPZKCODG-ACRUOGEOSA-N 0.000 description 3
- MMJJFXWMCMJMQA-STQMWFEESA-N Phe-Pro-Gly Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)C1=CC=CC=C1 MMJJFXWMCMJMQA-STQMWFEESA-N 0.000 description 3
- WWPAHTZOWURIMR-ULQDDVLXSA-N Phe-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 WWPAHTZOWURIMR-ULQDDVLXSA-N 0.000 description 3
- ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 description 3
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 3
- BSKMOCNNLNDIMU-CDMKHQONSA-N Phe-Thr-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O BSKMOCNNLNDIMU-CDMKHQONSA-N 0.000 description 3
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 3
- KIZQGKLMXKGDIV-BQBZGAKWSA-N Pro-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 KIZQGKLMXKGDIV-BQBZGAKWSA-N 0.000 description 3
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 description 3
- IHCXPSYCHXFXKT-DCAQKATOSA-N Pro-Arg-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O IHCXPSYCHXFXKT-DCAQKATOSA-N 0.000 description 3
- VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 description 3
- HAAQQNHQZBOWFO-LURJTMIESA-N Pro-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1 HAAQQNHQZBOWFO-LURJTMIESA-N 0.000 description 3
- OWQXAJQZLWHPBH-FXQIFTODSA-N Pro-Ser-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O OWQXAJQZLWHPBH-FXQIFTODSA-N 0.000 description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 description 3
- 240000003946 Saponaria officinalis Species 0.000 description 3
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 3
- JJKSSJVYOVRJMZ-FXQIFTODSA-N Ser-Arg-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N)CN=C(N)N JJKSSJVYOVRJMZ-FXQIFTODSA-N 0.000 description 3
- OYEDZGNMSBZCIM-XGEHTFHBSA-N Ser-Arg-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OYEDZGNMSBZCIM-XGEHTFHBSA-N 0.000 description 3
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 3
- GZSZPKSBVAOGIE-CIUDSAMLSA-N Ser-Lys-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O GZSZPKSBVAOGIE-CIUDSAMLSA-N 0.000 description 3
- AMRRYKHCILPAKD-FXQIFTODSA-N Ser-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)N AMRRYKHCILPAKD-FXQIFTODSA-N 0.000 description 3
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 3
- JURQXQBJKUHGJS-UHFFFAOYSA-N Ser-Ser-Ser-Ser Chemical compound OCC(N)C(=O)NC(CO)C(=O)NC(CO)C(=O)NC(CO)C(O)=O JURQXQBJKUHGJS-UHFFFAOYSA-N 0.000 description 3
- OLKICIBQRVSQMA-SRVKXCTJSA-N Ser-Ser-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OLKICIBQRVSQMA-SRVKXCTJSA-N 0.000 description 3
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 101150006914 TRP1 gene Proteins 0.000 description 3
- 229940123237 Taxane Drugs 0.000 description 3
- ASJDFGOPDCVXTG-KATARQTJSA-N Thr-Cys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O ASJDFGOPDCVXTG-KATARQTJSA-N 0.000 description 3
- KWQBJOUOSNJDRR-XAVMHZPKSA-N Thr-Cys-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@@H]1C(=O)O)N)O KWQBJOUOSNJDRR-XAVMHZPKSA-N 0.000 description 3
- DSLHSTIUAPKERR-XGEHTFHBSA-N Thr-Cys-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O DSLHSTIUAPKERR-XGEHTFHBSA-N 0.000 description 3
- GKWNLDNXMMLRMC-GLLZPBPUSA-N Thr-Glu-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O GKWNLDNXMMLRMC-GLLZPBPUSA-N 0.000 description 3
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 3
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 3
- DXPURPNJDFCKKO-RHYQMDGZSA-N Thr-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DXPURPNJDFCKKO-RHYQMDGZSA-N 0.000 description 3
- IVDFVBVIVLJJHR-LKXGYXEUSA-N Thr-Ser-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IVDFVBVIVLJJHR-LKXGYXEUSA-N 0.000 description 3
- BEZTUFWTPVOROW-KJEVXHAQSA-N Thr-Tyr-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)O BEZTUFWTPVOROW-KJEVXHAQSA-N 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- UKINEYBQXPMOJO-UBHSHLNASA-N Trp-Asn-Ser Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N UKINEYBQXPMOJO-UBHSHLNASA-N 0.000 description 3
- DQDXHYIEITXNJY-BPUTZDHNSA-N Trp-Gln-Gln Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N DQDXHYIEITXNJY-BPUTZDHNSA-N 0.000 description 3
- NLWCSMOXNKBRLC-WDSOQIARSA-N Trp-Lys-Val Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NLWCSMOXNKBRLC-WDSOQIARSA-N 0.000 description 3
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 3
- VCXWRWYFJLXITF-AUTRQRHGSA-N Tyr-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VCXWRWYFJLXITF-AUTRQRHGSA-N 0.000 description 3
- SCCKSNREWHMKOJ-SRVKXCTJSA-N Tyr-Asn-Ser Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O SCCKSNREWHMKOJ-SRVKXCTJSA-N 0.000 description 3
- MQGGXGKQSVEQHR-KKUMJFAQSA-N Tyr-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MQGGXGKQSVEQHR-KKUMJFAQSA-N 0.000 description 3
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 3
- WYOBRXPIZVKNMF-IRXDYDNUSA-N Tyr-Tyr-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(O)=O)C1=CC=C(O)C=C1 WYOBRXPIZVKNMF-IRXDYDNUSA-N 0.000 description 3
- LTFLDDDGWOVIHY-NAKRPEOUSA-N Val-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)N LTFLDDDGWOVIHY-NAKRPEOUSA-N 0.000 description 3
- VJOWWOGRNXRQMF-UVBJJODRSA-N Val-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 VJOWWOGRNXRQMF-UVBJJODRSA-N 0.000 description 3
- LMSBRIVOCYOKMU-NRPADANISA-N Val-Gln-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N LMSBRIVOCYOKMU-NRPADANISA-N 0.000 description 3
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 3
- HPANGHISDXDUQY-ULQDDVLXSA-N Val-Lys-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HPANGHISDXDUQY-ULQDDVLXSA-N 0.000 description 3
- DEGUERSKQBRZMZ-FXQIFTODSA-N Val-Ser-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DEGUERSKQBRZMZ-FXQIFTODSA-N 0.000 description 3
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 3
- UJMCYJKPDFQLHX-XGEHTFHBSA-N Val-Ser-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N)O UJMCYJKPDFQLHX-XGEHTFHBSA-N 0.000 description 3
- TVGWMCTYUFBXAP-QTKMDUPCSA-N Val-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N)O TVGWMCTYUFBXAP-QTKMDUPCSA-N 0.000 description 3
- LLJLBRRXKZTTRD-GUBZILKMSA-N Val-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N LLJLBRRXKZTTRD-GUBZILKMSA-N 0.000 description 3
- JVGDAEKKZKKZFO-RCWTZXSCSA-N Val-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O JVGDAEKKZKKZFO-RCWTZXSCSA-N 0.000 description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
- 238000012452 Xenomouse strains Methods 0.000 description 3
- 108010081404 acein-2 Proteins 0.000 description 3
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000009098 adjuvant therapy Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical class C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 3
- 108010008355 arginyl-glutamine Proteins 0.000 description 3
- 108010089975 arginyl-glycyl-aspartyl-serine Proteins 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical class N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 239000003124 biologic agent Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 238000006298 dechlorination reaction Methods 0.000 description 3
- 238000010520 demethylation reaction Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 229960005542 ethidium bromide Drugs 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 108010078144 glutaminyl-glycine Proteins 0.000 description 3
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 230000003862 health status Effects 0.000 description 3
- 108010018006 histidylserine Proteins 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 229940127121 immunoconjugate Drugs 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 3
- 108010034529 leucyl-lysine Proteins 0.000 description 3
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229960005558 mertansine Drugs 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 108010076042 phenomycin Proteins 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 108010031719 prolyl-serine Proteins 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 102220067552 rs794727294 Human genes 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 108010069117 seryl-lysyl-aspartic acid Proteins 0.000 description 3
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 3
- 108010026333 seryl-proline Proteins 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000011255 standard chemotherapy Methods 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- 108010044292 tryptophyltyrosine Proteins 0.000 description 3
- 230000004565 tumor cell growth Effects 0.000 description 3
- 108010079202 tyrosyl-alanyl-cysteine Proteins 0.000 description 3
- 108010071635 tyrosyl-prolyl-arginine Proteins 0.000 description 3
- 229960003048 vinblastine Drugs 0.000 description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 description 2
- GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 2
- DIBLBAURNYJYBF-XLXZRNDBSA-N (2s)-2-[[(2s)-2-[[2-[[(2s)-6-amino-2-[[(2s)-2-amino-3-methylbutanoyl]amino]hexanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@H](NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 DIBLBAURNYJYBF-XLXZRNDBSA-N 0.000 description 2
- XSAKVDNHFRWJKS-IIZANFQQSA-N (2s)-n-benzyl-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC=2C=CC=CC=2)CCC1 XSAKVDNHFRWJKS-IIZANFQQSA-N 0.000 description 2
- SRNFODIJXVPXHO-FSJWMSIRSA-N (4r,4ar,5'r,7r,8r,8as)-5'-(furan-3-yl)-4,7-dimethylspiro[1,3,4,4a,5,6,7,8a-octahydronaphthalene-8,3'-oxolane]-2,2'-dione Chemical compound C=1([C@H]2C[C@@]3(C(O2)=O)[C@H](C)CC[C@H]2[C@@H]3CC(=O)C[C@H]2C)C=COC=1 SRNFODIJXVPXHO-FSJWMSIRSA-N 0.000 description 2
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 2
- PBSPQZHJEDTHTL-UHFFFAOYSA-N 2-benzoylpentanoic acid Chemical compound CCCC(C(O)=O)C(=O)C1=CC=CC=C1 PBSPQZHJEDTHTL-UHFFFAOYSA-N 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
- VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
- QBHDSQZASIBAAI-UHFFFAOYSA-N 4-acetylbenzoic acid Chemical compound CC(=O)C1=CC=C(C(O)=O)C=C1 QBHDSQZASIBAAI-UHFFFAOYSA-N 0.000 description 2
- DLGUWNCNEGCFAV-UHFFFAOYSA-N 4-methoxythiane Chemical compound COC1CCSCC1 DLGUWNCNEGCFAV-UHFFFAOYSA-N 0.000 description 2
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 description 2
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical group [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 241000186046 Actinomyces Species 0.000 description 2
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 2
- FXKNPWNXPQZLES-ZLUOBGJFSA-N Ala-Asn-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O FXKNPWNXPQZLES-ZLUOBGJFSA-N 0.000 description 2
- WCBVQNZTOKJWJS-ACZMJKKPSA-N Ala-Cys-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O WCBVQNZTOKJWJS-ACZMJKKPSA-N 0.000 description 2
- RXTBLQVXNIECFP-FXQIFTODSA-N Ala-Gln-Gln Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O RXTBLQVXNIECFP-FXQIFTODSA-N 0.000 description 2
- WKOBSJOZRJJVRZ-FXQIFTODSA-N Ala-Glu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WKOBSJOZRJJVRZ-FXQIFTODSA-N 0.000 description 2
- PAIHPOGPJVUFJY-WDSKDSINSA-N Ala-Glu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PAIHPOGPJVUFJY-WDSKDSINSA-N 0.000 description 2
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 2
- AJBVYEYZVYPFCF-CIUDSAMLSA-N Ala-Lys-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O AJBVYEYZVYPFCF-CIUDSAMLSA-N 0.000 description 2
- RAAWHFXHAACDFT-FXQIFTODSA-N Ala-Met-Asn Chemical compound CSCC[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CC(N)=O)C(O)=O RAAWHFXHAACDFT-FXQIFTODSA-N 0.000 description 2
- IORKCNUBHNIMKY-CIUDSAMLSA-N Ala-Pro-Glu Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O IORKCNUBHNIMKY-CIUDSAMLSA-N 0.000 description 2
- WQLDNOCHHRISMS-NAKRPEOUSA-N Ala-Pro-Ile Chemical compound [H]N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WQLDNOCHHRISMS-NAKRPEOUSA-N 0.000 description 2
- BTRULDJUUVGRNE-DCAQKATOSA-N Ala-Pro-Lys Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O BTRULDJUUVGRNE-DCAQKATOSA-N 0.000 description 2
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 2
- ZVWXMTTZJKBJCI-BHDSKKPTSA-N Ala-Trp-Ala Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](C)C(O)=O)=CNC2=C1 ZVWXMTTZJKBJCI-BHDSKKPTSA-N 0.000 description 2
- BGGAIXWIZCIFSG-XDTLVQLUSA-N Ala-Tyr-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O BGGAIXWIZCIFSG-XDTLVQLUSA-N 0.000 description 2
- OMSKGWFGWCQFBD-KZVJFYERSA-N Ala-Val-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OMSKGWFGWCQFBD-KZVJFYERSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- KGSJCPBERYUXCN-BPNCWPANSA-N Arg-Ala-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KGSJCPBERYUXCN-BPNCWPANSA-N 0.000 description 2
- HJVGMOYJDDXLMI-AVGNSLFASA-N Arg-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCCNC(N)=N HJVGMOYJDDXLMI-AVGNSLFASA-N 0.000 description 2
- HKRXJBBCQBAGIM-FXQIFTODSA-N Arg-Asp-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N)CN=C(N)N HKRXJBBCQBAGIM-FXQIFTODSA-N 0.000 description 2
- YWENWUYXQUWRHQ-LPEHRKFASA-N Arg-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O YWENWUYXQUWRHQ-LPEHRKFASA-N 0.000 description 2
- HPKSHFSEXICTLI-CIUDSAMLSA-N Arg-Glu-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O HPKSHFSEXICTLI-CIUDSAMLSA-N 0.000 description 2
- PBSOQGZLPFVXPU-YUMQZZPRSA-N Arg-Glu-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PBSOQGZLPFVXPU-YUMQZZPRSA-N 0.000 description 2
- OMKZPCPZEFMBIT-SRVKXCTJSA-N Arg-Met-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O OMKZPCPZEFMBIT-SRVKXCTJSA-N 0.000 description 2
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 2
- XRLOBFSLPCHYLQ-ULQDDVLXSA-N Arg-Tyr-His Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O XRLOBFSLPCHYLQ-ULQDDVLXSA-N 0.000 description 2
- QEYJFBMTSMLPKZ-ZKWXMUAHSA-N Asn-Ala-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O QEYJFBMTSMLPKZ-ZKWXMUAHSA-N 0.000 description 2
- GNKVBRYFXYWXAB-WDSKDSINSA-N Asn-Glu-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O GNKVBRYFXYWXAB-WDSKDSINSA-N 0.000 description 2
- NUCUBYIUPVYGPP-XIRDDKMYSA-N Asn-Leu-Trp Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O NUCUBYIUPVYGPP-XIRDDKMYSA-N 0.000 description 2
- BYLSYQASFJJBCL-DCAQKATOSA-N Asn-Pro-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O BYLSYQASFJJBCL-DCAQKATOSA-N 0.000 description 2
- JWQWPRCDYWNVNM-ACZMJKKPSA-N Asn-Ser-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N JWQWPRCDYWNVNM-ACZMJKKPSA-N 0.000 description 2
- LGCVSPFCFXWUEY-IHPCNDPISA-N Asn-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N LGCVSPFCFXWUEY-IHPCNDPISA-N 0.000 description 2
- UZFHNLYQWMGUHU-DCAQKATOSA-N Asp-Lys-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UZFHNLYQWMGUHU-DCAQKATOSA-N 0.000 description 2
- ZKAOJVJQGVUIIU-GUBZILKMSA-N Asp-Pro-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ZKAOJVJQGVUIIU-GUBZILKMSA-N 0.000 description 2
- SQIARYGNVQWOSB-BZSNNMDCSA-N Asp-Tyr-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SQIARYGNVQWOSB-BZSNNMDCSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- AUJXLBOHYWTPFV-BLWRDSOESA-N CS[C@H]1SC[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H]1N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 Chemical compound CS[C@H]1SC[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H]1N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 AUJXLBOHYWTPFV-BLWRDSOESA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 2
- 108010084457 Cathepsins Proteins 0.000 description 2
- SRNFODIJXVPXHO-UHFFFAOYSA-N Crotonin Natural products CC1CC(=O)CC2C1CCC(C)C2(C(O1)=O)CC1C=1C=COC=1 SRNFODIJXVPXHO-UHFFFAOYSA-N 0.000 description 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 2
- NDNZRWUDUMTITL-FXQIFTODSA-N Cys-Ser-Val Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NDNZRWUDUMTITL-FXQIFTODSA-N 0.000 description 2
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 2
- 101800000585 Diphtheria toxin fragment A Proteins 0.000 description 2
- LQKSHSFQQRCAFW-UHFFFAOYSA-N Dolastatin 15 Natural products COC1=CC(=O)N(C(=O)C(OC(=O)C2N(CCC2)C(=O)C2N(CCC2)C(=O)C(C(C)C)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C)C(C)C)C(C)C)C1CC1=CC=CC=C1 LQKSHSFQQRCAFW-UHFFFAOYSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 108010009858 Echinomycin Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 101710082714 Exotoxin A Proteins 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- WUAYFMZULZDSLB-ACZMJKKPSA-N Gln-Ala-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O WUAYFMZULZDSLB-ACZMJKKPSA-N 0.000 description 2
- REJJNXODKSHOKA-ACZMJKKPSA-N Gln-Ala-Asp Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N REJJNXODKSHOKA-ACZMJKKPSA-N 0.000 description 2
- DHNWZLGBTPUTQQ-QEJZJMRPSA-N Gln-Asp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N DHNWZLGBTPUTQQ-QEJZJMRPSA-N 0.000 description 2
- LWDGZZGWDMHBOF-FXQIFTODSA-N Gln-Glu-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O LWDGZZGWDMHBOF-FXQIFTODSA-N 0.000 description 2
- GNMQDOGFWYWPNM-LAEOZQHASA-N Gln-Gly-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@@H](N)CCC(N)=O)C(O)=O GNMQDOGFWYWPNM-LAEOZQHASA-N 0.000 description 2
- XKPACHRGOWQHFH-IRIUXVKKSA-N Gln-Thr-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XKPACHRGOWQHFH-IRIUXVKKSA-N 0.000 description 2
- FITIQFSXXBKFFM-NRPADANISA-N Gln-Val-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FITIQFSXXBKFFM-NRPADANISA-N 0.000 description 2
- HNAUFGBKJLTWQE-IFFSRLJSSA-N Gln-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)N)O HNAUFGBKJLTWQE-IFFSRLJSSA-N 0.000 description 2
- MXOODARRORARSU-ACZMJKKPSA-N Glu-Ala-Ser Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)O)N MXOODARRORARSU-ACZMJKKPSA-N 0.000 description 2
- GLWXKFRTOHKGIT-ACZMJKKPSA-N Glu-Asn-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O GLWXKFRTOHKGIT-ACZMJKKPSA-N 0.000 description 2
- JRCUFCXYZLPSDZ-ACZMJKKPSA-N Glu-Asp-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O JRCUFCXYZLPSDZ-ACZMJKKPSA-N 0.000 description 2
- PVBBEKPHARMPHX-DCAQKATOSA-N Glu-Gln-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCC(O)=O PVBBEKPHARMPHX-DCAQKATOSA-N 0.000 description 2
- NKLRYVLERDYDBI-FXQIFTODSA-N Glu-Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NKLRYVLERDYDBI-FXQIFTODSA-N 0.000 description 2
- MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 2
- KASDBWKLWJKTLJ-GUBZILKMSA-N Glu-Glu-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O KASDBWKLWJKTLJ-GUBZILKMSA-N 0.000 description 2
- OGNJZUXUTPQVBR-BQBZGAKWSA-N Glu-Gly-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O OGNJZUXUTPQVBR-BQBZGAKWSA-N 0.000 description 2
- WVTIBGWZUMJBFY-GUBZILKMSA-N Glu-His-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O WVTIBGWZUMJBFY-GUBZILKMSA-N 0.000 description 2
- YGLCLCMAYUYZSG-AVGNSLFASA-N Glu-Lys-His Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 YGLCLCMAYUYZSG-AVGNSLFASA-N 0.000 description 2
- DXVOKNVIKORTHQ-GUBZILKMSA-N Glu-Pro-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O DXVOKNVIKORTHQ-GUBZILKMSA-N 0.000 description 2
- GZUKEVBTYNNUQF-WDSKDSINSA-N Gly-Ala-Gln Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GZUKEVBTYNNUQF-WDSKDSINSA-N 0.000 description 2
- VSVZIEVNUYDAFR-YUMQZZPRSA-N Gly-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN VSVZIEVNUYDAFR-YUMQZZPRSA-N 0.000 description 2
- GRIRDMVMJJDZKV-RCOVLWMOSA-N Gly-Asn-Val Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O GRIRDMVMJJDZKV-RCOVLWMOSA-N 0.000 description 2
- LXXLEUBUOMCAMR-NKWVEPMBSA-N Gly-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)CN)C(=O)O LXXLEUBUOMCAMR-NKWVEPMBSA-N 0.000 description 2
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 2
- NSTUFLGQJCOCDL-UWVGGRQHSA-N Gly-Leu-Arg Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NSTUFLGQJCOCDL-UWVGGRQHSA-N 0.000 description 2
- LIXWIUAORXJNBH-QWRGUYRKSA-N Gly-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)CN LIXWIUAORXJNBH-QWRGUYRKSA-N 0.000 description 2
- IKAIKUBBJHFNBZ-LURJTMIESA-N Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-LURJTMIESA-N 0.000 description 2
- FHQRLHFYVZAQHU-IUCAKERBSA-N Gly-Lys-Gln Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O FHQRLHFYVZAQHU-IUCAKERBSA-N 0.000 description 2
- ZLCLYFGMKFCDCN-XPUUQOCRSA-N Gly-Ser-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CO)NC(=O)CN)C(O)=O ZLCLYFGMKFCDCN-XPUUQOCRSA-N 0.000 description 2
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- CNHSMSFYVARZLI-YJRXYDGGSA-N His-His-Thr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CNHSMSFYVARZLI-YJRXYDGGSA-N 0.000 description 2
- NDKSHNQINMRKHT-PEXQALLHSA-N His-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CN=CN1)N NDKSHNQINMRKHT-PEXQALLHSA-N 0.000 description 2
- TWROVBNEHJSXDG-IHRRRGAJSA-N His-Leu-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O TWROVBNEHJSXDG-IHRRRGAJSA-N 0.000 description 2
- VDHOMPFVSABJKU-ULQDDVLXSA-N His-Phe-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CN=CN2)N VDHOMPFVSABJKU-ULQDDVLXSA-N 0.000 description 2
- BZAQOPHNBFOOJS-DCAQKATOSA-N His-Pro-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O BZAQOPHNBFOOJS-DCAQKATOSA-N 0.000 description 2
- XGBVLRJLHUVCNK-DCAQKATOSA-N His-Val-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O XGBVLRJLHUVCNK-DCAQKATOSA-N 0.000 description 2
- MKWSZEHGHSLNPF-NAKRPEOUSA-N Ile-Ala-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O)N MKWSZEHGHSLNPF-NAKRPEOUSA-N 0.000 description 2
- UAVQIQOOBXFKRC-BYULHYEWSA-N Ile-Asn-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O UAVQIQOOBXFKRC-BYULHYEWSA-N 0.000 description 2
- FADXGVVLSPPEQY-GHCJXIJMSA-N Ile-Cys-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O)N FADXGVVLSPPEQY-GHCJXIJMSA-N 0.000 description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- DUBAVOVZNZKEQQ-AVGNSLFASA-N Leu-Arg-Val Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CCCN=C(N)N DUBAVOVZNZKEQQ-AVGNSLFASA-N 0.000 description 2
- OIARJGNVARWKFP-YUMQZZPRSA-N Leu-Asn-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O OIARJGNVARWKFP-YUMQZZPRSA-N 0.000 description 2
- ZYLJULGXQDNXDK-GUBZILKMSA-N Leu-Gln-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ZYLJULGXQDNXDK-GUBZILKMSA-N 0.000 description 2
- CQGSYZCULZMEDE-SRVKXCTJSA-N Leu-Gln-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O CQGSYZCULZMEDE-SRVKXCTJSA-N 0.000 description 2
- ZFNLIDNJUWNIJL-WDCWCFNPSA-N Leu-Glu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZFNLIDNJUWNIJL-WDCWCFNPSA-N 0.000 description 2
- DSFYPIUSAMSERP-IHRRRGAJSA-N Leu-Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DSFYPIUSAMSERP-IHRRRGAJSA-N 0.000 description 2
- IAJFFZORSWOZPQ-SRVKXCTJSA-N Leu-Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IAJFFZORSWOZPQ-SRVKXCTJSA-N 0.000 description 2
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 2
- KYIIALJHAOIAHF-KKUMJFAQSA-N Leu-Leu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 KYIIALJHAOIAHF-KKUMJFAQSA-N 0.000 description 2
- HDHQQEDVWQGBEE-DCAQKATOSA-N Leu-Met-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O HDHQQEDVWQGBEE-DCAQKATOSA-N 0.000 description 2
- YESNGRDJQWDYLH-KKUMJFAQSA-N Leu-Phe-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CS)C(=O)O)N YESNGRDJQWDYLH-KKUMJFAQSA-N 0.000 description 2
- HGUUMQWGYCVPKG-DCAQKATOSA-N Leu-Pro-Cys Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)O)N HGUUMQWGYCVPKG-DCAQKATOSA-N 0.000 description 2
- CHJKEDSZNSONPS-DCAQKATOSA-N Leu-Pro-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O CHJKEDSZNSONPS-DCAQKATOSA-N 0.000 description 2
- SBANPBVRHYIMRR-GARJFASQSA-N Leu-Ser-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N SBANPBVRHYIMRR-GARJFASQSA-N 0.000 description 2
- QWWPYKKLXWOITQ-VOAKCMCISA-N Leu-Thr-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(C)C QWWPYKKLXWOITQ-VOAKCMCISA-N 0.000 description 2
- GZRABTMNWJXFMH-UVOCVTCTSA-N Leu-Thr-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZRABTMNWJXFMH-UVOCVTCTSA-N 0.000 description 2
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- IXHKPDJKKCUKHS-GARJFASQSA-N Lys-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N IXHKPDJKKCUKHS-GARJFASQSA-N 0.000 description 2
- SWWCDAGDQHTKIE-RHYQMDGZSA-N Lys-Arg-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SWWCDAGDQHTKIE-RHYQMDGZSA-N 0.000 description 2
- CTJUSALVKAWFFU-CIUDSAMLSA-N Lys-Ser-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N CTJUSALVKAWFFU-CIUDSAMLSA-N 0.000 description 2
- SBQDRNOLGSYHQA-YUMQZZPRSA-N Lys-Ser-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SBQDRNOLGSYHQA-YUMQZZPRSA-N 0.000 description 2
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 2
- XYLSGAWRCZECIQ-JYJNAYRXSA-N Lys-Tyr-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(O)=O)CC1=CC=C(O)C=C1 XYLSGAWRCZECIQ-JYJNAYRXSA-N 0.000 description 2
- XABXVVSWUVCZST-GVXVVHGQSA-N Lys-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN XABXVVSWUVCZST-GVXVVHGQSA-N 0.000 description 2
- HMZPYMSEAALNAE-ULQDDVLXSA-N Lys-Val-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O HMZPYMSEAALNAE-ULQDDVLXSA-N 0.000 description 2
- 229930126263 Maytansine Natural products 0.000 description 2
- RMLLCGYYVZKKRT-CIUDSAMLSA-N Met-Ser-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O RMLLCGYYVZKKRT-CIUDSAMLSA-N 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 231100000678 Mycotoxin Toxicity 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 2
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 108010047562 NGR peptide Proteins 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical class C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 108091005461 Nucleic proteins Chemical group 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- HXSUFWQYLPKEHF-IHRRRGAJSA-N Phe-Asn-Arg Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N HXSUFWQYLPKEHF-IHRRRGAJSA-N 0.000 description 2
- KZRQONDKKJCAOL-DKIMLUQUSA-N Phe-Leu-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KZRQONDKKJCAOL-DKIMLUQUSA-N 0.000 description 2
- JDMKQHSHKJHAHR-UHFFFAOYSA-N Phe-Phe-Leu-Tyr Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)CC1=CC=CC=C1 JDMKQHSHKJHAHR-UHFFFAOYSA-N 0.000 description 2
- IIEOLPMQYRBZCN-SRVKXCTJSA-N Phe-Ser-Cys Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O IIEOLPMQYRBZCN-SRVKXCTJSA-N 0.000 description 2
- BPCLGWHVPVTTFM-QWRGUYRKSA-N Phe-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O BPCLGWHVPVTTFM-QWRGUYRKSA-N 0.000 description 2
- VFDRDMOMHBJGKD-UFYCRDLUSA-N Phe-Tyr-Arg Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N VFDRDMOMHBJGKD-UFYCRDLUSA-N 0.000 description 2
- SJRQWEDYTKYHHL-SLFFLAALSA-N Phe-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)O SJRQWEDYTKYHHL-SLFFLAALSA-N 0.000 description 2
- 101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- TUYWCHPXKQTISF-LPEHRKFASA-N Pro-Cys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N2CCC[C@@H]2C(=O)O TUYWCHPXKQTISF-LPEHRKFASA-N 0.000 description 2
- UAYHMOIGIQZLFR-NHCYSSNCSA-N Pro-Gln-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O UAYHMOIGIQZLFR-NHCYSSNCSA-N 0.000 description 2
- LGSANCBHSMDFDY-GARJFASQSA-N Pro-Glu-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O LGSANCBHSMDFDY-GARJFASQSA-N 0.000 description 2
- FKLSMYYLJHYPHH-UWVGGRQHSA-N Pro-Gly-Leu Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O FKLSMYYLJHYPHH-UWVGGRQHSA-N 0.000 description 2
- CLJLVCYFABNTHP-DCAQKATOSA-N Pro-Leu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O CLJLVCYFABNTHP-DCAQKATOSA-N 0.000 description 2
- HFNPOYOKIPGAEI-SRVKXCTJSA-N Pro-Leu-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 HFNPOYOKIPGAEI-SRVKXCTJSA-N 0.000 description 2
- ZLXKLMHAMDENIO-DCAQKATOSA-N Pro-Lys-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLXKLMHAMDENIO-DCAQKATOSA-N 0.000 description 2
- PCWLNNZTBJTZRN-AVGNSLFASA-N Pro-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 PCWLNNZTBJTZRN-AVGNSLFASA-N 0.000 description 2
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 2
- GMJDSFYVTAMIBF-FXQIFTODSA-N Pro-Ser-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GMJDSFYVTAMIBF-FXQIFTODSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 101710120463 Prostate stem cell antigen Proteins 0.000 description 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 2
- 102220563012 Protein aurora borealis_I75A_mutation Human genes 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 2
- QVOGDCQNGLBNCR-FXQIFTODSA-N Ser-Arg-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O QVOGDCQNGLBNCR-FXQIFTODSA-N 0.000 description 2
- VGNYHOBZJKWRGI-CIUDSAMLSA-N Ser-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO VGNYHOBZJKWRGI-CIUDSAMLSA-N 0.000 description 2
- XWCYBVBLJRWOFR-WDSKDSINSA-N Ser-Gln-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O XWCYBVBLJRWOFR-WDSKDSINSA-N 0.000 description 2
- DSGYZICNAMEJOC-AVGNSLFASA-N Ser-Glu-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O DSGYZICNAMEJOC-AVGNSLFASA-N 0.000 description 2
- AEGUWTFAQQWVLC-BQBZGAKWSA-N Ser-Gly-Arg Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O AEGUWTFAQQWVLC-BQBZGAKWSA-N 0.000 description 2
- GZFAWAQTEYDKII-YUMQZZPRSA-N Ser-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO GZFAWAQTEYDKII-YUMQZZPRSA-N 0.000 description 2
- CXBFHZLODKPIJY-AAEUAGOBSA-N Ser-Gly-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N CXBFHZLODKPIJY-AAEUAGOBSA-N 0.000 description 2
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 2
- FPCGZYMRFFIYIH-CIUDSAMLSA-N Ser-Lys-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O FPCGZYMRFFIYIH-CIUDSAMLSA-N 0.000 description 2
- QJKPECIAWNNKIT-KKUMJFAQSA-N Ser-Lys-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O QJKPECIAWNNKIT-KKUMJFAQSA-N 0.000 description 2
- FZEUTKVQGMVGHW-AVGNSLFASA-N Ser-Phe-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZEUTKVQGMVGHW-AVGNSLFASA-N 0.000 description 2
- RWDVVSKYZBNDCO-MELADBBJSA-N Ser-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CO)N)C(=O)O RWDVVSKYZBNDCO-MELADBBJSA-N 0.000 description 2
- ADJDNJCSPNFFPI-FXQIFTODSA-N Ser-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO ADJDNJCSPNFFPI-FXQIFTODSA-N 0.000 description 2
- CKDXFSPMIDSMGV-GUBZILKMSA-N Ser-Pro-Val Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O CKDXFSPMIDSMGV-GUBZILKMSA-N 0.000 description 2
- PYTKULIABVRXSC-BWBBJGPYSA-N Ser-Ser-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PYTKULIABVRXSC-BWBBJGPYSA-N 0.000 description 2
- DYEGLQRVMBWQLD-IXOXFDKPSA-N Ser-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CO)N)O DYEGLQRVMBWQLD-IXOXFDKPSA-N 0.000 description 2
- ZKOKTQPHFMRSJP-YJRXYDGGSA-N Ser-Thr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKOKTQPHFMRSJP-YJRXYDGGSA-N 0.000 description 2
- PQEQXWRVHQAAKS-SRVKXCTJSA-N Ser-Tyr-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)N)CC1=CC=C(O)C=C1 PQEQXWRVHQAAKS-SRVKXCTJSA-N 0.000 description 2
- JZRYFUGREMECBH-XPUUQOCRSA-N Ser-Val-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O JZRYFUGREMECBH-XPUUQOCRSA-N 0.000 description 2
- RCOUFINCYASMDN-GUBZILKMSA-N Ser-Val-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(O)=O RCOUFINCYASMDN-GUBZILKMSA-N 0.000 description 2
- HNDMFDBQXYZSRM-IHRRRGAJSA-N Ser-Val-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HNDMFDBQXYZSRM-IHRRRGAJSA-N 0.000 description 2
- JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 description 2
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 2
- XFTYVCHLARBHBQ-FOHZUACHSA-N Thr-Gly-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O XFTYVCHLARBHBQ-FOHZUACHSA-N 0.000 description 2
- IHAPJUHCZXBPHR-WZLNRYEVSA-N Thr-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N IHAPJUHCZXBPHR-WZLNRYEVSA-N 0.000 description 2
- FIFDDJFLNVAVMS-RHYQMDGZSA-N Thr-Leu-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O FIFDDJFLNVAVMS-RHYQMDGZSA-N 0.000 description 2
- NCXVJIQMWSGRHY-KXNHARMFSA-N Thr-Leu-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O NCXVJIQMWSGRHY-KXNHARMFSA-N 0.000 description 2
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 2
- BDGBHYCAZJPLHX-HJGDQZAQSA-N Thr-Lys-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O BDGBHYCAZJPLHX-HJGDQZAQSA-N 0.000 description 2
- JLNMFGCJODTXDH-WEDXCCLWSA-N Thr-Lys-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O JLNMFGCJODTXDH-WEDXCCLWSA-N 0.000 description 2
- XSEPSRUDSPHMPX-KATARQTJSA-N Thr-Lys-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O XSEPSRUDSPHMPX-KATARQTJSA-N 0.000 description 2
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 2
- MROIJTGJGIDEEJ-RCWTZXSCSA-N Thr-Pro-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 MROIJTGJGIDEEJ-RCWTZXSCSA-N 0.000 description 2
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- NKUIXQOJUAEIET-AQZXSJQPSA-N Trp-Asp-Thr Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@H](O)C)C(O)=O)=CNC2=C1 NKUIXQOJUAEIET-AQZXSJQPSA-N 0.000 description 2
- JVTHMUDOKPQBOT-NSHDSACASA-N Trp-Gly-Gly Chemical compound C1=CC=C2C(C[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O)=CNC2=C1 JVTHMUDOKPQBOT-NSHDSACASA-N 0.000 description 2
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 2
- IEESWNWYUOETOT-BVSLBCMMSA-N Trp-Val-Phe Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(O)=O IEESWNWYUOETOT-BVSLBCMMSA-N 0.000 description 2
- HKYTWJOWZTWBQB-AVGNSLFASA-N Tyr-Glu-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HKYTWJOWZTWBQB-AVGNSLFASA-N 0.000 description 2
- IWRMTNJCCMEBEX-AVGNSLFASA-N Tyr-Glu-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N)O IWRMTNJCCMEBEX-AVGNSLFASA-N 0.000 description 2
- SINRIKQYQJRGDQ-MEYUZBJRSA-N Tyr-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 SINRIKQYQJRGDQ-MEYUZBJRSA-N 0.000 description 2
- NHOVZGFNTGMYMI-KKUMJFAQSA-N Tyr-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NHOVZGFNTGMYMI-KKUMJFAQSA-N 0.000 description 2
- RIVVDNTUSRVTQT-IRIUXVKKSA-N Tyr-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O RIVVDNTUSRVTQT-IRIUXVKKSA-N 0.000 description 2
- GNWUWQAVVJQREM-NHCYSSNCSA-N Val-Asn-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N GNWUWQAVVJQREM-NHCYSSNCSA-N 0.000 description 2
- TZVUSFMQWPWHON-NHCYSSNCSA-N Val-Asp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N TZVUSFMQWPWHON-NHCYSSNCSA-N 0.000 description 2
- DDNIHOWRDOXXPF-NGZCFLSTSA-N Val-Asp-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N DDNIHOWRDOXXPF-NGZCFLSTSA-N 0.000 description 2
- SCBITHMBEJNRHC-LSJOCFKGSA-N Val-Asp-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)N SCBITHMBEJNRHC-LSJOCFKGSA-N 0.000 description 2
- VLDMQVZZWDOKQF-AUTRQRHGSA-N Val-Glu-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N VLDMQVZZWDOKQF-AUTRQRHGSA-N 0.000 description 2
- WDIGUPHXPBMODF-UMNHJUIQSA-N Val-Glu-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N WDIGUPHXPBMODF-UMNHJUIQSA-N 0.000 description 2
- UEHRGZCNLSWGHK-DLOVCJGASA-N Val-Glu-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UEHRGZCNLSWGHK-DLOVCJGASA-N 0.000 description 2
- ZIGZPYJXIWLQFC-QTKMDUPCSA-N Val-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](C(C)C)N)O ZIGZPYJXIWLQFC-QTKMDUPCSA-N 0.000 description 2
- XTDDIVQWDXMRJL-IHRRRGAJSA-N Val-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N XTDDIVQWDXMRJL-IHRRRGAJSA-N 0.000 description 2
- DIOSYUIWOQCXNR-ONGXEEELSA-N Val-Lys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O DIOSYUIWOQCXNR-ONGXEEELSA-N 0.000 description 2
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 2
- GBIUHAYJGWVNLN-AEJSXWLSSA-N Val-Ser-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N GBIUHAYJGWVNLN-AEJSXWLSSA-N 0.000 description 2
- ZLNYBMWGPOKSLW-LSJOCFKGSA-N Val-Val-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLNYBMWGPOKSLW-LSJOCFKGSA-N 0.000 description 2
- ZHWZDZFWBXWPDW-GUBZILKMSA-N Val-Val-Cys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(O)=O ZHWZDZFWBXWPDW-GUBZILKMSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 2
- 229930183665 actinomycin Natural products 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 108010047495 alanylglycine Proteins 0.000 description 2
- 108010087924 alanylproline Proteins 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 230000003388 anti-hormonal effect Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 2
- 229940125644 antibody drug Drugs 0.000 description 2
- 238000011230 antibody-based therapy Methods 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 108010038633 aspartylglutamate Proteins 0.000 description 2
- 108010047857 aspartylglycine Proteins 0.000 description 2
- 108010092854 aspartyllysine Proteins 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 239000012867 bioactive agent Substances 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000002725 brachytherapy Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 201000005200 bronchus cancer Diseases 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 108010046713 cemadotin Proteins 0.000 description 2
- 229950009017 cemadotin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical class CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 2
- 229960005501 duocarmycin Drugs 0.000 description 2
- 229930184221 duocarmycin Natural products 0.000 description 2
- 239000012893 effector ligand Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 2
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 2
- 229960001842 estramustine Drugs 0.000 description 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 238000002710 external beam radiation therapy Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000004052 folic acid antagonist Substances 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 2
- 108010020688 glycylhistidine Proteins 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 150000007857 hydrazones Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 150000002463 imidates Chemical class 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 208000030776 invasive breast carcinoma Diseases 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 150000002540 isothiocyanates Chemical class 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 108010051673 leucyl-glycyl-phenylalanine Proteins 0.000 description 2
- 108010038320 lysylphenylalanine Proteins 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical group COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 description 2
- 230000008880 microtubule cytoskeleton organization Effects 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 108010010621 modeccin Proteins 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000002636 mycotoxin Substances 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- IDBIFFKSXLYUOT-UHFFFAOYSA-N netropsin Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)CN=C(N)N)=CN1C IDBIFFKSXLYUOT-UHFFFAOYSA-N 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 2
- 108010051242 phenylalanylserine Proteins 0.000 description 2
- 108010025488 pinealon Proteins 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 108010090894 prolylleucine Proteins 0.000 description 2
- 108010053725 prolylvaline Proteins 0.000 description 2
- 208000023958 prostate neoplasm Diseases 0.000 description 2
- 230000006916 protein interaction Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- AUJXLBOHYWTPFV-UHFFFAOYSA-N quinomycin A Natural products CN1C(=O)C(C)NC(=O)C(NC(=O)C=2N=C3C=CC=CC3=NC=2)COC(=O)C(C(C)C)N(C)C(=O)C2N(C)C(=O)C(C)NC(=O)C(NC(=O)C=3N=C4C=CC=CC4=NC=3)COC(=O)C(C(C)C)N(C)C(=O)C1CSC2SC AUJXLBOHYWTPFV-UHFFFAOYSA-N 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 108010091078 rigin Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 150000003335 secondary amines Chemical group 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 108010047846 soblidotin Proteins 0.000 description 2
- DZMVCVHATYROOS-ZBFGKEHZSA-N soblidotin Chemical group CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCC1=CC=CC=C1 DZMVCVHATYROOS-ZBFGKEHZSA-N 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 125000005156 substituted alkylene group Chemical group 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical group NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 108010029384 tryptophyl-histidine Proteins 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 108010052774 valyl-lysyl-glycyl-phenylalanyl-tyrosine Proteins 0.000 description 2
- 108010073969 valyllysine Proteins 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- FKBHRUQOROFRGD-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2[C]3C=CC=CC3=NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC FKBHRUQOROFRGD-IELIFDKJSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108010027345 wheylin-1 peptide Proteins 0.000 description 2
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 2
- AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 description 1
- FLCQLSRLQIPNLM-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-acetylsulfanylacetate Chemical compound CC(=O)SCC(=O)ON1C(=O)CCC1=O FLCQLSRLQIPNLM-UHFFFAOYSA-N 0.000 description 1
- BSPMWFRGZQDRIU-UHFFFAOYSA-N (2-amino-1h-imidazol-5-yl)methanol Chemical class NC1=NC(CO)=CN1 BSPMWFRGZQDRIU-UHFFFAOYSA-N 0.000 description 1
- ZFPKPFDUWUEXOZ-SJEAMFKXSA-N (2s)-2-(cyclohexylamino)propanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@H](C)NC1CCCCC1 ZFPKPFDUWUEXOZ-SJEAMFKXSA-N 0.000 description 1
- LGNCNVVZCUVPOT-FUVGGWJZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 LGNCNVVZCUVPOT-FUVGGWJZSA-N 0.000 description 1
- PCDUALPXEOKZPE-DXCABUDRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O PCDUALPXEOKZPE-DXCABUDRSA-N 0.000 description 1
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical group NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 description 1
- HOVQQFUTZFIEIT-LMECJBHSSA-N (2s)-2-amino-4-phenylbutanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC1=CC=CC=C1 HOVQQFUTZFIEIT-LMECJBHSSA-N 0.000 description 1
- OIXLLKLZKCBCPS-RZVRUWJTSA-N (2s)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic acid Chemical compound OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)[C@@H](N)CCCNC(N)=N OIXLLKLZKCBCPS-RZVRUWJTSA-N 0.000 description 1
- INAUWOVKEZHHDM-PEDBPRJASA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1 INAUWOVKEZHHDM-PEDBPRJASA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- DNKORVAXOJKDEO-UHFFFAOYSA-N 1,1,1-trichloro-2-(2,2,2-trichloroethoxymethoxymethoxy)ethane Chemical compound ClC(Cl)(Cl)COCOCOCC(Cl)(Cl)Cl DNKORVAXOJKDEO-UHFFFAOYSA-N 0.000 description 1
- POTIYWUALSJREP-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoline Chemical compound N1CCCC2CCCCC21 POTIYWUALSJREP-UHFFFAOYSA-N 0.000 description 1
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- 125000004955 1,4-cyclohexylene group Chemical group [H]C1([H])C([H])([H])C([H])([*:1])C([H])([H])C([H])([H])C1([H])[*:2] 0.000 description 1
- VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
- PZLRTZKNXNAQNA-UHFFFAOYSA-N 1-(2-fluorophenyl)-4-[1-(2-fluorophenyl)-4-methoxypiperidin-4-yl]oxy-4-methoxypiperidine Chemical compound C1CC(OC)(OC2(CCN(CC2)C=2C(=CC=CC=2)F)OC)CCN1C1=CC=CC=C1F PZLRTZKNXNAQNA-UHFFFAOYSA-N 0.000 description 1
- LUTZCBQFCCYXAD-UHFFFAOYSA-N 1-(butoxymethoxymethoxy)butane Chemical group CCCCOCOCOCCCC LUTZCBQFCCYXAD-UHFFFAOYSA-N 0.000 description 1
- GAHRWPUTGHCERR-UHFFFAOYSA-N 1-[bis(2-chloroethoxy)methoxy-(2-chloroethoxy)methoxy]-2-chloroethane Chemical compound ClCCOC(OCCCl)OC(OCCCl)OCCCl GAHRWPUTGHCERR-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical group CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- URUJZHZLCCIILC-UHFFFAOYSA-N 1-chloro-4-(4-chlorophenoxy)benzene Chemical group C1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1 URUJZHZLCCIILC-UHFFFAOYSA-N 0.000 description 1
- PPJVXZVTPWQOQS-UHFFFAOYSA-N 1-ethoxy-1-(1-ethoxyethoxy)ethane Chemical compound CCOC(C)OC(C)OCC PPJVXZVTPWQOQS-UHFFFAOYSA-N 0.000 description 1
- TZWQLTARMYBCOA-UHFFFAOYSA-N 1-methoxy-1-(1-methoxycyclohexyl)oxycyclohexane Chemical compound C1CCCCC1(OC)OC1(OC)CCCCC1 TZWQLTARMYBCOA-UHFFFAOYSA-N 0.000 description 1
- GPAAEZIXSQCCES-UHFFFAOYSA-N 1-methoxy-2-(2-methoxyethoxymethoxymethoxy)ethane Chemical compound COCCOCOCOCCOC GPAAEZIXSQCCES-UHFFFAOYSA-N 0.000 description 1
- CBDLNOVOFXJEOB-UHFFFAOYSA-N 1-methoxy-4-(4-methoxyphenoxy)benzene Chemical group C1=CC(OC)=CC=C1OC1=CC=C(OC)C=C1 CBDLNOVOFXJEOB-UHFFFAOYSA-N 0.000 description 1
- WPGFNVSGRUMSRU-UHFFFAOYSA-N 1-methoxy-4-[(4-methoxyphenoxy)methoxymethoxy]benzene Chemical compound C1=CC(OC)=CC=C1OCOCOC1=CC=C(OC)C=C1 WPGFNVSGRUMSRU-UHFFFAOYSA-N 0.000 description 1
- UUAKOKFSMXRGJP-UHFFFAOYSA-N 1-methoxy-4-[(4-methoxyphenyl)methoxymethoxymethoxymethyl]benzene Chemical compound C1=CC(OC)=CC=C1COCOCOCC1=CC=C(OC)C=C1 UUAKOKFSMXRGJP-UHFFFAOYSA-N 0.000 description 1
- SDTORDSXCYSNTD-UHFFFAOYSA-N 1-methoxy-4-[(4-methoxyphenyl)methoxymethyl]benzene Chemical group C1=CC(OC)=CC=C1COCC1=CC=C(OC)C=C1 SDTORDSXCYSNTD-UHFFFAOYSA-N 0.000 description 1
- QXNYDLUVCLLPDG-UHFFFAOYSA-N 1-nitro-2-[(2-nitrophenyl)methoxymethoxymethoxymethyl]benzene Chemical compound [O-][N+](=O)C1=CC=CC=C1COCOCOCC1=CC=CC=C1[N+]([O-])=O QXNYDLUVCLLPDG-UHFFFAOYSA-N 0.000 description 1
- XTJYSYQSGSOHNH-UHFFFAOYSA-N 1-nitro-4-[(4-nitrophenyl)methoxymethoxymethoxymethyl]benzene Chemical compound C1=CC([N+](=O)[O-])=CC=C1COCOCOCC1=CC=C([N+]([O-])=O)C=C1 XTJYSYQSGSOHNH-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- DGHHQBMTXTWTJV-BQAIUKQQSA-N 119413-54-6 Chemical compound Cl.C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 DGHHQBMTXTWTJV-BQAIUKQQSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical group C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- XDQFBMPFEBUDIC-UHFFFAOYSA-N 1h-pyrimidine-2,4-dione Chemical compound O=C1C=CNC(=O)N1.O=C1C=CNC(=O)N1 XDQFBMPFEBUDIC-UHFFFAOYSA-N 0.000 description 1
- KEQTWHPMSVAFDA-UHFFFAOYSA-N 2,3-dihydro-1h-pyrazole Chemical group C1NNC=C1 KEQTWHPMSVAFDA-UHFFFAOYSA-N 0.000 description 1
- FFMBYMANYCDCMK-UHFFFAOYSA-N 2,5-dihydro-1h-imidazole Chemical group C1NCN=C1 FFMBYMANYCDCMK-UHFFFAOYSA-N 0.000 description 1
- VFXFHLGYUDXEKM-UHFFFAOYSA-N 2-(1,4-dioxan-2-yloxy)-1,4-dioxane Chemical compound C1OCCOC1OC1OCCOC1 VFXFHLGYUDXEKM-UHFFFAOYSA-N 0.000 description 1
- UFCRQKWENZPCAD-UHFFFAOYSA-N 2-(2-aminophenyl)propanamide Chemical compound NC(=O)C(C)C1=CC=CC=C1N UFCRQKWENZPCAD-UHFFFAOYSA-N 0.000 description 1
- FUADWGHSDKHNMC-UHFFFAOYSA-N 2-(2-phenoxypropan-2-yloxy)propan-2-yloxybenzene Chemical compound C=1C=CC=CC=1OC(C)(C)OC(C)(C)OC1=CC=CC=C1 FUADWGHSDKHNMC-UHFFFAOYSA-N 0.000 description 1
- KDRPMSNOKACXPD-UHFFFAOYSA-N 2-(2-phenylmethoxypropan-2-yloxy)propan-2-yloxymethylbenzene Chemical compound C=1C=CC=CC=1COC(C)(C)OC(C)(C)OCC1=CC=CC=C1 KDRPMSNOKACXPD-UHFFFAOYSA-N 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical compound O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
- YFEXZJKJPFNYKB-UHFFFAOYSA-N 2-(oxolan-2-yloxy)oxolane Chemical compound C1CCOC1OC1OCCC1 YFEXZJKJPFNYKB-UHFFFAOYSA-N 0.000 description 1
- JMTBNBFBHBCERV-UHFFFAOYSA-N 2-(thiolan-2-yloxy)thiolane Chemical compound C1CCSC1OC1SCCC1 JMTBNBFBHBCERV-UHFFFAOYSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- QMOQBVOBWVNSNO-UHFFFAOYSA-N 2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(O)=O QMOQBVOBWVNSNO-UHFFFAOYSA-N 0.000 description 1
- FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
- FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 1
- YVOOPGWEIRIUOX-UHFFFAOYSA-N 2-azanyl-3-sulfanyl-propanoic acid Chemical compound SCC(N)C(O)=O.SCC(N)C(O)=O YVOOPGWEIRIUOX-UHFFFAOYSA-N 0.000 description 1
- QXPXILGITKUCLM-UHFFFAOYSA-N 2-benzylidenepropane-1,3-diol Chemical compound OCC(CO)=CC1=CC=CC=C1 QXPXILGITKUCLM-UHFFFAOYSA-N 0.000 description 1
- KLZNYOUPZVOAMY-UHFFFAOYSA-N 2-fluoroacetic acid;2,2,2-trichloroacetic acid Chemical group OC(=O)CF.OC(=O)C(Cl)(Cl)Cl KLZNYOUPZVOAMY-UHFFFAOYSA-N 0.000 description 1
- DTCYSRAEJHGSNY-UHFFFAOYSA-N 2-methoxy-2-(2-methoxypropan-2-yloxy)propane Chemical compound COC(C)(C)OC(C)(C)OC DTCYSRAEJHGSNY-UHFFFAOYSA-N 0.000 description 1
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004922 2-methyl-3-pentyl group Chemical group CC(C)C(CC)* 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- KCMCIQNPQUSQKQ-UHFFFAOYSA-N 2-oxido-1,2,5-oxadiazol-2-ium Chemical group [O-][N+]1=CC=NO1 KCMCIQNPQUSQKQ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical group C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- GPVOTFQILZVCFP-UHFFFAOYSA-N 2-trityloxyacetic acid Chemical group C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCC(=O)O)C1=CC=CC=C1 GPVOTFQILZVCFP-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- YIMDLWDNDGKDTJ-QLKYHASDSA-N 3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-QLKYHASDSA-N 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical group C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
- HRDCVMSNCBAMAM-UHFFFAOYSA-N 3-prop-2-ynoxyprop-1-yne Chemical group C#CCOCC#C HRDCVMSNCBAMAM-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical group C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical group C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 description 1
- KTFBMMKWTQVUIV-UHFFFAOYSA-N 4-[(3,4-dimethoxyphenyl)methoxymethyl]-1,2-dimethoxybenzene Chemical group C1=C(OC)C(OC)=CC=C1COCC1=CC=C(OC)C(OC)=C1 KTFBMMKWTQVUIV-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- WCVPFJVXEXJFLB-UHFFFAOYSA-N 4-aminobutanamide Chemical class NCCCC(N)=O WCVPFJVXEXJFLB-UHFFFAOYSA-N 0.000 description 1
- KIHBMNGVZAZFCM-UHFFFAOYSA-N 4-azido-N-[6-[(4-azidobenzoyl)amino]hexyl]benzamide Chemical compound N(=[N+]=[N-])C1=CC=C(C(=O)NCCCCCCNC(C2=CC=C(C=C2)N=[N+]=[N-])=O)C=C1 KIHBMNGVZAZFCM-UHFFFAOYSA-N 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- 125000004937 4H-carbazolyl group Chemical group C=1(C=CCC2=C3C=CC=CC3=NC12)* 0.000 description 1
- NDYCVFBVUXMWQI-UHFFFAOYSA-N 5-(pent-4-enoxymethoxymethoxy)pent-1-ene Chemical group C=CCCCOCOCOCCCC=C NDYCVFBVUXMWQI-UHFFFAOYSA-N 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 1
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- CHFFHQUVXHEGBY-GARJFASQSA-N Ala-Lys-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N CHFFHQUVXHEGBY-GARJFASQSA-N 0.000 description 1
- MDNAVFBZPROEHO-DCAQKATOSA-N Ala-Lys-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O MDNAVFBZPROEHO-DCAQKATOSA-N 0.000 description 1
- XSTZMVAYYCJTNR-DCAQKATOSA-N Ala-Met-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O XSTZMVAYYCJTNR-DCAQKATOSA-N 0.000 description 1
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 1
- YXXPVUOMPSZURS-ZLIFDBKOSA-N Ala-Trp-Leu Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](C)N)=CNC2=C1 YXXPVUOMPSZURS-ZLIFDBKOSA-N 0.000 description 1
- QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- VBFJESQBIWCWRL-DCAQKATOSA-N Arg-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VBFJESQBIWCWRL-DCAQKATOSA-N 0.000 description 1
- PQWTZSNVWSOFFK-FXQIFTODSA-N Arg-Asp-Asn Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)CN=C(N)N PQWTZSNVWSOFFK-FXQIFTODSA-N 0.000 description 1
- RKRSYHCNPFGMTA-CIUDSAMLSA-N Arg-Glu-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O RKRSYHCNPFGMTA-CIUDSAMLSA-N 0.000 description 1
- OHYQKYUTLIPFOX-ZPFDUUQYSA-N Arg-Glu-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O OHYQKYUTLIPFOX-ZPFDUUQYSA-N 0.000 description 1
- QKSAZKCRVQYYGS-UWVGGRQHSA-N Arg-Gly-His Chemical compound N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O QKSAZKCRVQYYGS-UWVGGRQHSA-N 0.000 description 1
- OQCWXQJLCDPRHV-UWVGGRQHSA-N Arg-Gly-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O OQCWXQJLCDPRHV-UWVGGRQHSA-N 0.000 description 1
- HJDNZFIYILEIKR-OSUNSFLBSA-N Arg-Ile-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HJDNZFIYILEIKR-OSUNSFLBSA-N 0.000 description 1
- JEXPNDORFYHJTM-IHRRRGAJSA-N Arg-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCN=C(N)N JEXPNDORFYHJTM-IHRRRGAJSA-N 0.000 description 1
- BECXEHHOZNFFFX-IHRRRGAJSA-N Arg-Ser-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BECXEHHOZNFFFX-IHRRRGAJSA-N 0.000 description 1
- QHUOOCKNNURZSL-IHRRRGAJSA-N Arg-Tyr-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O QHUOOCKNNURZSL-IHRRRGAJSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BVLIJXXSXBUGEC-SRVKXCTJSA-N Asn-Asn-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BVLIJXXSXBUGEC-SRVKXCTJSA-N 0.000 description 1
- OLVIPTLKNSAYRJ-YUMQZZPRSA-N Asn-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N OLVIPTLKNSAYRJ-YUMQZZPRSA-N 0.000 description 1
- QUAWOKPCAKCHQL-SRVKXCTJSA-N Asn-His-Lys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N QUAWOKPCAKCHQL-SRVKXCTJSA-N 0.000 description 1
- RCFGLXMZDYNRSC-CIUDSAMLSA-N Asn-Lys-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O RCFGLXMZDYNRSC-CIUDSAMLSA-N 0.000 description 1
- RBOBTTLFPRSXKZ-BZSNNMDCSA-N Asn-Phe-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O RBOBTTLFPRSXKZ-BZSNNMDCSA-N 0.000 description 1
- PLTGTJAZQRGMPP-FXQIFTODSA-N Asn-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(N)=O PLTGTJAZQRGMPP-FXQIFTODSA-N 0.000 description 1
- SNYCNNPOFYBCEK-ZLUOBGJFSA-N Asn-Ser-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O SNYCNNPOFYBCEK-ZLUOBGJFSA-N 0.000 description 1
- KBQOUDLMWYWXNP-YDHLFZDLSA-N Asn-Val-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC(=O)N)N KBQOUDLMWYWXNP-YDHLFZDLSA-N 0.000 description 1
- KNMRXHIAVXHCLW-ZLUOBGJFSA-N Asp-Asn-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N)C(=O)O KNMRXHIAVXHCLW-ZLUOBGJFSA-N 0.000 description 1
- XAJRHVUUVUPFQL-ACZMJKKPSA-N Asp-Glu-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O XAJRHVUUVUPFQL-ACZMJKKPSA-N 0.000 description 1
- VFUXXFVCYZPOQG-WDSKDSINSA-N Asp-Glu-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O VFUXXFVCYZPOQG-WDSKDSINSA-N 0.000 description 1
- POTCZYQVVNXUIG-BQBZGAKWSA-N Asp-Gly-Pro Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O POTCZYQVVNXUIG-BQBZGAKWSA-N 0.000 description 1
- WSGVTKZFVJSJOG-RCOVLWMOSA-N Asp-Gly-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O WSGVTKZFVJSJOG-RCOVLWMOSA-N 0.000 description 1
- KTTCQQNRRLCIBC-GHCJXIJMSA-N Asp-Ile-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O KTTCQQNRRLCIBC-GHCJXIJMSA-N 0.000 description 1
- HJZLUGQGJWXJCJ-CIUDSAMLSA-N Asp-Pro-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O HJZLUGQGJWXJCJ-CIUDSAMLSA-N 0.000 description 1
- YFGUZQQCSDZRBN-DCAQKATOSA-N Asp-Pro-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O YFGUZQQCSDZRBN-DCAQKATOSA-N 0.000 description 1
- YIDFBWRHIYOYAA-LKXGYXEUSA-N Asp-Ser-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YIDFBWRHIYOYAA-LKXGYXEUSA-N 0.000 description 1
- JSNWZMFSLIWAHS-HJGDQZAQSA-N Asp-Thr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O JSNWZMFSLIWAHS-HJGDQZAQSA-N 0.000 description 1
- YUELDQUPTAYEGM-XIRDDKMYSA-N Asp-Trp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)O)N YUELDQUPTAYEGM-XIRDDKMYSA-N 0.000 description 1
- GIKOVDMXBAFXDF-NHCYSSNCSA-N Asp-Val-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O GIKOVDMXBAFXDF-NHCYSSNCSA-N 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 229930190007 Baccatin Natural products 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 206010006417 Bronchial carcinoma Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- TWJPKRPAWOEANM-UHFFFAOYSA-N C[ClH]C Chemical compound C[ClH]C TWJPKRPAWOEANM-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241001092081 Carpenteria Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010055114 Colon cancer metastatic Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- NDUSUIGBMZCOIL-ZKWXMUAHSA-N Cys-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)N NDUSUIGBMZCOIL-ZKWXMUAHSA-N 0.000 description 1
- PJWIPBIMSKJTIE-DCAQKATOSA-N Cys-His-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CS)N PJWIPBIMSKJTIE-DCAQKATOSA-N 0.000 description 1
- SRIRHERUAMYIOQ-CIUDSAMLSA-N Cys-Leu-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SRIRHERUAMYIOQ-CIUDSAMLSA-N 0.000 description 1
- SMEYEQDCCBHTEF-FXQIFTODSA-N Cys-Pro-Ala Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O SMEYEQDCCBHTEF-FXQIFTODSA-N 0.000 description 1
- ALTQTAKGRFLRLR-GUBZILKMSA-N Cys-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N ALTQTAKGRFLRLR-GUBZILKMSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 1
- OFDNQWIFNXBECV-UHFFFAOYSA-N Dolastatin 10 Natural products CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)CC)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 229930189413 Esperamicin Natural products 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 241001200922 Gagata Species 0.000 description 1
- 102100039554 Galectin-8 Human genes 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- MWLYSLMKFXWZPW-ZPFDUUQYSA-N Gln-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O MWLYSLMKFXWZPW-ZPFDUUQYSA-N 0.000 description 1
- IKDOHQHEFPPGJG-FXQIFTODSA-N Gln-Asp-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O IKDOHQHEFPPGJG-FXQIFTODSA-N 0.000 description 1
- ZNZPKVQURDQFFS-FXQIFTODSA-N Gln-Glu-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZNZPKVQURDQFFS-FXQIFTODSA-N 0.000 description 1
- HMIXCETWRYDVMO-GUBZILKMSA-N Gln-Pro-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O HMIXCETWRYDVMO-GUBZILKMSA-N 0.000 description 1
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 1
- XQDGOJPVMSWZSO-SRVKXCTJSA-N Gln-Pro-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)N)N XQDGOJPVMSWZSO-SRVKXCTJSA-N 0.000 description 1
- RDDSZZJOKDVPAE-ACZMJKKPSA-N Glu-Asn-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RDDSZZJOKDVPAE-ACZMJKKPSA-N 0.000 description 1
- VAIWPXWHWAPYDF-FXQIFTODSA-N Glu-Asp-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O VAIWPXWHWAPYDF-FXQIFTODSA-N 0.000 description 1
- IQACOVZVOMVILH-FXQIFTODSA-N Glu-Glu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O IQACOVZVOMVILH-FXQIFTODSA-N 0.000 description 1
- VGUYMZGLJUJRBV-YVNDNENWSA-N Glu-Ile-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O VGUYMZGLJUJRBV-YVNDNENWSA-N 0.000 description 1
- MWMJCGBSIORNCD-AVGNSLFASA-N Glu-Leu-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O MWMJCGBSIORNCD-AVGNSLFASA-N 0.000 description 1
- YHOJJFFTSMWVGR-HJGDQZAQSA-N Glu-Met-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YHOJJFFTSMWVGR-HJGDQZAQSA-N 0.000 description 1
- AAJHGGDRKHYSDH-GUBZILKMSA-N Glu-Pro-Gln Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O AAJHGGDRKHYSDH-GUBZILKMSA-N 0.000 description 1
- BFEZQZKEPRKKHV-SRVKXCTJSA-N Glu-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H](CCCCN)C(=O)O BFEZQZKEPRKKHV-SRVKXCTJSA-N 0.000 description 1
- NNQDRRUXFJYCCJ-NHCYSSNCSA-N Glu-Pro-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O NNQDRRUXFJYCCJ-NHCYSSNCSA-N 0.000 description 1
- MWTGQXBHVRTCOR-GLLZPBPUSA-N Glu-Thr-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MWTGQXBHVRTCOR-GLLZPBPUSA-N 0.000 description 1
- ZALGPUWUVHOGAE-GVXVVHGQSA-N Glu-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZALGPUWUVHOGAE-GVXVVHGQSA-N 0.000 description 1
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- MFVQGXGQRIXBPK-WDSKDSINSA-N Gly-Ala-Glu Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O MFVQGXGQRIXBPK-WDSKDSINSA-N 0.000 description 1
- PYUCNHJQQVSPGN-BQBZGAKWSA-N Gly-Arg-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN)CN=C(N)N PYUCNHJQQVSPGN-BQBZGAKWSA-N 0.000 description 1
- KRRMJKMGWWXWDW-STQMWFEESA-N Gly-Arg-Phe Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KRRMJKMGWWXWDW-STQMWFEESA-N 0.000 description 1
- GWCRIHNSVMOBEQ-BQBZGAKWSA-N Gly-Arg-Ser Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O GWCRIHNSVMOBEQ-BQBZGAKWSA-N 0.000 description 1
- XCLCVBYNGXEVDU-WHFBIAKZSA-N Gly-Asn-Ser Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O XCLCVBYNGXEVDU-WHFBIAKZSA-N 0.000 description 1
- IWAXHBCACVWNHT-BQBZGAKWSA-N Gly-Asp-Arg Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IWAXHBCACVWNHT-BQBZGAKWSA-N 0.000 description 1
- JLJLBWDKDRYOPA-RYUDHWBXSA-N Gly-Gln-Tyr Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 JLJLBWDKDRYOPA-RYUDHWBXSA-N 0.000 description 1
- FSPVILZGHUJOHS-QWRGUYRKSA-N Gly-His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CNC=N1 FSPVILZGHUJOHS-QWRGUYRKSA-N 0.000 description 1
- ITZOBNKQDZEOCE-NHCYSSNCSA-N Gly-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)CN ITZOBNKQDZEOCE-NHCYSSNCSA-N 0.000 description 1
- 108010009504 Gly-Phe-Leu-Gly Chemical group 0.000 description 1
- IEGFSKKANYKBDU-QWHCGFSZSA-N Gly-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)CN)C(=O)O IEGFSKKANYKBDU-QWHCGFSZSA-N 0.000 description 1
- JJGBXTYGTKWGAT-YUMQZZPRSA-N Gly-Pro-Glu Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O JJGBXTYGTKWGAT-YUMQZZPRSA-N 0.000 description 1
- HAOUOFNNJJLVNS-BQBZGAKWSA-N Gly-Pro-Ser Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O HAOUOFNNJJLVNS-BQBZGAKWSA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 1
- CUVBTVWFVIIDOC-YEPSODPASA-N Gly-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CN CUVBTVWFVIIDOC-YEPSODPASA-N 0.000 description 1
- GJHWILMUOANXTG-WPRPVWTQSA-N Gly-Val-Arg Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GJHWILMUOANXTG-WPRPVWTQSA-N 0.000 description 1
- FULZDMOZUZKGQU-ONGXEEELSA-N Gly-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)CN FULZDMOZUZKGQU-ONGXEEELSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 229940123011 Growth factor receptor antagonist Drugs 0.000 description 1
- 241000989913 Gunnera petaloidea Species 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- MPXGJGBXCRQQJE-MXAVVETBSA-N His-Ile-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O MPXGJGBXCRQQJE-MXAVVETBSA-N 0.000 description 1
- TVMNTHXFRSXZGR-IHRRRGAJSA-N His-Lys-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O TVMNTHXFRSXZGR-IHRRRGAJSA-N 0.000 description 1
- FHKZHRMERJUXRJ-DCAQKATOSA-N His-Ser-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 FHKZHRMERJUXRJ-DCAQKATOSA-N 0.000 description 1
- 108091006054 His-tagged proteins Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000608769 Homo sapiens Galectin-8 Proteins 0.000 description 1
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 238000012450 HuMAb Mouse Methods 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- NKVZTQVGUNLLQW-JBDRJPRFSA-N Ile-Ala-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)O)N NKVZTQVGUNLLQW-JBDRJPRFSA-N 0.000 description 1
- HLYBGMZJVDHJEO-CYDGBPFRSA-N Ile-Arg-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N HLYBGMZJVDHJEO-CYDGBPFRSA-N 0.000 description 1
- FVEWRQXNISSYFO-ZPFDUUQYSA-N Ile-Arg-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N FVEWRQXNISSYFO-ZPFDUUQYSA-N 0.000 description 1
- NZGTYCMLUGYMCV-XUXIUFHCSA-N Ile-Lys-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N NZGTYCMLUGYMCV-XUXIUFHCSA-N 0.000 description 1
- PNTWNAXGBOZMBO-MNXVOIDGSA-N Ile-Lys-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N PNTWNAXGBOZMBO-MNXVOIDGSA-N 0.000 description 1
- QQFSKBMCAKWHLG-UHFFFAOYSA-N Ile-Phe-Pro-Pro Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(NC(=O)C(N)C(C)CC)CC1=CC=CC=C1 QQFSKBMCAKWHLG-UHFFFAOYSA-N 0.000 description 1
- ZLFNNVATRMCAKN-ZKWXMUAHSA-N Ile-Ser-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N ZLFNNVATRMCAKN-ZKWXMUAHSA-N 0.000 description 1
- DTPGSUQHUMELQB-GVARAGBVSA-N Ile-Tyr-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=C(O)C=C1 DTPGSUQHUMELQB-GVARAGBVSA-N 0.000 description 1
- NXRNRBOKDBIVKQ-CXTHYWKRSA-N Ile-Tyr-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N NXRNRBOKDBIVKQ-CXTHYWKRSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical group C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- DBVWMYGBVFCRBE-CIUDSAMLSA-N Leu-Asn-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O DBVWMYGBVFCRBE-CIUDSAMLSA-N 0.000 description 1
- ULXYQAJWJGLCNR-YUMQZZPRSA-N Leu-Asp-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O ULXYQAJWJGLCNR-YUMQZZPRSA-N 0.000 description 1
- MMEDVBWCMGRKKC-GARJFASQSA-N Leu-Asp-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N MMEDVBWCMGRKKC-GARJFASQSA-N 0.000 description 1
- HFBCHNRFRYLZNV-GUBZILKMSA-N Leu-Glu-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HFBCHNRFRYLZNV-GUBZILKMSA-N 0.000 description 1
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 1
- VWHGTYCRDRBSFI-ZETCQYMHSA-N Leu-Gly-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 1
- BKTXKJMNTSMJDQ-AVGNSLFASA-N Leu-His-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N BKTXKJMNTSMJDQ-AVGNSLFASA-N 0.000 description 1
- UBZGNBKMIJHOHL-BZSNNMDCSA-N Leu-Leu-Phe Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 UBZGNBKMIJHOHL-BZSNNMDCSA-N 0.000 description 1
- RZXLZBIUTDQHJQ-SRVKXCTJSA-N Leu-Lys-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O RZXLZBIUTDQHJQ-SRVKXCTJSA-N 0.000 description 1
- VCHVSKNMTXWIIP-SRVKXCTJSA-N Leu-Lys-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O VCHVSKNMTXWIIP-SRVKXCTJSA-N 0.000 description 1
- AUNMOHYWTAPQLA-XUXIUFHCSA-N Leu-Met-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AUNMOHYWTAPQLA-XUXIUFHCSA-N 0.000 description 1
- WMIOEVKKYIMVKI-DCAQKATOSA-N Leu-Pro-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WMIOEVKKYIMVKI-DCAQKATOSA-N 0.000 description 1
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 1
- LINKCQUOMUDLKN-KATARQTJSA-N Leu-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)N)O LINKCQUOMUDLKN-KATARQTJSA-N 0.000 description 1
- MVJRBCJCRYGCKV-GVXVVHGQSA-N Leu-Val-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MVJRBCJCRYGCKV-GVXVVHGQSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- NTSPQIONFJUMJV-AVGNSLFASA-N Lys-Arg-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O NTSPQIONFJUMJV-AVGNSLFASA-N 0.000 description 1
- YKIRNDPUWONXQN-GUBZILKMSA-N Lys-Asn-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N YKIRNDPUWONXQN-GUBZILKMSA-N 0.000 description 1
- KWUKZRFFKPLUPE-HJGDQZAQSA-N Lys-Asp-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWUKZRFFKPLUPE-HJGDQZAQSA-N 0.000 description 1
- SSYOBDBNBQBSQE-SRVKXCTJSA-N Lys-Cys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O SSYOBDBNBQBSQE-SRVKXCTJSA-N 0.000 description 1
- XNKDCYABMBBEKN-IUCAKERBSA-N Lys-Gly-Gln Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O XNKDCYABMBBEKN-IUCAKERBSA-N 0.000 description 1
- ISHNZELVUVPCHY-ZETCQYMHSA-N Lys-Gly-Gly Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O ISHNZELVUVPCHY-ZETCQYMHSA-N 0.000 description 1
- GQFDWEDHOQRNLC-QWRGUYRKSA-N Lys-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN GQFDWEDHOQRNLC-QWRGUYRKSA-N 0.000 description 1
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 1
- LNMKRJJLEFASGA-BZSNNMDCSA-N Lys-Phe-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O LNMKRJJLEFASGA-BZSNNMDCSA-N 0.000 description 1
- MIFFFXHMAHFACR-KATARQTJSA-N Lys-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN MIFFFXHMAHFACR-KATARQTJSA-N 0.000 description 1
- CAVRAQIDHUPECU-UVOCVTCTSA-N Lys-Thr-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAVRAQIDHUPECU-UVOCVTCTSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- KMSMNUFBNCHMII-IHRRRGAJSA-N Met-Leu-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN KMSMNUFBNCHMII-IHRRRGAJSA-N 0.000 description 1
- KLGIQJRMFHIGCQ-ZFWWWQNUSA-N Met-Trp-Gly Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CCSC)C(=O)NCC(O)=O)=CNC2=C1 KLGIQJRMFHIGCQ-ZFWWWQNUSA-N 0.000 description 1
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 101710043865 Nectin-4 Proteins 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 108010042309 Netropsin Proteins 0.000 description 1
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 241000192656 Nostoc Species 0.000 description 1
- CVMOPKROILOZFI-UHFFFAOYSA-N O=S(=O)=Cl Chemical compound O=S(=O)=Cl CVMOPKROILOZFI-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101100081884 Oryza sativa subsp. japonica OSA15 gene Proteins 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 101150082245 PSAG gene Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- BWTKUQPNOMMKMA-FIRPJDEBSA-N Phe-Ile-Phe Chemical compound C([C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 BWTKUQPNOMMKMA-FIRPJDEBSA-N 0.000 description 1
- RFCVXVPWSPOMFJ-STQMWFEESA-N Phe-Leu Chemical group CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 RFCVXVPWSPOMFJ-STQMWFEESA-N 0.000 description 1
- KNYPNEYICHHLQL-ACRUOGEOSA-N Phe-Leu-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 KNYPNEYICHHLQL-ACRUOGEOSA-N 0.000 description 1
- ZIQQNOXKEFDPBE-BZSNNMDCSA-N Phe-Lys-His Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N ZIQQNOXKEFDPBE-BZSNNMDCSA-N 0.000 description 1
- BPIMVBKDLSBKIJ-FCLVOEFKSA-N Phe-Thr-Phe Chemical compound C([C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 BPIMVBKDLSBKIJ-FCLVOEFKSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 240000007643 Phytolacca americana Species 0.000 description 1
- 235000009074 Phytolacca americana Nutrition 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- SSSFPISOZOLQNP-GUBZILKMSA-N Pro-Arg-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O SSSFPISOZOLQNP-GUBZILKMSA-N 0.000 description 1
- LHALYDBUDCWMDY-CIUDSAMLSA-N Pro-Glu-Ala Chemical compound C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1)C(O)=O LHALYDBUDCWMDY-CIUDSAMLSA-N 0.000 description 1
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 1
- NXEYSLRNNPWCRN-SRVKXCTJSA-N Pro-Glu-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NXEYSLRNNPWCRN-SRVKXCTJSA-N 0.000 description 1
- KWMUAKQOVYCQJQ-ZPFDUUQYSA-N Pro-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@@H]1CCCN1 KWMUAKQOVYCQJQ-ZPFDUUQYSA-N 0.000 description 1
- ULWBBFKQBDNGOY-RWMBFGLXSA-N Pro-Lys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)O ULWBBFKQBDNGOY-RWMBFGLXSA-N 0.000 description 1
- KBUAPZAZPWNYSW-SRVKXCTJSA-N Pro-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KBUAPZAZPWNYSW-SRVKXCTJSA-N 0.000 description 1
- JDJMFMVVJHLWDP-UNQGMJICSA-N Pro-Thr-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JDJMFMVVJHLWDP-UNQGMJICSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- UEJYSALTSUZXFV-SRVKXCTJSA-N Rigin Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O UEJYSALTSUZXFV-SRVKXCTJSA-N 0.000 description 1
- BTKUIVBNGBFTTP-WHFBIAKZSA-N Ser-Ala-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(O)=O BTKUIVBNGBFTTP-WHFBIAKZSA-N 0.000 description 1
- FCRMLGJMPXCAHD-FXQIFTODSA-N Ser-Arg-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O FCRMLGJMPXCAHD-FXQIFTODSA-N 0.000 description 1
- YUSRGTQIPCJNHQ-CIUDSAMLSA-N Ser-Arg-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O YUSRGTQIPCJNHQ-CIUDSAMLSA-N 0.000 description 1
- ZXLUWXWISXIFIX-ACZMJKKPSA-N Ser-Asn-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZXLUWXWISXIFIX-ACZMJKKPSA-N 0.000 description 1
- BGOWRLSWJCVYAQ-CIUDSAMLSA-N Ser-Asp-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BGOWRLSWJCVYAQ-CIUDSAMLSA-N 0.000 description 1
- SWSRFJZZMNLMLY-ZKWXMUAHSA-N Ser-Asp-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O SWSRFJZZMNLMLY-ZKWXMUAHSA-N 0.000 description 1
- KCFKKAQKRZBWJB-ZLUOBGJFSA-N Ser-Cys-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O KCFKKAQKRZBWJB-ZLUOBGJFSA-N 0.000 description 1
- KNCJWSPMTFFJII-ZLUOBGJFSA-N Ser-Cys-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(O)=O KNCJWSPMTFFJII-ZLUOBGJFSA-N 0.000 description 1
- MOVJSUIKUNCVMG-ZLUOBGJFSA-N Ser-Cys-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O)N)O MOVJSUIKUNCVMG-ZLUOBGJFSA-N 0.000 description 1
- BQWCDDAISCPDQV-XHNCKOQMSA-N Ser-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N)C(=O)O BQWCDDAISCPDQV-XHNCKOQMSA-N 0.000 description 1
- HMRAQFJFTOLDKW-GUBZILKMSA-N Ser-His-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O HMRAQFJFTOLDKW-GUBZILKMSA-N 0.000 description 1
- YIUWWXVTYLANCJ-NAKRPEOUSA-N Ser-Ile-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O YIUWWXVTYLANCJ-NAKRPEOUSA-N 0.000 description 1
- UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 description 1
- XUDRHBPSPAPDJP-SRVKXCTJSA-N Ser-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO XUDRHBPSPAPDJP-SRVKXCTJSA-N 0.000 description 1
- GDUZTEQRAOXYJS-SRVKXCTJSA-N Ser-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GDUZTEQRAOXYJS-SRVKXCTJSA-N 0.000 description 1
- XVWDJUROVRQKAE-KKUMJFAQSA-N Ser-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CC=CC=C1 XVWDJUROVRQKAE-KKUMJFAQSA-N 0.000 description 1
- FBLNYDYPCLFTSP-IXOXFDKPSA-N Ser-Phe-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FBLNYDYPCLFTSP-IXOXFDKPSA-N 0.000 description 1
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 1
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 1
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 1
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 1
- CUXJENOFJXOSOZ-BIIVOSGPSA-N Ser-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CO)N)C(=O)O CUXJENOFJXOSOZ-BIIVOSGPSA-N 0.000 description 1
- FLMYSKVSDVHLEW-SVSWQMSJSA-N Ser-Thr-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FLMYSKVSDVHLEW-SVSWQMSJSA-N 0.000 description 1
- PCJLFYBAQZQOFE-KATARQTJSA-N Ser-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N)O PCJLFYBAQZQOFE-KATARQTJSA-N 0.000 description 1
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 1
- HSWXBJCBYSWBPT-GUBZILKMSA-N Ser-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(O)=O HSWXBJCBYSWBPT-GUBZILKMSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- IGROJMCBGRFRGI-YTLHQDLWSA-N Thr-Ala-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O IGROJMCBGRFRGI-YTLHQDLWSA-N 0.000 description 1
- XSLXHSYIVPGEER-KZVJFYERSA-N Thr-Ala-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XSLXHSYIVPGEER-KZVJFYERSA-N 0.000 description 1
- UKBSDLHIKIXJKH-HJGDQZAQSA-N Thr-Arg-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UKBSDLHIKIXJKH-HJGDQZAQSA-N 0.000 description 1
- VFEHSAJCWWHDBH-RHYQMDGZSA-N Thr-Arg-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O VFEHSAJCWWHDBH-RHYQMDGZSA-N 0.000 description 1
- LAFLAXHTDVNVEL-WDCWCFNPSA-N Thr-Gln-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O LAFLAXHTDVNVEL-WDCWCFNPSA-N 0.000 description 1
- KGKWKSSSQGGYAU-SUSMZKCASA-N Thr-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KGKWKSSSQGGYAU-SUSMZKCASA-N 0.000 description 1
- LHEZGZQRLDBSRR-WDCWCFNPSA-N Thr-Glu-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LHEZGZQRLDBSRR-WDCWCFNPSA-N 0.000 description 1
- WBCCCPZIJIJTSD-TUBUOCAGSA-N Thr-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H]([C@@H](C)O)N WBCCCPZIJIJTSD-TUBUOCAGSA-N 0.000 description 1
- AMXMBCAXAZUCFA-RHYQMDGZSA-N Thr-Leu-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AMXMBCAXAZUCFA-RHYQMDGZSA-N 0.000 description 1
- RFKVQLIXNVEOMB-WEDXCCLWSA-N Thr-Leu-Gly Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N)O RFKVQLIXNVEOMB-WEDXCCLWSA-N 0.000 description 1
- JMBRNXUOLJFURW-BEAPCOKYSA-N Thr-Phe-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N)O JMBRNXUOLJFURW-BEAPCOKYSA-N 0.000 description 1
- ZMYCLHFLHRVOEA-HEIBUPTGSA-N Thr-Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ZMYCLHFLHRVOEA-HEIBUPTGSA-N 0.000 description 1
- LECUEEHKUFYOOV-ZJDVBMNYSA-N Thr-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](N)[C@@H](C)O LECUEEHKUFYOOV-ZJDVBMNYSA-N 0.000 description 1
- RPECVQBNONKZAT-WZLNRYEVSA-N Thr-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H]([C@@H](C)O)N RPECVQBNONKZAT-WZLNRYEVSA-N 0.000 description 1
- OGOYMQWIWHGTGH-KZVJFYERSA-N Thr-Val-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O OGOYMQWIWHGTGH-KZVJFYERSA-N 0.000 description 1
- XGFYGMKZKFRGAI-RCWTZXSCSA-N Thr-Val-Arg Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N XGFYGMKZKFRGAI-RCWTZXSCSA-N 0.000 description 1
- FYBFTPLPAXZBOY-KKHAAJSZSA-N Thr-Val-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O FYBFTPLPAXZBOY-KKHAAJSZSA-N 0.000 description 1
- QNXZCKMXHPULME-ZNSHCXBVSA-N Thr-Val-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O QNXZCKMXHPULME-ZNSHCXBVSA-N 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 description 1
- CXPJPTFWKXNDKV-NUTKFTJISA-N Trp-Leu-Ala Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O)=CNC2=C1 CXPJPTFWKXNDKV-NUTKFTJISA-N 0.000 description 1
- 108010070096 Trp-Leu-Leu-Leu-Leu-Leu Proteins 0.000 description 1
- QHWMVGCEQAPQDK-UMPQAUOISA-N Trp-Thr-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N)O QHWMVGCEQAPQDK-UMPQAUOISA-N 0.000 description 1
- SSSDKJMQMZTMJP-BVSLBCMMSA-N Trp-Tyr-Val Chemical compound C([C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CC=C(O)C=C1 SSSDKJMQMZTMJP-BVSLBCMMSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- BURPTJBFWIOHEY-UWJYBYFXSA-N Tyr-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BURPTJBFWIOHEY-UWJYBYFXSA-N 0.000 description 1
- QJBWZNTWJSZUOY-UWJYBYFXSA-N Tyr-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QJBWZNTWJSZUOY-UWJYBYFXSA-N 0.000 description 1
- HVHJYXDXRIWELT-RYUDHWBXSA-N Tyr-Glu-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O HVHJYXDXRIWELT-RYUDHWBXSA-N 0.000 description 1
- SLCSPPCQWUHPPO-JYJNAYRXSA-N Tyr-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 SLCSPPCQWUHPPO-JYJNAYRXSA-N 0.000 description 1
- WURLIFOWSMBUAR-SLFFLAALSA-N Tyr-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)C(=O)O WURLIFOWSMBUAR-SLFFLAALSA-N 0.000 description 1
- YYLHVUCSTXXKBS-IHRRRGAJSA-N Tyr-Pro-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O YYLHVUCSTXXKBS-IHRRRGAJSA-N 0.000 description 1
- LUMQYLVYUIRHHU-YJRXYDGGSA-N Tyr-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LUMQYLVYUIRHHU-YJRXYDGGSA-N 0.000 description 1
- MWUYSCVVPVITMW-IGNZVWTISA-N Tyr-Tyr-Ala Chemical compound C([C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 MWUYSCVVPVITMW-IGNZVWTISA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- JIODCDXKCJRMEH-NHCYSSNCSA-N Val-Arg-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N JIODCDXKCJRMEH-NHCYSSNCSA-N 0.000 description 1
- COYSIHFOCOMGCF-WPRPVWTQSA-N Val-Arg-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCN=C(N)N COYSIHFOCOMGCF-WPRPVWTQSA-N 0.000 description 1
- COYSIHFOCOMGCF-UHFFFAOYSA-N Val-Arg-Gly Natural products CC(C)C(N)C(=O)NC(C(=O)NCC(O)=O)CCCN=C(N)N COYSIHFOCOMGCF-UHFFFAOYSA-N 0.000 description 1
- YLHLNFUXDBOAGX-DCAQKATOSA-N Val-Cys-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N YLHLNFUXDBOAGX-DCAQKATOSA-N 0.000 description 1
- LHADRQBREKTRLR-DCAQKATOSA-N Val-Cys-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)N LHADRQBREKTRLR-DCAQKATOSA-N 0.000 description 1
- OQWNEUXPKHIEJO-NRPADANISA-N Val-Glu-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N OQWNEUXPKHIEJO-NRPADANISA-N 0.000 description 1
- RKIGNDAHUOOIMJ-BQFCYCMXSA-N Val-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 RKIGNDAHUOOIMJ-BQFCYCMXSA-N 0.000 description 1
- XXROXFHCMVXETG-UWVGGRQHSA-N Val-Gly-Val Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXROXFHCMVXETG-UWVGGRQHSA-N 0.000 description 1
- CPGJELLYDQEDRK-NAKRPEOUSA-N Val-Ile-Ala Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](C)C(O)=O CPGJELLYDQEDRK-NAKRPEOUSA-N 0.000 description 1
- HGJRMXOWUWVUOA-GVXVVHGQSA-N Val-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N HGJRMXOWUWVUOA-GVXVVHGQSA-N 0.000 description 1
- SBJCTAZFSZXWSR-AVGNSLFASA-N Val-Met-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N SBJCTAZFSZXWSR-AVGNSLFASA-N 0.000 description 1
- HJSLDXZAZGFPDK-ULQDDVLXSA-N Val-Phe-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)N HJSLDXZAZGFPDK-ULQDDVLXSA-N 0.000 description 1
- KSFXWENSJABBFI-ZKWXMUAHSA-N Val-Ser-Asn Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KSFXWENSJABBFI-ZKWXMUAHSA-N 0.000 description 1
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 1
- GVNLOVJNNDZUHS-RHYQMDGZSA-N Val-Thr-Lys Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O GVNLOVJNNDZUHS-RHYQMDGZSA-N 0.000 description 1
- BGTDGENDNWGMDQ-KJEVXHAQSA-N Val-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N)O BGTDGENDNWGMDQ-KJEVXHAQSA-N 0.000 description 1
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 1
- AEFJNECXZCODJM-UWVGGRQHSA-N Val-Val-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C(=O)NCC([O-])=O AEFJNECXZCODJM-UWVGGRQHSA-N 0.000 description 1
- 240000001866 Vernicia fordii Species 0.000 description 1
- MVEJKKYETBXLAA-UHFFFAOYSA-N [1-fluoro-2-(1-fluoro-2-phenylmethoxypropan-2-yl)oxypropan-2-yl]oxymethylbenzene Chemical compound C=1C=CC=CC=1COC(C)(CF)OC(CF)(C)OCC1=CC=CC=C1 MVEJKKYETBXLAA-UHFFFAOYSA-N 0.000 description 1
- KWSUZUAUJVMRAE-UHFFFAOYSA-N [diethyl(propan-2-yl)silyl]oxy-diethyl-propan-2-ylsilane Chemical group CC[Si](CC)(C(C)C)O[Si](CC)(CC)C(C)C KWSUZUAUJVMRAE-UHFFFAOYSA-N 0.000 description 1
- KVLXXFQNLJRDCG-UHFFFAOYSA-N [dimethyl(phenyl)silyl]methoxymethoxymethoxymethyl-dimethyl-phenylsilane Chemical group C=1C=CC=CC=1[Si](C)(C)COCOCOC[Si](C)(C)C1=CC=CC=C1 KVLXXFQNLJRDCG-UHFFFAOYSA-N 0.000 description 1
- DSLOWNUUMZVCAC-UHFFFAOYSA-N [dimethyl(propan-2-yl)silyl]oxy-dimethyl-propan-2-ylsilane Chemical group CC(C)[Si](C)(C)O[Si](C)(C)C(C)C DSLOWNUUMZVCAC-UHFFFAOYSA-N 0.000 description 1
- 238000010317 ablation therapy Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Chemical group CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000005910 alkyl carbonate group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 108010001818 alpha-sarcin Proteins 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 229940045696 antineoplastic drug podophyllotoxin derivative Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 108010010430 asparagine-proline-alanine Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 108010056028 auromycin Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- LJWBIAMZBJWAOW-UHFFFAOYSA-N benzhydryloxysilane Chemical group C=1C=CC=CC=1C(O[SiH3])C1=CC=CC=C1 LJWBIAMZBJWAOW-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical group OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000004305 biphenyl Chemical class 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000000339 bright-field microscopy Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 150000001656 butanoic acid esters Chemical class 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 229950007296 cantuzumab mertansine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229940097647 casodex Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical group [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 1
- 229940089960 chloroacetate Drugs 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- GICLSALZHXCILJ-UHFFFAOYSA-N ctk5a5089 Chemical compound NCC(O)=O.NCC(O)=O GICLSALZHXCILJ-UHFFFAOYSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000009799 cystectomy Methods 0.000 description 1
- 108010060199 cysteinylproline Proteins 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 229940119679 deoxyribonucleases Drugs 0.000 description 1
- 150000001975 deuterium Chemical class 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229930191339 dianthin Natural products 0.000 description 1
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical class CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical group C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 229940120124 dichloroacetate Drugs 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical group OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 108010045524 dolastatin 10 Proteins 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003118 drug derivative Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- XOPYFXBZMVTEJF-PDACKIITSA-N eleutherobin Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 description 1
- XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 108010028531 enomycin Proteins 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- LJQQFQHBKUKHIS-WJHRIEJJSA-N esperamicin Chemical compound O1CC(NC(C)C)C(OC)CC1OC1C(O)C(NOC2OC(C)C(SC)C(O)C2)C(C)OC1OC1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)C(OC3OC(C)C(O)C(OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)C3)C2(O)C#C\C=C/C#C1 LJQQFQHBKUKHIS-WJHRIEJJSA-N 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000003168 generic drug Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical class N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 108010013768 glutamyl-aspartyl-proline Proteins 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 108010079547 glutamylmethionine Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 108010084389 glycyltryptophan Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical group C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- LOBVCQUMXHOALK-UHFFFAOYSA-N hexyl-[hexyl(dimethyl)silyl]oxy-dimethylsilane Chemical group CCCCCC[Si](C)(C)O[Si](C)(C)CCCCCC LOBVCQUMXHOALK-UHFFFAOYSA-N 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-M hydrosulfide Chemical compound [SH-] RWSOTUBLDIXVET-UHFFFAOYSA-M 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical group C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229940055742 indium-111 Drugs 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Chemical group CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Chemical group C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000004926 indolenyl group Chemical group 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000004936 isatinoyl group Chemical group N1(C(=O)C(=O)C2=CC=CC=C12)C(=O)* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 108010027338 isoleucylcysteine Proteins 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- RMIODHQZRUFFFF-UHFFFAOYSA-M methoxyacetate Chemical group COCC([O-])=O RMIODHQZRUFFFF-UHFFFAOYSA-M 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- CPZBTYRIGVOOMI-UHFFFAOYSA-N methylsulfanyl(methylsulfanylmethoxy)methane Chemical group CSCOCSC CPZBTYRIGVOOMI-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- ZDZOTLJHXYCWBA-BSEPLHNVSA-N molport-006-823-826 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-BSEPLHNVSA-N 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- NHWKHNPRDPAXLM-UHFFFAOYSA-N n-(2-aminoethyl)benzamide Chemical compound NCCNC(=O)C1=CC=CC=C1 NHWKHNPRDPAXLM-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- OWIUPIRUAQMTTK-UHFFFAOYSA-M n-aminocarbamate Chemical compound NNC([O-])=O OWIUPIRUAQMTTK-UHFFFAOYSA-M 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007524 negative regulation of DNA replication Effects 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- 229940085033 nolvadex Drugs 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 1
- WXVUCMFEGJUVTN-UHFFFAOYSA-N phenyl methanesulfonate Chemical compound CS(=O)(=O)OC1=CC=CC=C1 WXVUCMFEGJUVTN-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical group OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 108010073101 phenylalanylleucine Proteins 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- FAQJJMHZNSSFSM-UHFFFAOYSA-N phenylglyoxylic acid Chemical group OC(=O)C(=O)C1=CC=CC=C1 FAQJJMHZNSSFSM-UHFFFAOYSA-N 0.000 description 1
- 125000006245 phosphate protecting group Chemical group 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical class COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 239000003600 podophyllotoxin derivative Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108010014614 prolyl-glycyl-proline Proteins 0.000 description 1
- RXZQNZROTOXEFG-UHFFFAOYSA-N prop-1-ene-1,2,3-tricarboxamide Chemical compound NC(=O)CC(C(N)=O)=CC(N)=O RXZQNZROTOXEFG-UHFFFAOYSA-N 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000011471 prostatectomy Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001273 protein sequence alignment Methods 0.000 description 1
- 239000001990 protein-drug conjugate Substances 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000649 purine antagonist Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical group C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 description 1
- 125000004942 pyridazin-6-yl group Chemical group N1=NC=CC=C1* 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000005494 pyridonyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 1
- 238000009801 radical cystectomy Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 102220011812 rs141140415 Human genes 0.000 description 1
- 102220011819 rs143985153 Human genes 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 150000007659 semicarbazones Chemical class 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 108010007375 seryl-seryl-seryl-arginine Proteins 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000000547 structure data Methods 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical group CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Chemical group 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 1
- RUELTTOHQODFPA-UHFFFAOYSA-N toluene 2,6-diisocyanate Chemical compound CC1=C(N=C=O)C=CC=C1N=C=O RUELTTOHQODFPA-UHFFFAOYSA-N 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 230000007888 toxin activity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical group OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- LZAJKCZTKKKZNT-PMNGPLLRSA-N trichothecene Chemical compound C12([C@@]3(CC[C@H]2OC2C=C(CCC23C)C)C)CO1 LZAJKCZTKKKZNT-PMNGPLLRSA-N 0.000 description 1
- 229930013292 trichothecene Natural products 0.000 description 1
- WILBTFWIBAOWLN-UHFFFAOYSA-N triethyl(triethylsilyloxy)silane Chemical group CC[Si](CC)(CC)O[Si](CC)(CC)CC WILBTFWIBAOWLN-UHFFFAOYSA-N 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- QWEJGTIVESCYNM-UHFFFAOYSA-N trimethyl-[2-(2-trimethylsilylethoxymethoxymethoxy)ethyl]silane Chemical compound C[Si](C)(C)CCOCOCOCC[Si](C)(C)C QWEJGTIVESCYNM-UHFFFAOYSA-N 0.000 description 1
- DOMWIMKGCFOHBG-UHFFFAOYSA-N trimethyl-[2-[1-[1-(2-trimethylsilylethoxy)ethoxy]ethoxy]ethyl]silane Chemical compound C[Si](C)(C)CCOC(C)OC(C)OCC[Si](C)(C)C DOMWIMKGCFOHBG-UHFFFAOYSA-N 0.000 description 1
- KHQZLUVCZCAMFU-UHFFFAOYSA-N tripropyl(tripropylsilyloxy)silane Chemical group CCC[Si](CCC)(CCC)O[Si](CCC)(CCC)CCC KHQZLUVCZCAMFU-UHFFFAOYSA-N 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 239000002383 tung oil Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000009808 unilateral salpingo-oophorectomy Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 108010009962 valyltyrosine Proteins 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- ABDKAPXRBAPSQN-UHFFFAOYSA-N veratrole Chemical compound COC1=CC=CC=C1OC ABDKAPXRBAPSQN-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-OUBTZVSYSA-N water-17o Chemical compound [17OH2] XLYOFNOQVPJJNP-OUBTZVSYSA-N 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
- 125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本發明提供與191P4D12蛋白及其變異體結合之抗體藥物共軛物(antibody drug conjugate,ADC)。191P4D12在正常成人組織中展現組織特異性表現,且在表I中所列之癌症中異常地表現。因此,本發明之ADC提供一種用於治療癌症之治療性組合物。
Description
本文所述之本發明係關於結合稱為191P4D12之蛋白質的抗體、其結合片段及抗體藥物共軛物(ADC)。本發明此外係關於適用於治療表現191P4D12之癌症的預後、預防及治療方法及組合物。
相關申請案的交叉引用
本申請案為非臨時專利申請案,其主張2010年9月29日申請之美國臨時專利申請案第61/387,933號的優先權。此段落中所列之每一申請案的內容全部以引用的方式併入本文中。
根據聯邦政府資助研究所作之本發明之權利聲明不適用。
癌症係僅次於冠脈疾病之第二大人類死亡原因。在全世界範圍內,每年有數百萬人死於癌症。僅在美國,據美國癌症學會(American Cancer Society)報導,每年死於癌症之人數遠遠超過五十萬,其中每年診斷出超過一百二十萬例新病例。雖然因心臟病所致之死亡已明顯減少,但癌症所致之死亡卻普遍上升。在下個世紀初,預計癌症將成為首要死亡原因。
在全世界範圍內,有數種癌症作為主要殺手而浮現出。詳言之,肺癌、前列腺癌、乳癌、結腸癌、胰腺癌、卵巢癌及膀胱癌代表主要癌症死亡原因。此等及幾乎所有其他癌瘤均具有共同的致命特點。除了極少數例外情況,癌症轉移性疾病為致命性的。此外,即使對於最初倖免於其原發性癌症之彼等癌症患者,共同經歷已顯示其壽命發生戲劇性的變化。許多癌症患者因知道可能會復發或治療失敗而經歷嚴重焦慮症。許多癌症患者在治療後身體衰弱。此外,許多癌症患者會復發。
在全世界範圍內,前列腺癌為男性第四大最常發生之癌症。在北美及北歐,迄今為止,其仍為男性最常見癌症且為男性第二大癌症死亡原因。僅在美國,每年死於此疾病之男性遠遠超過30,000人,僅次於肺癌。雖然此等數字龐大,但對於轉移性前列腺癌仍無有效的治療法。手術前列腺切除術、放射療法、激素切除療法、手術閹割及化學療法仍為主要治療形式。遺憾的是,此等治療對於許多人無效且往往會伴隨不良後果。
在診斷前沿,缺乏可準確偵測早期局部腫瘤之前列腺腫瘤標誌仍為此疾病之診斷及控制中的明顯侷限。儘管血清前列腺特異性抗原(PSA)檢定已成為十分有用的工具,但其特異性及一般效用普遍認為在數個重要方面欠缺。
在鑑別針對前列腺癌之其他特定標誌方面的進展已藉由產生可在小鼠中再現該疾病之不同階段的前列腺癌異種移植物有所改進。LAPC(洛杉磯前列腺癌,Los Angeles Prostate Cancer)異種移植物為如下前列腺癌異種移植物,其已在重度複合性免疫缺陷(severe combined immune deficient,SCID)小鼠體內繼代存活且已展現模擬自雄激素依賴性向雄激素獨立性轉變之能力(Klein等人1997, Nat. Med. 3:402)。近年來,已鑑別出之前列腺癌標誌包括PCTA-1(Su等人1996, Proc. Natl. Acad. Sci. USA 93: 7252)、前列腺特異性膜抗原(PSMA)(Pinto等人Clin Cancer Res 1996 Sep 2 (9): 1445-51)、STEAP(Hubert等人Proc Natl Acad Sci U S A. 1999 Dec 7; 96(25): 14523-8)及前列腺幹細胞抗原(PSCA)(Reiter等人1998, Proc. Natl. Acad. Sci. USA 95: 1735)。
雖然先前鑑別出之標誌(諸如PSA)已有助於試圖診斷及治療前列腺癌,但仍需要鑑別前列腺及相關癌症之其他標誌及治療性標靶以進一步改良診斷及療法。2000年在美國估計出現130,200例結腸直腸癌,包括93,800例結腸癌及36,400例直腸癌。
結腸直腸癌為男性及女性之第三大最常見癌症。在1992年-1996年期間,發病率明顯降低(每年降低2.1%)。研究顯示,此等降低係歸因於篩檢增多及息肉移除,從而預防息肉發展為侵入性癌症。2000年,估計有56,300例死亡(47,700例死於結腸癌、8,600例死於直腸癌),佔美國所有癌症死亡數之約11%。
目前,手術為結腸直腸癌之最常見治療形式,且對於尚未擴散之癌症而言,其通常有療效。對於癌症已深深穿透腸壁或已擴散至淋巴結之大部分患者,在手術之前或之後進行化學療法或化學療法加放射。結腸癌有時需要永久結腸造口術(在腹部造出開口以排出身體廢物)且直腸癌偶爾需要之。仍需要針對結腸直腸癌之有效診斷及治療形式。
在美國所有癌症新病例中,膀胱癌在男性中佔約5%(第五大最常見贅瘤)且在女性中佔3%(第八大最常見贅瘤)。隨著老年人口的增多,發病率緩慢上升。1998年,估計有54,500例,包括男性39,500例及女性15,000例。在美國,按年齡調整後之發病率為每100,000名男性中有32名及每100,000名女性中有8名。男性/女性之3:1歷史性比率可能不斷降低,此與女性吸菸行為有關。1998年,估計膀胱癌導致11,000例死亡(男性7,800例且女性3,900例)。膀胱癌發病率及死亡率隨年齡急劇上升且將因人口老齡化而逐漸成為問題。
大部分膀胱癌會在膀胱復發。用經尿道膀胱切除術(TUR)與膀胱內化學療法或免疫療法之組合來控制膀胱癌。膀胱癌之多灶及復發性質說明了TUR之侷限性。大部分肌肉侵入性癌症無法藉由單獨TUR來治癒。根治性膀胱切除術及尿流改道為除去癌症之最有效方法,但對泌尿功能及性功能具有不可否認的影響。仍亟需有益於膀胱癌患者之治療形式。
2000年,估計有164,100例肺及支氣管癌新病例,佔美國所有癌症診斷之14%。肺及支氣管癌之發病率在男性中明顯降低,自1984年每100,000名中有86.5名之高發病率降低至1996年之70.0名。在1990年代,女性增加速率開始減緩。1996年,女性發病率為每100,000名中有42.3名。
2000年,肺及支氣管癌估計導致156,900例死亡,佔所有癌症死亡數之28%。在1992年-1996年期間,肺癌死亡率在男性中明顯降低(每年降低1.7%),而女性死亡率仍顯著上升(每年上升0.9%)。自1987年以來,每年死於肺癌的女性比死於乳癌的女性要多,此為40多年來女性之主要癌症死亡原因。肺癌發病率及死亡率的降低很可能由前30年來吸菸率的降低引起;然而,女性吸菸行為的減少落後於男性。令人擔憂的是,雖然成人之菸草使用的降低已減緩,但青少年之菸草使用卻再次上升。
肺及支氣管癌之治療選擇方案係依據癌症之類型及階段來判定且包括手術、放射療法及化學療法。對於許多局部癌症,一般選擇手術治療。由於疾病到發現時一般已擴散,因此往往需要將放射療法及化學療法與手術結合。單獨化學療法或化學療法與放射之組合為選擇用於小細胞肺癌之治療;按照此療法,大部分患者經歷緩解,在一些情況下,此緩解為長久的。然而,不斷需要針對肺及支氣管癌之有效治療及診斷方法。
預期在2000年期間在美國女性中估計有182,800例侵入性乳癌新病例。另外,預期2000年在男性中診斷出約1,400例乳癌新病例。在1980年代每年增加約4%後,1990年代的女性乳癌發病率已平穩至每100,000名中有約110.6例。
僅在美國,2000年估計就有41,200例(女性40,800例、男性400例)死於乳癌。乳癌在女性癌症死亡中位居第二位。根據最新資料,在1992年-1996年期間,死亡率顯著降低,其中白人與黑人年輕女性的降幅最大。此等降低多半為早期偵測及改進治療之結果。
考慮到醫療環境及患者偏好,乳癌治療可包括乳房腫瘤切除術(局部移除腫瘤)及腋下淋巴結移除;乳房切除術(手術移除乳房)及腋下淋巴結移除;放射療法;化學療法;或激素療法。通常將兩種或兩種以上方法組合使用。許多研究已顯示,對於早期疾病,乳房腫瘤切除術加放射療法後之長期存活率類似於改良型根治性乳房切除術後之存活率。重建技術之顯著進步為乳房切除術後之乳房重建提供數種選擇方案。最近,該重建術已與乳房切除術同時進行。
具有足量周圍正常乳房組織之乳腺管原位癌(DCIS)之局部切除術可防止DCIS之局部復發。乳房放射及/或他莫昔芬(tamoxifen)可降低其餘乳房組織中DCIS之發生機率。此為重要的,原因在於若不治療,則DCIS會發展成侵入性乳癌。儘管如此,此等治療仍存在嚴重的副作用或後遺症。因此,需要有效的乳癌治療。
2000年在美國估計有23,100例的卵巢癌新病例。其佔所有女性癌症之4%且在婦科癌症中位居第二位。在1992年-1996年期間,卵巢癌發病率顯著降低。2000年估計有14,000例因卵巢癌而引起的死亡。卵巢癌引起之死亡數比女性生殖系統之任何其他癌症多。
手術、放射療法及化學療法為卵巢癌之治療選擇方案。手術一般包括移除一或兩個卵巢、輸卵管(輸卵管卵巢切除術)及子宮(子宮切除術)。在一些極早期腫瘤中,僅移除所涉及之卵巢,尤其在希望擁有孩子之年輕女性中。在晚期疾病中,設法移除所有腹內疾病以增強化學療法之效果。仍非常需要針對卵巢癌之有效治療選擇方案。
2000年在美國估計有28,300例胰臟癌新病例。在過去20年中,男性胰臟癌發病率已降低。女性胰臟癌發病率保持大致恆定,而且可能開始降低。2000年在美國估計胰腺癌導致28,200例死亡。在過去20年中,男性死亡率存在微小但明顯的降低(每年降低約0.9%),而女性死亡率略有上升。
手術、放射療法及化學療法為胰臟癌之治療選擇方案。此等治療選擇方案可延長許多患者之存活時間及/或減輕其症狀,但對於大部分患者而言,不大可能治癒。亟需針對癌症之其他治療及診斷選擇方案。此等選擇方案包括使用抗體、疫苗及小分子作為治療形式。另外,在癌症治療及研究之所有領域中,亦需要使用此等形式作為診斷、偵測、監測及促進先前技術之研究工具。
單株抗體(mAb)之治療效用(G. Kohler及C. Milstein, Nature 256:495-497 (1975))正在瞭解中。單株抗體現已獲准作為移植、癌症、感染性疾病、心血管疾病及炎症之療法。不同同型具有不同效應功能。該等功能差異反映在各種免疫球蛋白同型之不同三維結構上(P.M. Alzari等人Annual Rev. Immunol., 6:555-580 (1988))。
因為小鼠方便進行免疫接種且將大部分人類抗原識別為外來抗原,所以具有治療潛力之針對人類標靶的mAb通常來源於鼠類。然而,鼠類mAb作為人類治療劑具有固有缺陷。由於mAb在人體中具有比人類抗體短的循環半衰期,因此其需要更頻繁的給藥。更關鍵的是,將鼠類抗體重複投與人類免疫系統會引起人類免疫系統產生如下反應:將小鼠蛋白質識別為外來蛋白質且產生人類抗小鼠抗體(HAMA)反應。該HAMA反應可引起過敏反應及鼠類抗體自系統中快速清除,從而使鼠類抗體治療無用。為避免該等影響,已設法在小鼠體內形成人類免疫系統。
初始嘗試希望用具有人類序列之抗體產生能夠對抗原有反應之轉殖基因小鼠(參見Bruggemann等人Proc. Nat'l. Acad. Sci. USA 86:6709-6713 (1989)),但其受可由可用選殖運載工具穩定維持之DNA量的限制。酵母人工染色體(YAC)選殖載體之使用對於將人類Ig基因座之大生殖系片段引入轉殖基因哺乳動物體內起到導引作用。存在於人類基因組及人類恆定區中之以相同間距排列之大部分人類V、D及J區基因基本上係使用YAC引入小鼠體內。一種該轉殖基因小鼠品系稱為XenoMouse®小鼠且購自Amgen Fremont, Inc.(Fremont CA)。
本發明提供與191P4D12蛋白及191P4D12蛋白之多肽片段結合的抗體、其結合片段及抗體藥物共軛物(ADC)。在一些實施例中,本發明包含與治療劑共軛之全人類抗體。在某些實施例中,限制條件為不編碼圖3之整個核酸序列及/或不製備圖2之整個胺基酸序列。在某些實施例中,編碼圖3之整個核酸序列及/或製備圖2之整個胺基酸序列,兩者皆採用各別人類單位劑型。
本發明進一步提供各種免疫原性或治療性組合物,諸如抗體藥物共軛物,及治療表現191P4D12之癌症(諸如表I中所列之組織癌症)的策略。
章節大綱I.) 定義
II.) 191P4D12抗體
III.) 抗體藥物共軛物概述
III(A). 類美登素(maytansinoid)
III(B). 奧瑞他汀(auristatin)及海兔毒素(dolostatin)
III(C). 卡奇黴素(calicheamicin)
III(D). 其他細胞毒性劑
IV.) 結合191P4D12之抗體藥物共軛物
V.) 連接子單元
VI.) 延伸子單元
VII.) 胺基酸單元
VIII.) 間隔子單元
IX.) 藥物單元
X.) 藥物負載
XI.) 測定ADC之細胞毒性作用的方法
XII.) 治療表現191P4D12之癌症
XIII.) 作為基於抗體之療法的標靶之191P4D12
XIV.) 191P4D12 ADC混合物
XV.) 組合療法
XVI.) 套組/製品
I.) 定義:
除非另外定義,否則本文中所用之所有技術術語、註釋及其他科學術語意欲具有熟習本發明所屬技術者通常所瞭解之含義。在一些情況下,為清楚起見及/或供及時參考,具有通常所瞭解含義之術語如本文所定義,且本文包括該等定義應不必理解為表示與此項技術中一般所瞭解之定義相差很大。本文所述或所參考之許多技術及程序經充分瞭解且通常由熟習此項技術者使用習知方法來使用,例如Sambrook等人
Molecular Cloning: A Laboratory Manual第2版(1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.中所述之廣泛使用的分子選殖方法。除非另有說明,否則視情況,涉及使用市售套組及試劑之程序一般根據製造商指定之方案及/或參數來進行。
除非本文另有指示,否則當本文使用商品名稱時,對商品名稱之提及亦指產品調配物、通用藥物及商品名稱產品之活性醫藥成分。
術語「晚期癌症」、「局部晚期癌症」、「晚期疾病」及「局部晚期疾病」意謂已貫穿相關組織被膜之癌症,且意欲包括依據美國泌尿學學會(American Urological Association,AUA)系統之C期疾病;依據Whitmore-Jewett系統之C1-C2期疾病;及依據TNM(腫瘤、結節、轉移)系統之T3-T4期及N+疾病。一般而言,對於患有局部晚期疾病之患者不推薦手術,且與患有臨床上局部(侷限於器官)癌症之患者相比,此等患者具有實質上較不利之結果。
縮寫「AFP」係指二甲基纈胺酸-纈胺酸-多拉異白胺酸(dolaisoleuine)-多拉脯胺酸(dolaproine)-苯丙胺酸-對苯二胺(參見下文式XVI)。
縮寫「MMAE」係指單甲基奧瑞他汀E(monomethyl auristatin E)(參見下文式XI)。
縮寫「AEB」係指藉由使奧瑞他汀E與對乙醯基苯甲酸反應所產生之酯(參見下文式XX)。
縮寫「AEVB」係指藉由使奧瑞他汀E與苯甲醯基戊酸反應所產生之酯(參見下文式XXI)。
縮寫「MMAF」係指多纈胺酸(dovaline)-纈胺酸-多拉異白胺酸-多拉脯胺酸-苯丙胺酸(參見下文式XVIV)。
除非另外說明,否則術語「烷基」係指具有約1至約20個碳原子(及其中之碳原子範圍及特定數目之所有組合及子組合)、較佳約1至約8個碳原子之飽和直鏈或分支鏈烴。烷基之實例為甲基、乙基、正丙基、異丙基、正丁基、異丁基、第二丁基、第三丁基、正戊基、2-戊基、3-戊基、2-甲基-2-丁基、正己基、正庚基、正辛基、正壬基、正癸基、3-甲基-2-丁基、3-甲基-1-丁基、2-甲基-1-丁基、1-己基、2-己基、3-己基、2-甲基-2-戊基、3-甲基-2-戊基、4-甲基-2-戊基、3-甲基-3-戊基、2-甲基-3-戊基、2,3-二甲基-2-丁基及3,3-二甲基-2-丁基。
單獨或作為另一基團之一部分的伸烷基可視情況經一或多個基團、較佳1至3個基團(及選自鹵素之任何其他取代基)取代,該等基團包括(但不限於)-鹵素、-O-(C
1-C
8烷基)、-O-(C
2-C
8烯基)、-O-(C
2-C
8炔基)、-芳基、-C(O)R'、-OC(O)R'、-C(O)OR'、-C(O)NH
2、-C(O)NHR'、-C(O)N(R')
2、-NHC(O)R'、-SR'、-SO
3R'、-S(O)
2R'、-S(O)R'、-OH、=O、-N
3、-NH
2、-NH(R')、-N(R')
2及-CN,其中各R'係獨立地選自-H、-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基或-芳基,且其中該等-O-(C
1-C
8烷基)、-O-(C
2-C
8烯基)、-O-(C
2-C
8炔基)、-芳基、-C
1-C
8烷基、-C
2-C
8烯基及-C
2-C
8炔基可視情況進一步經一或多個基團取代,該等基團包括(但不限於)-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基、-鹵素、-O-(C
1-C
8烷基)、-O-(C
2-C
8烯基)、-O-(C
2-C
8炔基)、-芳基、-C(O)R''、-OC(O)R''、-C(O)OR''、-C(O)NH
2、-C(O)NHR''、-C(O)N(R'')
2、-NHC(O)R''、-SR''、-SO
3R''、-S(O)
2R''、-S(O)R''、-OH、-N
3、-NH
2、-NH(R'')、-N(R'')
2及-CN,其中各R''係獨立地選自-H、-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基或-芳基。
除非另外說明,否則術語「烯基」及「炔基」係指具有約2至約20個碳原子(及其中之碳原子範圍及特定數目之所有組合及子組合)、較佳約2至約8個碳原子之直鏈及分支鏈碳鏈。烯基鏈在鏈中具有至少一個雙鍵且炔基鏈在鏈中具有至少一個參鍵。烯基之實例包括(但不限於)乙烯(ethylene)或乙烯基、烯丙基、-1-丁烯基、-2-丁烯基、-異丁烯基、-1-戊烯基、-2-戊烯基、-3-甲基-1-丁烯基、-2-甲基-2-丁烯基及-2,3-二甲基-2-丁烯基。炔基之實例包括(但不限於)炔系(acetylenic)、炔丙基、乙炔基、丙炔基、-1-丁炔基、-2-丁炔基、-1-戊炔基、-2-戊炔基及-3-甲基-1丁炔基。
單獨或作為另一基團之一部分的烯基及炔基可視情況經一或多個基團、較佳1至3個基團(及選自鹵素之任何其他取代基)取代,該等基團包括(但不限於)-鹵素、-O-(C
1-C
8烷基)、-O-(C
2-C
8烯基)、-O-(C
2-C
8炔基)、-芳基、-C(O)R'、-OC(O)R'、-C(O)OR'、-C(O)NH
2、-C(O)NHR'、-C(O)N(R')
2、-NHC(O)R'、-SR'、-SO
3R'、-S(O)
2R'、-S(O)R'、-OH、=O、-N
3、-NH
2、-NH(R')、-N(R')
2及-CN,其中各R'係獨立地選自-H、-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基或-芳基,且其中該等-O-(C
1-C
8烷基)、-O-(C
2-C
8烯基)、-O-(C
2-C
8炔基)、-芳基、-C
1-C
8烷基、-C
2-C
8烯基及-C
2-C
8炔基可視情況進一步經一或多個取代基取代,該等取代基包括(但不限於)-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基、-鹵素、-O-(C
1-C
8烷基)、-O-(C
2-C
8烯基)、-O-(C
2C
8炔基)、-芳基、-C(O)R''、-OC(O)R''、-C(O)OR''、-C(O)NH
2、-C(O)NHR''、-C(O)N(R'')
2、-NHC(O)R''、-SR''、-SO
3R''、-S(O)
2R''、-S(O)R''、-OH、-N
3、-NH
2、-NH(R'')、-N(R'')
2及-CN,其中各R''係獨立地選自-H、-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基或-芳基。
除非另外說明,否則術語「伸烷基」係指具有約1至約20個碳原子(及其中之碳原子範圍及特定數目之所有組合及子組合)、較佳具有約1至約8個碳原子且具有藉由自母烷烴之同一個碳原子或兩個不同碳原子移除兩個氫原子獲得之兩個單價基團中心的飽和分支鏈或直鏈烴基。典型伸烷基包括(但不限於)亞甲基、伸乙基、伸丙基、伸丁基、伸戊基、伸己基、伸庚基、伸辛基、伸壬基、伸癸基、1,4-伸環己基及其類似基團。單獨或作為另一基團之一部分的伸烷基可視情況經一或多個基團、較佳1至3個基團(及選自鹵素之任何其他取代基)取代,該等基團包括(但不限於)-鹵素、-O-(C
1-C
8烷基)、-O-(C
2-C
8烯基)、-O-(C
2-C
8炔基)、-芳基、-C(O)R'、-OC(O)R'、-C(O)OR'、-C(O)NH
2、-C(O)NHR'、-C(O)N(R')
2、-NHC(O)R'、-SR'、-SO
3R'、-S(O)
2R'、-S(O)R'、-OH、=O、-N
3、-NH
2、-NH(R')、-N(R')
2及-CN,其中各R'係獨立地選自-H、-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基或-芳基,且其中該等-O-(C
1-C
8烷基)、-O-(C
2-C
8烯基)、-O-(C
2-C
8炔基)、-芳基、-C
1-C
8烷基、-C
2-C
8烯基及-C
2-C
8炔基可進一步視情況經一或多個取代基取代,該等取代基包括(但不限於)-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基、-鹵素、-O-(C
1-C
8烷基)、-O-(C
2-C
8烯基)、-O-(C
2-C
8炔基)、-芳基、-C(O)R''、-OC(O)R''、-C(O)OR''、-C(O)NH
2、-C(O)NHR''、-C(O)N(R'')
2、-NHC(O)R''、-SR''、-SO
3R''、-S(O)
2R''、-S(O)R''、-OH、-N
3、-NH
2、-NH(R'')、-N(R'')
2及-CN,其中各R''係獨立地選自-H、-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基或-芳基。
除非另外說明,否則術語「伸烯基」係指含有至少一個碳-碳雙鍵之視情況經取代的伸烷基。例示性伸烯基包括例如伸乙烯基(-CH=
CH-)及伸丙烯基(-CH=CHCH
2-)。
除非另外說明,否則術語「伸炔基」係指含有至少一個碳-碳參鍵之視情況經取代的伸烷基。例示性伸炔基包括例如乙炔(-C≡C-)、炔丙基(-CH
2C≡C-)及4-戊炔基(-CH
2CH
2CH
2C≡CH-)。
除非另外說明,否則術語「芳基」係指具有6-20個碳原子(及其中之碳原子範圍及特定數目之所有組合及子組合)且藉由自母芳族環系統之單個碳原子移除一個氫原子獲得的單價芳族烴基。在例示性結構中一些芳基以「Ar」表示。典型芳基包括(但不限於)自苯、經取代之苯、苯基、萘、蒽、聯苯及其類似基團得到之基團。
單獨或作為另一基團之一部分的芳基可視情況經一或多個基團、較佳1至5個或甚至1至2個基團取代,該等基團包括(但不限於)-鹵素、-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基、-O-(C
1-C
8烷基)、-O-(C
2-C
8烯基)、-O-(C
2-C
8炔基)、-芳基、-C(O)R'、-OC(O)R'、-C(O)OR'、-C(O)NH
2、-C(O)NHR'、-C(O)N(R')
2、-NHC(O)R'、-SR'、-SO
3R'、-S(O)
2R'、-S(O)R'、-OH、-NO
2、-N
3、-NH
2、-NH(R')、-N(R')
2及-CN,其中各R'係獨立地選自-H、-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基或-芳基,且其中該等-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基、O-(C
1-C
8烷基)、-O-(C
2-C
8烯基)、-O-(C
2-C
8炔基)及-芳基可進一步視情況經一或多個取代基取代,該等取代基包括(但不限於)-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基、-鹵素、-O-(C
1-C
8烷基)、-O-(C
2-C
8烯基)、-O-(C
2-C
8炔基)、-芳基、-C(O)R''、-OC(O)R''、-C(O)OR''、-C(O)NH
2、-C(O)NHR''、-C(O)N(R'')
2、-NHC(O)R''、-SR''、-SO
3R''、-S(O)
2R''、-S(O)R''、-OH、-N
3、-NH
2、-NH(R'')、-N(R'')
2及-CN,其中各R''係獨立地選自-H、-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基或-芳基。
除非另外說明,否則術語「伸芳基」係指視情況經取代之芳基,其為二價基團(亦即藉由自母芳族環系統之同一個碳原子或兩個不同碳原子移除兩個氫原子獲得)且可如以下結構中用苯基作為例示性芳基所示呈鄰位、間位或對位組態。
典型「-(C
1-C
8伸烷基)芳基」、「-(C
2-C
8伸烯基)芳基」及「-(C
2-C
8伸炔基)芳基」包括(但不限於)苯甲基、2-苯基乙-1-基、2-苯基乙烯-1-基、萘基甲基、2-萘基乙-1-基、2-萘基乙烯-1-基、萘幷苯甲基、2-萘幷苯基乙-1-基及其類似基團。
除非另外說明,否則術語「雜環」係指如下具有3至14個環原子(亦稱作環成員)之單環、雙環或多環系統,其中至少一個環中之至少一個環原子為選自N、O、P或S之雜原子(及其中之碳原子及雜原子的範圍及特定數目之所有組合及子組合)。雜環可具有1至4個獨立地選自N、O、P或S之環雜原子。雜環中之一或多個N、C或S原子可經氧化。單環雜環較佳具有3至7個環成員(例如2至6個碳原子及1至3個獨立地選自N、O、P或S之雜原子),且雙環雜環較佳具有5至10個環成員(例如4至9個碳原子及1至3個獨立地選自N、O、P或S之雜原子)。包括雜原子之環可為芳族或非芳族環。除非另外說明,否則雜環在產生穩定結構之任何雜原子或碳原子處連接於其側基。
雜環描述於以下文獻中:Paquette, 「
Principles of Modern Heterocyclic Chemistry」(W.A. Benjamin, New York, 1968),尤其第1章、第3章、第4章、第6章、第7章及第9章;「
The Chemistry of Heterocyclic Compounds, A series of Monographs」(John Wiley & Sons, New York, 1950年至今),尤其第13卷、第14卷、第16卷、第19卷及第28卷;及
J. Am. Chem. Soc.82:5566 (1960)。
「雜環」之實例包括例如且不限於吡啶基、二氫吡啶基、四氫吡啶基(哌啶基)、噻唑基、嘧啶基、呋喃基、噻吩基、吡咯基、吡唑基、咪唑基、四唑基、苯并呋喃基、噻萘基、吲哚基、吲哚烯基、喹啉基、異喹啉基、苯并咪唑基、哌啶基、4-哌啶酮基、吡咯啶基、2-吡咯啶酮基、吡咯啉基、四氫呋喃基、雙四氫呋喃基、四氫哌喃基、雙四氫哌喃基、四氫喹啉基、四氫異喹啉基、十氫喹啉基、八氫異喹啉基、吖基、三嗪基、6H-1,2,5-噻二嗪基、2H,6H-1,5,2-二噻嗪基、噻吩基、噻嗯基、哌喃基、異苯并呋喃基、烯基、𠮿基、啡噁噻基、2H-吡咯基、異噻唑基、異噁唑基、吡嗪基、噠嗪基、吲哚嗪基、異吲哚基、3H-吲哚基、1H-吲唑基、嘌呤基、4H-喹嗪基、呔嗪基、啶基、喹喏啉基、喹唑啉基、啉基、喋啶基、4H-咔唑基、咔唑基、β-咔啉基、啡啶基、吖啶基、嘧啶基、啡啉基、啡嗪基、啡噻嗪基、呋呫基、啡噁嗪基、異烷基、烷基、咪唑啶基、咪唑啉基、吡唑啶基、吡唑啉基、哌嗪基、吲哚啉基、異吲哚啉基、啶基、嗎啉基、噁唑啶基、苯并三唑基、苯并異噁唑基、羥吲哚基、苯并噁唑啉基及靛紅醯基(isatinoyl)。較佳「雜環」基包括(但不限於)苯并呋喃基、苯并噻吩基、吲哚基、苯并吡唑基、香豆素基、異喹啉基、吡咯基、噻吩基、呋喃基、噻唑基、咪唑基、吡唑基、三唑基、喹啉基、嘧啶基、吡啶基、吡啶酮基、吡嗪基、噠嗪基、異噻唑基、異噁唑基及四唑基。
單獨或作為另一基團之一部分的雜環基可視情況經一或多個基團、較佳1至2個基團取代,該等基團包括(但不限於)-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基、-鹵素、-O-(C
1-C
8烷基)、-O-(C
2-C
8烯基)、-O-(C
2-C
8炔基)、-芳基、-C(O)R'、-OC(O)R'、-C(O)OR'、-C(O)NH
2、-C(O)NHR'、-C(O)N(R')
2、-NHC(O)R'、-SR'、-SO
3R'、-S(O)
2R'、-S(O)R'、-OH、-N
3、-NH
2、-NH(R')、-N(R')
2及-CN,其中各R'係獨立地選自-H、-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基或-芳基,且其中該等-O-(C
1-C
8烷基)、-O-(C
2-C
8烯基)、-O-(C
2-C
8炔基)、-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基及-芳基可進一步視情況經一或多個取代基取代,該等取代基包括(但不限於)-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基、-鹵素、-O-(C
1-C
8烷基)、-O-(C
2-C
8烯基)、-O-(C
2-C
8炔基)、-芳基、-C(O)R''、-OC(O)R''、-C(O)OR''、-C(O)NH
2、-C(O)NHR''、-C(O)N(R'')
2、-NHC(O)R''、-SR''、-SO
3R''、-S(O)
2R''、-S(O)R''、-OH、-N
3、-NH
2、-NH(R'')、-N(R'')
2及-CN,其中各R''係獨立地選自-H、-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基或芳基。
舉例而言且不加限制,碳鍵結之雜環可在以下位置鍵結:吡啶之位置2、3、4、5或6;噠嗪之位置3、4、5或6;嘧啶之位置2、4、5或6;吡嗪之位置2、3、5或6;呋喃、四氫呋喃、硫代呋喃、噻吩、吡咯或四氫吡咯之位置2、3、4或5;噁唑、咪唑或噻唑之位置2、4或5;異噁唑、吡唑或異噻唑之位置3、4或5;氮丙啶之位置2或3;氮雜環丁烷之位置2、3或4;喹啉之位置2、3、4、5、6、7或8;或異喹啉之位置1、3、4、5、6、7或8。碳鍵結之雜環更通常包括2-吡啶基、3-吡啶基、4-吡啶基、5-吡啶基、6-吡啶基、3-噠嗪基、4-噠嗪基、5-噠嗪基、6-噠嗪基、2-嘧啶基、4-嘧啶基、5-嘧啶基、6-嘧啶基、2-吡嗪基、3-吡嗪基、5-吡嗪基、6-吡嗪基、2-噻唑基、4-噻唑基或5-噻唑基。
舉例而言且不加限制,氮鍵結之雜環可在以下位置鍵結:氮丙啶、氮雜環丁烷、吡咯、吡咯啶、2-吡咯啉、3-吡咯啉、咪唑、咪唑啶、2-咪唑啉、3-咪唑啉、吡唑、吡唑啉、2-吡唑啉、3-吡唑啉、哌啶、哌嗪、吲哚、吲哚啉或1H-吲唑之位置1;異吲哚或異吲哚啉之位置2;嗎啉之位置4;及咔唑或β-咔啉之位置9。氮鍵結之雜環更通常包括1-氮丙啶基、1-氮雜環丁烷基(1-azetedyl)、1-吡咯基、1-咪唑基、1-吡唑基及1-哌啶基。
除非另外說明,否則術語「碳環」係指具有3至14個環原子(及其中之碳原子範圍及特定數目之所有組合及子組合)之飽和或不飽和非芳族單環、雙環或多環系統,其中所有環原子均為碳原子。單環碳環較佳具有3至6個環原子,更佳具有5或6個環原子。雙環碳環較佳具有7至12個環原子,例如排列成雙環[4,5]、[5,5]、[5,6]或[6,6]系統;或9或10個環原子,排列成雙環[5,6]或[6,6]系統。術語「碳環」包括例如稠合於芳環之單環碳環(例如稠合於苯環之單環碳環)。碳環較佳具有3至8個碳環原子。
單獨或作為另一基團之一部分的碳環基可視情況經例如一或多個基團、較佳1或2個基團(及選自鹵素之任何其他取代基)取代,該等基團包括(但不限於)-鹵素、-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基、-O-(C
1-C
8烷基)、-O-(C
2-C
8烯基)、-O-(C
2-C
8炔基)、-芳基、-C(O)R'、-OC(O)R'、-C(O)OR'、-C(O)NH
2、-C(O)NHR'、-C(O)N(R')
2、-NHC(O)R'、-SR'、-SO
3R'、-S(O)
2R'、-S(O)R'、-OH、=O、-N
3、-NH
2、-NH(R')、-N(R')
2及-CN,其中各R'係獨立地選自-H、-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基或-芳基,且其中該等-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基、-O-(C
1-C
8烷基)、-O-(C
2-C
8烯基)、-O-(C
2-C
8炔基)及-芳基可進一步視情況經一或多個取代基取代,該等取代基包括(但不限於)-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基、-鹵素、-O-(C
1-C
8烷基)、-O-(C
2-C
8烯基)、-O-(C
2-C
8炔基)、-芳基、-C(O)R''、-OC(O)R''、-C(O)OR''、-C(O)NH
2、-C(O)NHR''、-C(O)N(R'')
2、-NHC(O)R''、-SR''、-SO
3R''、-S(O)
2R''、-S(O)R''、-OH、-N
3、-NH
2、-NH(R'')、-N(R'')
2及-CN,其中各R''係獨立地選自-H、-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基或-芳基。
單環碳環取代基之實例包括-環丙基、-環丁基、-環戊基、-1-環戊-1-烯基、-1-環戊-2-烯基、-1-環戊-3-烯基、環己基、-1-環己-1-烯基、-1-環己-2-烯基、-1-環己-3-烯基、-環庚基、-環辛基、-1,3-環已二烯基、-1,4-環已二烯基、-1,3-環庚二烯基、-1,3,5-環庚三烯基及-環辛二烯基。
單獨或作為另一基團之一部分使用的「碳環」係指視情況經取代之如上文所定義之碳環基,其為二價基團(亦即藉由自母碳環系統之同一個碳原子或兩個不同碳原子移除兩個氫原子獲得)。
除非本文另外指示,否則連字符(-)表示與側位分子之連接點。因此,術語「-(C
1-C
8伸烷基)芳基」或「-C
1-C
8伸烷基(芳基)」係指如本文所定義之C
1-C
8伸烷基,其中該伸烷基在伸烷基之任一碳原子處連接於側位分子,且鍵結於伸烷基碳原子的一個氫原子經如本文所定義之芳基置換。
當特定基團「經取代」時,該基團可具有一或多個取代基、較佳1至5個取代基、更佳1至3個取代基、最佳1至2個取代基,該等取代基係獨立地選自取代基之清單。然而,該基團一般可具有任何數目之選自鹵素之取代基。經取代之基團如所指示。
規定在分子中之特定位置處之任何取代基或變數的定義與其在彼分子中之其他位置處之定義無關。應瞭解,本發明化合物上之取代基及取代模式可由一般技術者選擇以提供化學上穩定且可容易由此項技術中已知之技術以及本文所述方法合成之化合物。
如本文中所使用,保護基係指暫時或永久地選擇性阻斷多官能化合物中之一個反應性位點的基團。適用於本發明之羥基保護基為醫藥學上可接受的,且可能需要或可能不需要在投與個體後自母化合物裂解以使化合物具有活性。裂解係經由體內之正常代謝過程達成。羥基保護基為此項技術中所熟知,參見T. W.
Greene及P. G. M. Wuts之
Protective Groups in Organic Synthesis(John Wiley & sons, 第3版)(以全文引用的方式且出於所有目的併入本文中),且包括例如醚(例如烷基醚及矽烷基醚,包括例如二烷基矽烷基醚、三烷基矽烷基醚、二烷基烷氧基矽烷基醚)、酯、碳酸酯、胺基甲酸酯、磺酸酯及磷酸酯保護基。羥基保護基之實例包括(但不限於)甲基醚;甲氧基甲基醚、甲基硫甲基醚、(苯基二甲基矽烷基)甲氧基甲基醚、苯甲氧基甲基醚、對甲氧基苯甲氧基甲基醚、對硝基苯甲氧基甲基醚、鄰硝基苯甲氧基甲基醚、(4-甲氧基苯氧基)甲基醚、愈創木酚甲基醚、第三丁氧基甲基醚、4-戊烯氧基甲基醚、矽烷氧基甲基醚、2-甲氧基乙氧基甲基醚、2,2,2-三氯乙氧基甲基醚、雙(2-氯乙氧基)甲基醚、2-(三甲基矽烷基)乙氧基甲基醚、甲氧基甲基醚、四氫哌喃基醚、1-甲氧基環己基醚、4-甲氧基四氫硫哌喃醚、4-甲氧基四氫硫哌喃醚S,S-二氧化物、1-[(2-氯-4-甲基)苯基]-4-甲氧基哌啶-4-基醚、1-(2-氟苯基)-4-甲氧基哌啶-4-基醚、1,4-二噁烷-2-基醚、四氫呋喃基醚、四氫硫代呋喃基醚;經取代之乙基醚,諸如1-乙氧基乙基醚、1-(2-氯乙氧基)乙基醚、1-[2-(三甲基矽烷基)乙氧基]乙基醚、1-甲基-1-甲氧基乙基醚、1-甲基-1-苯甲氧基乙基醚、1-甲基-1-苯甲氧基-2-氟乙基醚、1-甲基-1苯氧基乙基醚;2-三甲基矽烷基醚、第三丁基醚、烯丙基醚、炔丙基醚、對氯苯基醚、對甲氧基苯基醚、苯甲基醚、對甲氧基苯甲基醚、3,4-二甲氧基苯甲基醚、三甲基矽烷基醚、三乙基矽烷基醚、三丙基矽烷基醚、二甲基異丙基矽烷基醚、二乙基異丙基矽烷基醚、二甲基己基矽烷基醚、第三丁基二甲基矽烷基醚、二苯基甲基矽烷基醚、苯甲醯基甲酸酯、乙酸酯、氯乙酸酯、二氯乙酸酯、三氯乙酸酯、三氟乙酸酯、甲氧基乙酸酯、三苯基甲氧基乙酸酯、苯基乙酸酯、苯甲酸酯、碳酸烷酯甲酯、碳酸烷酯9-茀基甲酯、碳酸烷酯乙酯、碳酸烷酯2,2,2,-三氯乙酯、碳酸1,1,-二甲基-2,2,2-三氯乙酯、烷基磺酸酯、甲烷磺酸酯、苯甲基磺酸酯、甲苯磺酸酯、亞甲基縮醛、亞乙基縮醛及第三丁基次甲基縮酮。較佳保護基由式-R
a、-Si(R
a)(R
a)(R
a)、-C(O)R
a、-C(O)OR
a、-C(O)NH(R
a)、-S(O)
2R
a、-S(O)
2OH、P(O)(OH)
2及-P(O)(OH)OR
a表示,其中R
a為C
1-C
20烷基、C
2-C
20烯基、C
2-C
20炔基、-C
1-C
20伸烷基(碳環)、-C
2-C
20伸烯基(碳環)、-C
2-C
20伸炔基(碳環)、-C
6-C
10芳基、-C
1-C
20伸烷基(芳基)、-C
2-C
20伸烯基(芳基)、-C
2-C
20伸炔基(芳基)、-C
1-C
20伸烷基(雜環)、-C
2-C
20伸烯基(雜環)或-C
2-C
20伸炔基(雜環),其中單獨或作為另一基團之一部分的該等烷基、烯基、炔基、伸烷基、伸烯基、伸炔基、芳基、碳環及雜環視情況經取代。
出於本文目的,「改變天然糖基化模式」意欲意謂刪去天然序列191P4D12中存在之一或多個碳水化合物部分(藉由移除潛在糖基化位點或藉由經由化學及/或酶促方法刪去糖基化),及/或添加天然序列191P4D12中不存在之一或多個糖基化位點。另外,該片語包括天然蛋白質之糖基化的性質變化(qualitative change),涉及所存在之各種碳水化合物部分之性質及比例的變化。
術語「類似物」係指結構上與另一分子(例如191P4D12相關蛋白)類似或與其共有類似或相應屬性之分子。舉例而言,191P4D12蛋白之類似物可由與191P4D12特異性結合之抗體或T細胞特異性結合。
除非另外明確指示,否則術語「抗體」以最廣泛意義使用。因此,「抗體」可為天然存在之抗體或人造抗體,諸如藉由習知融合瘤技術製備之單株抗體。191P4D12抗體包含單株及多株抗體以及含有此等抗體之抗原結合域及/或一或多個互補決定區的片段。如本文中所使用,術語「抗體」係指特異性結合191P4D12及/或展現所需生物活性之任何形式的抗體或其片段,且特別涵蓋單株抗體(包括全長單株抗體)、多株抗體、多特異性抗體(例如雙特異性抗體)及抗體片段,只要其特異性結合191P4D12及/或展現所需生物活性即可。在本文所提供之方法及組合物中可使用任何特異性抗體。因此,在一實施例中,術語「抗體」涵蓋包含至少一個來自免疫球蛋白輕鏈分子之可變區及至少一個來自重鏈分子之可變區的分子,該等可變區組合形成標靶抗原之特異性結合位點。在一實施例中,抗體為IgG抗體。舉例而言,抗體為IgG1、IgG2、IgG3或IgG4抗體。適用於本發明方法及組合物中之抗體可在細胞培養物、噬菌體或各種動物中產生,包括(但不限於)母牛、兔、山羊、小鼠、大鼠、倉鼠、天竺鼠、綿羊、狗、貓、猴、黑猩猩及猿。因此,在一實施例中,本發明之抗體為哺乳動物抗體。可使用噬菌體技術來分離初始抗體或產生特異性或親合力特徵發生改變之變異體。該等技術為常規技術且為此項技術所熟知。在一實施例中,抗體由此項技術中已知之重組手段產生。舉例而言,重組抗體可經由用包含編碼該抗體之DNA序列的載體轉染宿主細胞來產生。可使用一或多個載體將表現至少一個VL及至少一個VH區之DNA序列轉染至宿主細胞中。抗體產生及製備之重組手段的例示性描述包括Delves, ANTIBODY PRODUCTION: ESSENTIAL TECHNIQUES (Wiley, 1997);Shephard等人MONOCLONAL ANTIBODIES (Oxford University Press, 2000);Goding, MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE (Academic Press, 1993);及CURRENT PROTOCOLS IN IMMUNOLOGY (John Wiley & Sons, 最新版)。本發明之抗體可藉由重組手段進行修飾以增加抗體在介導所需功能方面之功效。因此,使用重組手段藉由取代來修飾抗體係在本發明之範疇內。該等取代通常將為保守性取代。舉例而言,抗體恆定區中之至少一個胺基酸可經不同殘基置換。參見例如美國專利第5,624,821號、美國專利第6,194,551號、申請案第WO 9958572號;及Angal等人
Mol. Immunol. 30: 105-08 (1993)。胺基酸之修飾包括胺基酸之缺失、添加及取代。在一些情況下,該等改變旨在減少非所需活性,例如補體依賴性細胞毒性。抗體通常藉由與提供可偵測信號之物質共價或非共價連接來標記。已知各種標記及共軛技術且在科學文獻與專利文獻中皆有廣泛報導。可針對與正常或缺陷191P4D12之結合篩選此等抗體。參見例如
Antibody Engineering: A Practical Approach(Oxford University Press, 1996)。適合之具有所需生物活性的抗體可使用以下活體外檢定來鑑別,該等檢定包括(但不限於):增殖、遷移、黏附、軟瓊脂生長、血管生成、細胞間通訊、細胞凋亡、轉運、信號轉導及以下活體內檢定,諸如腫瘤生長之抑制。本文所提供之抗體亦可用於診斷性應用。作為捕捉抗體或非中和抗體,可針對與特異性抗原結合而不抑制抗原之受體結合或生物活性的能力對其進行篩選。作為中和抗體,抗體可用於競爭性結合檢定。其亦可用於定量191P4D12或其受體。
如本文中所使用,術語抗體之「抗原結合部分」或「抗體片段」(或簡稱為「抗體部分」)係指191P4D12抗體之保留與抗原(例如191P4D12及變異體;圖1)特異性結合之能力的一或多個片段。已顯示抗體之抗原結合功能可由全長抗體之片段來執行。術語抗體之「抗原結合部分」中所涵蓋之結合片段的實例包括:(i)Fab片段:由V
L、V
H、C
L及C
H1域組成之單價片段;(ii)F(ab')
2片段:包含由位於鉸鏈區之二硫橋鍵連接的兩個Fab片段之二價片段;(iii)由V
H及C
H1域組成之Fd片段;(iv)由抗體之單一臂的V
L及V
H域組成之Fv片段;(v)由V
H域組成之dAb片段(Ward等人(1989)
Nature341:544-546);及(vi)分離之互補決定區(CDR)。此外,儘管Fv片段之兩個結構域(V
L及V
H)由各別基因編碼,但其可使用重組法由合成連接子連接,該連接子能夠使其製備成V
L及V
H區配對形成單價分子之單蛋白質鏈(稱為單鏈Fv(scFv);參見例如Bird等人(1988)
Science242:423-426;及Huston等人(1988)
Proc. Natl. Acad. Sci. USA85:5879-5883)。該等單鏈抗體亦意欲涵蓋於術語抗體之「抗原結合部分」內。此等抗體片段係使用熟習此項技術者已知之習知技術獲得,且以與完整抗體相同之方式針對效用對該等片段進行篩選。
如本文中所使用,可使用任何形式之「抗原」產生對於191P4D12具有特異性之抗體。因此,引發抗原可為單抗原決定基、多抗原決定基、或單獨完整蛋白質或完整蛋白質與此項技術中已知之一或多種免疫原性增強劑的組合。引發抗原可為分離之全長蛋白質、細胞表面蛋白質(例如免疫接種經抗原之至少一部分轉染之細胞)或可溶性蛋白質(例如僅免疫接種蛋白質之細胞外域部分)。抗原可在經基因改造之細胞中產生。編碼抗原之DNA可為基因組DNA或非基因組DNA(例如cDNA)且編碼細胞外域之至少一部分。如本文中所使用,術語「部分」係指視情況組成所關注抗原之免疫原性抗原決定基的最少數目之胺基酸或核酸。可使用適合於使所關注細胞轉型之任何遺傳載體,包括(但不限於)腺病毒載體、質體及非病毒載體,諸如陽離子性脂質。在一實施例中,本文方法及組合物中的抗體特異性結合所關注之191P4D12之細胞外域的至少一部分。
本文所提供之抗體或其抗原結合片段可與「生物活性劑」共軛。如本文中所使用,術語「生物活性劑」係指結合抗原及/或增強或介導所需生物效應以增加殺死細胞之毒素的任何合成化合物或天然存在之化合物。在一實施例中,適用於本發明之結合片段為生物活性片段。如本文中所使用,術語「生物活性」係指抗體或抗體片段能夠結合所需抗原決定基且直接或間接發揮生物效應。直接作用包括(但不限於):調節、刺激及/或抑制生長信號;調節、刺激及/或抑制抗細胞凋亡信號;調節、刺激及/或抑制細胞凋亡或壞死信號;調節、刺激及/或抑制ADCC級聯反應;及調節、刺激及/或抑制CDC級聯反應。
「雙特異性」抗體亦適用於本發明方法及組合物。如本文中所使用,術語「雙特異性抗體」係指對至少兩種不同抗原決定基具有結合特異性之抗體,通常為單株抗體。在一實施例中,抗原決定基來自同一抗原。在另一實施例中,抗原決定基來自兩種不同抗原。製備雙特異性抗體之方法為此項技術所知。舉例而言,雙特異性抗體可使用兩個免疫球蛋白重鏈/輕鏈對之共表現來重組產生。參見例如Milstein等人
Nature305:537-39 (1983)。或者,雙特異性抗體可使用化學鍵聯來製備。參見例如Brennan等人
Science229:81 (1985)。雙特異性抗體包括雙特異性抗體片段。參見例如Hollinger等人
Proc. Natl. Acad. Sci. U.S.A. 90:6444-48 (1993),Gruber等人
J. Immunol. 152:5368 (1994)。
本文所述之單株抗體具體包括「嵌合」抗體,其中重鏈及/或輕鏈之一部分與來源於特定物種或屬於特定抗體類別或亞類之抗體中的相應序列一致或同源,而該(等)鏈之其餘部分與來源於另一物種或屬於另一抗體類別或亞類之抗體中的相應序列一致或同源;以及該等抗體之片段,只要其特異性結合標靶抗原及/或展現所需生物活性即可(美國專利第4,816,567號;及Morrison等人
Proc. Natl. Acad. Sci. USA81: 6851-6855 (1984))。
術語「化學治療劑」係指有效抑制腫瘤生長之所有化合物。化學治療劑之非限制性實例包括烷基化劑,例如氮芥、伸乙亞胺化合物及烷基磺酸酯;抗代謝物,例如葉酸、嘌呤或嘧啶拮抗劑;有絲分裂抑制劑,例如抗微管蛋白劑,諸如長春花生物鹼、奧瑞他汀及鬼臼毒素(podophyllotoxin)衍生物;細胞毒性抗生素;損壞或干擾DNA表現或複製之化合物,例如DNA小溝結合物;及生長因子受體拮抗劑。另外,化學治療劑包括細胞毒性劑(如本文所定義)、抗體、生物分子及小分子。
術語「化合物」係指且涵蓋化合物自身以及以下各物(無論明確陳述或未明確陳述,且除非上下文講明以下各物將被排除):化合物之非晶形及結晶形式,包括多晶形式,其中此等形式可為混合物之一部分或呈分離形式;化合物之游離酸及游離鹼形式,其通常為本文所提供之結構中所示的形式;化合物之異構體,其係指光學異構體及互變異構異構體,其中光學異構體包括對映異構體及非對映異構體、對掌性異構體及非對掌性異構體,且光學異構體包括分離之光學異構體以及光學異構體之混合物,包括外消旋及非外消旋混合物;其中異構體可呈分離形式或與一或多種其他異構體之混合物形式;化合物之同位素,包括含有氘及氚之化合物,且包括含有放射性同位素(包括治療及診斷有效之放射性同位素)之化合物;化合物之多聚形式,包括二聚、三聚等形式;化合物之鹽,較佳為醫藥學上可接受之鹽,包括酸加成鹽及鹼加成鹽,包括具有有機相對離子及無機相對離子之鹽,且包括兩性離子形式,其中若化合物與兩個或兩個以上相對離子締合,則該兩個或兩個以上相對離子可相同或不同;及化合物之溶劑合物,包括半溶劑合物、單溶劑合物、二溶劑合物等,包括有機溶劑合物及無機溶劑合物,該等無機溶劑合物包括水合物;其中若化合物與兩種或兩種以上溶劑分子締合,則該兩種或兩種以上溶劑分子可相同或不同。在一些情況下,本文對本發明之化合物的提及將包括對上述形式中之一或多者的明確提及,例如鹽及/或溶劑合物;然而,此提及僅用於強調,且不應理解為排除如上文所鑑別之上述形式中之其他形式。
如本文中所使用,術語「保守性取代」係指為熟習此項技術者所知且一般可在不改變所得分子之生物活性的情況下進行的胺基酸取代。熟習此項技術者應認識到,一般而言,多肽之非必需區中的單一胺基酸取代不會實質上改變生物活性(參見例如Watson等人MOLECULAR BIOLOGY OF THE GENE, The Benjamin/Cummings Pub. Co., 第224頁(1987年第4版))。該例示性取代較佳根據表II及表III(a-b)中所示之取代來進行。舉例而言,該等改變包括用異白胺酸(I)、纈胺酸(V)及白胺酸(L)中之任一者取代此等疏水性胺基酸中之任何另一者;用天冬胺酸(D)取代麩胺酸(E)且反之亦然;用麩胺醯胺酸(Q)取代天冬醯胺酸(N)且反之亦然;及用絲胺酸(S)取代蘇胺酸(T)且反之亦然。視特定胺基酸之環境及其在蛋白質之三維結構中的作用而定,其他取代亦可視為保守性取代。舉例而言,甘胺酸(G)與丙胺酸(A)通常可互換,如同丙胺酸(A)與纈胺酸(V)亦可互換一樣。相對疏水性之甲硫胺酸(M)通常可與白胺酸及異白胺酸互換,且有時與纈胺酸互換。離胺酸(K)及精胺酸(R)在胺基酸殘基之重要特點為其電荷且此兩種胺基酸殘基之pK並無顯著不同的位置處通常可互換。其他改變在特殊環境下可視為「保守性」(參見例如本文中之表III(a);「Biochemistry」第2版,第13-15頁,Lubert Stryer編 (Stanford University);Henikoff等人PNAS 1992第89卷10915-10919;Lei等人J Biol Chem 1995年5月19日; 270(20):11882-11886)。其他取代亦為容許的且可依據經驗或依照已知之保守性取代來判定。
術語「細胞毒性劑」係指抑制或阻止細胞之表現活性、細胞功能及/或引起細胞破損的物質。該術語意欲包括放射性同位素、化學治療劑及毒素,諸如細菌、真菌、植物或動物來源之小分子毒素或酶促活性毒素,包括其片段及/或變異體。細胞毒性劑之實例包括(但不限於)奧瑞他汀(例如奧瑞他汀E、奧瑞他汀F、MMAE及MMAF)、金黴素(auromycin)、類美登素、蓖麻毒素、蓖麻毒素A鏈、考布他汀(combrestatin)、倍癌黴素(duocarmycin)、海兔毒素、阿黴素(doxorubicin)、道諾黴素(daunorubicin)、紫杉醇(taxol)、順鉑(cisplatin)、cc1065、溴化乙錠、絲裂黴素(mitomycin)、依託泊苷(etoposide)、特諾波賽(tenoposide)、長春新鹼(vincristine)、長春鹼(vinblastine)、秋水仙鹼(colchicine)、二羥基炭疽菌素二酮(dihydroxy anthracin dione)、放線菌素(actinomycin)、白喉毒素、綠膿桿菌外毒素(Pseudomonas exotoxin,PE)A、PE40、相思豆毒素、相思豆毒素A鏈、莫迪素(modeccin)A鏈、α-帚麴菌素(alpha-sarcin)、白樹素(gelonin)、有絲分裂素(mitogellin)、侷限麴菌素(retstrictocin)、酚黴素(phenomycin)、伊諾黴素(enomycin)、麻瘋樹毒蛋白(curcin)、巴豆毒素(crotin)、卡奇黴素、肥皂草(Sapaonaria officinalis)抑制劑及糖皮質激素及其他化學治療劑,以及放射性同位素,諸如At
211、I
131、I
125、Y
90、Re
186、Re
188、Sm
153、Bi
212或
213、P
32及Lu之放射性同位素(包括Lu
177)。抗體亦可與能夠將前藥轉化為其活性形式之抗癌前藥活化酶共軛。
如本文中所使用,術語「雙功能抗體」係指具有兩個抗原結合位點之小抗體片段,該等片段包含在同一多肽鏈(V
H-V
L)中相連接之重鏈可變域(V
H)與輕鏈可變域(V
L)。因使用的連接子過短而無法使同一鏈上兩個域之間配對,該等域被迫與另一鏈之互補域配對且產生兩個抗原結合位點。雙功能抗體更全面地描述於以下文獻中:例如EP 404,097;WO 93/11161;及Hollinger等人Proc. Natl. Acad. Sci. USA 90:6444-48 (1993)。
在191P4D12表現細胞上之191P4D12結合劑之作用的情況下,術語「空乏」係指191P4D12表現細胞之數目減少或消除。
術語「基因產物」在本文中用於指示肽/蛋白質或mRNA。舉例而言,「本發明之基因產物」在本文中有時稱為「癌症胺基酸序列」、「癌症蛋白質」、「表I中所列之癌症蛋白質」、「癌症mRNA」、「表I中所列癌症之mRNA」等。在一實施例中,癌症蛋白質由圖1之核酸編碼。癌症蛋白質可為片段,或者為由圖1之核酸編碼之全長蛋白質。在一實施例中,使用癌症胺基酸序列測定序列一致性或相似性。在另一實施例中,該等序列為由圖1之核酸編碼的蛋白質之天然存在的對偶基因變異體。在另一實施例中,序列為如本文進一步所述之序列變異體。
「異共軛」抗體適用於本發明方法及組合物中。如本文中所使用,術語「異共軛抗體」係指兩個共價連接之抗體。該等抗體可使用合成蛋白質化學技術中之已知方法(包括使用交聯劑)來製備。參見例如美國專利第4,676,980號。
術語「同源物」係指與另一分子展現同源性之分子,例如所具有之化學殘基序列在相應位置處相同或類似。
在一實施例中,本文所提供之抗體為「人類抗體」。如本文中所使用,術語「人類抗體」係指輕鏈與重鏈序列之整個序列(包括互補決定區(CDR))基本上來自人類基因的抗體。在一實施例中,人類單株抗體藉由以下技術製備:三瘤體(trioma)技術、人類B細胞技術(參見例如Kozbor等人Immunol. Today 4: 72 (1983))、EBV轉型技術(參見例如Cole等人
Monoclonal Antibodies And Cancer Therapy77-96 (1985))或使用噬菌體呈現(參見例如Marks等人
J. Mol. Biol.222:581 (1991))。在一特定實施例中,在轉殖基因小鼠中產生人類抗體。製備該等部分至完全人類抗體之技術為此項技術所知且可使用任何該等技術。根據一尤其較佳實施例,在經工程改造以表現人類重鏈及輕鏈抗體基因之轉殖基因小鼠中製備完全人類抗體序列。製備可產生人類抗體之轉殖基因小鼠的例示性描述可見於申請案第WO 02/43478號及美國專利6,657,103(Abgenix)及其後續案中。接著可將產生所需抗體之轉殖基因小鼠的B細胞融合以製備融合瘤細胞株,以用於連續產生抗體。參見例如美國專利第5,569,825號;第5,625,126號;第5,633,425號;第5,661,016號;及第5,545,806號;及Jakobovits,
Adv. Drug Del. Rev.31:33-42 (1998);Green等人
J. Exp. Med. 188:483-95 (1998)。
如本文中所使用,術語「人類化抗體」係指含有來自非人類(例如鼠類)抗體以及人類抗體之序列的抗體形式。該等抗體為嵌合抗體,其含有來源於非人類免疫球蛋白之最小序列。一般而言,人類化抗體將包含至少一個且通常兩個可變域之實質上全部,其中所有或實質上所有高變環對應於非人類免疫球蛋白之高變環,且所有或實質上所有FR區為人類免疫球蛋白序列之FR區。人類化抗體視情況亦將包含免疫球蛋白恆定區(Fc)之至少一部分,通常為人類免疫球蛋白恆定區之至少一部分。參見例如Cabilly之美國專利第4,816,567號;Queen等人(1989)
Proc. Nat'l Acad. Sci. USA86:10029-10033;及
Antibody Engineering: A Practical Approach(Oxford University Press 1996)。
如本文中所使用,術語「抑制」或「...之抑制」意欲減少可量測之量或完全防止。
片語「分離之」或「生物學上純的」係指物質實質上或基本上不含該物質以其天然狀態存在時通常伴隨該物質之組分。因此,本發明之分離之肽較佳不含在其原始環境下通常與該等肽締合之物質。舉例而言,當聚核苷酸與對應於除191P4D12基因外之基因或與其互補或編碼除191P4D12基因產物或其片段外之多肽的污染物聚核苷酸實質上分離時,稱該聚核苷酸為「分離之」聚核苷酸。熟習此項技術者可容易使用核酸分離程序來獲得分離之191P4D12聚核苷酸。舉例而言,當使用物理、機械或化學方法將191P4D12蛋白自通常與蛋白質締合之細胞組分中移除時,稱該蛋白質為「分離之」蛋白質。熟習此項技術者可容易使用標準純化方法來獲得分離之191P4D12蛋白。或者,可藉由化學手段製備分離之蛋白質。
適合之「標記」包括放射性核素、酶、受質、輔因子、抑制劑、螢光部分、化學發光部分、磁性粒子及其類似物。教示該等標記之使用的專利包括美國專利第3,817,837號;第3,850,752號;第3,939,350號;第3,996,345號;第4,277,437號;第4,275,149號;及第4,366,241號。另外,本文所提供之抗體可用作螢光體(fluorobody)之抗原結合組分。參見例如Zeytun等人
Nat. Biotechnol.21:1473-79 (2003)。
術語「哺乳動物」係指歸類為哺乳動物之任何生物體,包括小鼠、大鼠、兔、狗、貓、母牛、馬及人類。在本發明之一實施例中,哺乳動物為小鼠。在本發明之另一實施例中,哺乳動物為人類。
術語「轉移性癌症」及「轉移性疾病」意謂已擴散至區域淋巴結或遠端部位之癌症,且意欲包括依據AUA系統之D期疾病及依據TNM系統之TxNxM+期疾病。
如本文中所使用,術語「調節劑」或「測試化合物」或「候選藥物」或語法上等同者描述任何欲測試直接或間接改變癌症表現型或癌症序列(例如核酸或蛋白質序列)之表現或癌症序列之作用(例如信號傳導、基因表現、蛋白質相互作用等)的分子,例如蛋白質、寡肽、小有機分子、多醣、聚核苷酸等。在一態樣中,調節劑將中和本發明之癌症蛋白質的作用。「中和」意謂將蛋白質活性以及隨之對細胞的影響抑制或阻斷。在另一態樣中,調節劑將藉由使該蛋白質之含量正常化來中和本發明之基因及其相應蛋白質的作用。在較佳實施例中,調節劑改變表現概況,或本文所提供之核酸或蛋白質之表現概況,或下游效應途徑。在一實施例中,調節劑將癌症表現型抑制為例如正常組織指紋圖譜。在另一實施例中,調節劑誘發癌症表現型。通常以不同藥劑濃度對複數種檢定混合物進行平行試驗,以獲得對各種濃度之差別反應。此等濃度之一通常用作陰性對照,亦即零濃度或偵測水準以下。
調節劑、候選藥物或測試化合物涵蓋許多化學類別,但其通常為有機分子,較佳為分子量大於100道爾頓(Dalton)且小於約2,500道爾頓之有機小化合物。較佳小分子小於2000 D、或小於1500 D、或小於1000 D、或小於500 D。候選藥劑包含結構上與蛋白質相互作用所必需之官能基,尤其氫鍵,且通常至少包括胺、羰基、羥基或羧基,較佳為官能化學基團中之至少兩者。候選藥劑經常包含經一或多個上述官能基取代之環碳或雜環結構及/或芳族或聚芳族結構。調節劑亦包含生物分子,諸如肽、醣、脂肪酸、類固醇、嘌呤、嘧啶、其衍生物、結構類似物或組合。肽尤其較佳。一類調節劑為例如具有約5至約35個胺基酸、較佳約5至約20個胺基酸且尤其較佳約7至約15個胺基酸之肽。較佳地,癌症調節蛋白質為可溶的,包括非跨膜區及/或具有有助於溶解之N端Cys。在一實施例中,片段之C端保持呈游離酸形式且N端為有助於偶合(亦即偶合於半胱胺酸)之游離胺。在一實施例中,本發明之癌症蛋白質與如本文所論述之免疫原性藥劑共軛。在一實施例中,癌症蛋白質與BSA共軛。本發明之肽(例如具有較佳長度)可彼此連接或連接於其他胺基酸以形成更長的肽/蛋白質。調節肽可為如上文所概述之天然存在之蛋白質的消化物、隨機肽或「偏性」隨機肽。在一較佳實施例中,基於肽/蛋白質之調節劑為如本文所定義之抗體及其片段。
如本文中所使用,術語「單株抗體」係指自實質上均質抗體之群體獲得的抗體,亦即除了可少量存在可能天然存在之突變外,構成該群體之個別抗體為一致的。單株抗體具有針對單一抗原決定基之高度特異性。相比之下,習知(多株)抗體製劑通常包括針對不同抗原決定基(或對其具有特異性)之多種抗體。在一實施例中,多株抗體含有複數種單株抗體,在含有多個抗原決定基之單一抗原內,該等單株抗體具有不同抗原決定基特異性、親和性或親合力。修飾語「單株」指示抗體自實質上均質之抗體群體獲得的特徵,且不應理解為需要藉由任何特定方法產生該抗體。舉例而言,根據本發明欲使用之單株抗體可藉由最初由Kohler等人Nature 256:495 (1975)所述之融合瘤方法來製成,或可藉由重組DNA方法(參見例如美國專利第4,816,567號)來製成。「單株抗體」亦可使用例如Clackson等人
Nature352:624-628 (1991)及Marks等人
J. Mol. Biol.222:581-597 (1991)中所述之技術自噬菌體抗體庫中分離。一般藉由ELISA所測定,此等單株抗體一般將以至少約1 μM、更一般至少約300 nM、通常至少約30 nM、較佳至少約10 nM、更佳至少約3 nM或更好之Kd結合。
「醫藥賦形劑」包含諸如佐劑、載劑、pH值調節劑及緩衝劑、張力調節劑、濕潤劑、防腐劑及其類似藥劑之物質。
「醫藥學上可接受」係指無毒、惰性及/或生理學上與人類或其他哺乳動物相容之組合物。
術語「聚核苷酸」意謂長度為至少10個鹼基或鹼基對之核苷酸(核糖核苷酸或去氧核苷酸或任一類型核苷酸之經修飾形式)之聚合形式,且意欲包括DNA及/或RNA之單股形式及雙股形式。在此項技術中,此術語通常可與「寡核苷酸」互換使用。聚核苷酸可包含本文所揭示之核苷酸序列,其中例如圖1中所示之胸苷(T)亦可為尿嘧啶(U);此定義與DNA與RNA之化學結構之間的差異有關,尤其與以下觀察結果有關:RNA中之四種主要鹼基之一為尿嘧啶(U)而非胸苷(T)。
術語「多肽」意謂具有至少約4、5、6、7或8個胺基酸之聚合物。在整篇說明書中,使用胺基酸之標準三字母或單字母名稱。在此項技術中,此術語通常可與「肽」或「蛋白質」互換使用。
「重組」DNA或RNA分子為已經受活體外分子操作之DNA或RNA分子。
如本文中所使用,術語「單鏈Fv」或「scFv」或「單鏈」抗體係指包含抗體之V
H域及V
L域的抗體片段,其中此等域存在於單一多肽鏈中。Fv多肽一般進一步包含V
H域與V
L域之間的多肽連接子,該多肽連接子能夠使sFv形成抗原結合之所需結構。關於sFv之評述,參見Pluckthun,
The Pharmacology Of Monoclonal Antibodies ,第113卷,Rosenburg及Moore編Springer-Verlag, New York,第269-315頁(1994)。
如本文中所使用,術語「特異性」及「特異性結合」係指抗體與標靶抗原決定基之選擇性結合。藉由在一組特定條件下將與適當抗原之結合同與無關抗原或抗原混合物之結合進行比較來測試抗體之結合特異性。若抗體與適當抗原之結合為抗體與無關抗原或抗原混合物之結合的至少2倍、5倍、7倍及較佳10倍,則其視為具有特異性。在一實施例中,特異性抗體為僅結合191P4D12抗原、而不與無關抗原結合之抗體。在另一實施例中,特異性抗體為結合人類191P4D12抗原、而不結合非人類191P4D12抗原之抗體,其與191P4D12抗原具有70%、75%、80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%以上胺基酸同源性。在另一實施例中,特異性抗體為結合人類191P4D12抗原及結合鼠類191P4D12抗原之抗體,但其結合人類抗原之程度較高。在另一實施例中,特異性抗體為結合人類191P4D12抗原及結合靈長類191P4D12抗原之抗體,但其結合人類抗原之程度較高。在另一實施例中,特異性抗體與人類191P4D12抗原及任何非人類191P4D12抗原結合,但其結合人類抗原或其任何組合之程度較高。
如本文中所使用,「治療」或「治療性」及語法上相關術語係指任何疾病後果之任何改善,諸如存活時間延長、發病率減小及/或作為替代治療形式之副產物的副作用減輕;如此項技術中容易瞭解,疾病完全根治雖非治療行為之要求,但為較佳。
術語「變異體」係指展現與所述類型或正常型之變異的分子,諸如在具體描述之蛋白質(例如圖1中所示之191P4D12蛋白)之相應位置處具有一或多個不同胺基酸殘基的蛋白質。類似物為變異蛋白之一實例。剪接同功異型物及單核苷酸多態型(SNP)為變異體之其他實例。
本發明之「191P4D12蛋白」及/或「191P4D12相關蛋白」包括本文特定鑑別之蛋白(參見圖1),以及按照本文所概述或此項技術中容易得到之方法不經過度實驗可分離/產生及表徵之對偶基因變異體、保守性取代變異體、類似物及同源物。亦包括組合不同191P4D12蛋白或其片段之一部分的融合蛋白以及191P4D12蛋白與異源多肽之融合蛋白。該等191P4D12蛋白共同稱為191P4D12相關蛋白、本發明之蛋白質或191P4D12。術語「191P4D12相關蛋白」係指具有以下數目胺基酸之多肽片段或191P4D12蛋白序列:4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25個或大於25個;或至少30、35、40、45、50、55、60、65、70、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、195、200、225、250、275、300、325、330、335、339個或339個以上胺基酸。
II.) 191P4D12抗體
本發明之另一態樣提供與191P4D12相關蛋白結合之抗體(參見圖1)。在一實施例中,與191P4D12相關蛋白結合之抗體為與包含SEQ ID NO.: 2之胺基酸序列的191P4D12蛋白特異性結合之抗體。與包含SEQ ID NO.: 2之胺基酸序列的191P4D12蛋白特異性結合之抗體包括可與其他191P4D12相關蛋白結合之抗體。舉例而言,結合包含SEQ ID NO.:2之胺基酸序列的191P4D12蛋白之抗體可結合191P4D12相關蛋白,諸如191P4D12變異體及其同源物或類似物。
本發明之191P4D12抗體尤其適用於癌症(參見例如表I)預後檢定、成像及治療性方法。類似地,該等抗體適用於結腸癌及其他癌症之治療及/或預後,達191P4D12亦在此等其他癌症中表現或過表現之程度。此外,細胞內表現抗體(例如單鏈抗體)在治療上適用於治療涉及191P4D12表現之癌症,諸如晚期或轉移性結腸癌或其他晚期或轉移性癌症。
製備抗體、具體而言單株抗體之各種方法為此項技術所熟知。舉例而言,抗體可藉由使用呈分離或免疫共軛形式之191P4D12相關蛋白、肽或片段為適合之哺乳動物宿主免疫接種來製備(Antibodies: A Laboratory Manual, CSH Press編, Harlow, and Lane (1988);Harlow, Antibodies, Cold Spring Harbor Press, NY (1989))。另外,亦可使用191P4D12之融合蛋白,諸如191P4D12 GST融合蛋白。在一特定實施例中,製備包含圖1之胺基酸序列之全部或大部分的GST融合蛋白,接著作為免疫原用於產生適當抗體。在另一實施例中,191P4D12相關蛋白經合成且用作免疫原。
另外,使用此項技術中已知之裸DNA免疫接種技術(用或不用經純化之191P4D12相關蛋白或191P4D12表現細胞)來對所編碼之免疫原產生免疫反應(關於評論,參見Donnelly等人1997, Ann. Rev. Immunol. 15: 617-648)。
可分析如圖1中所示之191P4D12蛋白的胺基酸序列以選擇191P4D12蛋白之特異性區域來產生抗體。舉例而言,使用191P4D12胺基酸序列之疏水性及親水性分析來鑑別191P4D12結構中之親水性區域。顯示免疫原性結構之191P4D12蛋白的區域以及其他區域及結構域可容易地使用此項技術中已知之多種其他方法加以鑑別,諸如Chou-Fasman、Garnier-Robson、Kyte-Doolittle、Eisenberg、Karplus-Schultz或Jameson-Wolf分析法。親水性概況可使用Hopp, T.P.及Woods, K.R., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828之方法產生。疏水性概況可使用Kyte, J.及Doolittle, R.F., 1982, J. Mol. Biol. 157:105-132之方法產生。可接近殘基百分比(%)概況可使用Janin J., 1979, Nature 277:491-492之方法產生。平均可撓性概況可使用Bhaskaran R., Ponnuswamy P.K., 1988, Int. J. Pept. Protein Res. 32:242-255之方法產生。β-轉角概況可使用Deleage, G., Roux B., 1987, Protein Engineering 1:289-294之方法來產生。因此,藉由任一此等程序或方法所鑑別之每一區域均在本發明之範疇內。產生191P4D12抗體之較佳方法進一步以本文所提供之實例之方式來說明。製備用作免疫原之蛋白質或多肽的方法為此項技術所熟知。製備蛋白質與載體(諸如BSA、KLH或其他載體蛋白質)之免疫原性共軛物的方法亦為此項技術所熟知。在一些情況下,使用直接共軛,使用例如碳化二亞胺試劑;在其他情況下,連接試劑(諸如Pierce Chemical Co.(Rockford, IL)供應之連接試劑)為有效的。191P4D12免疫原通常藉由注射一段適合之時間且使用適合之佐劑來投與,如此項技術中所瞭解。在免疫接種時程期間,可獲得抗體之效價以測定抗體形成之適當性。
191P4D12單株抗體可藉由此項技術中熟知之各種方法來產生。舉例而言,分泌所需單株抗體之永生化細胞株係使用使產生抗體之B細胞永生化的Kohler及Milstein之標準融合瘤技術或修改來製備,如一般所知。藉由抗原為191P4D12相關蛋白之免疫檢定篩選分泌所需抗體之永生化細胞株。當鑑別適當永生化細胞培養物時,可繁殖細胞並自活體外培養物或腹水液產生抗體。
本發明之抗體或片段亦可藉由重組方式來產生。與191P4D12蛋白之所需區域特異性結合的區域亦可在來源於多種物種之嵌合抗體或互補決定區(CDR)移植抗體之情形下產生。亦可產生人類化或人類191P4D12抗體,且其較佳用於治療性情況。藉由用一或多種非人類抗體CDR取代對應人類抗體序列來使鼠類及其他非人類抗體人類化之方法為眾所周知(參見例如Jones等人1986, Nature 321: 522-525;Riechmann等人1988, Nature 332: 323-327;Verhoeyen等人1988, Science 239: 1534-1536)。亦參見Carter等人1993, Proc. Natl. Acad. Sci. USA 89: 4285及Sims等人1993, J. Immunol. 151: 2296。
在一較佳實施例中,本發明之抗體包含全人類191P4D12抗體(191P4D12 MAb)。此項技術中之各種方法提供產生全人類191P4D12 MAb之方式。舉例而言,一較佳實施例提供使用針對抗體產生不活化、用稱為Xenomouse之人類重鏈及輕鏈基因座(Amgen Fremont, Inc.)工程改造的轉殖基因小鼠的技術。製備產生人類抗體之轉殖基因小鼠的例示性描述可見於U.S. 6,657,103中。亦參見美國專利第5,569,825號;第5,625,126號;第5,633,425號;第5,661,016號;及第5,545,806號;及Mendez等人Nature Genetics, 15: 146-156 (1998);Kellerman, S.A.及Green, L.L., Curr. Opin. Biotechnol 13, 593-597 (2002)。
另外,本發明之人類抗體可使用HuMAb小鼠(Medarex, Inc.)產生,該HuMAb小鼠含有編碼未重排人類重鏈(μ及γ)及κ輕鏈免疫球蛋白序列之人類免疫球蛋白基因小基因座,以及不活化內源性μ及κ鏈基因座之靶向突變(參見例如Lonberg等人(1994) Nature 368(6474): 856-859)。
在另一實施例中,本發明之全人類抗體可使用在轉殖基因及轉殖染色體(transchomosome)上帶有人類免疫球蛋白序列之小鼠(諸如帶有人類重鏈轉殖基因及人類輕鏈轉殖染色體之小鼠)來培育。該等小鼠在本文中稱為「KM小鼠」,該等小鼠描述於Tomizuka等人(2000) Proc. Natl. Acad. Sci. USA 97:722-727及Tomizuka等人之PCT公開案WO 02/43478中。
本發明之人類單株抗體亦可使用用於篩選人類免疫球蛋白基因庫之噬菌體呈現法來製備。分離人類抗體之該等噬菌體呈現法在此項技術中建立。參見例如:Ladner等人之美國專利第5,223,409號;第5,403,484號;及第5,571,698號;Dower等人之美國專利第5,427,908號及第5,580,717號;McCafferty等人之美國專利第5,969,108號及第6,172,197號;及Griffiths等人之美國專利第5,885,793號;第6,521,404號;第6,544,731號;第6,555,313號;第6,582,915號及第6,593,081號。
本發明之人類單株抗體亦可使用已將人類免疫細胞重新組構於其中以使得可在免疫接種後產生人類抗體反應之SCID小鼠來製備。該等小鼠描述於例如Wilson等人之美國專利第5,476,996號及第5,698,767號中。
在一較佳實施例中,本發明之191P4D12 MAb包含以寄存編號PTA-11267寄存於美國菌種保存中心(American Type Culture Collection,ATCC)之融合瘤所產生之稱為Ha22-2(2,4)6.1之抗體的重鏈及輕鏈可變區(參見圖3),或包含與Ha22-2(2,4)6.1之重鏈及輕鏈可變區的胺基酸序列同源之胺基酸序列之重及輕可變區,且其中該等抗體保留本發明之191P4D12 MAb的所需功能性質。Ha22-2(2,4)6.1之重鏈可變區由範圍為SEQ ID NO:7之第20位之E殘基至第136位之S殘基的胺基酸序列組成,且Ha22-2(2,4)6.1之輕鏈可變區由範圍為SEQ ID NO:8之第23位之D殘基至第130位之R殘基的胺基酸序列組成。作為本發明之抗體的恆定區,可選擇恆定區之任何亞類。在一實施例中,可使用人類IgG1恆定區作為重鏈恆定區及人類Ig κ恆定區作為輕鏈恆定區。
舉例而言,本發明提供一種包含重鏈可變區及輕鏈可變區之分離之單株抗體或其抗原結合部分,其中:
(a) 重鏈可變區包含與圖3中所示之重鏈可變區胺基酸序列至少80%同源的胺基酸序列;及
(b) 輕鏈可變區包含與圖3中所示之輕鏈可變區胺基酸序列至少80%同源的胺基酸序列。
在其他實施例中,V
H及/或V
L胺基酸序列可與圖3中所示之V
H及V
L序列85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%同源。
在另一實施例中,本發明提供一種分離之單株抗體或其抗原結合部分,其包含人類化重鏈可變區及人類化輕鏈可變區,其中:
(a) 該重鏈可變區包含具有圖3中所示之重鏈可變區CDR之胺基酸序列的互補決定區(CDR);
(b) 該輕鏈可變區包含具有圖3中所示之輕鏈可變區之胺基酸序列的CDR。
本發明之經工程改造抗體包括已對V
H及/或V
L內之構架殘基進行修飾(例如用於改良抗體性質)的抗體。通常進行該等構架修飾以降低抗體之免疫原性。舉例而言,一種方法為使一或多個構架殘基「回復突變(backmutate)」成相應生殖系序列。更特定言之,已經受體細胞突變之抗體可含有與獲得該抗體之生殖系序列不同的構架殘基。該等殘基可藉由將抗體構架序列與獲得抗體之生殖系序列相比較來鑑別。為使構架區序列恢復至其生殖系組態,體細胞突變可藉由例如定點突變誘發或PCR介導突變誘發而「回復突變」至生殖系序列(例如自白胺酸「回復突變」至甲硫胺酸)。該等「回復突變」之抗體亦意欲為本發明所涵蓋。
另一類型之構架修飾涉及使構架區內或甚至一或多個CDR區內之一或多個殘基突變以移除T細胞抗原決定基,由此降低抗體之潛在免疫原性。此方法亦稱為「去免疫(deimmunization)」,且進一步詳細描述於Carr等人之美國專利公開案第2003/0153043號中。
除構架區或CDR區內所作之修飾外,或取而代之,本發明之抗體可經工程改造以包括Fc區內之修飾,通常以改變抗體之一或多種功能性質,諸如血清半衰期、補體固著、Fc受體結合及/或抗原依賴性細胞毒性。此外,本發明之191P4D12 MAb可經化學修飾(例如一或多個化學部分可連接於該抗體)或經修飾以改變其糖基化,再次改變該MAb之一或多種功能性質。以下進一步詳細描述此等實施例中之每一者。
在一實施例中,CH1之鉸鏈區經修飾以使得該鉸鏈區中之半胱胺酸殘基數發生改變,例如增加或減少。此方法進一步描述於Bodmer等人之美國專利第5,677,425號中。CH1之鉸鏈區中的半胱胺酸殘基數發生改變以例如有利於輕鏈及重鏈之組裝或增強或降低191P4D12 MAb之穩定性。
在另一實施例中,抗體之Fc鉸鏈區突變以縮短191P4D12 MAb之生物半衰期。更特定言之,將一或多種胺基酸突變引入Fc鉸鏈片段之CH2-CH3域界面區內以使得抗體之葡萄球菌蛋白A(Staphylococcyl protein A,SpA)結合相對於天然Fc鉸鏈域SpA結合有所削弱。此方法進一步詳細描述於Ward等人之美國專利第6,165,745號中。
在另一實施例中,191P4D12 MAb經修飾以延長其生物半衰期。多種方法可行。舉例而言,可如Ward之美國專利第6,277,375號中所述引入突變。或者,為延長生物半衰期,抗體可在CH1或CL區內發生改變以含有取自IgG之Fc區之CH2域的兩個環之救助受體結合抗原決定基,如Presta等人之美國專利第5,869,046號及第6,121,022號中所述。
在其他實施例中,藉由用不同胺基酸殘基置換至少一個胺基酸殘基來改變Fc區以改變191P4D12 MAb之效應功能。舉例而言,一或多個選自胺基酸特異性殘基之胺基酸可由不同胺基酸殘基置換以使得抗體對於效應配位體之親和性發生改變,但保留親本抗體之抗原結合能力。親和性改變之效應配位體可為例如Fc受體或補體之C1組分。此方法進一步詳細描述於Winter等人之美國專利第5,624,821號及第5,648,260號中。
191P4D12抗體與191P4D12相關蛋白之反應性可藉由包括西方墨點法(Western blot)、免疫沈澱、ELISA及FACS分析之多種熟知方法,視情況使用191P4D12相關蛋白、191P4D12表現細胞或其萃取物來確定。191P4D12抗體或其片段可經可偵測標誌標記或與第二分子共軛。適合之可偵測標誌包括(但不限於)放射性同位素、螢光化合物、生物發光化合物、化學發光化合物、金屬螯合劑或酶。此外,對於兩個或兩個以上191P4D12抗原決定基具有特異性之雙特異性抗體係使用此項技術中一般已知之方法來產生。均二聚抗體亦可藉由此項技術中已知之交聯技術(例如Wolff等人Cancer Res. 53: 2560-2565)來產生。
在另一較佳實施例中,本發明之191P4D12 MAb為包含稱為Ha22-2(2,4)6.1之抗體之重鏈及輕鏈的抗體。Ha22-2(2,4)6.1之重鏈由範圍為SEQ ID NO:7之第20位之E殘基至第466位之K殘基的胺基酸序列組成,且Ha22-2(2,4)6.1之輕鏈由範圍為SEQ ID NO:8序列之第23位之D殘基至第236位之C殘基的胺基酸序列組成。該等序列如圖2及圖3中所示。在一較佳實施例中,Ha22-2(2,4)6.1與細胞毒性劑共軛。
產生稱為
Ha22-2(2,4)6.1之抗體的融合瘤於
2010 年 8 月 18 日(經由Federal Express)送至美國菌種保存中心(ATCC),郵政信箱1549,Manassas,VA 20108且給予寄存編號
PTA-11267。
III.) 抗體-藥物共軛物概述
在另一態樣中,本發明提供抗體藥物共軛物(ADC),其包含抗體與細胞毒性劑共軛,該細胞毒性劑諸如化學治療劑、藥物、生長抑制劑、毒素(例如細菌、真菌、植物或動物來源之酶促活性毒素,或其片段)或放射性同位素(亦即放射性共軛物)。在另一態樣中,本發明進一步提供使用ADC之方法。在一態樣中,ADC包含本文191P4D12 MAb中之任一者共價連接於細胞毒性劑或可偵測藥劑。
使用抗體-藥物共軛物局部傳遞細胞毒性劑或細胞生長抑制劑(亦即在治療癌症中殺死或抑制腫瘤細胞之藥物)(Syrigos及Epenetos (1999) Anticancer Research 19:605-614; Niculescu-Duvaz and Springer (1997) Adv. Drg Del. Rev. 26:151-172;美國專利4,975,278)允許將藥物部分靶向傳遞至腫瘤,且在腫瘤中進行細胞內積累,其中全身投與此等未共軛之藥物藥劑會對正常細胞以及設法消除之腫瘤細胞產生不可接受之毒性程度(Baldwin等人(1986) Lancet 頁碼(1986年3月15日):603-05;Thorpe, (1985) 「Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review,」 Monoclonal Antibodies '84: Biological And Clinical Applications, A. Pinchera等人(編),第475-506頁)。因此,應設法使毒性最小而功效最大。已報導多株抗體與單株抗體皆適用於此等策略(Rowland等人(1986) Cancer Immunol. Immunother., 21:183-87)。此等方法中所用之藥物包括道諾黴素(daunomycin)、阿黴素、甲胺喋呤(methotrexate)及長春地辛(vindesine)(Rowland等人(1986)同上)。抗體-毒素共軛物中所用之毒素包括細菌毒素,諸如白喉毒素;植物毒素,諸如蓖麻毒素;小分子毒素,諸如格爾德黴素(geldanamycin)(Mandler等人(2000) Jour. of the Nat. Cancer Inst. 92(19):1573-1581;Mandler等人(2000) Bioorganic & Med. Chem. Letters 10:1025-1028;Mandler等人(2002) Bioconjugate Chem. 13:786-791)、類美登素(EP 1391213;Liu等人(1996) Proc. Natl. Acad. Sci. USA 93:8618-8623)及卡奇黴素(Lode等人(1998) Cancer Res. 58:2928;Hinman等人(1993) Cancer Res.53:3336-3342)。該等毒素可藉由包括微管蛋白結合、DNA結合或拓撲異構酶抑制之機制來實現其細胞毒性及細胞抑制作用。一些細胞毒性藥物在與大抗體或蛋白質受體配位體共軛時趨於變成非活性的或弱活性的。
抗體藥物共軛物之實例為ZEVALIN® (替伊莫單抗(ibritumomab tiuxetan),Biogen/Idec),其為由針對存在於正常及惡性B淋巴細胞表面上的CD20抗原之鼠類IgG1 κ單株抗體及由硫脲連接子-螯合劑結合之
111In或
90Y放射性同位素構成之抗體-放射性同位素共軛物(Wiseman等人(2000) Eur. Jour. Nucl. Med. 27(7):766-77;Wiseman等人(2002) Blood 99(12):4336-42;Witzig等人(2002) J. Clin. Oncol. 20(10):2453-63;Witzig等人(2002) J. Clin. Oncol. 20(15):3262-69)。
另外,MYLOTARG
TM(奧吉妥珠單抗(gemtuzumab ozogamicin),Wyeth Pharmaceuticals),一種由hu CD33抗體連接於卡奇黴素構成之抗體藥物共軛物,於2000年獲准用於注射治療急性骨髓性白血病(Drugs of the Future (2000) 25 (7):686;美國專利第4970198號;第5079233號;第5585089號;第5606040號;第5693762號;第5739116號;第5767285號;第5773001號)。
另外,美坎珠單抗(Cantuzumab mertansine)(Immunogen, Inc.),一種由huC242抗體經由二硫化物連接子SPP連接於類美登素藥物部分DM1構成之抗體藥物共軛物,正進入表現CanAg之癌症(諸如結腸癌、胰臟癌、胃癌及其他癌症)治療的II期試驗。
另外,MLN-2704(Millennium Pharm., BZL Biologics, Immunogen Inc.),一種由抗前列腺特異性膜抗原(PSMA)單株抗體連接於類美登素藥物部分DM1構成之抗體藥物共軛物,正在開發用於前列腺腫瘤之潛在治療。
最後,奧瑞他汀肽、奧瑞他汀E(AE)及單甲基奧瑞他汀(MMAE),海兔毒素之合成類似物,係與嵌合單株抗體cBR96(對癌瘤上之Lewis Y具有特異性)及cAC10(對血液惡性腫瘤上之CD30具有特異性)共軛(Doronina等人(2003) Nature Biotechnology 21 (7):778-784)且正在治療開發中。
此外,本文描述適用於產生ADC之化學治療劑。可使用之酶促活性毒素及其片段包括白喉A鏈、白喉毒素之非結合活性片段、外毒素A鏈(來自綠膿桿菌(Pseudomonas aeruginosa))、篦麻毒素A鏈、相思豆毒素A鏈、莫迪素(modeccin)A鏈、α-帚麴菌素、油桐(Aleurites fordii)蛋白、石竹素(dianthin)蛋白、美洲商陸(Phytolaca americana)蛋白(PAPI、PAPII及PAP-S)、苦瓜(momordica charantia)抑制劑、麻瘋樹毒蛋白、巴豆毒素、肥皂草抑制劑、白樹素、有絲分裂素、侷限麴菌素、酚黴素、伊諾黴素及黴菌毒素(tricothecene)。參見例如1993年10月28日公開之WO 93/21232。多種放射性核素可用於產生放射性共軛之抗體。實例包括
212Bi、
131I、
131In、
90Y及
186Re。抗體與細胞毒性劑之共軛物可使用多種雙官能蛋白偶合劑製得,該等蛋白偶合劑諸如N-丁二醯亞胺基-3-(2-吡啶基二硫醇)丙酸酯(SPDP)、亞胺基硫雜環戊烷(IT)、醯亞胺酯之雙官能衍生物(諸如二亞胺代己二酸二甲酯鹽酸鹽)、活性酯(諸如辛二酸二丁二醯亞胺酯)、醛(諸如戊二醛)、雙疊氮基化合物(諸如雙(對疊氮基苯甲醯基)己二胺)、雙重氮鹽衍生物(諸如雙(對重氮鹽苯甲醯基)-乙二胺)、二異氰酸酯(諸如甲苯2,6-二異氰酸酯)及雙活性氟化合物(諸如1,5-二氟-2,4-二硝基苯)。舉例而言,蓖麻毒素免疫毒素可如Vitetta等人(1987) Science, 238:1098中所述來製備。標記碳14之1-異硫氰基苯甲基-3-甲基二伸乙三胺五乙酸(MX-DTPA)為使放射性核苷酸與抗體共軛之例示性螯合劑(WO94/11026)。
本文亦涵蓋抗體與一或多種小分子毒素(諸如卡奇黴素、類美登素、海兔毒素、奧瑞他汀、新月毒素(trichothecene)及CC1065以及此等毒素具有毒素活性之衍生物)之共軛物。
III(A). 類美登素適合用作類美登素藥物部分之美登素(maytansine)化合物為此項技術所熟知,且可根據已知方法自天然來源分離,使用基因工程改造技術產生(參見Yu等人(2002) PNAS 99:7968-7973),或根據已知方法合成製備美登醇(maytansinol)及美登醇類似物。
例示性類美登素藥物部分包括具有經修飾之芳族環的類美登素藥物部分,該等修飾諸如:C-19-去氯(US 4256746)(藉由安絲菌素(ansamytocin)P2之氫化鋰鋁還原來製備);C-20-羥基(或C-20-去甲基)+/-C-19-去氯(美國專利第4,361,650號及第4,307,016號)(藉由使用鏈黴菌(Streptomyces)或放線菌(Actinomyces)去甲基或使用LAH去氯來製備);及C-20-去甲氧基、C-20-醯氧基(-OCOR)、+/-去氯(美國專利第4,294,757號)(藉由使用醯氯醯化來製備);及在其他位置具有修飾之類美登素藥物部分。
例示性類美登素藥物部分亦包括具有諸如以下修飾之類美登素藥物部分:C-9-SH(US 4,424,219)(藉由美登醇與H
2S或P
2S
5反應來製備);C-14-烷氧基甲基(去甲氧基/CH
2OR)(US 4331598);C-14-羥甲基或醯氧基甲基(CH
2OH或CH
2OAc)(US 4450254)(由奴卡菌(Nocardia)製備);C-15-羥基/醯氧基(US 4,364,866)(藉由鏈黴菌轉化美登醇來製備);C-15-甲氧基(美國專利第4,313,946號及第4,315,929號)(自滑桃木(Trewia nudlflora)分離);C-18-N-去甲基(美國專利第4,362,663號及第4,322,348號)(藉由鏈黴菌使美登醇去甲基來製備);及4,5-去氧(US 4,371,533)(藉由美登醇之三氯化鈦/LAH還原來製備)。
含有類美登素之ADC、製備其之方法及其治療用途揭示於例如美國專利第5,208,020號、第5,416,064號、第6,441,163號及歐洲專利EP 0 425 235 B1中,該等專利之揭示內容以引用的方式明確地併入本文中。Liu等人Proc. Natl. Acad. Sci. USA
93:8618-8623 (1996)描述包含類美登素(稱為DM1)連接於針對人類結腸直腸癌之單株抗體C242的ADC。已發現該共軛物對所培養之結腸癌細胞具有高細胞毒性且在活體內腫瘤生長檢定中顯示抗腫瘤活性。Chari等人Cancer Research 52:127-131 (1992)描述如下ADC,其中類美登素經由二硫化物連接子與結合於人類結腸癌細胞株上之抗原的鼠類抗體A7共軛,或與結合HER-2/neu致癌基因之另一鼠類單株抗體TA.1共軛。活體外測試TA.1-類美登素共軛物對人類乳癌細胞株SK-BR-3之細胞毒性,該細胞株每個細胞表現3×10
5個HER-2表面抗原。藥物共軛物達成與游離類美登素藥物類似之細胞毒性程度,該細胞毒性程度可藉由增加每個抗體分子類美登素化合物分子之數目而增加。A7-類美登素共軛物在小鼠體內顯示低全身性細胞毒性。
III(B). 奧瑞他汀及海兔毒素在一些實施例中,ADC包含本發明之抗體與海兔毒素或海兔毒素肽類似物及衍生物,奧瑞他汀共軛(美國專利第5,635,483號、第5,780,588號)。已顯示海兔毒素及奧瑞他汀干擾微管動力學、GTP水解及核分裂與細胞分裂(Woyke等人(2001) Antimicrob. Agents and Chemother. 45(12):3580-3584)且具有抗癌活性(US 5,663,149)及抗真菌活性(Pettit等人(1998) Antimicrob. Agents Chemother.42:2961-2965)。海兔毒素或奧瑞他汀藥物部分可經由肽藥物部分之N(胺基)端或C(羧基)端連接於抗體(WO 02/088172)。
例示性奧瑞他汀實施例包括「Senter等人Proceedings of the American Association for Cancer Research,第45卷,摘要編號623, 2004年3月28日提交」中所揭示及美國專利公開案第2005/0238649號中所述之N端連接之單甲基奧瑞他汀藥物部分DE及DF,該等專利之揭示內容以全文引用的方式明確地併入本文中。
一例示性奧瑞他汀實施例為MMAE(其中波形線指示共價連接於抗體藥物共軛物之連接子(L))。
MMAE
另一例示性奧瑞他汀實施例為MMAF,其中波形線指示共價連接於抗體藥物共軛物之連接子(L)(US 2005/0238649):
MMAF。
包含MMAE或MMAF及各種連接子組分(本文進一步描述)之其他例示性實施例具有以下結構及縮寫(其中Ab意謂抗體,S為抗體之硫,且p為1至約8):
Ab-MC-vc-PAB-MMAF
Ab-MC-vc-PAB-MMAE
Ab-MC-MMAF。
肽基藥物部分通常可藉由在兩個或兩個以上胺基酸及/或肽片段之間形成肽鍵來製備。該等肽鍵可例如根據肽化學領域中熟知之液相合成法(參見E. Schröder及K. Lübke, 「The Peptides」,第1卷,第76-136頁,1965, Academic Press)來製備。奧瑞他汀/海兔毒素藥物部分可根據以下方法來製備:US 5635483;US 5780588;Pettit等人(1989) J. Am. Chem. Soc. 111:5463-5465;Pettit等人(1998) Anti-Cancer Drug Design 13:243-277;Pettit, G.R.等人Synthesis, 1996, 719-725;Pettit等人(1996) J. Chem. Soc. Perkin Trans. 1 5:859-863;及Doronina (2003) Nat Biotechnol 21(7):778-784。
III(C). 卡奇黴素在其他實施例中,ADC包含本發明之抗體與一或多個卡奇黴素分子共軛。抗生素之卡奇黴素家族能夠在次皮莫耳濃度下產生雙股DNA碎片。關於卡奇黴素家族共軛物之製備,參見美國專利第5,712,374號、第5,714,586號、第5,739,116號、第5,767,285號、第5,770,701號、第5,770,710號、第5,773,001號、第5,877,296號(全部均屬於American Cyanamid Company)。可使用之卡奇黴素的結構類似物包括(但不限於)γ
1 I、α
2 I、α
3 I、N-醯基-γ
1 I、PSAG及θ
I 1(Hinman等人Cancer Research 53:3336-3342 (1993);Lode等人Cancer Research 58:2925-2928 (1998);及屬於American Cyanamid之上述美國專利)。可與抗體共軛之另一抗腫瘤藥物為QFA,其為抗葉酸劑。卡奇黴素與QFA皆具有細胞內作用位點且不易跨過質膜。因此,細胞經由抗體介導之內化作用攝取此等藥劑可顯著增強其細胞毒性作用。
III(D). 其他細胞毒性劑可與本發明之抗體共軛的其他抗腫瘤劑包括BCNU、鏈脲黴素(streptozoticin)、長春新鹼及5-氟尿嘧啶,美國專利第5,053,394號、第5,770,710號中所述之共同稱為LL-E33288複合物的藥劑家族,以及埃坡黴素(esperamicin)(美國專利第5,877,296號)。
可使用之酶促活性毒素及其片段包括白喉A鏈、白喉毒素之非結合活性片段、外毒素A鏈(來自綠膿桿菌)、篦麻毒素A鏈、相思豆毒素A鏈、莫迪素A鏈、α-帚麴菌素、油桐蛋白、石竹素蛋白、美洲商陸蛋白(PAPI、PAPII及PAP-S)、苦瓜抑制劑、麻瘋樹毒蛋白、巴豆毒素、肥皂草抑制劑、白樹素、有絲分裂素、侷限麴菌素、酚黴素、伊諾黴素及黴菌毒素。參見例如1993年10月28日公開之WO 93/21232。
本發明進一步涵蓋抗體與具有核分解活性之化合物(例如核糖核酸酶或DNA內切酶,諸如去氧核糖核酸酶;DNA酶)之間所形成的ADC。
為選擇性破壞腫瘤,抗體可包含高放射性原子。可使用多種放射性同位素產生放射性共軛抗體。實例包括At
211、I
131、I
125、Y
90、Re
186、Re
188、Sm
153、Bi
212、P
32、Pb
212及Lu之放射性同位素。當使用共軛物進行偵測時,其可包含用於閃爍攝影研究之放射性原子,例如tc
99m或I
123;或用於核磁共振(NMR)成像(亦稱為磁共振成像,mri)之自旋標記,諸如又為碘-123、碘-131、銦-111、氟-19、碳-13、氮-15、氧-17、釓、錳或鐵。
可以已知方式將放射性標記或其他標記併入共軛物中。舉例而言,肽可經生物合成,或可藉由使用涉及例如以氟-19替代氫之適合胺基酸前驅物進行化學胺基酸合成來合成。諸如tc
99m或I
123、Re
186、Re
188及In
111之標記可經由肽中之半胱胺酸殘基連接。釔-90可經由離胺酸殘基連接。IODOGEN方法(Fraker等人(1978) Biochem. Biophys. Res. Commun. 80: 49-57)可用於合併碘-123。「Monoclonal Antibodies in Immunoscintigraphy」(Chatal,CRC Press 1989)詳細地描述其他方法。
IV.) 結合191P4D12之抗體-藥物共軛物化合物
本發明提供用於靶向傳遞藥物之抗體-藥物共軛物化合物。發明者已發現抗體-藥物共軛物化合物具有針對表現191P4D12之細胞的有效細胞毒性及/或細胞生長抑制活性。抗體-藥物共軛物化合物包含抗體單元共價連接於至少一個藥物單元。該等藥物單元可直接或經由連接子單元(LU)共價連接。
在一些實施例中,抗體藥物共軛物化合物具有下式:
L-(LU-D)
p (I)或其醫藥學上可接受之鹽或溶劑合物,其中
L為抗體單元,例如本發明之191P4D12 MAb,且
(LU-D)為連接子單元-藥物單元部分,其中:
LU-為連接子單元,且
-D為具有針對標靶細胞之細胞生長抑制活性或細胞毒性活性的藥物單元;且
p為整數1至20。
在一些實施例中,p在1至10、1至9、1至8、1至7、1至6、1至5、1至4、1至3或1至2之範圍內。在一些實施例中,p在2至10、2至9、2至8、2至7、2至6、2至5、2至4或2至3之範圍內。在其他實施例中,p為1、2、3、4、5或6。在一些實施例中,p為2或4。
在一些實施例中,抗體藥物共軛物化合物具有下式:
L-(A
a-W
w-Y
y-D)
p (II)或其醫藥學上可接受之鹽或溶劑合物,其中:
L為抗體單元,例如191P4D12 MAb;且
-A
a-W
w-Y
y-為連接子單元(LU),其中:
-A-為延伸子單元,
a為0或1,
各-W-獨立地為胺基酸單元,
w為0至12範圍內之整數,
-Y-為自我分解型間隔子單元,
y為0、1或2;
-D為具有針對標靶細胞之細胞生長抑制活性或細胞毒性活性的藥物單元;且
p為整數1至20。
在一些實施例中,a為0或1,w為0或1,且y為0、1或2。在一些實施例中,a為0或1,w為0或1,且y為0或1。在一些實施例中,p在1至10、1至9、1至8、1至7、1至6、1至5、1至4、1至3或1至2之範圍內。在一些實施例中,p在2至8、2至7、2至6、2至5、2至4或2至3之範圍內。在其他實施例中,p為1、2、3、4、5或6。在一些實施例中,p為2或4。在一些實施例中,當w不為0時,y為1或2。在一些實施例中,當w為1至12時,y為1或2。在一些實施例中,w為2至12且y為1或2。在一些實施例中,a為1且w及y為0。
對於包含複數個抗體之組合物,藥物負載由每個抗體藥物分子之平均數目p表示。藥物負載可在每個抗體1至20個藥物(D)之範圍內。在預備共軛反應時每個抗體之藥物平均數目可藉由諸如質譜法、ELISA檢定及HPLC之習知手段來表徵。亦可根據p確定抗體-藥物共軛物之定量分佈。在一些情況下,均質抗體-藥物共軛物可藉由諸如逆相HPLC或電泳之手段來分離、純化及表徵,其中p為具有其他藥物負載之抗體藥物共軛物的某一值。在例示性實施例中,p為2至8。
抗體-藥物共軛物化合物可藉由熟習此項技術者已知之任何技術來產生。簡言之,抗體-藥物共軛物化合物包含191P4D12 MAb作為抗體單元、藥物及視情況存在之連接藥物與結合劑之連接子。在一較佳實施例中,抗體為包含上述稱為Ha22-2(2,4)6.1之抗體之重鏈及輕鏈可變區的191P4D12 MAb。在更佳實施例中,抗體為包含上述稱為Ha22-2(2,4)6.1之抗體之重鏈及輕鏈的191P4D12 MAb。多種不同反應可用於使藥物及/或連接子共價連接於結合劑。此通常藉由使結合劑(例如抗體分子)之胺基酸殘基反應來完成,該等胺基酸殘基包括離胺酸之胺基、麩胺酸及天冬胺酸之游離羧酸基、半胱胺酸之氫硫基及芳族胺基酸之各種部分。共價連接之最常用非特異性方法之一為使化合物之羧基(或胺基)連接於抗體之胺基(或羧基)之碳化二亞胺反應。另外,已使用雙官能劑(諸如二醛或醯亞胺酯)使化合物之胺基連接於抗體分子之胺基。席夫鹼反應(Schiff base reaction)亦可用於使藥物連接於結合劑。此方法涉及含有二醇或羥基之藥物的過碘酸鹽氧化,從而形成醛,接著使其與結合劑反應。經由用結合劑之胺基形成席夫鹼來進行連接。異硫氰酸酯亦可用作使藥物共價連接於結合劑之偶合劑。其他技術為熟習此項技術者所知且在本發明之範疇內。
在某些實施例中,在適當條件下使作為連接子之前驅體的中間物與藥物反應。在某些實施例中,使用藥物及/或中間物上之反應性基團。隨後在適當條件下使藥物與中間物之間的反應產物或衍生藥物與191P4D12 MAb反應。
本文更詳細地描述抗體-藥物共軛物化合物之各特定單元。例示性連接子單元、延伸子單元、胺基酸單元、自我分解型間隔子單元及藥物單元之合成及結構亦描述於美國專利申請公開案第2003-0083263號、第2005-0238649號及第2005-0009751號中,其中每一者均以全文引用的方式且出於所有目的併入本文中。
V.) 連接子單元
通常,抗體-藥物共軛物化合物在藥物單元與抗體單元之間包含連接子單元。在一些實施例中,連接子在細胞內條件下可裂解,以使得在細胞內環境中連接子之裂解可自抗體釋放藥物單元。在其他實施例中,連接子單元不可裂解且藥物例如藉由抗體降解而釋放。
在一些實施例中,連接子可由細胞內環境中(例如溶酶體或內體或胞膜窖(caveolea)內)存在之裂解劑裂解。連接子可為例如肽基連接子,其可由細胞內之肽酶或蛋白酶(包括(但不限於)溶酶體或內體蛋白酶)裂解。在一些實施例中,肽基連接子為至少兩個胺基酸長或至少三個胺基酸長。裂解藥劑可包括組織蛋白酶B及D及纖維蛋白溶酶,已知其全部均可水解二肽藥物衍生物,使得活性藥物在標靶細胞內釋放(參見例如Dubowchik及Walker, 1999,
Pharm.
Therapeutics83:67-123)。更典型為可由191P4D12表現細胞中存在之酶裂解的肽基連接子。舉例而言,可使用可由在癌性組織中高度表現之硫醇依賴性蛋白酶組織蛋白酶B裂解的肽基連接子(例如Phe-Leu或Gly-Phe-Leu-Gly連接子(SEQ ID NO:9))。該等連接子之其他實例描述於例如美國專利第6,214,345號中,該專利以全文引用的方式且出於所有目的併入本文中。在一特定實施例中,可由細胞內蛋白酶裂解之肽基連接子為Val-Cit連接子或Phe-Lys連接子(參見例如美國專利6,214,345,其描述具有Val-Cit連接子之阿黴素的合成)。細胞內蛋白水解釋放治療劑之一優勢為藥劑通常在共軛時會減毒且共軛物之血清穩定性通常較高。
在其他實施例中,可裂解連接子對pH值敏感,亦即對在某些pH值下水解敏感。通常,pH值敏感性連接子可在酸性條件下水解。舉例而言,可使用可在溶酶體中水解之酸不穩定性連接子(例如腙、半卡巴腙(semicarbazone)、硫半卡巴腙(thiosemicarbazone)、順烏頭醯胺、原酸酯、縮醛、縮酮或其類似物)。(參見例如美國專利第5,122,368號;第5,824,805號;第5,622,929號;Dubowchik and Walker, 1999,
Pharm. Therapeutics83:67-123; Neville等人1989,
Biol. Chem.264:14653-14661。)該等連接子在中性pH值條件(諸如血液中之pH值條件)下相對穩定,但在低於pH 5.5或5.0(近似溶酶體之pH值)下不穩定。在某些實施例中,可水解連接子為硫醚連接子(諸如經由醯基腙鍵連接於治療劑之硫醚(參見例如美國專利第5,622,929號))。
在其他實施例中,連接子可在還原條件下裂解(例如二硫化物連接子)。各種二硫化物連接子為此項技術所知,包括例如可使用以下形成之二硫化物連接子:SATA(N-丁二醯亞胺基-S-乙醯基硫基乙酸酯)、SPDP(N-丁二醯亞胺基-3-(2-吡啶基二硫基)丙酸酯)、SPDB(N-丁二醯亞胺基-3-(2-吡啶基二硫基)丁酸酯)及SMPT(N-丁二醯亞胺基-氧羰基-α-甲基-α-(2-吡啶基-二硫基)甲苯)、SPDB及SMPT。(參見例如Thorpe等人1987,
Cancer Res. 47:5924-5931;Wawrzynczak等人
Immunoconjugates: Antibody Conjugates in Radioimagery and Therapy of Cancer(C. W. Vogel編,Oxford U. Press, 1987。亦參見美國專利第4,880,935號。)
在其他特定實施例中,連接子為丙二酸酯連接子(Johnson等人1995,
Anticancer Res. 15:1387-93)、順丁烯二醯亞胺基苯甲醯基連接子(Lau等人1995,
Bioorg-Med-Chem.3(10):1299-1304)或3'-N-醯胺類似物(Lau等人1995,
Bioorg-Med-Chem.3(10):1305-12)。
在其他實施例中,連接子單元不可裂解且藥物藉由抗體降解而釋放。(參見美國公開案第2005/0238649號,該案以全文引用的方式且出於所有目的併入本文中)。
通常,連接子不對細胞外環境相當敏感。如本文中所使用,在連接子之情況下,「不對細胞外環境相當敏感」意謂當抗體-藥物共軛物化合物呈現於細胞外環境中(例如血漿中)時,抗體藥物共軛物化合物之樣品中不超過約20%、通常不超過約15%、更通常不超過約10%且甚至更通常不超過約5%、不超過約3%或不超過約1%之連接子裂解。連接子是否不對細胞外環境相當敏感可例如藉由使抗體-藥物共軛物化合物與血漿一起培育一段預定時間(例如2、4、8、16或24小時),接著定量血漿中存在之游離藥物的量來判定。
在其他非互斥實施例中,連接子促進細胞內化。在某些實施例中,當連接子與治療劑共軛時(亦即在如本文所述之抗體藥物共軛物化合物的連接子-治療劑部分的環境下),其促進細胞內化。在其他實施例中,當連接子與奧瑞他汀化合物與191P4D12 MAb共軛時,其促進細胞內化。
可用於本發明組合物及方法之各種例示性連接子描述於WO 2004-010957、美國公開案第2006/0074008號、美國公開案第20050238649號及美國公開案第2006/0024317號(其中每一者均以全文引用的方式且出於所有目的併入本文中)中。
「連接子單元」(LU)為可用於連接藥物單元及抗體單元以形成抗體-藥物共軛物化合物之雙官能化合物。在一些實施例中,連接子單元具有下式:
-A
a-W
w-Y
y-
其中:-A-為延伸子單元,
a為0或1,
各-W-獨立地為胺基酸單元,
w為0至12範圍內之整數,
-Y-為自我分解型間隔子單元,且
y為0、1或2。
在一些實施例中,a為0或1,w為0或1,且y為0、1或2。在一些實施例中,a為0或1,w為0或1,且y為0或1。在一些實施例中,當w為1至12時,y為1或2。在一些實施例中,w為2至12且y為1或2。在一些實施例中,a為1且w及y為0。
VI.) 延伸子單元
延伸子單元(A)(若存在)能夠使抗體單元連接於胺基酸單元(-W-)(若存在)、連接於間隔子單元(-Y-)(若存在)或連接於藥物單元(-D)。可存在於191P4D12 MAb(例如Ha22-2(2,4)6.1)上之天然或經由化學處理的適用官能基包括(但不限於)氫硫基、胺基、羥基、碳水化合物之變旋異構羥基及羧基。適合之官能基為氫硫基及胺基。在一實例中,氫硫基可藉由還原191P4D12 MAb之分子內二硫鍵來產生。在另一實施例中,氫硫基可藉由使191P4D12 MAb之離胺酸部分的胺基與2-亞胺基硫雜環戊烷(陶氏試劑(Traut's reagent))或其他氫硫基產生劑反應來產生。在某些實施例中,191P4D12 MAb為重組抗體且經工程改造以帶有一或多個離胺酸。在某些其他實施例中,重組191P4D12 MAb經工程改造以帶有其他氫硫基,例如其他半胱胺酸。
在一實施例中,延伸子單元與抗體單元之硫原子形成一鍵。該硫原子可來源於抗體之氫硫基。此實施例之代表性延伸子單元描繪於式IIIa及IIIb之方括號中,其中L-、-W-、-Y-、-D、w及y如上文所定義,且R
17係選自-C
1-C
10伸烷基-、-C
1-C
10伸烯基-、-C
1-C
10伸炔基-、碳環基-、-O-(C
1-C
8伸烷基)-、O-(C
1-C
8伸烯基)-、-O-(C
1-C
8伸炔基)-、-伸芳基-、-C
1-C
10伸烷基-伸芳基-、-C
2-C
10伸烯基-伸芳基、-C
2-C
10伸炔基-伸芳基、-伸芳基-C
1-C
10伸烷基-、-伸芳基-C
2-C
10伸烯基-、-伸芳基-C
2-C
10伸炔基-、-C
1-C
10伸烷基-(碳環基)-、-C
2-C
10伸烯基-(碳環基)-、-C
2-C
10伸炔基-(碳環基)-、-(碳環基)-C
1-C
10伸烷基-、-(碳環基)-C
2-C
10伸烯基-、-(碳環基)-C
2-C
10伸炔基、-雜環-、-C
1-C
10伸烷基-(雜環)-、-C
2-C
10伸烯基-(雜環)-、-C
2-C
10伸炔基-(雜環)-、-(雜環)-C
1-C
10伸烷基-、-(雜環)-C
2-C
10伸烯基-、-(雜環)-C
1-C
10伸炔基-、-(CH
2CH
2O)
r-或-(CH
2CH
2O)
r-CH
2-,且r為1-10範圍內之整數,其中單獨或另一基團之一部分的該等烷基、烯基、炔基、伸烷基、伸烯基、伸炔基、芳基、碳環、碳環基、雜環及伸芳基視情況經取代。在一些實施例中,單獨或作為另一基團之一部分的該等烷基、烯基、炔基、伸烷基、伸烯基、伸炔基、芳基、碳環、碳環基、雜環基及伸芳基未經取代。在一些實施例中,R
17係選自-C
1-C
10伸烷基-、-碳環基-、-O-(C
1-C
8伸烷基)-、-伸芳基-、-C
1-C
10伸烷基-伸芳基-、-伸芳基-C
1-C
10伸烷基-、-C
1-C
10伸烷基-(碳環基)-、-(碳環基)-C
1-C
10伸烷基-、-C
3-C
8雜環基-、-C
1-C
10伸烷基-(雜環基)-、-(雜環基)-C
1-C
10伸烷基-、-(CH
2CH
2O)
r-及-(CH
2CH
2O)
r-CH
2-;且r為1-10範圍內之整數,其中該等伸烷基未經取代且該等基團之其餘部分視情況經取代。
自所有例示性實施例應瞭解,當未明確表示時,1至20個藥物部分可連接於抗體(p=1-20)。
IIIa
IIIb
說明性延伸子單元為式IIIa之延伸子單元,其中R
17為-(CH
2)
5-:
。
另一說明性延伸子單元為式IIIa之延伸子單元,其中R
17為-(CH
2CH
2O)
r-CH
2-;且r為2:
。
說明性延伸子單元為式IIIa之延伸子單元,其中R
17為伸芳基-或伸芳基-C
1-C
10伸烷基-。在一些實施例中,該芳基為未經取代之苯基。
又一說明性延伸子單元為式IIIb之延伸子單元,其中R
17為-(CH
2)
5-:
。
在某些實施例中,延伸子單元經由抗體單元之硫原子與延伸子單元之硫原子之間的二硫鍵連接於抗體單元。此實施例之代表性延伸子單元描繪於式IV之方括號中,其中R
17、L-、-W-、-Y-、-D、w及y如上文所定義。
IV應注意在本申請案中,除非本文另有指示,否則下式中之S部分係指抗體單元之硫原子。
在其他實施例中,延伸子含有可與抗體之一級或二級胺基形成一鍵的反應性位點。此等反應性位點之實例包括(但不限於)活化酯,諸如丁二醯亞胺酯、4-硝基苯酯、五氟苯酯、四氟苯酯、酸酐、酸氯化物、磺醯氯、異氰酸酯及異硫氰酸酯。此實施例之代表性延伸子單元描繪於式Va及Vb之方括號中,其中-R
17-、L-、-W-、-Y-、-D、w及y如上文所定義;
Va Vb。
在一些實施例中,延伸子含有可與可存在於抗體上之經修飾之碳水化合物的(-CHO)基團反應之反應性位點。舉例而言,碳水化合物可使用諸如過碘酸鈉之試劑適度氧化且所產生的氧化碳水化合物之(-CHO)單元可與含有諸如醯肼、肟、一級或二級胺、肼、硫半卡巴腙、羧酸肼及芳基醯肼之官能基的延伸子縮合,諸如Kaneko等人1991,
Bioconjugate Chem.2:133-41所述之延伸子。此實施例之代表性延伸子單元描繪於式VIa、VIb及VIc之方括號中,其中-R
17-、L-、-W-、-Y-、-D、w及y如上文所定義。
Via VIb Vic
VII.) 胺基酸單元
若間隔子單元存在,則胺基酸單元(-W-)(若存在)使延伸子單元連接於間隔子單元,若間隔子單元不存在,則使延伸子單元連接於藥物部分,且若延伸子單元及間隔子單元不存在,則使抗體單元連接於藥物單元。
W
w-可為例如單肽、二肽、三肽、四肽、五肽、六肽、七肽、八肽、九肽、十肽、十一肽或十二肽單元。各-W-單元獨立地具有以下方括號中所示之式,且w為0至12範圍內之整數:
或
其中R
19為氫、甲基、異丙基、異丁基、第二丁基、苯甲基、對羥基苯甲基、-CH
2OH、-CH(OH)CH
3、-CH
2CH
2SCH
3、-CH
2CONH
2、-CH
2COOH、-CH
2CH
2CONH
2、-CH
2CH
2COOH、-(CH
2)
3NHC(=NH)NH
2
、-(CH
2)
3NH
2、-(CH
2)
3NHCOCH
3、-(CH
2)
3NHCHO、-(CH
2)
4NHC(=NH)NH
2
、-(CH
2)
4NH
2、-(CH
2)
4NHCOCH
3、-(CH
2)
4NHCHO、-(CH
2)
3NHCONH
2
、-(CH
2)
4NHCONH
2、-CH
2CH
2CH(OH)CH
2NH
2、2-吡啶基甲基-、3-吡啶基甲基-、4-吡啶基甲基-、苯基、環己基、
在一些實施例中,胺基酸單元可以酶方法由一或多種酶(包括癌症或腫瘤相關蛋白酶)裂解,以釋放藥物單元(-D),在一實施例中,其在釋放後在活體內經質子化以提供藥物(D)。
在某些實施例中,胺基酸單元可包含天然胺基酸。在其他實施例中,胺基酸單元可包含非天然胺基酸。說明性Ww單元由式(VII)-(IX)表示:
(
VII)
其中R
20及R
21如下:
(
VIII)
其中R
20、R
21及R
22如下:
(
IX)
其中R
20、R
21、R
22及R
23如下:
例示性胺基酸單元包括(但不限於)式VII之單元,其中:R
20為苯甲基且R
21為-(CH
2)
4NH
2;R
20為異丙基且R
21為-(CH
2)
4NH
2;或R
20為異丙基且R
21為-(CH
2)
3NHCONH
2。另一例示性胺基酸單元為式VIII之單元,其中R
20為苯甲基,R
21為苯甲基,且R
22為-(CH
2)
4NH
2。
適用-W
w-單元可關於其對由特定酶(例如腫瘤相關蛋白酶)酶促裂解之選擇性進行設計及最佳化。在一實施例中,-W
w-單元為其裂解由組織蛋白酶B、C及D或纖維蛋白溶酶蛋白酶催化之單元。
在一實施例中,-W
w-為二肽、三肽、四肽或五肽。當R
19、R
20、R
21、R
22或R
23不為氫時,R
19、R
20、R
21、R
22或R
23所連接之碳原子為對掌性碳原子。
R
19、R
20、R
21、R
22或R
23所連接之各碳原子獨立地呈(S)或(R)組態。
在胺基酸單元之一態樣中,胺基酸單元為纈胺酸-瓜胺酸(vc或Val-Cit)。在另一態樣中,胺基酸單元為苯丙胺酸-離胺酸(亦即fk)。在胺基酸單元之另一態樣中,胺基酸單元為N-甲基纈胺酸-瓜胺酸。在另一態樣中,胺基酸單元為5-胺基戊酸、高苯丙胺酸離胺酸、四異喹啉甲酸離胺酸、環己基丙胺酸離胺酸、異哌啶甲酸離胺酸、β-丙胺酸離胺酸、甘胺酸絲胺酸纈胺酸麩醯胺酸及異哌啶甲酸。
VIII.) 間隔子單元
當胺基酸單元存在時,間隔子單元(-Y-)(若存在)使胺基酸單元連接於藥物單元。或者,當胺基酸單元不存在時,間隔子單元使延伸子單元連接於藥物單元。當胺基酸單元與延伸子單元皆不存在時,間隔子單元亦使藥物單元連接於抗體單元。
間隔子單元具有兩種一般類型:非自我分解型或自我分解型。非自我分解型間隔子單元為在胺基酸單元自抗體-藥物共軛物裂解(尤其酶促)後間隔子單元之部分或全部保持與藥物部分結合的間隔子單元。非自我分解型間隔子單元之實例包括(但不限於)(甘胺酸-甘胺酸)間隔子單元及甘胺酸間隔子單元(兩者皆描繪於流程1中)(下文)。當含有甘胺酸-甘胺酸間隔子單元或甘胺酸間隔子單元之共軛物經歷經由酶(例如腫瘤細胞相關蛋白酶、癌症細胞相關蛋白酶或淋巴細胞相關蛋白酶)進行酶促裂解時,甘胺酸-甘胺酸-藥物部分或甘胺酸-藥物部分自L-Aa-Ww-裂解。在一實施例中,在標靶細胞內進行獨立的水解反應,從而使甘胺酸-藥物部分之鍵裂解且釋放藥物。
流程1
在一些實施例中,非自我分解型間隔子單元(-Y-)為-Gly-。在一些實施例中,非自我分解型間隔子單元(-Y-)為-Gly-Gly-。
在一實施例中,提供不存在間隔子單元(-Y
y-,其中y=0)之藥物-連接子共軛物或其醫藥學上可接受之鹽或溶劑合物。
或者,含有自我分解型間隔子單元之共軛物可釋放-D。如本文中所使用,術語「自我分解型間隔子」係指能夠將兩個間隔之化學部分共價連接在一起形成穩定三聯分子之雙官能化學部分。若其與第一部分之鍵裂解,則其將自發地與第二化學部分分離。
在一些實施例中,-Y
y-為對胺基苯甲醇(PAB)單元(參見流程2及3),其伸苯基部分經Q
m取代,其中Q為-C
1-C
8烷基、-C
1-C
8烯基、-C
1-C
8炔基、-O-(C
1-C
8烷基)、-O-(C
1-C
8烯基)、-O-(C
1-C
8炔基)、-鹵素、-硝基或-氰基;且m為0-4範圍內之整數。單獨或作為另一基團之一部分的烷基、烯基及炔基可視情況經取代。
在一些實施例中,-Y-為經由PAB基團之胺基氮原子連接於-W
w-且經由碳酸酯、胺基甲酸酯或醚基直接連接於-D之PAB基團。在不受任何特定理論或機制束縛之情況下,流程2描繪如Toki等人2002,
J. Org. Chem.67:1866-1872所述經由胺基甲酸酯基或碳酸酯基直接連接於-D之PAB基團之藥物釋放的可能機制。
流程 2 在流程2中,Q為-C
1-C
8烷基、-C
1-C
8烯基、-C
1-C
8炔基、-O-(C
1-C
8烷基)、-O-(C
1-C
8烯基)、-O-(C
1-C
8炔基)、-鹵素、-硝基或-氰基;m為0-4範圍內之整數;且p在1至約20之範圍內。單獨或作為另一基團之一部分的烷基、烯基及炔基可視情況經取代。
在不受任何特定理論或機制束縛之情況下,流程3描繪經由醚或胺鍵直接連接於-D之PAB基團之藥物釋放的可能機制,其中D包括作為藥物單元之一部分的氧或氮基團。
流程3
在流程3中,Q為-C
1-C
8烷基、-C
1-C
8烯基、-C
1-C
8炔基、-O-(C
1-C
8烷基)、-O-(C
1-C
8烯基)、-O-(C
1-C
8炔基)、-鹵素、-硝基或-氰基;m為0-4範圍內之整數;且p在1至約20之範圍內。單獨或作為另一基團之一部分的烷基、烯基及炔基可視情況經取代。
自我分解型間隔子之其他實例包括(但不限於)電子方面類似於PAB基團之芳族化合物,諸如2-胺基咪唑-5-甲醇衍生物(Hay等人1999,
Bioorg. Med. Chem. Lett.9:2237)及鄰胺基苯甲基縮醛或對胺基苯甲基縮醛。可使用在醯胺鍵水解後經歷環化之間隔子,諸如經取代及未經取代之4-胺基丁酸醯胺(Rodrigues等人1995,
Chemistry Biology2:223);經適當取代之雙環[2.2.1]及雙環[2.2.2]環系統(Storm等人1972,
J. Amer. Chem. Soc.94:5815);及2-胺基苯基丙酸醯胺(Amsberry等人1990,
J. Org. Chem.55:5867)。消除甘胺酸之α位經取代之含胺藥物(Kingsbury等人1984,
J. Med. Chem.27:1447)亦為自我分解型間隔子之實例。
在一實施例中,間隔子單元為如流程4中所描繪之分支鏈雙(羥甲基)-苯乙烯(BHMS)單元,其可用於併入多種藥物中並釋放多種藥物。
流程 4 在流程4中,Q為-C
1-C
8烷基、-C
1-C
8烯基、-C
1-C
8炔基、-O-(C
1-C
8烷基)、-O-(C
1-C
8烯基)、-O-(C
1-C
8炔基)、-鹵素、-硝基或-氰基;m為0-4範圍內之整數;n為0或1;且p在1至約20之範圍內。單獨或作為另一基團之一部分的烷基、烯基及炔基可視情況經取代。
在一些實施例中,-D部分相同。在另一實施例中,-D部分不同。
在一態樣中,間隔子單元(-Y
y-)由式(
X)-(
XII)表示:
X其中Q為-C
1-C
8烷基、-C
1-C
8烯基、-C
1-C
8炔基、-O-(C
1-C
8烷基)、-O-(C
1-C
8烯基)、-O-(C
1-C
8炔基)、-鹵素、-硝基或-氰基;且m為0-4範圍內之整數。單獨或作為另一基團之一部分的烷基、烯基及炔基可視情況經取代。
XI及
XII。
包含抗體-藥物共軛物化合物之式I及II的實施例可包括:
其中w及y各為0、1或2,及
其中w及y各為0,
及
。
IX.) 藥物單元
藥物部分(D)可為任何細胞毒性、細胞生長抑制或免疫調節(例如免疫抑制)藥物。D為具有可與間隔子單元、與胺基酸單元、與延伸子單元或與抗體單元形成一鍵的原子之藥物單元(部分)。在一些實施例中,藥物單元D具有可與間隔子單元形成一鍵之氮原子。如本文中所使用,術語「藥物單元」及「藥物部分」為同義詞且可互換使用。
適用種類之細胞毒性劑、細胞生長抑制劑或免疫調節劑包括例如抗微管蛋白劑、DNA小溝結合物、DNA複製抑制劑及烷基化劑。
在一些實施例中,藥物為奧瑞他汀,諸如奧瑞他汀E(此項技術中亦稱為海兔毒素-10之衍生物)或其衍生物。奧瑞他汀可為例如奧瑞他汀E與酮酸之間形成的酯。舉例而言,可使奧瑞他汀E與對乙醯基苯甲酸或苯甲醯基戊酸反應以分別產生AEB及AEVB。其他典型奧瑞他汀包括AFP、MMAF及MMAE。例示性奧瑞他汀之合成及結構描述於以下專利中:美國專利申請公開案第2003-0083263號;國際專利公開案第WO 04/010957號、國際專利公開案第WO 02/088172號及美國專利第7,498,298號、第6,884,869號、第6,323,315號;第6,239,104號;第6,034,065號;第5,780,588號;第5,665,860號;第5,663,149號;第5,635,483號;第5,599,902號;第5,554,725號;第5,530,097號;第5,521,284號;第5,504,191號;第5,410,024號;第5,138,036號;第5,076,973號;第4,986,988號;第4,978,744號;第4,879,278號;第4,816,444號;及第4,486,414號,其中每一者均以全文引用的方式且出於所有目的併入本文中。
已顯示奧瑞他汀可干擾微管動力學及細胞核及細胞分裂並具有抗癌活性。奧瑞他汀結合微管蛋白且可對191P4D12表現細胞發揮細胞毒性或細胞生長抑制作用。存在此項技術中已知之多種不同檢定,其可用於判定奧瑞他汀或所得抗體-藥物共軛物是否對所需細胞株發揮細胞生長抑制或細胞毒性作用。
判定化合物是否結合微管蛋白之方法為此項技術中所知。參見例如Muller等人
Anal. Chem2006, 78, 4390-4397;Hamel等人
Molecular Pharmacology,1995 47: 965-976;及Hamel等人
The Journal of Biological Chemistry, 1990 265:28, 17141-17149。出於本發明之目的,可測定化合物對微管蛋白之相對親和性。本發明之一些較佳奧瑞他汀結合微管蛋白之親和性在為MMAE結合微管蛋白之親和性的1/10(較弱親和性)至為MMAE結合微管蛋白之親和性的10倍、20倍或甚至100倍(較高親和性)之範圍內。
在一些實施例中,-D為式
D
E 或
D
F 之奧瑞他汀:
D
E D
F 或其醫藥學上可接受之鹽或溶劑合物形式;
其中在各位置獨立地:
波形線指示一鍵;
R
2 為-C
1-C
20烷基、-C
2-C
20烯基或-C
2-C
20炔基;
R
3 為-H、-C
1-C
20烷基、-C
2-C
20烯基、-C
2-C
20炔基、-碳環、-C
1-C
20伸烷基(碳環)、-C
2-C
20伸烯基(碳環)、-C
2-C
20伸炔基(碳環)、-芳基、-C
1-C
20伸烷基(芳基)、-C
2-C
20伸烯基(芳基)、-C
2-C
20伸炔基(芳基)、雜環、-C
1-C
20伸烷基(雜環)、-C
2-C
20伸烯基(雜環)或-C
2-C
20伸炔基(雜環);
R
4 為-H、-C
1-C
20烷基、-C
2-C
20烯基、-C
2-C
20炔基、碳環、-C
1-C
20伸烷基(碳環)、-C
2-C
20伸烯基(碳環)、-C
2-C
20伸炔基(碳環)、-芳基、-C
1-C
20伸烷基(芳基)、-C
2-C
20伸烯基(芳基)、-C
2-C
20伸炔基(芳基)、-雜環、-C
1-C
20伸烷基(雜環)、-C
2-C
20伸烯基(雜環)或-C
2-C
20伸炔基(雜環);
R
5 為-H或-C
1-C
8烷基;
或
R
4 與 R
5 共同形成碳環且具有式-(CR
aR
b)
s-,其中R
a及R
b獨立地為-H、-C
1-C
20烷基、-C
2-C
20烯基、-C
2-C
20炔基或-碳環,且s為2、3、4、5或6,
R
6 為-H、-C
1-C
20烷基、-C
2-C
20烯基或-C
2-C
20炔基;
R
7 為-H、-C
1-C
20烷基、-C
2-C
20烯基、-C
2-C
20炔基、碳環、-C
1-C
20伸烷基(碳環)、-C
2-C
20伸烯基(碳環)、-C
2-C
20伸炔基(碳環)、-芳基、-C
1-C
20伸烷基(芳基)、-C
2-C
20伸烯基(芳基)、-C
2-C
20伸炔基(芳基)、雜環、-C
1-C
20伸烷基(雜環)、-C
2-C
20伸烯基(雜環)或-C
2-C
20伸炔基(雜環);
各
R
8 獨立地為-H、-OH、-C
1-C
20烷基、-C
2-C
20烯基、-C
2-C
20炔基、-O-(C
1-C
20烷基)、-O-(C
2-C
20烯基)、-O-(C
1-C
20炔基)或-碳環;
R
9 為-H、-C
1-C
20烷基、-C
2-C
20烯基或-C
2-C
20炔基;
R
24 為-芳基、-雜環或-碳環;
R
25 為-H、-C
1-C
20烷基、-C
2-C
20烯基、-C
2-C
20炔基、-碳環、-O-(C
1-C
20烷基)、-O-(C
2-C
20烯基)、-O-(C
2-C
20炔基)或O
R
18 ,其中
R
18 為-H、羥基保護基、或當O
R
18 表示=O時為直接鍵;
R
26 為-H、-C
1-C
20烷基、-C
2-C
20烯基或-C
2-C
20炔基、-芳基、-雜環或-碳環;
R
10 為-芳基或-雜環;
Z為-O、-S、-NH或-NR
12,其中
R
12 為-C
1-C
20烷基、-C
2-C
20烯基或-C
2-C
20炔基;
R
11 為-H、-C
1-C
20烷基、--C
2-C
20烯基、-C
2-C
20炔基、-芳基、-雜環、-(R
13O)
m-R
14或-(R
13O)
m-CH(R
15)
2;
m為1-1000範圍內之整數或m=0-1000;
R
13 為-C
2-C
20伸烷基、-C
2-C
20伸烯基或-C
2-C
20伸炔基;
R
14 為-H、-C
1-C
20烷基、-C
2-C
20烯基或-C
2-C
20炔基;
R
15 在每次出現時獨立地為-H、-COOH、-(CH
2)
n-N(R
16)
2、-(CH
2)
n-SO
3H、-(CH
2)
n-SO
3-C
1-C
20烷基、-(CH
2)
n-SO
3-C
2-C
20烯基或-(CH
2)
n-SO
3-C
2-C
20炔基;
R
16 在每次出現時獨立地為-H、-C
1-C
20烷基、-C
2-C
20烯基、-C
2-C
20炔基或-(CH
2)
n-COOH;且
n為0至6範圍內之整數;
其中單獨或作為另一基團之一部分的該等烷基、烯基、炔基、伸烷基、伸烯基、伸炔基、芳基、碳環及雜環基視情況經取代。
式
D
E 之奧瑞他汀包括該等烷基、烯基、炔基、伸烷基、伸烯基、伸炔基、芳基、碳環及雜環基未經取代之奧瑞他汀。
式
D
E 之奧瑞他汀包括R
2、R
3、R
4、R
5、R
6、R
7、R
8及R
9基團未經取代且R
19、R
20及R
21基團如本文所述視情況經取代之奧瑞他汀。
式
D
E 之奧瑞他汀包括如下奧瑞他汀,其中
R
2 為C
1-C
8烷基;
R
3 、
R
4 及
R
7 係獨立地選自-H、-C
1-C
20烷基、-C
2-C
20烯基、-C
2-C
20炔基、單環C
3-C
6碳環、-C
1-C
20伸烷基(單環C
3-C
6碳環)、-C
2-C
20伸烯基(單環C
3-C
6碳環)、-C
2-C
20伸炔基(單環C
3-C
6碳環)、C
6-C
10芳基、-C
1-C
20伸烷基(C
6-C
10芳基)、-C
2-C
20伸烯基(C
6-C
10芳基)、-C
2-C
20伸炔基(C
6-C
10芳基)、雜環、-C
1-C
20伸烷基(雜環)、-C
2-C
20伸烯基(雜環)或-C
2-C
20伸炔基(雜環);其中該等烷基、烯基、炔基、伸烷基、伸烯基、伸炔基、碳環、芳基及雜環基視情況經取代;
R
5 為-H;
R
6 為-C
1-C
8烷基;
各
R
8 係獨立地選自-OH、-O-(C
1-C
20烷基)、-O-(C
2-C
20烯基)或-O-(C
2-C
20炔基),其中該等烷基、烯基及炔基視情況經取代;
R
9 為-H或-C
1-C
8烷基;
R
24 為視情況經取代之-苯基;
R
25 為-O
R
18 ;其中
R
18 為H、羥基保護基、或當O
R
18 表示=O時為直接鍵;
R
26 係選自-H、-C
1-C
20烷基、-C
2-C
20烯基、-C
2-C
20炔基或-碳環;其中該等烷基、烯基、炔基及碳環基視情況經取代;或其醫藥學上可接受之鹽或溶劑合物形式。
式
D
E 之奧瑞他汀包括如下奧瑞他汀,其中
R
2 為甲基;
R
3 為-H、-C
1-C
8烷基、-C
2-C
8烯基或C
2-C
8炔基,其中該等烷基、烯基及炔基視情況經取代;
R
4 為-H、-C
1-C
8烷基、-C
2-C
8烯基、-C
2-C
8炔基、單環C
3-C
6碳環、-C
6-C
10芳基、-C
1-C
8伸烷基(C
6-C
10芳基)、-C
2-C
8伸烯基(C
6-C
10芳基)、-C
2-C
8伸炔基(C
6-C
10芳基)、-C
1-C
8伸烷基(單環C
3-C
6碳環)、-C
2-C
8伸烯基(單環C
3-C
6碳環)、-C
2-C
8伸炔基(單環C
3-C
6碳環);其中單獨或作為另一基團之一部分的該等烷基、烯基、炔基、伸烷基、伸烯基、伸炔基、芳基及碳環基視情況經取代;
R
5 為H;
R
6 為甲基;
R
7 為-C
1-C
8烷基、-C
2-C
8烯基或-C
2-C
8炔基;
各
R
8 為甲氧基;
R
9 為-H或-C
1-C
8烷基;
R
24 為-苯基;
R
25 為-O
R
18 ;其中
R
18 為H、羥基保護基、或當O
R
18 表示=O時為直接鍵;
R
26 為甲基;
或其醫藥學上可接受之鹽形式。
式
D
E 之奧瑞他汀包括如下奧瑞他汀,其中
R
2 為甲基;
R
3 為-H或-C
1-C
3烷基;
R
4 為-C
1-C
5烷基;
R
5 為-H;
R
6 為甲基;
R
7 為異丙基或第二丁基;
R
8 為甲氧基;
R
9 為-H或-C
1-C
8烷基;
R
24 為苯基;
R
25 為-O
R
18 ;其中
R
18 為-H、羥基保護基、或當OR
18表示=O時為直接鍵;且
R
26 為甲基;或其醫藥學上可接受之鹽或溶劑合物形式。
式
D
E 之奧瑞他汀包括如下奧瑞他汀,其中
R
2 為甲基或C
1-C
3烷基;
R
3 為-H或-C
1-C
3烷基;
R
4 為-C
1-C
5烷基;
R
5 為H;
R
6 為C
1-C
3烷基;
R
7 為-C
1-C
5烷基;
R 8為-C
1-C
3烷氧基;
R 9為-H或-C
1-C
8烷基;
R
24 為苯基;
R
25 為-O
R
18 ;其中
R
18 為-H、羥基保護基、或當O
R
18 表示=O時為直接鍵;且
R
26 為-C
1-C
3烷基;
或其醫藥學上可接受之鹽形式。
式
D
F 之奧瑞他汀包括如下奧瑞他汀,其中
R
2 為甲基;
R
3 、
R
4 及
R
7 係獨立地選自-H、-C
1-C
20烷基、-C
2-C
20烯基、-C
2-C
20炔基、單環C
3-C
6碳環、-C
1-C
20伸烷基(單環C
3-C
6碳環)、-C
2-C
20伸烯基(單環C
3-C
6碳環)、-C
2-C
20伸炔基(單環C
3-C
6碳環)、-C
6-C
10芳基、-C
1-C
20伸烷基(C
6-C
10芳基)、-C
2-C
20伸烯基(C
6-C
10芳基)、-C
2-C
20伸炔基(C
6-C
10芳基)、雜環、-C
1-C
20伸烷基(雜環)、-C
2-C
20伸烯基(雜環)或-C
2-C
20伸炔基(雜環);其中單獨或作為另一基團之一部分的該等烷基、烯基、炔基、伸烷基、伸烯基、伸炔基、碳環、芳基及雜環基視情況經取代;
R
5 為-H;
R
6 為甲基;
各
R
8 為甲氧基;
R
9 為-H、-C
1-C
20烷基、-C
2-C
20烯基或-C
2-C
20炔基;其中該等烷基、烯基及炔基視情況經取代;
R
10 為視情況經取代之芳基或視情況經取代之雜環;
Z為-O-、-S-、-NH-或-NR
12-,其中
R
12 為-C
1-C
20烷基、-C
2-C
20烯基或-C
2-C
20炔基,其各自視情況經取代;
R
11 為-H、-C
1-C
20烷基、-C
2-C
20烯基、-C
2-C
20炔基、-芳基、-雜環、-(R
13O)
m-R
14或-(R
13O)
m-CH(R
15)
2,其中該等烷基、烯基、炔基、芳基及雜環基視情況經取代;
m為1-1000範圍內之整數或m=0;
R
13 為-C
2-C
20伸烷基、-C
2-C
20伸烯基或-C
2-C
20伸炔基,其各自視情況經取代;
R
14 為-H、-C
1-C
20烷基、-C
2-C
20烯基或-C
2-C
20炔基,其中該等烷基、烯基及炔基視情況經取代;
R
15 在每次出現時獨立地為-H、-COOH、-(CH
2)
n-N(R
16)
2、-(CH
2)
n-SO
3H、-(CH
2)
n-SO
3-C
1-C
20烷基、-(CH
2)
n-SO
3-C
2-C
20烯基或-(CH
2)
n-SO
3-C
2-C
20炔基,其中該等烷基、烯基及炔基視情況經取代;
R
16 在每次出現時獨立地為-H、-C
1-C
20烷基、-C
2-C
20烯基、-C
2-C
20炔基或-(CH
2)
n-COOH,其中該等烷基、烯基及炔基視情況經取代;
n為0至6範圍內之整數;
或其醫藥學上可接受之鹽。
在某些此等實施例中,
R
10 為視情況經取代之苯基。
式
D
F 之奧瑞他汀包括R
2、R
3、R
4、R
5、R
6、R
7、R
8及R
9基團未經取代且R
10及R
11基團如本文所述之奧瑞他汀。
式
D
F 之奧瑞他汀包括該等烷基、烯基、炔基、伸烷基、伸烯基、伸炔基、芳基、碳環及雜環基未經取代之奧瑞他汀。
式
D
F 之奧瑞他汀包括如下奧瑞他汀,其中
R
2 為-C
1-C
3烷基;
R
3 為-H或-C
1-C
3烷基;
R
4 為-C
1-C
5烷基;
R
5 為-H;
R
6 為-C
1-C
3烷基;
R
7 為-C
1-C
5烷基;
R
8 為-C
1-C
3烷氧基;
R
9 為-H或-C
1-C
8烷基;
R
10 為視情況經取代之苯基;
Z為-O-、-S-或-NH-;
R
11 如本文所定義;或其醫藥學上可接受之鹽。
式
D
F 之奧瑞他汀包括如下奧瑞他汀,其中
R
2 為甲基;
R
3 為-H或-C
1-C
3烷基;
R
4 為-C
1-C
5烷基;
R
5 為-H;
R
6 為甲基;
R
7 為異丙基或第二丁基;
R
8 為甲氧基;
R
9 為-H或-C
1-C
8烷基;
R
10 為視情況經取代之苯基;
Z為-O-、-S-或-NH-;且R
11 如本文所定義;或其醫藥學上可接受之鹽。
式
D
F 之奧瑞他汀包括如下奧瑞他汀,其中
R
2 為甲基;
R
3 為-H或-C
1-C
3烷基;
R
4 為-C
1-C
5烷基;
R
5 為-H;
R
6 為甲基;
R
7 為異丙基或第二丁基;
R
8 為甲氧基;
R
9 為-H或C
1-C
8烷基;
R
10 為苯基;且Z為-O-或-NH-,且R
11 如本文所定義,較佳為氫;或其醫藥學上可接受之鹽形式。
式
D
F 之奧瑞他汀包括如下奧瑞他汀,其中
R
2 為-C
1-C
3烷基;
R
3 為-H或-C
1-C
3烷基;
R
4 為-C
1-C
5烷基;
R
5 為-H;
R
6 為-C
1-C
3烷基;
R
7 為-C
1-C
5烷基;
R
8 為-C
1-C
3烷氧基;
R
9 為-H或-C
1-C
8烷基;
R
10 為苯基;且
Z為-O-或-NH-,且R
11 如本文所定義,較佳為氫;或其醫藥學上可接受之鹽形式。
式
D
E 或
D
F 之奧瑞他汀包括R
3、R
4及R
7獨立地為異丙基或第二丁基且R
5為-H之奧瑞他汀。在一例示性實施例中,R
3及R
4各為異丙基,R
5為H,且R
7為第二丁基。其餘取代基如本文所定義。
式
D
E 或
D
F 之奧瑞他汀包括R
2及R
6各為甲基且R
9為H之奧瑞他汀。其餘取代基如本文所定義。
式
D
E 或
D
F 之奧瑞他汀包括R
8在每次出現時為-OCH
3之奧瑞他汀。其餘取代基如本文所定義。
式
D
E 或
D
F 之奧瑞他汀包括如下奧瑞他汀,其中R
3及R
4各為異丙基,R
2及R
6各為甲基,R
5為H,R
7為第二丁基,R
8在每次出現時為-OCH
3,且R
9為H。其餘取代基如本文所定義。
式
D
F 之奧瑞他汀包括其中Z為-O-或-NH-之奧瑞他汀。其餘取代基如本文所定義。
式
D
F 之奧瑞他汀包括R
10為芳基之奧瑞他汀。其餘取代基如本文所定義。
式
D
F 之奧瑞他汀包括R
10為-苯基之奧瑞他汀。其餘取代基如本文所定義。
式
D
F 之奧瑞他汀包括Z為-O-且R
11為H、甲基或第三丁基之奧瑞他汀。其餘取代基如本文所定義。
式
D
F 之奧瑞他汀包括如下奧瑞他汀,其中當Z為-NH-時,R
11為-(R
13O)
m-CH(R
15)
2,其中R
15為-(CH
2)
n-N(R
16)
2,且R
16為-C
1-C
8烷基或-(CH
2)
n-COOH。其餘取代基如本文所定義。
式
D
F 之奧瑞他汀包括如下奧瑞他汀,其中當Z為-NH-時,R
11為-(R
13O)
m-CH(R
15)
2,其中R
15為-(CH
2)
n-SO
3H。其餘取代基如本文所定義。
在較佳實施例中,當D為式
D
E 之奧瑞他汀時,w為1至12、較佳2至12範圍內之整數,y為1或2,且a較佳為1。
在一些實施例中,當D為式
D
F 之奧瑞他汀時,a為1且w及y為0。
說明性藥物單元(-D)包括具有以下結構之藥物單元:
、
、
、
、
、
、
、
、
、
、
、
及
或其醫藥學上可接受之鹽或溶劑合物。
在一態樣中,諸如(但不限於)三乙二醇酯(TEG)之親水性基團可連接於藥物單元之R
11。在不受理論束縛之情況下,親水性基團幫助藥物單元之內化及非聚結。
在一些實施例中,藥物單元不為TZT-1027。在一些實施例中,藥物單元不為奧瑞他汀E、海兔毒素10或奧瑞他汀PE。
例示性抗體-藥物共軛物化合物具有以下結構,其中「L」或「mAb-s」表示本文所述之稱為Ha22-2(2,4)6.1的191P4D12 MAb:
L-MC-vc-PAB-MMAF或
L-MC-vc-PAB-MMAE.或
L-MC-MMAF或其醫藥學上可接受之鹽。
在一些實施例中,藥物單元為卡奇黴素、喜樹鹼(camptothecin)、類美登素或蒽環黴素(anthracycline)。在一些實施例中,藥物為紫杉烷、拓撲異構酶抑制劑、長春花生物鹼或其類似物。
在一些典型實施例中,適合之細胞毒性劑包括例如DNA小溝結合物(例如烯二炔類及雷西曲星(lexitropsins)、CBI化合物;亦參見美國專利第6,130,237號)、倍癌黴素、紫杉烷(例如太平洋紫杉醇(paclitaxel)及多西他賓(docetaxel))、嘌呤黴素(puromycin)及長春花生物鹼。其他細胞毒性劑包括例如CC-1065、SN-38、拓朴替康(topotecan)、嗎啉基-阿黴素、根瘤菌素(rhizoxin)、氰基嗎啉基-阿黴素、棘黴素(echinomycin)、考布他汀、紡錘菌素(netropsin)、埃坡黴素(epothilone)A及B、雌莫司汀(estramustine)、念珠藻環肽(cryptophysins)、西馬多丁(cemadotin)、類美登素、迪斯德莫來(discodermolide)、艾榴素(eleutherobin)及米托蒽醌(mitoxantrone)。
在一些實施例中,藥物為抗微管蛋白劑。抗微管蛋白劑之實例包括奧瑞他汀、紫杉烷(例如Taxol®(太平洋紫杉醇)、Taxotere®(多西他賓))、T67(Tularik)及長春花生物鹼(例如長春新鹼、長春鹼、長春地辛及長春瑞濱(vinorelbine))。其他抗微管蛋白劑包括例如漿果赤黴素(baccatin)衍生物、紫杉烷類似物(例如埃坡黴素A及B)、諾考達唑(nocodazole)、秋水仙鹼及秋水醯胺(colcimid)、雌莫司汀、念珠藻環肽、西馬多丁、類美登素、考布他汀、迪斯德莫來及艾榴素。
在某些實施例中,細胞毒性劑為類美登素,另一組抗微管蛋白劑。舉例而言,在特定實施例中,類美登素為美登素或DM-1(ImmunoGen, Inc.;亦參見Chari等人1992, Cancer Res. 52:127-131)。
在某些實施例中,細胞毒性劑或細胞生長抑制劑為海兔毒素。在某些實施例中,細胞毒性劑或細胞生長抑制劑為奧瑞他汀種類。因此,在一特定實施例中,細胞毒性劑或細胞生長抑制劑為MMAE(式
XI)。在另一特定實施例中,細胞毒性劑或細胞生長抑制劑為AFP(式
XVI)。
(XI)在某些實施例中,細胞毒性劑或細胞生長抑制劑為式
XII-XXI之化合物或其醫藥學上可接受之鹽:
(XII) (XIII) (XIV) (XV) (XVI) (XVII) (
XVIII)
(XVIV) (XX) (XXI)X.) 藥物負載
藥物負載由p表示且為分子中每個抗體的藥物部分之平均數目。藥物負載可在每個抗體1至20個藥物部分(D)之範圍內。本發明之ADC包括與1至20個範圍內之藥物部分共軛的抗體之集合。在由共軛反應製備ADC中每個抗體的藥物部分之平均數目可藉由諸如質譜法及ELISA檢定之習知手段來表徵。亦可測定ADC中p之定量分佈。在一些情況下,均質ADC可藉由諸如電泳之手段來分離、純化及表徵,其中p為具有其他藥物負載之ADC的某一值。
對於一些抗體藥物共軛物,p可能受抗體上之連接位點數目的限制。舉例而言,若如以上例示性實施例中連接為半胱胺酸硫氫基,則抗體可能僅具有一個或數個半胱胺酸硫氫基,或可能僅具有一個或數個具有足夠反應性之硫氫基,連接子可經由該等硫氫基連接。在某些實施例中,較高藥物負載(例如p>5)可能使得某些抗體藥物共軛物凝集、不溶、具毒性或喪失細胞滲透性。在某些實施例中,本發明之ADC的藥物負載在以下範圍內:1至約8;約2至約6;約3至約5;約3至約4;約3.1至約3.9;約3.2至約3.8;約3.2至約3.7;約3.2至約3.6;約3.3至約3.8;或約3.3至約3.7。實際上,已顯示對於某些ADC,每個抗體的藥物部分之最佳比率可小於8,且可為約2至約5。參見美國專利第7,498,298號(以全文引用的方式併入本文中)。
在某些實施例中,在共軛反應期間,少於理論最大值之藥物部分與抗體共軛。抗體可含有例如不與藥物-連接子中間物或連接子試劑反應之離胺酸殘基,如下文所論述。一般,抗體不含有可連接於藥物部分之許多游離及反應性半胱胺酸硫醇基;實際上,抗體中大多數半胱胺酸硫醇殘基以二硫橋鍵形式存在。在某些實施例中,抗體可在部分或完全還原條件下用諸如二硫蘇糖醇(DTT)或三羰基乙基膦(TCEP)之還原劑還原,產生反應性半胱胺酸硫醇基。在某些實施例中,使抗體經受變性條件以暴露諸如離胺酸或半胱胺酸之反應性親核基團。
ADC之負載(藥物/抗體比)可以不同方式進行控制,例如藉由:(i)相對於抗體限制藥物-連接子中間物或連接子試劑之莫耳過量;(ii)限制共軛反應時間或溫度;(iii)部分限制或限制半胱胺酸硫醇修飾之還原條件;(iv)藉由重組技術對抗體之胺基酸序列進行工程改造以使得半胱胺酸殘基之數目及位置經調節以控制連接子-藥物連接數目及/或位置(諸如如本文及WO 2006/034488(以全文引用的方式併入本文中)中所揭示製得之thioMab或thioFab)。
應瞭解當一個以上親核基團與藥物-連接子中間物或連接子試劑、隨後藥物部分試劑反應時,所得產物為具有一或多個藥物部分連接於抗體之分佈的ADC化合物之混合物。每個抗體之藥物平均數目可由該混合物藉由雙ELISA抗體檢定計算,該檢定對於抗體具有特異性且對於藥物具有特異性。個別ADC分子可藉由質譜法在混合物中鑑別出且藉由HPLC(例如疏水性相互作用層析)分離(參見例如Hamblett, K.J.等人「Effect of drug loading on the pharmacology, pharmacokinetics, and toxicity of an anti-CD30 antibody-drug conjugate,」摘要編號624, American Association for Cancer Research, 2004 Annual Meeting, 2004年3月27-31日, Proceedings of the AACR, 第45卷,2004年3月;Alley, S.C.等人「Controlling the location of drug attachment in antibody-drug conjugates,」摘要編號627, American Association for Cancer Research, 2004 Annual Meeting, 2004年3月27-31日, Proceedings of the AACR,第45卷,2004年3月)。在某些實施例中,可藉由電泳或層析自共軛混合物分離具有單一負載值之均質ADC。
XI.) 測定ADC之細胞毒性作用的方法
判定藥物或抗體-藥物共軛物是否對細胞發揮細胞生長抑制及/或細胞毒性作用之方法為已知的。一般,抗體藥物共軛物之細胞毒性或細胞生長抑制活性可藉由以下量測:使表現抗體藥物共軛物之標靶蛋白的哺乳動物細胞暴露於細胞培養基中;培養該等細胞約6小時至約5天之時段;及量測細胞活力。可使用基於細胞之活體外檢定量測抗體藥物共軛物之活力(增殖)、細胞毒性及細胞凋亡之誘導(卡斯蛋白酶(caspase)活化)。
為判定抗體藥物共軛物是否發揮細胞生長抑制作用,可使用胸苷併入檢定。舉例而言,可在96孔板中以每孔5,000個細胞之密度培養表現標靶抗原之癌細胞72小時時段,且在72小時時段之最後8小時期間暴露於0.5 μCi
3H-胸苷。在抗體藥物共軛物存在及不存在下量測培養物之細胞中
3H-胸苷之併入。
為測定細胞毒性,可量測壞死或細胞凋亡(漸進式細胞死亡)。壞死通常伴有質膜之滲透性增加;細胞膨脹及質膜破裂。細胞凋亡通常特徵為膜起泡、細胞質凝聚及內源核酸內切酶活化。測定出對癌細胞之任一此等作用指示抗體藥物共軛物適用於治療癌症。
細胞活力可藉由測定細胞中染料(諸如中性紅(neutral red)、錐蟲藍(trypan blue)或ALAMAR™藍)之吸收來量測(參見例如Page等人1993,
Intl. J. Oncology3:473-476)。在該種檢定中,在含有染料之培養基中培育細胞,洗滌細胞,且以分光光度法量測剩餘染料,其反映細胞對染料之吸收。亦可使用結合蛋白質之染料磺酸基若丹明B(sulforhodamine B,SRB)量測細胞毒性(Skehan等人1990,
J. Natl. Cancer Inst.82:1107-12)。
或者,在用於藉由偵測活的而非死的細胞來測定哺乳動物細胞存活及增殖之定量比色檢定中使用諸如MTT之四唑鎓鹽(參見例如Mosmann, 1983,
J. Immunol. Methods65:55-63)。
細胞凋亡可藉由量測例如DNA斷裂來定量。可利用用於活體外定量測定DNA斷裂之市售光度法。包括基於TUNEL(其偵測DNA片段中經標記核苷酸之併入)及ELISA之檢定的該等檢定之實例描述於
Biochemica, 1999,第2期,第34-37頁(Roche Molecular Biochemicals)中。
細胞凋亡亦可藉由量測細胞中之形態變化來測定。舉例而言,與壞死相同,喪失質膜完整性可藉由量測某些染料(例如螢光染料,諸如吖啶橙或溴化乙錠)之吸收來確定。量測凋亡細胞數目之方法已由Duke及Cohen, Current Protocols in Immunology(Coligan等人編,1992,第3.17.1-3.17.16頁)描述。亦可用DNA染料(例如吖啶橙、溴化乙錠或碘化丙錠)標記細胞,且觀察細胞之染色質凝聚及沿內部核膜之蝕邊現象。可量測以確定細胞凋亡之其他形態變化包括例如細胞質凝聚、膜起泡增加及細胞收縮。
可在培養物之附著與「漂浮」部分(compartment)中量測凋亡細胞之存在。舉例而言,收集的兩個部分皆可移除上清液、將附著之細胞胰蛋白酶化、在離心洗滌步驟(例如在2000 rpm下10分鐘)後合併製備物及偵測細胞凋亡(例如藉由量測DNA斷裂)。(參見例如Piazza等人1995,
Cancer Research55:3110-16)。
可在適合之動物模型中活體內評估191P4D12治療性組合物之作用。舉例而言,可使用異體癌症模型,其中將癌症外植體或繼代異種移植組織引入免疫受損動物體內,諸如裸小鼠或SCID小鼠(Klein等人1997, Nature Medicine 3: 402-408)。舉例而言,PCT專利申請案WO 98/16628及美國專利6,107,540描述人類前列腺癌之多種異種移植模型,該等模型能夠重演原發性腫瘤之發展、微轉移及晚期疾病之特徵成骨細胞轉移的形成。可使用對腫瘤形成之抑制、腫瘤消退或轉移及其類似過程進行量測之檢定預測功效。
評估細胞凋亡加快之活體內檢定適用於評估治療性組合物。在一實施例中,可檢查經治療性組合物處理之具有腫瘤之小鼠的異種移植物中細胞凋亡中心之存在且與未經處理之具有異種移植物之對照小鼠比較。經處理小鼠之腫瘤中存在細胞凋亡焦點的程度表明組合物之治療功效。
用於實施上述方法之治療性組合物可調配成包含適用於所需傳遞方法之載劑的醫藥組合物。適合之載劑包括與治療性組合物組合時保持該治療性組合物之抗腫瘤功能且與患者免疫系統通常無反應性的任何物質。實例包括(但不限於)多種標準醫藥載劑中之任一者,諸如無菌磷酸鹽緩衝生理鹽水溶液、抑菌水及其類似物(一般參見Remington's Pharmaceutical Sciences第16版,A. Osal.編,1980)。
治療性調配物可溶解且可經由能夠將治療性組合物傳遞至腫瘤部位之任何途徑來投與。潛在有效的投藥途徑包括(但不限於)靜脈內、非經腸、腹膜內、肌肉內、腫瘤內、皮內、器官內、正位及其類似途徑。用於靜脈內注射之較佳調配物包含於經防腐處理之抑菌水、未經防腐處理之無菌水的溶液中及/或稀釋於含有0.9%注射用無菌氯化鈉(USP)之聚氯乙烯或聚乙烯袋中的治療性組合物。治療性蛋白質製劑可經凍乾,且可以無菌粉末形式,較佳在真空下儲存,接著用抑菌水(含有例如苯甲醇防腐劑)或無菌水復原後再注射。
使用上述方法治療癌症之劑量及投藥方案將隨方法及標靶癌症而變,且通常將視此項技術中所瞭解之多種其他因素而定。
XII.) 治療表現191P4D12之癌症
鑑別191P4D12為在一組有限組織中正常表現、但亦在癌症(諸如表I中所列之癌症)中表現之蛋白質為治療該等癌症開拓了多種治療方法。
值得注意的是,靶向抗腫瘤療法為有用的,即使當靶向蛋白在正常組織、甚至正常生命器官組織中表現時。生命器官為維持生命所必需之器官,諸如心臟或結腸。非生命器官為在移除後個體仍能存活之器官。非生命器官之實例為卵巢、乳房及前列腺。
標靶蛋白在正常組織、甚至正常生命組織中之表現並不能阻撓該蛋白質之靶向劑作為蛋白質亦過表現之某些腫瘤的治療劑之效用。舉例而言,在生命器官中進行表現本身並不有害。另外,視為不必要之器官(諸如前列腺及卵巢)可進行移除而不影響壽命。最後,一些生命器官因免疫赦免而不受正常器官表現影響。免疫赦免器官為受血液-器官障壁保護而與血液隔離之器官且因此免疫療法無法到達。免疫赦免器官之實例為腦及睪丸。
因此,抑制191P4D12蛋白活性之治療方法適用於罹患表現191P4D12之癌症的患者。此等治療方法通常分為三類。第一類調節191P4D12功能,因為其與腫瘤細胞生長有關,從而抑制或延緩腫瘤細胞生長或誘導將其殺死。第二類包含抑制191P4D12蛋白與其結合搭配物或與其他蛋白質之結合或締合的各種方法。第三類包含抑制191P4D12基因之轉錄或191P4D12 mRNA之轉譯的各種方法。
因此,可評估癌症患者之191P4D12表現的存在及水準,較佳使用腫瘤組織之免疫組織化學評估、定量191P4D12成像或可靠地指示191P4D12表現之存在及程度的其他技術。對腫瘤活檢體或手術試樣之免疫組織化學分析較佳用於此目的。腫瘤組織之免疫組織化學分析方法為此項技術中所熟知。
XIII.) 作為基於抗體之療法的標靶之191P4D12
191P4D12為用於基於抗體之治療性策略之吸引人的標靶。用於靶向細胞外分子與細胞內分子之多種抗體策略為此項技術中所知(參見例如補體及ADCC介導之殺死作用以及胞內抗體(intrabody)之使用)。因為相對於對應正常細胞,191P4D12由各種譜系之癌細胞表現,所以準備191P4D12免疫反應性組合物之全身投與,從而展現由免疫反應性組合物與非標靶器官及組織結合引起之極佳敏感性而無毒性、非特異性及/或非標靶作用。與191P4D12之結構域特異性反應的抗體適用於全身地治療表現191P4D12之癌症,較佳呈抗體藥物共軛物(亦即ADC)形式,其中該共軛物含有毒素或治療劑。
熟習此項技術者瞭解,抗體可用於特異性靶向及結合免疫原性分子,諸如圖1中所示之191P4D12序列的免疫原性區。另外,熟習此項技術者瞭解,抗體與細胞毒性劑共軛為慣例(參見例如Slevers等人Blood 93:11 3678-3684 (1999年6月1日))。當將細胞毒性劑及/或治療劑直接傳遞至細胞時(諸如藉由將其與對由彼細胞(例如191P4D12)表現之分子具有特異性的抗體共軛),細胞毒性劑對彼等細胞發揮已知生物效應(亦即細胞毒性)。
用於使用抗體-細胞毒性劑共軛物殺死細胞之各種組合物及方法為此項技術中所知。在癌症之情況下,典型方法需要向具有腫瘤之哺乳動物投與生物有效量之共軛物,該共軛物包含所選細胞毒性劑及/或治療劑連接於與所表現、易結合或定位於細胞表面上之抗原(例如191P4D12)結合的靶向劑(例如191P4D12 MAb,較佳為Ha22-2(2,4)6.1)。一典型實施例為將細胞毒性劑及/或治療劑傳遞至表現191P4D12之細胞的方法,其包含使該細胞毒性劑與免疫特異性結合於191P4D12抗原決定基之抗體共軛及使該細胞暴露於抗體藥物共軛物(ADC)。另一說明性實施例為治療懷疑罹患轉移癌之個體的方法,該方法包含向該個體非經腸投與醫藥組合物之步驟,該醫藥組合物包含治療有效量之抗體與細胞毒性劑及/或治療劑之共軛物。
使用191P4D12抗體之癌症免疫療法可根據已成功地用於治療其他類型癌症之各種方法來進行,該等癌症包括(但不限於)結腸癌(Arlen等人1998, Crit. Rev. Immunol. 18:133-138)、多發性骨髓瘤(Ozaki等人1997, Blood 90:3179-3186, Tsunenari等人1997, Blood 90:2437-2444)、胃癌(Kasprzyk等人1992, Cancer Res. 52:2771-2776)、B細胞淋巴瘤(Funakoshi等人1996, J. Immunother. Emphasis Tumor Immunol. 19:93-101)、白血病(Zhong等人1996, Leuk. Res. 20:581-589)、結腸直腸癌(Moun等人1994, Cancer Res. 54:6160-6166; Velders等人1995, Cancer Res. 55:4398-4403)及乳癌(Shepard等人1991, J. Clin. Immunol. 11:117-127)。一些治療方法包括將裸抗體與毒素或放射性同位素共軛,諸如分別將Y
91或I
131與抗CD20抗體(例如Zevalin
TM(IDEC Pharmaceuticals Corp.)或Bexxar
TM(Coulter Pharmaceuticals))共軛,而其他方法包括將抗體與其他治療劑共投與,諸如將Herceptin
TM(曲妥珠單抗(trastuzu Mab))與太平洋紫杉醇(Genentech, Inc)共投與。在一較佳實施例中,抗體將與細胞毒性劑(見上)、較佳稱為MMAE之奧瑞他汀衍生物(Seattle Genetics, Inc)共軛。
儘管191P4D12抗體療法適用於癌症之所有階段,但抗體療法可尤其適合於晚期或轉移性癌症。用本發明之抗體療法治療適用於已接受一或多輪化學療法之患者。或者,將本發明之抗體療法與化學療法或放射療法組合用於尚未接受化學療法治療之患者。另外,抗體療法能夠使用低劑量之伴隨化學療法,尤其對於不能極好地耐受化學治療劑毒性之患者。Fan等人(Cancer Res. 53:4637-4642, 1993)、Prewett等人(International J. of Onco. 9:217-224, 1996)及Hancock等人(Cancer Res. 51:4575-4580, 1991)描述各種抗體連同化學治療劑之使用。
治療表I中所示之癌症的191P4D12單株抗體包括引發針對腫瘤之有效免疫反應的抗體或直接具有細胞毒性之抗體。就此而言,191P4D12單株抗體(MAb)可藉由補體介導或抗體依賴性細胞毒性(ADCC)機制引起腫瘤細胞溶解,兩種機制皆需要免疫球蛋白分子之完整Fc部分與補體蛋白上之效應細胞Fc受體位點相互作用。另外,對腫瘤生長發揮直接生物作用之191P4D12 MAb適用於治療表現191P4D12之癌症。細胞毒性MAb直接起作用之機制包括:抑制細胞生長、調節細胞分化、調節腫瘤血管生成因子概況及誘導細胞凋亡。如此項技術中一般已知,使用多種活體外檢定評估特定191P4D12 MAb發揮抗腫瘤作用之機制,該等檢定評估諸如ADCC、補體介導細胞溶解等細胞死亡。
因此,用於本發明之治療方法中的較佳單株抗體為全人類單株抗體及以高親和性與標靶191P4D12抗原特異性結合之單株抗體。
XIV.) 191P4D12 ADC 混合物本發明之治療方法涵蓋投與單一191P4D12 ADC以及不同MAb(亦即191P4D12 MAb或結合另一蛋白質之Mab)之組合或混合物。該等MAb混合物由於含有靶向不同抗原決定基之MAb、利用不同效應機制或將直接細胞毒性MAb與依賴免疫效應功能之MAb組合而可具有某些優點。該等組合形式之MAb可展現協同治療作用。另外,191P4D12 MAb可伴隨其他治療形式投與,該等治療形式包括(但不限於)多種化學治療劑及生物藥劑、雄激素阻斷劑、免疫調節劑(例如IL-2、GM-CSF)、手術或放射。在一較佳實施例中,191P4D12 MAb以共軛形式投與。
191P4D12 ADC調配物經由能夠將抗體傳遞至腫瘤細胞之任何途徑來投與。投藥途徑包括(但不限於)靜脈內、腹膜內、肌肉內、腫瘤內、皮內及其類似途徑。治療通常包括經由可接受之投藥途徑(諸如靜脈內注射(IV))重複投與191P4D12 Mab製劑,其劑量範圍通常包括(但不限於)每公斤體重0.1、0.2、0.3、0.4、0.5、0.6、0.7、0.8、0.9、1、2、3、4、5、6、7、8、9、10、15、20或25 mg。一般而言,每週10-1,000 mg MAb之劑量範圍為有效的且耐受良好。
基於用Herceptin®(曲妥珠單抗(Trastuzumab))治療轉移性乳癌之臨床經驗,MAb製劑之每公斤患者體重約4 mg的靜脈內初始速效劑量、接著每週每公斤約2 mg之靜脈內劑量代表一種可接受之給藥方案。初始速效劑量較佳以90分鐘或長於90分鐘之輸注形式投與。定期維持劑量以30分鐘或長於30分鐘之輸注形式投與,其限制條件為初始劑量耐受良好。如熟習此項技術者所瞭解,在特定情況下,多種因素可影響理想給藥方案。該等因素包括例如所用MAb之結合親和性及半衰期;患者中之191P4D12表現程度;循環排出191P4D12抗原之程度;所需穩態抗體濃度水準;治療頻率;及化學治療劑或其他藥劑與本發明之治療方法組合使用的影響,以及特定患者之健康狀況。
視情況,應在特定樣品中評估患者之191P4D12含量(例如循環191P4D12抗原及/或191P4D12表現細胞之含量)以幫助確定最有效給藥方案等。該等評估亦用於監測治療目的,且適用於結合評估其他參數(例如膀胱癌療法中之尿細胞學及/或ImmunoCyt含量,或以此類推,前列腺癌療法中之血清PSA含量)估量治療成果。
本發明之目的在於提供191P4D12 ADC,其抑制或延緩表現191P4D12之腫瘤細胞的生長。本發明之另一目的在於提供使用該等191P4D12 ADC及尤其使用該等191P4D12 ADC與其他藥物或免疫學有效治療之組合來抑制血管生成及其他生物功能且由此減少哺乳動物(較佳為人類)之腫瘤生長的方法。
XV.) 組合療法在一實施例中,當用191P4D12 ADC結合化學治療劑或放射或其組合治療腫瘤(包括人類腫瘤)時,存在協同作用。換言之,當與化學治療劑或放射或其組合組合時,由191P4D12 ADC對腫瘤生長之抑制的增強超過預期。可例如藉由使用組合治療對腫瘤生長之抑制超過僅使用191P4D12 ADC之治療所預期的效應或使用191P4D12 ADC與化學治療劑或放射治療之累加效應來顯示協同作用。較佳地,藉由癌症緩解來說明協同作用,其中使用191P4D12 ADC之治療或使用191P4D12 ADC與化學治療劑或放射之累加組合的治療未預期有緩解。
使用191P4D12 ADC及化學療法或放射或兩者之組合來抑制腫瘤細胞生長之方法包含在開始化學療法或放射療法之前、期間或之後投與191P4D12 ADC,以及其任何組合(亦即在開始化學療法及/或放射療法之前與期間,之前與之後,期間與之後,或之前、期間及之後)。舉例而言,191P4D12 ADC通常在開始放射療法及/或化學療法前1至60天、較佳3至40天、更佳5至12天投與。然而,視治療方案及特定患者需要而定,該方法可以提供最有效治療且最終延長患者壽命之方式進行。
化學治療劑可以多種方式投與,包括藉由非經腸及經腸途徑全身性投與。在一實施例中,191P4D12 ADC及化學治療劑作為各別分子進行投與。化學治療劑或化學療法之特定實例包括順鉑、達卡巴嗪(dacarbazine,DTIC)、更生黴素(dactinomycin)、二氯甲二乙胺(mechlorethamine)(氮芥(nitrogen mustard))、鏈佐黴素(streptozocin)、環磷醯胺(cyclophosphamide)、卡莫司汀(carmustine,BCNU)、洛莫司汀(lomustine,CCNU)、阿黴素(阿德力黴素(adriamycin))、道諾黴素、丙卡巴肼(procarbazine)、絲裂黴素、阿糖胞苷(cytarabine)、依託泊苷、甲胺喋呤、5-氟尿嘧啶、長春鹼、長春新鹼、博萊黴素(bleomycin)、太平洋紫杉醇(紫杉醇)、多烯紫杉醇(紫杉德(taxotere))、阿地白介素(aldesleukin)、天冬醯胺酶、白消安(busulfan)、卡鉑(carboplatin)、克拉屈濱(cladribine)、達卡巴嗪、氟尿苷(floxuridine)、氟達拉濱(fludarabine)、羥基脲、異環磷醯胺(ifosfamide)、干擾素α、亮丙立德(leuprolide)、甲地孕酮(megestrol)、美法侖(melphalan)、巰嘌呤(mercaptopurine)、普卡黴素(plicamycin)、米托坦(mitotane)、培門冬酶(pegaspargase)、噴司他丁(pentostatin)、哌泊溴烷(pipobroman)、普卡黴素、鏈佐黴素、他莫昔芬、替尼泊苷(teniposide)、睪內酯(testolactone)、硫鳥嘌呤(thioguanine)、噻替派(thiotepa)、尿嘧啶氮芥(uracil mustard)、長春瑞濱、吉西他濱(gemcitabine)、苯丁酸氮芥(chlorambucil)、紫杉醇及其組合。
與191P4D12 ADC組合使用之放射源可在所治療患者外部或內部。當放射源在患者外部時,此療法稱為外部射束放射療法(external beam radiation therapy;EBRT)。當放射源在患者內部時,此療法稱為近接療法(called brachytherapy;BT)。
上述治療方案可進一步與其他癌症治療劑及/或方案組合,該等癌症治療劑及/或方案例如其他化學療法、癌症疫苗、信號轉導抑制劑、適用於治療異常細胞生長或癌症之藥劑、抗體(例如WO/2005/092380(Pfizer)中所述之抗CTLA-4抗體)或藉由與IGF-1R及細胞因子結合來抑制腫瘤生長之其他配位體。
當哺乳動物經受其他化學療法時,可使用上述化學治療劑。另外,可使用生長因子抑制劑、生物反應調節劑、抗激素療法、選擇性雌激素受體調節劑(SERM)、血管生成抑制劑及抗雄激素劑。舉例而言,可使用抗激素劑,例如抗雌激素劑,諸如諾瓦得士(Nolvadex)(他莫昔芬);或抗雄激素劑,諸如康士得(Casodex)(4'-氰基-3-(4-氟苯磺醯基)-2-羥基-2-甲基-3'-(三氟甲基)丙醯苯胺)。
可將上述治療方法與多種手術、化學療法或放射療法方案中之任一者組合。本發明之治療方法能夠使用低劑量之化學療法(或其他療法)及/或頻率較低的投藥,此對於所有患者且尤其對於不能良好耐受化學治療劑毒性之患者為一優點。
XVI.) 套組/製品
用於本文所述之實驗室、預後、預防、診斷及治療應用的套組在本發明之範疇內。該等套組可包含分成各區室以容納一或多個容器(諸如小瓶、試管及其類似物)之載器(carrier)、包裝或容器,各容器包含方法中欲使用之各別要素之一連同包含使用(諸如本文所述之使用)說明書之標籤或插頁。舉例而言,容器可包含標記可偵測物或可標記可偵測物之抗體。套組可包含含藥物單元之容器。套組可包括圖2或圖3中之胺基酸序列的全部或部分或其類似物,或編碼該等胺基酸序列之核酸分子。
本發明之套組通常將包含上述容器及一或多個與此相關之其他容器,該等容器包含依據商業及使用者立場所需之物質,包括緩衝液、稀釋劑、過濾器、針、注射器;列有內含物及/或使用說明書之載器、包裝、容器、小瓶及/或試管標籤;及具有使用說明書之包裝插頁。
標籤可存在於容器上或與容器一起存在,以指示組合物用於特定療法或非治療性應用,諸如預後、預防、診斷或實驗室應用,且亦可指示活體內或活體外使用指導,諸如本文所述之指導。與套組一起包括在內或包括於套組上之插頁或標籤上亦可包括指導及/或其他資訊。標籤可位於容器上或伴隨容器。當形成標籤之字母、數字或其他字符模製或蝕刻於容器自身時,標籤可位於容器上;當標籤存在於亦容納容器之貯器或載器內時,其可伴隨該容器,例如包裝插頁。標籤可指示組合物用於診斷、治療、預防或預後病狀,諸如表I中所示之組織癌症。
術語「套組」與「製品」可作為同義詞使用。
在本發明之另一實施例中,提供製品,其含有組合物,諸如抗體或抗體藥物共軛物(ADC),例如適用於診斷、預後、預防及/或治療組織癌症(諸如表I中所示之癌症)之物質。該製品通常包含至少一個容器及至少一個標籤。適合之容器包括例如瓶子、小瓶、注射器及試管。容器可由多種材料(諸如玻璃、金屬或塑膠)形成。容器可容納胺基酸序列、小分子、核酸序列、細胞群體及/或抗體。在另一實施例中,容器包含用於評估細胞及組織中之191P4D12的蛋白質表現或用於相關實驗室、預後、診斷、預防及治療目的之抗體、其結合片段或特異性結合蛋白質;關於該等用途之指示及/或指導可包括於容器上或與容器一起包括在內,用於此等目的之試劑及其他組合物或工具亦可包括於容器上或與容器一起包括在內。
容器可或者容納有效治療、診斷、預後或預防病狀之組合物且可具有無菌接取孔(例如容器可為靜脈內注射溶液袋或具有可由皮下注射針刺穿之塞子的小瓶)。組合物中之活性劑可為能夠特異性結合191P4D12之抗體或特異性結合於191P4D12之抗體藥物共軛物。
製品可進一步包含第二容器,該第二容器包含醫藥學上可接受之緩衝液,諸如磷酸鹽緩衝生理鹽水、林格氏溶液(Ringer's solution)及/或右旋糖溶液。其可進一步包括依據商業及使用者立場所需之其他物質,包括其他緩衝液、稀釋劑、過濾器、攪拌器、針、注射器及/或具有使用指示及/或指導之包裝插頁。
實例:藉由以下若干實例進一步描述並說明本發明之多種態樣,但不希望該等實例限制本發明之範疇。
實例 1 191P4D12 抗原使用此項技術中已知之抑制消減雜交(Suppression Subtractive Hybridization,SSH)顯現191P4D12基因序列。使用標準方法自膀胱腫瘤減去來源於9個正常組織混合物之cDNA而鑑別出223 bp之191P4D12 SSH序列。自膀胱癌cDNA文庫分離191P4D12之全長cDNA純系。cDNA之長度為3464 bp且編碼510個胺基酸之ORF(參見圖1)。191P4D12基因與Nectin-4基因顯示同源性。關於其他參考文獻,參見US 2004/0083497(Agensys, Inc., Santa Monica, CA)及PCT公開案WO 2004/016799(Agensys, Inc., Santa Monica, CA)。關於191P4D12抗原之例示性實施例,參見圖1。
實例 2 產生 191P4D12 單株抗體 (MAb)在一實施例中,191P4D12及191P4D12變異體之治療性單株抗體(「MAb」)包含與對於各蛋白質具有特異性之抗原決定基反應之單株抗體,或對於變異體之間共同的序列具有特異性之單株抗體,其將結合191P4D12或191P4D12變異體,使191P4D12或191P4D12變異體內化,破壞或調節191P4D12或191P4D12變異體之生物功能,例如將破壞與配位體、受質及結合搭配物之相互作用的單株抗體。產生該等MAb之免疫原包括設計成編碼或含有細胞外域或整個191P4D12蛋白序列、預計含有功能基元之區域、及由對胺基酸序列之電腦分析預計具有抗原性之191P4D12蛋白變異體之區域的免疫原。免疫原包括肽及重組蛋白質,諸如tag5-191P4D12,其為來源於經純化之哺乳動物細胞的標記His之蛋白質。另外,使用經工程改造以表現高含量之191P4D12(諸如RAT1-191P4D12或300.19-191P4D12)的細胞對小鼠進行免疫接種。
使用XenoMouse technology
®(Amgem Fremont)產生191P4D12之MAb,其中已使鼠類重鏈及κ輕鏈基因座不活化且已插入大部分人類重鏈及κ輕鏈免疫球蛋白基因座。稱為
Ha22-2(2,4)6.1之MAb自免疫接種具有pTag5/mychis-191P4D12(胺基酸23-351)之產生人類γ1之異種小鼠(XenoMice)產生。
191P4D12 MAb
Ha22-2(2,4)6.1藉由ELISA可知與pTag5/mychis-191P4D12蛋白以及與表現重組191P4D12之細胞及表現191P4D12之多種癌細胞株特異性結合。
產生稱為
Ha22-2(2,4)6.1之抗體的融合瘤於
2010 年 8 月 18 日(經由Federal Express)送至美國菌種保存中心(ATCC),郵政信箱1549,Manassas,VA 20108且給予寄存編號
PTA-11267。
用Trizol試劑(Life Technologies, Gibco BRL)自各別融合瘤細胞分離mRNA後,測定編碼191P4D12 MAb
Ha22-2(2,4)6.1之序列的DNA。
使用以下方案自融合瘤細胞對抗191P4D12 Ha22-2(2,4)6.1重鏈及輕鏈可變核酸序列進行測序。用Trizol試劑(Life Technologies, Gibco BRL)溶解分泌Ha22-2(2,4)6.1之融合瘤細胞。純化總RNA並進行定量。使用Gibco-BRL Superscript Preamplification系統用oligo (dT)12-18激活自總RNA產生第一股cDNA。使用人類免疫球蛋白可變重鏈引子及人類免疫球蛋白可變輕鏈引子擴增第一股cDNA。對PCR產物測序且測定可變重鏈及輕鏈區。
可變重鏈及輕鏈區之核酸及胺基酸序列列於圖2及圖3中。Ha22-2(2,4)6.1 MAb與人類Ig生殖系之比對陳列於圖4A-4B中。
實例 3 使用重組 DNA 方法表現 Ha22-2(2,4)6.1為在轉染細胞中重組表現Ha22-2(2,4)6.1 MAb,將Ha22-2(2,4)6.1 MAb可變重鏈及輕鏈序列分別選殖至人類重鏈IgG1及人類輕鏈Igκ恆定區之上游。將完整Ha22-2(2,4)6.1 MAb人類重鏈及輕鏈卡匣選殖至選殖載體中CMV啟動子/強化子之下游。在MAb編碼序列之下游包括聚腺苷酸化位點。將表現重組Ha22-2(2,4)6.1 MAb之構築體轉染至CHO細胞中。藉由流動式細胞測量術評估自重組細胞分泌之Ha22-2(2,4)6.1 MAb與細胞表面191P4D12之結合(圖5A)。用來自融合瘤或來自經Ha22-2(2,4)6.1重鏈及輕鏈載體構築體轉染之CHO細胞的Ha22-2(2,4)6.1 MAb將RAT-對照組及RAT-191P4D12細胞染色。藉由流動式細胞測量術偵測結合。
結果顯示類似於自融合瘤純化之Ha22-2(2,4)6.1,在CHO細胞中表現之重組表現的Ha22-2(2,4)6.1結合191P4D12。亦藉由ELISA評估自重組細胞分泌之Ha22-2(2,4)6.1 MAb與191P4D12重組蛋白之結合。如圖5B中所示,Ha22-2(2,4)6.1與191P4D12蛋白之結合在來源於CHO與來源於融合瘤細胞之MAb物質之間為一致的。
實例 4 Ha22-2(2,4)6.1 MAb 之抗體藥物共軛使用以下方案,使用本文所述之vc(Val-Cit)連接子使Ha22-2(2,4)6.1 MAb(圖2)與稱為MMAE(式XI)之奧瑞他汀衍生物共軛以形成本發明之稱為Ha22-2(2,4)6.1vcMMAE的抗體藥物共軛物(ADC)。使用表IV中所示之一般方法使vc(Val-Cit)連接子與MMAE(Seattle Genetics, Inc., Seattle, WA)共軛形成細胞毒性vcMMAE(參見美國專利第7,659,241號)。
接著使用以下方案製備本發明之稱為Ha22-2(2,4)6.1vcMMAE的抗體藥物共軛物(ADC)。
簡言之,將15 mg/mL之Ha22-2(2,4)6.1MAb於10 mM乙酸酯(pH 5.0)、1%山梨糖醇、3% L-精胺酸中之溶液與20%體積之0.1 M TrisCl(pH 8.4)、25 mM EDTA及750 mM NaCl一起添加以使溶液之pH值調整至7.5、5 mM EDTA及150 mM氯化鈉。接著藉由添加2.3莫耳當量TCEP(相對於MAb之莫耳數)部分還原MAb,接著在37℃下攪拌2小時。接著使部分還原之MAb溶液冷卻至5℃且以6% (v/v)DMSO溶液形式添加4.4莫耳當量vcMMAE(相對於抗體之莫耳數)。在5℃下攪拌混合物60分鐘,接著在添加1莫耳當量N-乙醯半胱胺酸(相對於vcMMAE)後再攪拌15分鐘。藉由用10體積之20 mM組胺酸(pH 6.0)超濾/透濾抗體藥物共軛物(ADC)來移除過量淬滅之vcMMAE及其他反應組分。
所得抗體藥物共軛物(ADC)稱為Ha22-2(2,4)6.1vcMMAE且具有下式:
其中MAb為Ha22-2(2,4)6.1(圖2及圖3)且p為1至8。此實例中所示之抗體藥物共軛物的p值為約3.8。
實例 5 Ha22-2(2,4)6.1vcMMAE 之表徵使用標題為「Ha22-2(2,4)6.1 MAb之抗體藥物共軛」之實例中所示的程序產生結合191P4D12之抗體藥物共軛物,且使用此項技術中已知之檢定組合篩選、鑑別及表徵。
A. 藉由 FACS 測定親和性測試Ha22-2(2,4)6.1vcMMAE對分別在PC3-人類-191P4D12、PC3-食蟹獼猴-191P4D12及PC3-大鼠-191P4D12細胞表面上表現之191P4D12的結合親和性。簡言之,在4℃下將11種Ha22-2(2,4)6.1vcMMAE稀釋液與各細胞類型(每孔50,000個細胞)一起培育隔夜,最終濃度為160 nM至0.011 nM。在培育結束時,洗滌細胞且在4℃下與抗hIgG-PE偵測抗體一起培育45分鐘。洗滌未結合之偵測抗體後,藉由FACS分析細胞。獲得如圖6-8中所列之平均螢光強度(Mean Florescence Intensity,MFI)值。將MFI值輸入Graphpad Prisim軟體中且使用單位點結合(雙曲線)方程式Y=Bmax*X/(Kd+X)分析,得到Ha22-2(2,4)6.1vcMMAE飽和曲線,其亦分別展示於圖6-8中。Bmax為Ha22-2(2,4)6.1vcMMAE與191P4D12之最大結合MFI值;Kd為達成半最大結合所需之Ha22-2(2,4)6.1vcMMAE濃度的Ha22-2(2,4)6.1vcMMAE結合親和性。
計算出的Ha22-2(2,4)6.1vcMMAE對分別在PC3-人類-191P4D12、PC3-食蟹獼猴-191P4D12及PC3-大鼠-191P4D12細胞表面上表現之191P4D12的親和性(Kd)為0.69 nM(圖6)、0.34 nM(圖7)及1.6 nM(圖8)。
B. 藉由 SPR 測定親和性藉由表面電漿子共振(SPR)(BIAcore)測定Ha22-2(2,4)6.1 MAb及Ha22-2(2,4)6.1vcMMAE對經純化之重組191P4D12 (ECD胺基酸1-348)的親和性。簡言之,將山羊-抗人類Fcγ多株Ab(Jackson Immuno Research Labs, Inc.)共價固定於CM5感應晶片(Biacore)之表面上。接著將經純化之Ha22-2(2,4)6.1 MAb或Ha22-2(2,4)6.1vcMMAE捕捉於該晶片之表面上。在每個循環中平均捕捉約300 RU之測試Ha22-2(2,4)6.1 MAb或Ha22-2(2,4)6.1vcMMAE。隨後,將一系列1 nM至100 nM範圍內之5至6個重組191P4D12(ECD胺基酸1-348)稀釋液注射到該表面上以產生結合曲線(感測器圖譜),使用BIAevaluation 3.2及CLAMP軟體(Myszka and Morton, 1998)處理該等曲線且整體擬合為1:1相互作用模型(表V)。表VI總結締合及解離速率常數以及Ha22-2(2,4)6.1 MAb及Ha22-2(2,4)6.1vcMMAE對重組191P4D12 (ECD胺基酸1-348)之親和性。
C. Ha22-2(2,4)6.1 MAb 之結構域定位為定位Ha22-2(2,4)6.1 MAb與191P4D12蛋白之特異性結構域的結合位點,產生表現該等結構域(或其組合)之若干種大鼠1(E)重組細胞株(表VII)。藉由FACS使用標準方案評估Ha22-2(2,4)6.1與細胞表面之結合。如圖10中所示,Ha22-2(2,4)6.1 MAb與表現VC1域之細胞以及野生型191P4D12結合,而不與表現C1C2域之細胞結合。另外,稱為Ha22-8e6.1之另一191P4D12 MAb識別細胞表面上之191P4D12的C1C2域而非VC1域。此表明Ha22-2(2,4)6.1 MAb之結合位點位於191P4D12之1-147 aa結構域中,而非與191P4D12結合之每個MAb均識別此結構域。
為進一步確證圖10中所示之結果,進行西方墨點分析(Western Blot Analysis)。簡言之,表VII中所示之191P4D12(全長)之整個細胞外部分以及特異性結構域在293T細胞中表現為鼠類Fc融合蛋白並加以純化。使用山羊抗小鼠-HRP作為對照組。如圖11中所示,當在SDS-PAGE(非還原)上解析且使用Ha22-2(2,4)6.1-生物素、隨後抗生蛋白鏈菌素-HRP作為探針時,認出對應於全長191P4D12(泳道1)、V(泳道2)及VC1(泳道3)融合構築體而非C1C2融合構築體(泳道4)之條帶。此進一步表明Ha22-2(2,4)6.1 MAb之結合抗原決定基位於191P4D12之1-147 aa結構域中。
實例 6 由 Ha22-2(2,4)6.1vcMMAE 介導之細胞毒性在經工程改造以表現人類191P4D12、食蟹獼猴191P4D12及大鼠191P4D12之PC3細胞中評估Ha22-2(2,4)6.1vcMMAE介導191P4D12依賴性細胞毒性之能力。簡言之,在第1天,將PC3-Neo、PC3-人類-191P4D12細胞、PC3-食蟹獼猴-191P4D12或PC3-大鼠-191P4D12細胞(每孔1500個細胞)接種至96孔盤中。第二天,向各孔中添加等體積的含有指定濃度之Ha22-2(2,4)6.1vcMMAE或與vcMMAE共軛之對照MAb(亦即對照-vcMMAE)的培養基。在37℃下培育細胞4天。在培育期結束時,向各孔中添加阿拉馬藍(Alamar Blue)且繼續再培育4小時。使用Biotek培養盤讀取器,在620 nM激發波長及540 nM發射波長下偵測所得螢光。
圖9A-9D中之結果顯示Ha22-2(2,4)6.1vcMMAE在PC3-人類-191P4D12(圖9A)、PC3-食蟹獼猴-191P4D12(圖9B)及PC3-大鼠-191P4D12細胞(圖9C)中介導細胞毒性,而與vcMMAE共軛之對照人類IgG無效。Ha22-2(2,4)6.1vcMMAE之特異性進一步藉由對不表現191P4D12之PC3-Neo細胞缺乏毒性來說明(圖9D)。因此,此等結果指示Ha22-2(2,4)6.1vcMMAE可將細胞毒性藥物選擇性傳遞至191P4D12表現細胞,從而將其殺死。
實例 7 Ha22-2(2,4)6.1vcMMAE 活體內抑制腫瘤生長191P4D12在腫瘤組織之細胞表面上的顯著表現以及其在正常組織中之有限表現使191P4D12成為抗體療法及類似地經由ADC之療法的良好標靶。因此,評估Ha22-2(2,4)6.1vcMMAE在人類膀胱癌、肺癌、乳癌及胰臟癌異種移植物小鼠模型中之治療功效。
在小鼠癌症異種移植物模型(例如皮下及正位)中研究抗體藥物共軛物對腫瘤生長及轉移形成之功效。
藉由在雄性SCID小鼠之右腹注射以1:1稀釋度與瑪崔膠(Matrigel)(Collaborative Research)混合之5×10
4-10
6個癌細胞來產生皮下(s.c.)腫瘤。為測試ADC對腫瘤形成之功效,在與腫瘤細胞注射的同一天開始ADC注射。作為對照組,給小鼠注射經純化之人類IgG或PBS;或識別不在人類細胞中表現之無關抗原的經純化MAb。在初級研究中,在對照IgG或PBS對腫瘤生長之作用之間未發現差異。藉由測徑器量測來測定腫瘤尺寸,且以寬度
2×長度/2計算腫瘤體積,其中寬度為最小尺寸且長度為最大尺寸。處死皮下腫瘤直徑大於1.5 cm之小鼠。
卵巢腫瘤通常發生轉移並在腹膜腔內生長。因此,藉由將2百萬細胞直接注入雌性小鼠之腹膜內來使小鼠卵巢腫瘤腹膜內生長。監測小鼠之一般健康狀況、身體活動及外觀,直至其瀕臨死亡。處死時,可檢查腹膜腔以測定腫瘤負荷且收集肺以評估向遠端部位之轉移。或者,可使用死亡作為終點。接著將小鼠分成用腹膜內注射之191P4D12或對照MAb適當處理之組。
異種移植物癌症模型之優點為研究新血管生成及血管生成之能力。腫瘤生長部分視新血管發育而定。儘管毛細管系統及發育中的血液網來源於宿主,但新血管之起始及結構由異種移植物腫瘤調節(Davidoff等人Clin Cancer Res. (2001) 7:2870;Solesvik等人Eur J Cancer Clin Oncol. (1984) 20:1295)。根據此項技術中已知之程序,諸如藉由腫瘤組織及其周圍微環境之IHC分析來研究抗體及小分子對新血管生成之作用。
Ha22-2(2,4)6.1ADC抑制肺癌、膀胱癌、乳癌及胰臟癌異種移植物之形成。此等結果指示Ha22-2(2,4)6.1ADC在治療局部及晚期癌症及較佳為表I中所示之彼等癌症中之效用。
191P4D12 ADC :如標題為「產生191P4D12單株抗體(MAb)」之實例中所述,產生針對191P4D12之單株抗體。此外,如標題為「Ha22-2(2,4)6.1 MAb之抗體藥物共軛」之實例中所述,使MAb與毒素共軛以形成Ha22-2(2,4)6.1vcMMAE。Ha22-2(2,4)6.1vcMMAE藉由FACS及此項技術中已知之其他方法表徵以測定其結合191P4D12之能力。
細胞株及異種移植物:如此項技術中已知,將BT-483及HPAC細胞維持於補充有L-麩醯胺酸及10% FBS之DMEM中。藉由連續繁殖將AG-B8、AG-Panc4、AG-Panc2、AG-B1、AG-L4及AG-Panc3異種移植物維持於SCID小鼠體內。
在 SCID 小鼠之人類肺癌異種移植物 AG-L4 的皮下腫瘤形成模型中評估 Ha22-2(2,4)6.1vcMMAE MAb在此實驗中,藉由連續繼代將來源於患者之肺癌異種移植物AG-L4維持於SCID小鼠體內。無菌收集腫瘤原料且以酶方法消化成單細胞懸浮液中。將兩百萬個細胞植入個別SCID小鼠之側腹中。接著將動物隨機分配成七組:六個191P4D12抗體處理組及一個對照抗體H3-1.10.1.2組(n=10)。所有抗體均以每隻動物750 μg腹膜內給藥,每週兩次直至研究結束。每3至4天使用測徑器量測來監測腫瘤生長。以寬度
2×長度/2計算腫瘤體積,其中寬度為最小尺寸且長度為最大尺寸。
結果顯示191P4D12 MAb在SCID小鼠之人類肺癌異種移植物AG-L4中不顯著抑制腫瘤生長。另外,在此研究中使用其他191P4D12 MAb。不展示結果。(圖12)。
在 SCID 小鼠之人類胰臟癌異種移植物 HPAC 的皮下腫瘤形成模型中評估 Ha22-2(2,4)6.1 MAb在另一實驗中,將人類胰臟癌HPAC細胞(每隻小鼠兩百萬個)注入個別SCID小鼠之側腹中。接著將動物隨機分配成八組:七個191P4D12抗體處理組及一個對照抗體H3-1.4.1.2組(n=10)。所有抗體均以每隻動物500 μg腹膜內給藥,每週兩次直至研究結束。每3至4天使用測徑器量測來監測腫瘤生長。以寬度
2×長度/2計算腫瘤體積,其中寬度為最小尺寸且長度為最大尺寸。
結果顯示與對照抗體相比,191P4D12 MAb在SCID小鼠之人類胰臟異種移植物中不抑制腫瘤生長。另外,在此研究中使用其他191P4D12 MAb。不展示結果。(圖13)。
在SCID小鼠之人類胰臟癌異種移植物AG-Panc3的皮下腫瘤形成模型中評估Ha22-2(2,4)6.1 MAb。
在另一實驗中,藉由連續繼代將來源於患者之胰臟癌異種移植物AG-Panc3維持於SCID小鼠體內。無菌收集腫瘤原料且切碎成1 mm
3的片。將六片植入個別SCID小鼠之側腹中。接著將動物隨機分配成以下各組(n=10):兩個191P4D12 MAb處理組及一個對照抗體H3-1.4.1.2組。所有抗體均以每隻動物500 μg腹膜內給藥,每週兩次直至研究結束。每3至4天使用測徑器量測來監測腫瘤生長。以寬度
2×長度/2計算腫瘤體積,其中寬度為最小尺寸且長度為最大尺寸。
結果顯示與對照抗體相比,191P4D12 MAb在SCID小鼠之人類胰臟異種移植物中不抑制腫瘤生長。另外,在此研究中使用其他191P4D12 MAb。不展示結果。(圖14)。
Ha22-2(2,4)6.1-vcMMAE 在 SCID 小鼠之皮下形成的人類肺癌異種移植物 AG-L4 中之功效在另一實驗中,藉由連續繼代將來源於患者之肺癌異種移植物AG-L13維持於SCID小鼠體內。無菌收集腫瘤原料且切碎成1 mm
3的片。將六片植入個別SCID小鼠之側腹中。在未處理之情況下使腫瘤生長直至其達到約200 mm
3之體積。每七天藉由靜脈內快速注射給與10 mg/kg之Ha22-2(2,4)6.1vcMMAE及對照ADC持續兩次劑量。ADC之投與量係基於在即將給藥前獲得之各動物之個別體重。每3至4天使用測徑器量測來監測腫瘤生長。以寬度
2×長度/2計算腫瘤體積,其中寬度為最小尺寸且長度為最大尺寸。
結果顯示與對照ADC相比,用Ha22-2(2,4)6.1-vcMMAE處理可顯著抑制皮下植入裸小鼠中之AG-L4肺癌異種移植物之生長。另外,在此研究中使用其他191P4D12 MAb。不展示結果。(圖15)。
Ha22-2(2,4)6.1-vcMMAE 在 SCID 小鼠之皮下形成的人類乳癌異種移植物 BT-483 中之功效在此實驗中,使用人類乳癌BT-483細胞產生異種移植物原料,其藉由連續繼代維持於SCID小鼠體內。無菌收集腫瘤原料且切碎成1 mm
3的片。將六片植入個別SCID小鼠之側腹中。在未處理之情況下使腫瘤生長直至其達到約100 mm
3之體積。每四天藉由靜脈內快速注射給與5 mg/kg之Ha22-2(2,4)6.1vcMMAE及對照ADC持續四次劑量。ADC之投與量係基於在即將給藥前獲得之各動物之個別體重。每3至4天使用測徑器量測來監測腫瘤生長。以寬度
2×長度/2計算腫瘤體積,其中寬度為最小尺寸且長度為最大尺寸。
結果顯示與對照ADC相比,用Ha22-2(2,4)6.1-vcMMAE處理可顯著抑制皮下植入SCID小鼠中之BT-483乳房腫瘤異種移植物的生長。另外,在此研究中使用其他191P4D12 MAb。不展示結果。(圖16)。
Ha22-2(2,4)6.1-vcMMAE 在 SCID 小鼠之皮下形成的人類膀胱癌異種移植物 AG-B1 中之功效在另一實驗中,藉由連續繼代將來源於患者之膀胱癌異種移植物AG-B1維持於SCID小鼠體內。無菌收集腫瘤原料且切碎成1 mm
3的片。將六片植入個別SCID小鼠之側腹中。在未處理之情況下使腫瘤生長直至其達到約230 mm
3之體積。藉由靜脈內快速注射給與4 mg/kg之Ha22-2(2,4)6.1vcMMAE及對照ADC一次。ADC之投與量係基於在即將給藥前獲得之各動物之個別體重。每3至4天使用測徑器量測來監測腫瘤生長。以寬度
2×長度/2計算腫瘤體積,其中寬度為最小尺寸且長度為最大尺寸。
結果顯示與對照ADC相比,用Ha22-2(2,4)6.1-vcMMAE處理可顯著抑制AG-B1膀胱癌異種移植物之生長。另外,在此研究中使用其他191P4D12 MAb。不展示結果。(圖17)。
Ha22-2(2,4)6.1-vcMMAE 在 SCID 小鼠之皮下形成的人類胰臟癌異種移植物 AG-Panc2 中之功效在另一實驗中,藉由連續繼代將來源於患者之胰臟癌異種移植物AG-Panc2維持於SCID小鼠體內。無菌收集腫瘤原料且切碎成1 mm
3的片。將五片植入個別SCID小鼠之側腹中。在未處理之情況下使腫瘤生長直至其達到約100 mm
3之體積。每四天藉由靜脈內快速注射給與5 mg/kg之Ha22-2(2,4)6.1vcMMAE及對照ADC持續四次劑量。ADC之投與量係基於在即將給藥前獲得之各動物之個別體重。每3至4天使用測徑器量測來監測腫瘤生長。以寬度
2×長度/2計算腫瘤體積,其中寬度為最小尺寸且長度為最大尺寸。
結果顯示與對照ADC相比,用Ha22-2(2,4)6.1-vcMMAE處理可顯著抑制AG-Panc2胰臟癌異種移植物之生長。另外,在此研究中使用其他191P4D12 MAb。不展示結果。(圖18)。
Ha22-2(2,4)6.1-vcMMAE 在 SCID 小鼠之皮下形成的人類胰臟癌異種移植物 AG-Panc4 中之功效在另一實驗中,藉由連續繼代將來源於患者之胰臟癌異種移植物AG-Panc4維持於SCID小鼠體內。無菌收集腫瘤原料且切碎成1 mm
3的片。將六片植入個別SCID小鼠之側腹中。每七天藉由靜脈內快速注射給與5 mg/kg之Ha22-2(2,4)6.1vcMMAE及對照ADC持續三次劑量。ADC之投與量係基於在即將給藥前獲得之各動物之個別體重。每3至4天使用測徑器量測來監測腫瘤生長。以寬度
2×長度/2計算腫瘤體積,其中寬度為最小尺寸且長度為最大尺寸。
結果顯示與對照ADC相比,用Ha22-2(2,4)6.1-vcMMAE處理可顯著抑制AG-Panc4胰臟癌異種移植物之生長。另外,在此研究中使用其他191P4D12 MAb。不展示結果。(圖19)。
Ha22-2(2,4)6.1-vcMMAE 以比較劑量在 SCID 小鼠之皮下形成的人類膀胱癌異種移植物 AG-B8 中之功效在此實驗中,藉由連續繼代將來源於患者之膀胱癌異種移植物AG-B8維持於SCID小鼠體內。無菌收集腫瘤原料且切碎成1 mm
3的片。將六片植入個別SCID小鼠之側腹中。在未處理之情況下使腫瘤生長直至其達到約200 mm
3之體積。接著將動物隨機分配成以下三組(n=6):兩個Ha22-2(2,4)6.1-vcMMAE處理組及一個對照ADC VCD37-5ce5p-vcMMAE組。給與5 mg/kg或10 mg/kg之Ha22-2(2,4)6.1-vcMMAE且給與5 mg/kg之對照ADC。所有ADC均藉由靜脈內快速注射給與一次。ADC之投與量係基於在即將給藥前獲得之各動物之個別體重。每3至4天使用測徑器量測來監測腫瘤生長。以寬度
2×長度/2計算腫瘤體積,其中寬度為最小尺寸且長度為最大尺寸。
結果顯示與5 mg/kg之Ha22-2(2,4)6.1vcMMAE相比,用10 mg/kg之Ha22-2(2,4)6.1vcMMAE處理可抑制AG-B8膀胱癌異種移植物之生長。(圖20)。
結論總而言之,圖12-20展示與對照ADC相比,稱為Ha22-2(2,4)6.1vcMMAE之191P4D12 ADC顯著抑制表現191P4D12之腫瘤細胞的生長。因此,Ha22-2(2,4)6.1vcMMAE可用於治療性目的以治療及控制表I中所示之癌症。
實例 8 經由使用 191P4D12 ADC 治療及診斷人類癌瘤之人類臨床試驗根據本發明使用與191P4D12特異性結合之191P4D12 ADC,且將其用於治療某些腫瘤、較佳為表I中所列之彼等腫瘤。關於此等適應症之每一者,成功地進行兩種臨床方法。
I.) 輔助療法:在輔助療法中,用191P4D12 ADC結合化學治療劑或抗贅生劑及/或放射療法或其組合治療患者。根據標準方案,藉由將191P4D12 ADC添加至標準第一及第二線療法中來治療諸如表I中所列之彼等標靶的原發性癌症標靶。方案設計致力於如藉由以下實例所評估之有效性,其包括(但不限於)原發性或轉移性病變之腫瘤質量減小、無進展存活時間增加、總存活時間增加、患者健康狀況改善、疾病穩定、以及減少標準化學療法及其他生物藥劑常用劑量的能力。此等劑量減少由於降低化學治療劑或生物藥劑之劑量相關毒性而使得可進行額外及/或延長之治療。在若干種輔助臨床試驗中使用191P4D12 ADC與化學治療劑或抗贅生劑之組合。
II.) 單一療法:關於191P4D12 ADC在腫瘤單一療法中之使用,向未投與化學治療劑或抗贅生劑之患者投與191P4D12 ADC。在一實施例中,臨床上對患廣泛轉移性疾病之末期癌症患者進行單一療法。方案設計致力於如藉由以下實例所評估之有效性,其包括(但不限於)原發性或轉移性病變之腫瘤質量減小、無進展存活時間增加、總存活時間增加、患者健康狀況改善、疾病穩定、以及減少標準化學療法及其他生物藥劑常用劑量的能力。
劑量可調節給藥方案以提供最佳所需反應。舉例而言,可投與單次劑量;可隨時間投與若干分次劑量;或可按治療情況之緊急需要指示按比例減小或增加劑量。為了便於投藥及劑量均一性,將非經腸組合物調配成單位劑型尤其有利。如本文中所使用,單位劑型係指適合作為單一劑量用於欲治療哺乳動物個體之物理個別單元;各單元含有經計算可產生所需治療作用的預定量之活性化合物與所需醫藥載劑結合。關於本發明之單位劑型的說明由以下決定且直接視以下而定:(a)抗體及/或ADC之獨特特徵及欲達成之特定治療性或預防性作用;及(b)此項技術中固有的混配用於治療個體敏感性之該活性化合物的侷限性。
根據本發明組合投與之191P4D12 ADC的治療有效量之例示性、非限制性範圍為約0.5至約10 mg/kg、約1至約5 mg/kg、至少1 mg/kg、至少2 mg/kg、至少3 mg/kg或至少4 mg/kg。其他例示性非限制性範圍為例如約0.5至約5 mg/kg、或例如約0.8至約5 mg/kg、或例如約1至約7.5 mg/kg。本發明之高劑量實施例係關於大於10 mg/kg之劑量。應注意劑量值可隨欲減輕之病狀的類型及嚴重程度而變化,且可包括單次或多次劑量。應進一步瞭解,對於任何特定個體而言,特定給藥方案應根據個體需要及投與或監督組合物投與之人士的專業判斷隨著時間來加以調整,且本文所述之劑量範圍僅為例示性的,而不欲限制所主張之組合物的範疇或實踐。
臨床開發計劃 (CDP)關於輔助療法或單一療法,隨後進行CDP且其開發191P4D12 ADC之治療。試驗最初證明安全性且之後證實重複劑量之功效。試驗為比較標準化學療法與標準療法加上191P4D12 ADC之開放標籤試驗(open label)。如所應瞭解,關於招募患者使用之一個非限制性準則為如藉由活組織檢查所測定之191P4D12在其腫瘤中之表現水準。
如同基於蛋白質或抗體輸注之任何療法,安全性考量主要係關於:(i)細胞因子釋放症候群,亦即低血壓、發燒、發抖、寒戰;(ii)對物質產生免疫原性反應(亦即患者針對抗體療法產生人類抗體,或HAHA反應);及(iii)對表現191P4D12之正常細胞具有毒性。使用標準測試及隨訪來監測此等安全性考量中之每一者。發現191P4D12 ADC在投與人類後為安全的。
實例 9 藉由 IHC 偵測癌症患者試樣中之 191P4D12 蛋白藉由免疫組織化學測試191P4D12蛋白在來自以下之患者腫瘤試樣中的表現:(i)膀胱癌、(ii)乳癌、(iii)胰臟癌、(iv)肺癌、(v)卵巢癌、(vi)食道癌及(vii)頭頸部癌患者。簡言之,將經福馬林(formalin)固定、石蠟包埋之組織切成4微米切片且安裝於玻璃載片上。除去該等切片之蠟,再水化且在95℃下在EZ-Retriever微波(Biogenex, San Ramon, CA)中用EDTA抗原修復溶液(Biogenex, San Ramon, CA)處理30分鐘。接著用3%過氧化氫溶液處理切片以使內源性過氧化酶活性不活化。使用無血清蛋白質阻斷劑(Dako, Carpenteria, CA)抑制非特異性結合,隨後與單株小鼠抗191P4D12抗體或同型對照組一起培育。隨後,用Super Sensitive™聚合物-辣根過氧化酶(HRP)偵測系統處理切片,該處理由在Super Enhancer™試劑中培育,隨後與聚合物-HRP二級抗體共軛物(BioGenex, San Ramon, CA)一起培育組成。接著使用DAB套組(BioGenex, San Ramon, CA)使切片顯影。使用蘇木素將細胞核染色,且藉由明視野顯微法分析。如藉由棕色染色所指示,使用191P4D12免疫反應性抗體在患者試樣中偵測特殊染色。(參見圖21(A)、21(C)、21(E)、21(G)、21(I)、21(K)及21(M))。相比之下,對照抗體不會使任一患者試樣染色。(參見圖21(B)、21(D)、21(F)、21(H)、21(J)、21(L)及21(N))。
結果顯示191P4D12在患者膀胱癌、乳癌、胰臟癌、肺癌、卵巢癌、食道癌及頭頸部癌組織之腫瘤細胞中表現。此等結果指示191P4D12在人類癌症中表現且針對此抗原之抗體及稱為Ha22-2(2,4)6.1vcMMAE之抗體藥物共軛物適用於診斷性及治療性目的。(圖21)。
實例 10 測定 Ha22-2(2,4)6.1 MAb 之結合抗原決定基人類、食蟹獼猴、大鼠及鼠類來源之191P4D12蛋白在PC3細胞株中重組過表現以測定Ha22-2(2,4)6.1與此等直系同源物之交叉反應性。顯示Ha22-2(2,4)6.1與191P4D12之食蟹獼猴及大鼠直系同源物高度交叉反應(表VIII)。EC50結合值展示於
表 IX中。Ha22-2(2,4)6.1與鼠類直系同源物之結合顯示結合EC50值顯著降低,其顯示V域中之重要胺基酸取代(與人類及大鼠序列相比)影響Ha22-2(2,4)6.1對191P4D12之親和性。
表 X展示含有V域之191P4D12直系同源物的aa 1-180蛋白質序列比對。大鼠直系同源物序列中僅兩個胺基酸,Thr-75及Ser-90分別取代鼠類直系同源物序列中之Ile及Asn(
以紅色標記)。應注意人類序列中之對應胺基酸為Ala-76及Ser-91。為判定此等胺基酸是否包含Ha22-2(2,4)6.1之結合抗原決定基,產生191P4D12及其鼠類直系同源物之若干種突變構築體且使其在PC3細胞中表現(
表 XI)。將「鼠類」胺基酸替代標準丙胺酸取代突變誘發引入人類序列中且亦反過來引入小鼠序列中。
顯示191P4D12中Ser-91突變為Asn嚴重地削弱Ha22-2(2,4)6.1之結合,從而證實此胺基酸Ser-91為結合所必需的且必須包含由Ha22-2(2,4)6.1 MAb識別之抗原決定基。亦將位置76之Ala的其他突變(A76I、S91N雙重突變體)引入191P4D12中。顯示Ha22-2(2,4)6.1與雙重突變體A76I、S91N之結合極類似於鼠類直系同源物結合(
表 XII)。相反,鼠類序列中之Asn-90突變為Ser顯著改良Ha22-2(2,4)6.1與鼠類突變體直系同源物之結合,其進一步證實此位置之胺基酸對於Ha22-2(2,4)6.1結合的重要性。Ha22-2(2,4)6.1與鼠類直系同源物雙重突變體A90S、I75A之結合似乎極類似於191P4D12之人類直系同源物。
綜上所述,此等數據證明Ser-91及Ala-76在Ha22-2(2,4)6.1與細胞表面上之191P4D12蛋白的結合中起關鍵作用且構成191P4D12表面上由Ha22-2(2,4)6.1識別的抗原決定基之一部分。
為觀察此概念,基於191P4D12及含有Ig域之蛋白質的家族成員之公開晶體結構資料,使用PyMOL產生191P4D12之V域的電腦模型(
表 XIII)。展示Ala-76(綠色)及Ser-91(紅色)之位置。
另外,為進一步修正191P4D12分子上之Ha22-2(2,4)6.1結合位點,設計並表現191P4D12中對應於大鼠(1)E細胞表面上之V域的片段。在反轉錄病毒載體中產生以下構築體:
191P4D12(aa1-150、347-510)。
藉由FACS評估Ha22-2(2,4)6.1 MAb之結合。如
表 XIV中所示,Ha22-2(2,4)6.1與表現V域之細胞(A)以及野生型191P4D12(B)結合,而不與較早產生之表現C1C2域之細胞(C)結合。此證實此抗體之結合位點位於191P4D12之V域的開頭150個胺基酸中。
結果顯示Ha22-2(2,4)6.1 Mab自位置aa 1-150與191P4D12蛋白之v域結合且另外顯示包含aa Ser-91及aa Ala-76之特異性抗原決定基為結合Ha22-2(2,4)6.1 MAb之關鍵。
在本申請案通篇中,參考多個網站資料內容、公開案、專利申請案及專利。(網站係依據其統一資源定位器(Uniform Resource Locator)或URL,全球資訊網(World Wide Web)上之位址來參考)。此等參考文獻各自之揭示內容係以全文引用的方式併入本文中。
本發明之範疇不欲受本文所揭示之實施例限制,該等實施例意欲單獨說明本發明之個別態樣,且任何功能等同者均在本發明之範疇內。除本文所述外,對本發明之模型及方法的各種修改對於熟習此項技術者根據以上描述及教示將顯而易知,且同樣意欲在本發明之範疇內。可在不脫離本發明之真實範疇及精神的情況下實施該等修改或其他實施例。
表格 表 I :當為惡性病時表現 191P4D12 之組織。結腸
胰臟
卵巢
乳房
肺
膀胱
表 II :胺基酸縮寫
表 III :胺基酸取代矩陣由GCG軟體9.0 BLOSUM62胺基酸取代矩陣(區塊取代矩陣)改編而來。值愈高,愈有可能在相關天然蛋白質中存在取代。
表 IV。合成vcMMAE之通用方法
其中: AA1=胺基酸1
AA2=胺基酸2
AA5=胺基酸5
DIL=多拉異白胺酸
DAP=多拉脯胺酸
連接子=Val-Cit(vc)
表 V 。用於經由SPR測定親和性之結合曲線(感測器圖譜)
表 VI 。拜克爾締合及解離速率及所得親和性計算結果
表 VII 。用於結構域定位檢定中之191P4D12構築體
表 VIIIHa22-2(2,4)6.1與表現191P4D12(A)及來自食蟹獼猴(B)、大鼠(C)及小鼠(D)之直系同源物的PC3細胞結合
A B
C D
表 IX
表 X 表 XI
表 XII 表 XIII 表 XIV A B C
R 20 | R 21 |
苯甲基 | (CH 2) 4NH 2; |
甲基 | (CH 2) 4NH 2; |
異丙基 | (CH 2) 4NH 2; |
異丙基 | (CH 2) 3NHCONH 2; |
苯甲基 | (CH 2) 3NHCONH 2; |
異丁基 | (CH 2) 3NHCONH 2; |
第二丁基 | (CH 2) 3NHCONH 2; |
(CH 2) 3NHCONH 2; | |
苯甲基 | 甲基; |
苯甲基 | (CH 2) 3NHC(=NH)NH 2; |
R 20 | R 21 | R 22 |
苯甲基 | 苯甲基 | (CH 2) 4NH 2; |
異丙基 | 苯甲基 | (CH 2) 4NH 2;及 |
H | 苯甲基 | (CH 2) 4NH 2; |
R 20 | R 21 | R 22 | R 23 |
H | 苯甲基 | 異丁基 | H;及 |
甲基 | 異丁基 | 甲基 | 異丁基。 |
單字母 | 三字母 | 全稱 |
F | Phe | 苯丙胺酸 |
L | Leu | 白胺酸 |
S | Ser | 絲胺酸 |
Y | Tyr | 酪胺酸 |
C | Cys | 半胱胺酸 |
W | Trp | 色胺酸 |
P | Pro | 脯胺酸 |
H | His | 組胺酸 |
Q | Gln | 麩醯胺酸 |
R | Arg | 精胺酸 |
I | Ile | 異白胺酸 |
M | Met | 甲硫胺酸 |
T | Thr | 蘇胺酸 |
N | Asn | 天冬醯胺 |
K | Lys | 離胺酸 |
V | Val | 纈胺酸 |
A | Ala | 丙胺酸 |
D | Asp | 天冬胺酸 |
E | Glu | 麩胺酸 |
G | Gly | 甘胺酸 |
kon, M-1s-1 | koff, s-1 | KD, M | |
Ha22-2(2,4)6.1 | 3.8E+05 | 5.8E-03 | 1.6E-08 |
Ha22-2(2,4)6.1vcMMAE | 4.5E+05 | 5.2E-03 | 1.1E-08 |
構築體 | 名稱 |
191P4D12(aa 1-242、347-510) | VC1,大鼠1(E)表現株 |
191P4D12(aa 1-31、147-510) | C1C2,大鼠1(E)表現株 |
191P4D12(aa 1-242) | mFc-VC1,融合蛋白 |
191P4D12(aa 1-31、147-346) | mFc-C1C2,融合蛋白 |
191P4D12(aa 1-141) | mFc-V,融合蛋白 |
PC3-191P4D12 | 食蟹獼猴直系同源物 | 大鼠直系同源物 | 鼠類直系同源物 | |
Bmax(MFI) | 816 | 1146 | 679 | 325 |
EC 50(nM) | 0.28 | 0.30 | 0.44 | 70.3 |
野生型構築體 | 突變型構築體 | 雙重突變體構築體 |
191P4D12,野生型 | S91N | S91N、A76I |
191P4D12之鼠類直系同源物,野生型 | N90S | N90S、I75A |
圖 1。191P4D12之cDNA (SEQ ID NO: 1)及胺基酸序列(SEQ ID NO: 2)展示於圖1中。對起始甲硫胺酸加下劃線。開放閱讀框架自核酸264延伸至核酸1796,包括終止密碼子。
圖 2。191P4D12抗體之核酸及胺基酸序列。
圖 2A 。Ha22-2(2,4)6.1重鏈之cDNA (SEQ ID NO: 3)及胺基酸序列(SEQ ID NO: 4)。對前導序列加雙下劃線,對重鏈可變區加下劃線,且對人類IgG1恆定區加虛下劃線。
圖 2B 。Ha22-2(2,4)6.1輕鏈之cDNA (SEQ ID NO: 5)及胺基酸序列(SEQ ID NO: 6)。對前導序列加雙下劃線,對輕鏈可變區加下劃線,且對人類κ恆定區加虛下劃線。
圖 3 。191P4D12抗體之胺基酸序列。
圖 3A 。Ha22-2(2,4)6.1重鏈之胺基酸序列(SEQ ID NO: 7)。對前導序列加雙下劃線,對重鏈可變區加下劃線,且對人類IgG1恆定區加虛下劃線。
圖 3B 。Ha22-2(2,4)6.1輕鏈之胺基酸序列(SEQ ID NO: 8)。對前導序列加雙下劃線,對輕鏈可變區加下劃線,且對人類κ恆定區加虛下劃線。
圖 4。Ha22-2(2,4)6.1抗體與人類Ig生殖系之比對。
圖 4A 。Ha22-2(2,4)6.1重鏈(SEQ ID NO: 3、4之一部分)與人類Ig生殖系VH3-48 (SEQ ID NO: 9)之比對。
圖 4B 。Ha22-2(2,4)6.1輕鏈(SEQ ID NO: 5、6之一部分)與人類Ig生殖系L5 (SEQ ID NO: 10)之比對。
圖 5 。Ha22-2(2,4)6.1 MAb結合檢定。
圖 5A :使用流動式細胞測量術偵測Ha22-2(2,4)6.1 MAb之結合。用來自融合瘤或CHO細胞之Ha22-2(2,4)6.1 MAb將RAT-對照組及RAT-191P4D12細胞染色。藉由流動式細胞測量術偵測結合。結果顯示在CHO細胞中重組表現之Ha22-2(2,4)6.1 MAb分泌且與細胞表面191P4D12特異性結合。
圖 5B :使用ELISA偵測Ha22-2(2,4)6.1 Mab之結合。藉由ELISA測試來自融合瘤或CHO細胞之Ha22-2(2,4)6.1 MAb與重組191P4D12純化細胞外蛋白質之結合。結果顯示結合於來源於CHO及融合瘤之Ha22-2(2,4)6.1的191P4D12蛋白為一致的。
圖 6。藉由FACS使用PC3-人類-191P4D12細胞測定Ha22-2(2,4)6.1vcMMAE親和性。親和性為0.69 Kd。
圖 7。藉由FACS使用PC3-食蟹獼猴-191P4D12細胞測定Ha22-2(2,4)6.1vcMMAE親和性。親和性為0.34 Kd。
圖 8。藉由FACS使用PC3-大鼠-191P4D12細胞測定Ha22-2(2,4)6.1vcMMAE親和性。親和性為1.6 Kd。
圖 9 。由Ha22-2(2,4)6.1vcMMAE介導之細胞毒性。
圖 9A :PC3-人類-191P4D12:4天殺死/每孔1500個細胞。使用PC3-人類-191P4D12細胞進行細胞毒性檢定。
圖 9B :PC3-食蟹獼猴-191P4D12:4天殺死/每孔1500個細胞。使用PC3-食蟹獼猴-191P4D12細胞進行細胞毒性檢定。
圖 9C :PC3-大鼠-191P4D12:4天殺死/每孔1500個細胞。使用PC3-大鼠-191P4D12細胞進行細胞毒性檢定。
圖 9D :PC-3 Neo:4天殺死/每孔1500個細胞。使用PC3-Neo細胞進行細胞毒性檢定。
圖 10 。藉由FACS進行Ha22-(2,4)6.1 MAb之結構域定位。
圖 11。藉由西方墨點分析進行Ha22-2(2,4)6.1 MAb結構域定位。
圖 12。在SCID小鼠之人類肺癌異種移植物AG-L4的皮下腫瘤形成模型中評估Ha22-2(2,4)6.1 MAb。結果顯示191P4D12 MAb在SCID小鼠之人類肺癌異種移植物AG-L4中不顯著抑制腫瘤生長。
圖 13。在SCID小鼠之人類胰臟癌異種移植物HPAC的皮下腫瘤形成模型中評估Ha22-2(2,4)6.1 MAb。結果顯示與對照抗體相比,191P4D12 MAb在SCID小鼠之人類胰臟異種移植物中不抑制腫瘤生長。
圖 14。在SCID小鼠之人類胰臟癌異種移植物AG-Panc3的皮下腫瘤形成模型中評估Ha22-2(2,4)6.1 MAb。結果顯示與對照抗體相比,191P4D12 MAb在SCID小鼠之人類胰臟異種移植物中不抑制腫瘤生長。
圖 15。Ha22-2(2,4)6.1-vcMMAE在SCID小鼠之皮下形成的人類肺癌異種移植物AG-L4中之功效。結果顯示與經處理與未經處理之對照組相比,用Ha22-2(2,4)6.1-vcMMAE處理可顯著抑制皮下植入裸小鼠之AG-L4肺癌異種移植物的生長。
圖 16。Ha22-2(2,4)6.1-vcMMAE在SCID小鼠之皮下形成的人類乳癌異種移植物BT-483中之功效。結果顯示與經處理與未經處理之對照ADC相比,用Ha22-2(2,4)6.1-vcMMAE處理可顯著抑制皮下植入SCID小鼠之BT-483乳房腫瘤異種移植物的生長。
圖 17。Ha22-2(2,4)6.1-vcMMAE在SCID小鼠之皮下形成的人類膀胱癌異種移植物AG-B1中之功效。結果顯示與對照ADC相比,用Ha22-2(2,4)6.1-vcMMAE處理可顯著抑制AG-B1膀胱癌異種移植物之生長。
圖 18。Ha22-2(2,4)6.1-vcMMAE在SCID小鼠之皮下形成的人類胰臟癌異種移植物AG-Panc2中之功效。結果顯示與對照ADC相比,用Ha22-2(2,4)6.1-vcMMAE處理可顯著抑制AG-Panc2胰臟癌異種移植物之生長。
圖 19。Ha22-2(2,4)6.1-vcMMAE在SCID小鼠之皮下形成的人類肺癌異種移植物AG-Panc4中之功效。結果顯示與對照ADC相比,用Ha22-2(2,4)6.1-vcMMAE處理可顯著抑制AG-Panc4胰臟癌異種移植物之生長。
圖 20。Ha22-2(2,4)6.1-vcMMAE以比較劑量在SCID小鼠之皮下形成的人類膀胱癌異種移植物AG-B8中之功效。結果顯示與5 mg/kg之Ha22-2(2,4)6.1vcMMAE相比,用10 mg/kg之Ha22-2(2,4)6.1vcMMAE處理可顯著抑制AG-B8膀胱癌異種移植物之生長。
圖 21。藉由免疫組織化學(IHC)偵測癌症患者試樣中之191P4D12蛋白。
圖 21(A) 及 (B)展示膀胱癌試樣。
圖 21(C) 及 (D)展示乳癌試樣。
圖 21(E) 及 (F)展示胰臟癌試樣。
圖 21(G) 及 (H)展示肺癌試樣。
圖 21(I) 及 (J)展示卵巢癌試樣。
圖 21(K) 及 (L)展示食道癌試樣。
圖 21(M) 及 (N)展示頭頸部癌試樣。
食品工業發展研究所;100年12月08日;BCRC 960435
美國;American Type Culture Collection (ATCC);2010年08月19日;PTA-11267
<![CDATA[<110> 美商艾澤西公司(AGENSYS, INC.)]]> 美商西雅圖遺傳學公司(SEATTLE GENETICS, INC.) <![CDATA[<120> 與191P4D12蛋白結合之抗體藥物共軛物(ADC)]]> <![CDATA[<130> TW 109135992]]> TW 107143990 TW 107103146 TW 104140581 TW 100135340 <![CDATA[<150> US 61/387,933 ]]> <![CDATA[<151> 2010-09-29 ]]> <![CDATA[<160> 13]]> <![CDATA[<170> FastSEQ for Windows Version 4.0]]> <![CDATA[<210> 1]]> <![CDATA[<211> 3464]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<220> ]]> <![CDATA[<221> CDS ]]> <![CDATA[<222> (264)...(1796)]]> <![CDATA[<220> ]]> <![CDATA[<221> misc_feature ]]> <![CDATA[<222> (1)...(3464)]]> <![CDATA[<223> 191P4D12]]> <![CDATA[<400> 1]]> ggccgtcgtt gttggccaca gcgtgggaag cagctctggg ggagctcgga gctcccgatc 60 acggcttctt gggggtagct acggctgggt gtgtagaacg gggccggggc tggggctggg 120 tcccctagtg gagacccaag tgcgagaggc aagaactctg cagcttcctg ccttctgggt 180 cagttcctta ttcaagtctg cagccggctc ccagggagat ctcggtggaa cttcagaaac 240 gctgggcagt ctgcctttca acc atg ccc ctg tcc ctg gga gcc gag atg tgg 293 Met Pro Leu Ser Leu Gly Ala Glu Met Trp 1 5 10 ggg cct gag gcc tgg ctg ctg ctg ctg cta ctg ctg gca tca ttt aca 341 Gly Pro Glu Ala Trp Leu Leu Leu Leu Leu Leu Leu Ala Ser Phe Thr 15 20 25 ggc cgg tgc ccc gcg ggt gag ctg gag acc tca gac gtg gta act gtg 389 Gly Arg Cys Pro Ala Gly Glu Leu Glu Thr Ser Asp Val Val Thr Val 30 35 40 gtg ctg ggc cag gac gca aaa ctg ccc tgc ttc tac cga ggg gac tcc 437 Val Leu Gly Gln Asp Ala Lys Leu Pro Cys Phe Tyr Arg Gly Asp Ser 45 50 55 ggc gag caa gtg ggg caa gtg gca tgg gct cgg gtg gac gcg ggc gaa 485 Gly Glu Gln Val Gly Gln Val Ala Trp Ala Arg Val Asp Ala Gly Glu 60 65 70 ggc gcc cag gaa cta gcg cta ctg cac tcc aaa tac ggg ctt cat gtg 533 Gly Ala Gln Glu Leu Ala Leu Leu His Ser Lys Tyr Gly Leu His Val 75 80 85 90 agc ccg gct tac gag ggc cgc gtg gag cag ccg ccg ccc cca cgc aac 581 Ser Pro Ala Tyr Glu Gly Arg Val Glu Gln Pro Pro Pro Pro Arg Asn 95 100 105 ccc ctg gac ggc tca gtg ctc ctg cgc aac gca gtg cag gcg gat gag 629 Pro Leu Asp Gly Ser Val Leu Leu Arg Asn Ala Val Gln Ala Asp Glu 110 115 120 ggc gag tac gag tgc cgg gtc agc acc ttc ccc gcc ggc agc ttc cag 677 Gly Glu Tyr Glu Cys Arg Val Ser Thr Phe Pro Ala Gly Ser Phe Gln 125 130 135 gcg cgg ctg cgg ctc cga gtg ctg gtg cct ccc ctg ccc tca ctg aat 725 Ala Arg Leu Arg Leu Arg Val Leu Val Pro Pro Leu Pro Ser Leu Asn 140 145 150 cct ggt cca gca cta gaa gag ggc cag ggc ctg acc ctg gca gcc tcc 773 Pro Gly Pro Ala Leu Glu Glu Gly Gln Gly Leu Thr Leu Ala Ala Ser 155 160 165 170 tgc aca gct gag ggc agc cca gcc ccc agc gtg acc tgg gac acg gag 821 Cys Thr Ala Glu Gly Ser Pro Ala Pro Ser Val Thr Trp Asp Thr Glu 175 180 185 gtc aaa ggc aca acg tcc agc cgt tcc ttc aag cac tcc cgc tct gct 869 Val Lys Gly Thr Thr Ser Ser Arg Ser Phe Lys His Ser Arg Ser Ala 190 195 200 gcc gtc acc tca gag ttc cac ttg gtg cct agc cgc agc atg aat ggg 917 Ala Val Thr Ser Glu Phe His Leu Val Pro Ser Arg Ser Met Asn Gly 205 210 215 cag cca ctg act tgt gtg gtg tcc cat cct ggc ctg ctc cag gac caa 965 Gln Pro Leu Thr Cys Val Val Ser His Pro Gly Leu Leu Gln Asp Gln 220 225 230 agg atc acc cac atc ctc cac gtg tcc ttc ctt gct gag gcc tct gtg 1013 Arg Ile Thr His Ile Leu His Val Ser Phe Leu Ala Glu Ala Ser Val 235 240 245 250 agg ggc ctt gaa gac caa aat ctg tgg cac att ggc aga gaa gga gct 1061 Arg Gly Leu Glu Asp Gln Asn Leu Trp His Ile Gly Arg Glu Gly Ala 255 260 265 atg ctc aag tgc ctg agt gaa ggg cag ccc cct ccc tca tac aac tgg 1109 Met Leu Lys Cys Leu Ser Glu Gly Gln Pro Pro Pro Ser Tyr Asn Trp 270 275 280 aca cgg ctg gat ggg cct ctg ccc agt ggg gta cga gtg gat ggg gac 1157 Thr Arg Leu Asp Gly Pro Leu Pro Ser Gly Val Arg Val Asp Gly Asp 285 290 295 act ttg ggc ttt ccc cca ctg acc act gag cac agc ggc atc tac gtc 1205 Thr Leu Gly Phe Pro Pro Leu Thr Thr Glu His Ser Gly Ile Tyr Val 300 305 310 tgc cat gtc agc aat gag ttc tcc tca agg gat tct cag gtc act gtg 1253 Cys His Val Ser Asn Glu Phe Ser Ser Arg Asp Ser Gln Val Thr Val 315 320 325 330 gat gtt ctt gac ccc cag gaa gac tct ggg aag cag gtg gac cta gtg 1301 Asp Val Leu Asp Pro Gln Glu Asp Ser Gly Lys Gln Val Asp Leu Val 335 340 345 tca gcc tcg gtg gtg gtg gtg ggt gtg atc gcc gca ctc ttg ttc tgc 1349 Ser Ala Ser Val Val Val Val Gly Val Ile Ala Ala Leu Leu Phe Cys 350 355 360 ctt ctg gtg gtg gtg gtg gtg ctc atg tcc cga tac cat cgg cgc aag 1397 Leu Leu Val Val Val Val Val Leu Met Ser Arg Tyr His Arg Arg Lys 365 370 375 gcc cag cag atg acc cag aaa tat gag gag gag ctg acc ctg acc agg 1445 Ala Gln Gln Met Thr Gln Lys Tyr Glu Glu Glu Leu Thr Leu Thr Arg 380 385 390 gag aac tcc atc cgg agg ctg cat tcc cat cac acg gac ccc agg agc 1493 Glu Asn Ser Ile Arg Arg Leu His Ser His His Thr Asp Pro Arg Ser 395 400 405 410 cag ccg gag gag agt gta ggg ctg aga gcc gag ggc cac cct gat agt 1541 Gln Pro Glu Glu Ser Val Gly Leu Arg Ala Glu Gly His Pro Asp Ser 415 420 425 ctc aag gac aac agt agc tgc tct gtg atg agt gaa gag ccc gag ggc 1589 Leu Lys Asp Asn Ser Ser Cys Ser Val Met Ser Glu Glu Pro Glu Gly 430 435 440 cgc agt tac tcc acg ctg acc acg gtg agg gag ata gaa aca cag act 1637 Arg Ser Tyr Ser Thr Leu Thr Thr Val Arg Glu Ile Glu Thr Gln Thr 445 450 455 gaa ctg ctg tct cca ggc tct ggg cgg gcc gag gag gag gaa gat cag 1685 Glu Leu Leu Ser Pro Gly Ser Gly Arg Ala Glu Glu Glu Glu Asp Gln 460 465 470 gat gaa ggc atc aaa cag gcc atg aac cat ttt gtt cag gag aat ggg 1733 Asp Glu Gly Ile Lys Gln Ala Met Asn His Phe Val Gln Glu Asn Gly 475 480 485 490 acc cta cgg gcc aag ccc acg ggc aat ggc atc tac atc aat ggg cgg 1781 Thr Leu Arg Ala Lys Pro Thr Gly Asn Gly Ile Tyr Ile Asn Gly Arg 495 500 505 gga cac ctg gtc tga cccaggcctg cctcccttcc ctaggcctgg ctccttctgt 1836 Gly His Leu Val * 510 tgacatggga gattttagct catcttgggg gcctccttaa acacccccat ttcttgcgga 1896 agatgctccc catcccactg actgcttgac ctttacctcc aacccttctg ttcatcggga 1956 gggctccacc aattgagtct ctcccaccat gcatgcaggt cactgtgtgt gtgcatgtgt 2016 gcctgtgtga gtgttgactg actgtgtgtg tgtggagggg tgactgtccg tggaggggtg 2076 actgtgtccg tggtgtgtat tatgctgtca tatcagagtc aagtgaactg tggtgtatgt 2136 gccacgggat ttgagtggtt gcgtgggcaa cactgtcagg gtttggcgtg tgtgtcatgt 2196 ggctgtgtgt gacctctgcc tgaaaaagca ggtattttct cagaccccag agcagtatta 2256 atgatgcaga ggttggagga gagaggtgga gactgtggct cagacccagg tgtgcgggca 2316 tagctggagc tggaatctgc ctccggtgtg agggaacctg tctcctacca cttcggagcc 2376 atgggggcaa gtgtgaagca gccagtccct gggtcagcca gaggcttgaa ctgttacaga 2436 agccctctgc cctctggtgg cctctgggcc tgctgcatgt acatattttc tgtaaatata 2496 catgcgccgg gagcttcttg caggaatact gctccgaatc acttttaatt tttttctttt 2556 ttttttcttg ccctttccat tagttgtatt ttttatttat ttttattttt attttttttt 2616 agagatggag tctcactatg ttgctcaggc tggccttgaa ctcctgggct caagcaatcc 2676 tcctgcctca gcctccctag tagctgggac tttaagtgta caccactgtg cctgctttga 2736 atcctttacg aagagaaaaa aaaaattaaa gaaagccttt agatttatcc aatgtttact 2796 actgggattg cttaaagtga ggcccctcca acaccagggg gttaattcct gtgattgtga 2856 aaggggctac ttccaaggca tcttcatgca ggcagcccct tgggagggca cctgagagct 2916 ggtagagtct gaaattaggg atgtgagcct cgtggttact gagtaaggta aaattgcatc 2976 caccattgtt tgtgatacct tagggaattg cttggacctg gtgacaaggg ctcctgttca 3036 atagtggtgt tggggagaga gagagcagtg attatagacc gagagagtag gagttgaggt 3096 gaggtgaagg aggtgctggg ggtgagaatg tcgcctttcc ccctgggttt tggatcacta 3156 attcaaggct cttctggatg tttctctggg ttggggctgg agttcaatga ggtttatttt 3216 tagctggccc acccagatac actcagccag aatacctaga tttagtaccc aaactcttct 3276 tagtctgaaa tctgctggat ttctggccta agggagaggc tcccatcctt cgttccccag 3336 ccagcctagg acttcgaatg tggagcctga agatctaaga tcctaacatg tacattttat 3396 gtaaatatgt gcatatttgt acataaaatg atattctgtt tttaaataaa cagacaaaac 3456 ttgaaaaa 3464 <![CDATA[<210> 2]]> <![CDATA[<211> 510]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 智人]]> <![CDATA[<220> ]]> <![CDATA[<221> misc_feature ]]> <![CDATA[<222> (1)...(510)]]> <![CDATA[<223> 191P4D12]]> <![CDATA[<400> 2]]> Met Pro Leu Ser Leu Gly Ala Glu Met Trp Gly Pro Glu Ala Trp Leu 1 5 10 15 Leu Leu Leu Leu Leu Leu Ala Ser Phe Thr Gly Arg Cys Pro Ala Gly 20 25 30 Glu Leu Glu Thr Ser Asp Val Val Thr Val Val Leu Gly Gln Asp Ala 35 40 45 Lys Leu Pro Cys Phe Tyr Arg Gly Asp Ser Gly Glu Gln Val Gly Gln 50 55 60 Val Ala Trp Ala Arg Val Asp Ala Gly Glu Gly Ala Gln Glu Leu Ala 65 70 75 80 Leu Leu His Ser Lys Tyr Gly Leu His Val Ser Pro Ala Tyr Glu Gly 85 90 95 Arg Val Glu Gln Pro Pro Pro Pro Arg Asn Pro Leu Asp Gly Ser Val 100 105 110 Leu Leu Arg Asn Ala Val Gln Ala Asp Glu Gly Glu Tyr Glu Cys Arg 115 120 125 Val Ser Thr Phe Pro Ala Gly Ser Phe Gln Ala Arg Leu Arg Leu Arg 130 135 140 Val Leu Val Pro Pro Leu Pro Ser Leu Asn Pro Gly Pro Ala Leu Glu 145 150 155 160 Glu Gly Gln Gly Leu Thr Leu Ala Ala Ser Cys Thr Ala Glu Gly Ser 165 170 175 Pro Ala Pro Ser Val Thr Trp Asp Thr Glu Val Lys Gly Thr Thr Ser 180 185 190 Ser Arg Ser Phe Lys His Ser Arg Ser Ala Ala Val Thr Ser Glu Phe 195 200 205 His Leu Val Pro Ser Arg Ser Met Asn Gly Gln Pro Leu Thr Cys Val 210 215 220 Val Ser His Pro Gly Leu Leu Gln Asp Gln Arg Ile Thr His Ile Leu 225 230 235 240 His Val Ser Phe Leu Ala Glu Ala Ser Val Arg Gly Leu Glu Asp Gln 245 250 255 Asn Leu Trp His Ile Gly Arg Glu Gly Ala Met Leu Lys Cys Leu Ser 260 265 270 Glu Gly Gln Pro Pro Pro Ser Tyr Asn Trp Thr Arg Leu Asp Gly Pro 275 280 285 Leu Pro Ser Gly Val Arg Val Asp Gly Asp Thr Leu Gly Phe Pro Pro 290 295 300 Leu Thr Thr Glu His Ser Gly Ile Tyr Val Cys His Val Ser Asn Glu 305 310 315 320 Phe Ser Ser Arg Asp Ser Gln Val Thr Val Asp Val Leu Asp Pro Gln 325 330 335 Glu Asp Ser Gly Lys Gln Val Asp Leu Val Ser Ala Ser Val Val Val 340 345 350 Val Gly Val Ile Ala Ala Leu Leu Phe Cys Leu Leu Val Val Val Val 355 360 365 Val Leu Met Ser Arg Tyr His Arg Arg Lys Ala Gln Gln Met Thr Gln 370 375 380 Lys Tyr Glu Glu Glu Leu Thr Leu Thr Arg Glu Asn Ser Ile Arg Arg 385 390 395 400 Leu His Ser His His Thr Asp Pro Arg Ser Gln Pro Glu Glu Ser Val 405 410 415 Gly Leu Arg Ala Glu Gly His Pro Asp Ser Leu Lys Asp Asn Ser Ser 420 425 430 Cys Ser Val Met Ser Glu Glu Pro Glu Gly Arg Ser Tyr Ser Thr Leu 435 440 445 Thr Thr Val Arg Glu Ile Glu Thr Gln Thr Glu Leu Leu Ser Pro Gly 450 455 460 Ser Gly Arg Ala Glu Glu Glu Glu Asp Gln Asp Glu Gly Ile Lys Gln 465 470 475 480 Ala Met Asn His Phe Val Gln Glu Asn Gly Thr Leu Arg Ala Lys Pro 485 490 495 Thr Gly Asn Gly Ile Tyr Ile Asn Gly Arg Gly His Leu Val 500 505 510 <![CDATA[<210> 3]]> <![CDATA[<211> 1432]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<220> ]]> <![CDATA[<221> CDS ]]> <![CDATA[<222> (32)...(1432)]]> <![CDATA[<220> ]]> <![CDATA[<221> misc_feature ]]> <![CDATA[<222> (1)...(1432)]]> <![CDATA[<223> Ha22-2(2,4)6.1重鏈]]> <![CDATA[<400> 3]]> ggtgatcagc actgaacaca gaggactcac c atg gag ttg ggg ctg tgc tgg 52 Met Glu Leu Gly Leu Cys Trp 1 5 gtt ttc ctt gtt gct att tta gaa ggt gtc cag tgt gag gtg cag ctg 100 Val Phe Leu Val Ala Ile Leu Glu Gly Val Gln Cys Glu Val Gln Leu 10 15 20 gtg gag tct ggg gga ggc ttg gta cag cct ggg ggg tcc ctg aga ctc 148 Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu 25 30 35 tcc tgt gca gcc tct gga ttc acc ttc agt agc tat aac atg aac tgg 196 Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Asn Met Asn Trp 40 45 50 55 gtc cgc cag gct cca ggg aag ggg ctg gag tgg gtt tca tac att agt 244 Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Ser 60 65 70 agt agt agt agt acc ata tac tac gca gac tct gtg aag ggc cga ttc 292 Ser Ser Ser Ser Thr Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe 75 80 85 acc atc tcc aga gac aat gcc aag aac tca ctg tct ctg caa atg aac 340 Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Ser Leu Gln Met Asn 90 95 100 agc ctg aga gac gag gac acg gct gtg tat tac tgt gcg aga gca tac 388 Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Tyr 105 110 115 tac tac ggt atg gac gtc tgg ggc caa ggg acc acg gtc acc gtc tcc 436 Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser 120 125 130 135 tca gcc tcc acc aag ggc cca tcg gtc ttc ccc ctg gca ccc tcc tcc 484 Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser 140 145 150 aag agc acc tct ggg ggc aca gcg gcc ctg ggc tgc ctg gtc aag gac 532 Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp 155 160 165 tac ttc ccc gaa ccg gtg acg gtg tcg tgg aac tca ggc gcc ctg acc 580 Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr 170 175 180 agc ggc gtg cac acc ttc ccg gct gtc cta cag tcc tca gga ctc tac 628 Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr 185 190 195 tcc ctc agc agc gtg gtg acc gtg ccc tcc agc agc ttg ggc acc cag 676 Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln 200 205 210 215 acc tac atc tgc aac gtg aat cac aag ccc agc aac acc aag gtg gac 724 Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp 220 225 230 aag aga gtt gag ccc aaa tct tgt gac aaa act cac aca tgc cca ccg 772 Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro 235 240 245 tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc 820 Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro 250 255 260 cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc aca 868 Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 265 270 275 tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc aac 916 Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 280 285 290 295 tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg 964 Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 300 305 310 gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc 1012 Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 315 320 325 ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc 1060 Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 330 335 340 aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa 1108 Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 345 350 355 ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg gag 1156 Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu 360 365 370 375 gag atg acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc 1204 Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 380 385 390 tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg gag 1252 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 395 400 405 aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc 1300 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 410 415 420 ttc ctc tat agc aag ctc acc gtg gac aag agc agg tgg cag cag ggg 1348 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 425 430 435 aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac tac 1396 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 440 445 450 455 acg cag aag agc ctc tcc ctg tcc ccg ggt aaa tga 1432 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys * 460 465 <![CDATA[<210> 4]]> <![CDATA[<211> 466]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 智人]]> <![CDATA[<220> ]]> <![CDATA[<221> misc_feature ]]> <![CDATA[<222> (1)...(466)]]> <![CDATA[<223> Ha22-2(2,4)6.1重鏈]]> <![CDATA[<400> 4]]> Met Glu Leu Gly Leu Cys Trp Val Phe Leu Val Ala Ile Leu Glu Gly 1 5 10 15 Val Gln Cys Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln 20 25 30 Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe 35 40 45 Ser Ser Tyr Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu 50 55 60 Glu Trp Val Ser Tyr Ile Ser Ser Ser Ser Ser Thr Ile Tyr Tyr Ala 65 70 75 80 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn 85 90 95 Ser Leu Ser Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val 100 105 110 Tyr Tyr Cys Ala Arg Ala Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln 115 120 125 Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 130 135 140 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 145 150 155 160 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 165 170 175 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 180 185 190 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 195 200 205 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 210 215 220 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 225 230 235 240 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 245 250 255 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 260 265 270 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 275 280 285 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 290 295 300 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 305 310 315 320 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 325 330 335 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 340 345 350 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 355 360 365 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 370 375 380 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 385 390 395 400 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 405 410 415 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 420 425 430 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 435 440 445 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 450 455 460 Gly Lys 465 <![CDATA[<210> 5]]> <![CDATA[<211> 735]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<220> ]]> <![CDATA[<221> CDS ]]> <![CDATA[<222> (25)...(735)]]> <![CDATA[<220> ]]> <![CDATA[<221> misc_feature ]]> <![CDATA[<222> (1)...(735)]]> <![CDATA[<223> Ha22-2(2,4)6.1輕鏈]]> <![CDATA[<400> 5]]> agtcagaccc agtcaggaca cagc atg gac atg agg gtc ccc gct cag ctc 51 Met Asp Met Arg Val Pro Ala Gln Leu 1 5 ctg ggg ctc ctg ctg ctc tgg ttc cca ggt tcc aga tgc gac atc cag 99 Leu Gly Leu Leu Leu Leu Trp Phe Pro Gly Ser Arg Cys Asp Ile Gln 10 15 20 25 atg acc cag tct cca tct tcc gtg tct gca tct gtt gga gac aga gtc 147 Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val 30 35 40 acc atc act tgt cgg gcg agt cag ggt att agc ggc tgg tta gcc tgg 195 Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Gly Trp Leu Ala Trp 45 50 55 tat cag cag aaa cca ggg aaa gcc cct aag ttc ctg atc tat gct gca 243 Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Phe Leu Ile Tyr Ala Ala 60 65 70 tcc act ttg caa agt ggg gtc cca tca agg ttc agc ggc agt gga tct 291 Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser 75 80 85 ggg aca gat ttc act ctc acc atc agc agc ctg cag cct gaa gat ttt 339 Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe 90 95 100 105 gca act tac tat tgt caa cag gct aac agt ttc cct ccc act ttc ggc 387 Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Pro Thr Phe Gly 110 115 120 gga ggg acc aag gtg gag atc aaa cga act gtg gct gca cca tct gtc 435 Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val 125 130 135 ttc atc ttc ccg cca tct gat gag cag ttg aaa tct gga act gcc tct 483 Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser 140 145 150 gtt gtg tgc ctg ctg aat aac ttc tat ccc aga gag gcc aaa gta cag 531 Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln 155 160 165 tgg aag gtg gat aac gcc ctc caa tcg ggt aac tcc cag gag agt gtc 579 Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val 170 175 180 185 aca gag cag gac agc aag gac agc acc tac agc ctc agc agc acc ctg 627 Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu 190 195 200 acg ctg agc aaa gca gac tac gag aaa cac aaa gtc tac gcc tgc gaa 675 Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu 205 210 215 gtc acc cat cag ggc ctg agc tcg ccc gtc aca aag agc ttc aac agg 723 Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg 220 225 230 gga gag tgt tag 735 Gly Glu Cys * 235 <![CDATA[<210> 6]]> <![CDATA[<211> 236]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 智人]]> <![CDATA[<220> ]]> <![CDATA[<221> misc_feature ]]> <![CDATA[<222> (1)...(236)]]> <![CDATA[<223> Ha22-2(2,4)6.1輕鏈]]> <![CDATA[<400> 6]]> Met Asp Met Arg Val Pro Ala Gln Leu Leu Gly Leu Leu Leu Leu Trp 1 5 10 15 Phe Pro Gly Ser Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ser Ser 20 25 30 Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser 35 40 45 Gln Gly Ile Ser Gly Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys 50 55 60 Ala Pro Lys Phe Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val 65 70 75 80 Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 85 90 95 Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln 100 105 110 Ala Asn Ser Phe Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 115 120 125 Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp 130 135 140 Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn 145 150 155 160 Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu 165 170 175 Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp 180 185 190 Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr 195 200 205 Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser 210 215 220 Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 225 230 235 <![CDATA[<210> 7]]> <![CDATA[<211> 466]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 智人]]> <![CDATA[<220> ]]> <![CDATA[<221> misc_feature ]]> <![CDATA[<222> (1)...(466)]]> <![CDATA[<223> Ha22-2(2,4)6.1重鏈]]> <![CDATA[<400> 7]]> Met Glu Leu Gly Leu Cys Trp Val Phe Leu Val Ala Ile Leu Glu Gly 1 5 10 15 Val Gln Cys Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln 20 25 30 Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe 35 40 45 Ser Ser Tyr Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu 50 55 60 Glu Trp Val Ser Tyr Ile Ser Ser Ser Ser Ser Thr Ile Tyr Tyr Ala 65 70 75 80 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn 85 90 95 Ser Leu Ser Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val 100 105 110 Tyr Tyr Cys Ala Arg Ala Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln 115 120 125 Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 130 135 140 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 145 150 155 160 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 165 170 175 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 180 185 190 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 195 200 205 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 210 215 220 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 225 230 235 240 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 245 250 255 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 260 265 270 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 275 280 285 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 290 295 300 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 305 310 315 320 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 325 330 335 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 340 345 350 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 355 360 365 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 370 375 380 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 385 390 395 400 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 405 410 415 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 420 425 430 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 435 440 445 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 450 455 460 Gly Lys 465 <![CDATA[<210> 8]]> <![CDATA[<211> 236]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 智人]]> <![CDATA[<220> ]]> <![CDATA[<221> misc_feature ]]> <![CDATA[<222> (1)...(236)]]> <![CDATA[<223> Ha22-2(2,4)6.1輕鏈]]> <![CDATA[<400> 8]]> Met Asp Met Arg Val Pro Ala Gln Leu Leu Gly Leu Leu Leu Leu Trp 1 5 10 15 Phe Pro Gly Ser Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ser Ser 20 25 30 Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser 35 40 45 Gln Gly Ile Ser Gly Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys 50 55 60 Ala Pro Lys Phe Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val 65 70 75 80 Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 85 90 95 Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln 100 105 110 Ala Asn Ser Phe Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 115 120 125 Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp 130 135 140 Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn 145 150 155 160 Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu 165 170 175 Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp 180 185 190 Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr 195 200 205 Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser 210 215 220 Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 225 230 235 <![CDATA[<210> 9]]> <![CDATA[<211> 98]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 智人]]> <![CDATA[<220> ]]> <![CDATA[<221> misc_feature ]]> <![CDATA[<222> (1)...(98)]]> <![CDATA[<223> 人類Ig生殖系VH3-48]]> <![CDATA[<400> 9]]> Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Tyr Ile Ser Ser Ser Ser Ser Thr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg <![CDATA[<210> 10]]> <![CDATA[<211> 96]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 智人]]> <![CDATA[<220> ]]> <![CDATA[<221> misc_feature ]]> <![CDATA[<222> (1)...(96)]]> <![CDATA[<223> 人類Ig生殖系L5]]> <![CDATA[<400> 10]]> Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Pro 85 90 95 <![CDATA[<210> 11]]> <![CDATA[<211> 179]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小家鼠]]> <![CDATA[<220> ]]> <![CDATA[<221> misc_feature ]]> <![CDATA[<222> (1)...(179)]]> <![CDATA[<223> 含有V域之191P4D12直系同源物]]> <![CDATA[<400> 11]]> Met Pro Leu Ser Leu Gly Ala Glu Met Trp Gly Pro Glu Ala Trp Leu 1 5 10 15 Arg Leu Leu Phe Leu Ala Ser Phe Thr Gly Gln Tyr Ser Ala Gly Glu 20 25 30 Leu Glu Thr Ser Asp Val Val Thr Val Val Leu Gly Gln Asp Ala Lys 35 40 45 Leu Pro Cys Phe Tyr Arg Gly Asp Pro Asp Glu Gln Val Gly Gln Val 50 55 60 Ala Trp Ala Arg Val Asp Pro Asn Glu Gly Ile Arg Glu Leu Ala Leu 65 70 75 80 Leu His Ser Lys Tyr Gly Leu His Val Asn Pro Ala Tyr Glu Asp Arg 85 90 95 Val Glu Gln Pro Pro Pro Pro Arg Asp Pro Leu Asp Gly Ser Val Leu 100 105 110 Leu Arg Asn Ala Val Gln Ala Asp Glu Gly Glu Tyr Glu Cys Arg Val 115 120 125 Ser Thr Phe Pro Ala Gly Ser Phe Gln Ala Arg Met Arg Leu Arg Val 130 135 140 Leu Val Pro Pro Leu Pro Ser Leu Asn Pro Gly Pro Pro Leu Glu Glu 145 150 155 160 Gly Gln Gly Leu Thr Leu Ala Ala Ser Cys Thr Ala Glu Gly Ser Pro 165 170 175 Ala Pro Ser <![CDATA[<210> 12]]> <![CDATA[<211> 179]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 褐家鼠]]> <![CDATA[<220> ]]> <![CDATA[<221> misc_feature ]]> <![CDATA[<222> (1)...(179)]]> <![CDATA[<223> 含有V域之191P4D12直系同源物]]> <![CDATA[<400> 12]]> Met Pro Leu Ser Leu Gly Ala Glu Met Trp Gly Pro Glu Ala Trp Leu 1 5 10 15 Leu Leu Leu Phe Leu Ala Ser Phe Thr Gly Arg Tyr Ser Ala Gly Glu 20 25 30 Leu Glu Thr Ser Asp Leu Val Thr Val Val Leu Gly Gln Asp Ala Lys 35 40 45 Leu Pro Cys Phe Tyr Arg Gly Asp Pro Asp Glu Gln Val Gly Gln Val 50 55 60 Ala Trp Ala Arg Val Asp Pro Asn Glu Gly Thr Arg Glu Leu Ala Leu 65 70 75 80 Leu His Ser Lys Tyr Gly Leu His Val Ser Pro Ala Tyr Glu Asp Arg 85 90 95 Val Glu Gln Pro Pro Pro Pro Arg Asp Pro Leu Asp Gly Ser Ile Leu 100 105 110 Leu Arg Asn Ala Val Gln Ala Asp Glu Gly Glu Tyr Glu Cys Arg Val 115 120 125 Ser Thr Phe Pro Ala Gly Ser Phe Gln Ala Arg Met Arg Leu Arg Val 130 135 140 Leu Val Pro Pro Leu Pro Ser Leu Asn Pro Gly Pro Pro Leu Glu Glu 145 150 155 160 Gly Gln Gly Leu Thr Leu Ala Ala Ser Cys Thr Ala Glu Gly Ser Pro 165 170 175 Ala Pro Ser <![CDATA[<210> 13]]> <![CDATA[<211> 180]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 智人]]> <![CDATA[<220> ]]> <![CDATA[<221> misc_feature ]]> <![CDATA[<222> (1)...(180)]]> <![CDATA[<223> 含有V域之191P4D12直系同源物]]> <![CDATA[<400> 13]]> Met Pro Leu Ser Leu Gly Ala Glu Met Trp Gly Pro Glu Ala Trp Leu 1 5 10 15 Leu Leu Leu Leu Leu Leu Ala Ser Phe Thr Gly Arg Cys Pro Ala Gly 20 25 30 Glu Leu Glu Thr Ser Asp Val Val Thr Val Val Leu Gly Gln Asp Ala 35 40 45 Lys Leu Pro Cys Phe Tyr Arg Gly Asp Ser Gly Glu Gln Val Gly Gln 50 55 60 Val Ala Trp Ala Arg Val Asp Ala Gly Glu Gly Ala Gln Glu Leu Ala 65 70 75 80 Leu Leu His Ser Lys Tyr Gly Leu His Val Ser Pro Ala Tyr Glu Gly 85 90 95 Arg Val Glu Gln Pro Pro Pro Pro Arg Asn Pro Leu Asp Gly Ser Val 100 105 110 Leu Leu Arg Asn Ala Val Gln Ala Asp Glu Gly Glu Tyr Glu Cys Arg 115 120 125 Val Ser Thr Phe Pro Ala Gly Ser Phe Gln Ala Arg Leu Arg Leu Arg 130 135 140 Val Leu Val Pro Pro Leu Pro Ser Leu Asn Pro Gly Pro Ala Leu Glu 145 150 155 160 Glu Gly Gln Gly Leu Thr Leu Ala Ala Ser Cys Thr Ala Glu Gly Ser 165 170 175 Pro Ala Pro Ser 180
Claims (15)
- 一種抗體藥物共軛物,其包含抗體或抗原結合片段與單甲基奧瑞他汀E(monomethyl auristatin E,MMAE)共軛,其中該抗體或片段包含由範圍為SEQ ID NO:7之第20位之E至第136位之S的胺基酸序列組成之重鏈可變區及由範圍為SEQ ID NO:8之第23位之D至第130位之R的胺基酸序列組成之輕鏈可變區。
- 如請求項1之抗體藥物共軛物,其中該抗體包含由範圍為SEQ ID NO:7之第20位之E至第466位之K的胺基酸序列組成之重鏈及由範圍為SEQ ID NO:8之第23位之D至第236位之C的胺基酸序列組成之輕鏈。
- 一種抗體藥物共軛物,其包含抗體或片段與單甲基奧瑞他汀E(MMAE)共軛,其中該抗體或片段包含由以美國菌種保存中心(American Type Culture Collection,ATCC)寄存編號PTA-11267寄存之融合瘤所產生的抗體重鏈可變區胺基酸序列組成之重鏈可變區,及由以ATCC寄存編號PTA-11267寄存之融合瘤所產生的抗體輕鏈可變區胺基酸序列組成之輕鏈可變區。
- 如請求項3之抗體藥物共軛物,其中該抗體包含由以ATCC寄存編號PTA-11267寄存之融合瘤所產生的抗體重鏈胺基酸序列組成之重鏈,及由以ATCC寄存編號PTA-11267寄存之融合瘤所產生的抗體輕鏈胺基酸序列組成之輕鏈。
- 如請求項1之抗體藥物共軛物,其中該片段為Fab、F(ab') 2、Fv或scFv片段。
- 如請求項1之抗體藥物共軛物,其中該抗體為全人類抗體。
- 如請求項1之抗體藥物共軛物,其中該抗體經重組產生。
- 一種醫藥組合物,其包含呈人類單位劑型之如請求項1之抗體藥物共軛物。
- 如請求項8之醫藥組合物,其中該組合物用於癌症治療。
- 如請求項9之醫藥組合物,其中該癌症係選自由胰臟癌、肺癌、膀胱癌及乳癌組成之群。
- 一種治療個體癌症之方法,其包含向該個體投與如請求項1之抗體藥物共軛物。
- 一種治療個體癌症之方法,其包含向該個體投與有效量之如請求項1之抗體藥物共軛物及放射。
- 一種治療個體癌症之方法,其包含向該個體投與有效量之如請求項1之抗體藥物共軛物及化學治療劑。
- 如請求項8之醫藥組合物,其中該組合物與放射或化學治療劑組合投與。
- 如請求項8之醫藥組合物,其包含呈人類單位劑型之如請求項1之抗體藥物共軛物及化學治療劑。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38793310P | 2010-09-29 | 2010-09-29 | |
US61/387,933 | 2010-09-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW202300174A true TW202300174A (zh) | 2023-01-01 |
TWI814373B TWI814373B (zh) | 2023-09-01 |
Family
ID=45871300
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW112112533A TW202344270A (zh) | 2010-09-29 | 2011-09-29 | 與191p4d12蛋白結合之抗體藥物共軛物(adc) |
TW109135992A TWI764324B (zh) | 2010-09-29 | 2011-09-29 | 與191p4d12蛋白結合之抗體藥物共軛物(adc) |
TW107103146A TWI674112B (zh) | 2010-09-29 | 2011-09-29 | 與191p4d12蛋白結合之抗體藥物共軛物(adc) |
TW100135340A TWI524901B (zh) | 2010-09-29 | 2011-09-29 | 與191p4d12蛋白結合之抗體藥物共軛物(adc) |
TW104140581A TWI651096B (zh) | 2010-09-29 | 2011-09-29 | 與191p4d12蛋白結合之抗體藥物共軛物(adc) |
TW107143990A TWI720377B (zh) | 2010-09-29 | 2011-09-29 | 與191p4d12蛋白結合之抗體藥物共軛物(adc) |
TW111117461A TWI814373B (zh) | 2010-09-29 | 2011-09-29 | 與191p4d12蛋白結合之抗體藥物共軛物(adc) |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW112112533A TW202344270A (zh) | 2010-09-29 | 2011-09-29 | 與191p4d12蛋白結合之抗體藥物共軛物(adc) |
TW109135992A TWI764324B (zh) | 2010-09-29 | 2011-09-29 | 與191p4d12蛋白結合之抗體藥物共軛物(adc) |
TW107103146A TWI674112B (zh) | 2010-09-29 | 2011-09-29 | 與191p4d12蛋白結合之抗體藥物共軛物(adc) |
TW100135340A TWI524901B (zh) | 2010-09-29 | 2011-09-29 | 與191p4d12蛋白結合之抗體藥物共軛物(adc) |
TW104140581A TWI651096B (zh) | 2010-09-29 | 2011-09-29 | 與191p4d12蛋白結合之抗體藥物共軛物(adc) |
TW107143990A TWI720377B (zh) | 2010-09-29 | 2011-09-29 | 與191p4d12蛋白結合之抗體藥物共軛物(adc) |
Country Status (29)
Country | Link |
---|---|
US (8) | US8637642B2 (zh) |
EP (3) | EP3903812A1 (zh) |
JP (8) | JP6083871B2 (zh) |
KR (9) | KR102353283B1 (zh) |
CN (2) | CN105567717B (zh) |
AU (1) | AU2011312417B2 (zh) |
BR (1) | BR112013007309B1 (zh) |
CA (1) | CA2811644C (zh) |
CY (2) | CY1121023T1 (zh) |
DK (2) | DK2621526T3 (zh) |
EA (2) | EA201790850A1 (zh) |
ES (2) | ES2874306T3 (zh) |
FR (1) | FR22C1050I2 (zh) |
HK (1) | HK1256964A1 (zh) |
HR (1) | HRP20181154T8 (zh) |
HU (3) | HUE054855T2 (zh) |
IL (5) | IL290591B1 (zh) |
LT (2) | LT2621526T (zh) |
MX (4) | MX347954B (zh) |
NL (1) | NL301198I2 (zh) |
NO (1) | NO2022039I1 (zh) |
PH (1) | PH12017501461A1 (zh) |
PL (2) | PL3409287T3 (zh) |
PT (2) | PT3409287T (zh) |
RS (1) | RS57483B1 (zh) |
SI (2) | SI2621526T1 (zh) |
TW (7) | TW202344270A (zh) |
UA (1) | UA110495C2 (zh) |
WO (1) | WO2012047724A1 (zh) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2874306T3 (es) | 2010-09-29 | 2021-11-04 | Agensys Inc | Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12 |
US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
EP3093294A1 (en) | 2012-02-24 | 2016-11-16 | Stemcentrx, Inc. | Dll3 modulators and methods of use |
SG11201405130UA (en) | 2012-02-24 | 2014-11-27 | Stemcentrx Inc | Anti sez6 antibodies and methods of use |
PL2887959T3 (pl) * | 2012-08-23 | 2019-04-30 | Agensys Inc | Koniugaty leków i przeciwciał (adc), które wiążą białka 158p1d7 |
WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
WO2014124326A1 (en) | 2013-02-08 | 2014-08-14 | Stem Centrx, Inc. | Novel multispecific constructs |
RS58873B1 (sr) | 2013-02-22 | 2019-08-30 | Abbvie Stemcentrx Llc | Antidll3-antitelo-pbd konjugati i njihova upotreba |
JP2016538318A (ja) | 2013-08-28 | 2016-12-08 | ステムセントリックス, インコーポレイテッド | 新規sez6モジュレーターおよび使用方法 |
WO2015031693A1 (en) * | 2013-08-28 | 2015-03-05 | Stem Centrx, Inc. | Engineered anti-dll3 conjugates and methods of use |
CN105848671B (zh) | 2013-08-28 | 2019-12-13 | 艾伯维施特姆森特克斯有限责任公司 | 位点特异性抗体缀合方法和组合物 |
MX2016010677A (es) | 2014-02-21 | 2017-04-10 | Abbvie Stemcentrx Llc | Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma. |
CN110841074B (zh) * | 2014-03-21 | 2023-07-18 | 艾伯维公司 | 抗-egfr抗体及抗体药物偶联物 |
CN104212698A (zh) * | 2014-10-01 | 2014-12-17 | 南京飞马食品有限公司 | 一种发芽糙米醋的制作方法 |
MY178919A (en) | 2015-03-09 | 2020-10-23 | Agensys Inc | Antibody drug conjugates (adc) that bind to flt3 proteins |
IL290959B2 (en) * | 2015-06-29 | 2023-04-01 | Daiichi Sankyo Co Ltd | Preparations containing antibody-drug conjugates and methods for their production |
EP3347048B1 (en) * | 2015-09-09 | 2020-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to nectin-4 and uses thereof |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
WO2018047154A1 (en) | 2016-09-07 | 2018-03-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-nkp46 antibodies and therapeutic use of same |
CN110392697A (zh) * | 2017-03-02 | 2019-10-29 | 国家医疗保健研究所 | 对nectin-4具有特异性的抗体及其用途 |
US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
KR20200024788A (ko) * | 2017-06-05 | 2020-03-09 | 어젠시스 인코포레이티드 | 넥틴-4 결합 단백질 및 이의 사용 방법 |
AU2018329937A1 (en) * | 2017-09-07 | 2020-03-19 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and nectin4 |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
AU2019240403A1 (en) | 2018-03-23 | 2020-10-08 | Seagen Inc. | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor |
WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
US11180531B2 (en) * | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
CA3121573A1 (en) * | 2018-12-03 | 2020-06-11 | Agensys, Inc. | Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof |
WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
MX2022001731A (es) * | 2019-08-13 | 2022-07-13 | Agensys Inc | Tratamiento de cánceres con conjugados anticuerpo-farmaco (adc) que se unen a las proteínas 191p4d12. |
WO2021108353A1 (en) * | 2019-11-25 | 2021-06-03 | Agensys, Inc. | Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins |
AU2021213421A1 (en) | 2020-01-31 | 2022-06-23 | Innate Pharma | Treatment of cancer |
US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
MX2022011770A (es) * | 2020-03-25 | 2022-10-18 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Composicion farmaceutica que contiene un conjugado de anticuerpo-farmaco y uso de la misma. |
CA3176248A1 (en) | 2020-04-10 | 2021-10-14 | Seagen Inc. | Charge variant linkers |
EP4208259A2 (en) | 2020-09-04 | 2023-07-12 | NovaRock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
CN117285629A (zh) | 2020-09-16 | 2023-12-26 | 四川科伦博泰生物医药股份有限公司 | 抗Nectin-4抗体、包含所述抗体的缀合物及其应用 |
WO2022060955A1 (en) * | 2020-09-17 | 2022-03-24 | Agensys, Inc. | Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins |
JP2023546493A (ja) | 2020-10-25 | 2023-11-02 | アラリス バイオテック アーゲー | 抗体-リンカーコンジュゲートを生成するための手段および方法 |
KR20230104659A (ko) | 2020-11-08 | 2023-07-10 | 씨젠 인크. | 면역 세포 억제제를 이용한 조합-요법 항체 약물 접합체 |
KR102408221B1 (ko) * | 2020-11-10 | 2022-06-13 | 삼성메카닉스 (주) | 그리드 커플링 성형장치 |
KR20230112656A (ko) | 2020-11-25 | 2023-07-27 | 이나뜨 파르마 에스.에이. | 암의 치료 |
EP4086284A1 (en) | 2021-05-07 | 2022-11-09 | Emergence Therapeutics AG | Anti-nectin-4 antibody exatecan conjugates |
AU2022248735A1 (en) | 2021-03-31 | 2023-08-03 | Centre National De La Recherche Scientifique - Cnrs | Anti-nectin-4 antibody exatecan conjugates |
CN117279664A (zh) | 2021-04-10 | 2023-12-22 | 普方生物制药美国公司 | Folr1结合剂、其偶联物及其使用方法 |
EP4326768A1 (en) | 2021-04-23 | 2024-02-28 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
BR112023022098A2 (pt) | 2021-04-26 | 2023-12-19 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Anticorpo anti-nectina-4 e conjugado anticorpo-fármaco anti-nectina-4 e uso medicinal dos mesmos |
CA3221398A1 (en) | 2021-05-28 | 2022-12-01 | Seagen Inc. | Anthracycline antibody conjugates |
KR20240042109A (ko) * | 2021-08-13 | 2024-04-01 | 어젠시스 인코포레이티드 | 191P4D12 단백질에 결합하는 항체 약물 접합체[Antibody Drug Conjugate, ADC]로 비근침윤성 방광암[Non-muscle invasive bladder cancer, NMIBC]을 치료하는 방법 |
CA3238167A1 (en) | 2021-11-19 | 2023-05-25 | Maria Leia Smith | Gpc3 binding agents, conjugates thereof and methods of using the same |
WO2023178289A2 (en) | 2022-03-17 | 2023-09-21 | Seagen Inc. | Camptothecin conjugates |
WO2023180490A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing nectin-4 |
WO2023227660A1 (en) | 2022-05-25 | 2023-11-30 | Innate Pharma | Nectin-4 binding agents |
US20240010701A1 (en) | 2022-06-01 | 2024-01-11 | ALX Oncology Inc. | Combination therapies for treating urothelial carcinoma |
EP4285935A1 (en) | 2022-06-03 | 2023-12-06 | Emergence Therapeutics AG | Novel anti-nectin-4 antibody camptothecin derivative conjugates |
EP4309676A1 (en) | 2022-07-22 | 2024-01-24 | Emergence Therapeutics AG | Novel anti-nectin-4 antibody camptothecin derivative conjugates |
EP4324849A1 (en) | 2022-08-18 | 2024-02-21 | Emergence Therapeutics AG | Humanized anti-nectin-4 antibodies |
WO2024052503A1 (en) | 2022-09-08 | 2024-03-14 | Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to ltbp2 and uses thereof |
EP4344707A1 (en) | 2022-09-29 | 2024-04-03 | Emergence Therapeutics AG | New anti-nectin-4 antibody drug conjugates |
Family Cites Families (151)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
US5079233A (en) | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
ES2241710T3 (es) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | Procedimiento para producir proteinas multivalentes de union a antigeno. |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US7625697B2 (en) | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
ES2195036T3 (es) | 1995-12-22 | 2003-12-01 | Bristol Myers Squibb Co | Conectores de hidrazona ramificados. |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
JP2001502537A (ja) | 1996-10-15 | 2001-02-27 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | ヒト前立腺ガンの進行の動物モデル |
EP1007663A2 (en) | 1997-01-21 | 2000-06-14 | Human Genome Sciences, Inc. | Human proteins |
EP0973540B1 (en) | 1997-02-25 | 2005-11-02 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
CA2290485C (en) | 1997-05-21 | 2008-08-05 | Biovation Limited | Method for the production of non-immunogenic proteins |
US20030065156A1 (en) | 1997-12-23 | 2003-04-03 | Williams Lewis T. | Novel human genes and gene expression products I |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DE69933661T3 (de) | 1998-04-15 | 2012-01-26 | Merck Serono Biodevelopment | Genomische sequenz des 5-lipoxygenase-aktivierenden proteins (flap), polymorphische marker und ihre anwendung in der diagnose von asthma |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US6264949B1 (en) | 1998-09-29 | 2001-07-24 | Mount Sinai School Of Medicine Of New York University | Noninvasive agents for diagnosis and prognosis of the progression of fibrosis |
WO2001057188A2 (en) | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
US20020137160A1 (en) | 1998-12-17 | 2002-09-26 | Byatt John C | Nucleic acid and other molecules associated with lactation and muscle and fat deposition |
US7160694B2 (en) | 1999-06-14 | 2007-01-09 | Millennium Pharmaceuticals, Inc. | Nucleic acids encoding TANGO405 and functional fragments and uses thereof |
WO2001002568A2 (en) | 1999-07-02 | 2001-01-11 | Chiron Corporation | Human genes and gene expression products |
EP1074617A3 (en) | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
EP1212407A4 (en) | 1999-09-03 | 2003-04-02 | Human Genome Sciences Inc | POLYNUCLEOTIDES, POLYPEPTIDES, AND ANTIBODIES OF THE IMMUNOGLOBULIN SUPERFAMILY |
US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
AU6063900A (en) | 1999-09-10 | 2001-04-10 | Millennium Pharmaceuticals, Inc. | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses |
EP1265582A2 (en) | 1999-09-29 | 2002-12-18 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
AU2001229340A1 (en) | 2000-01-14 | 2001-07-24 | Millennium Pharmaceuticals, Inc. | Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
WO2001055447A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
US20030139327A9 (en) | 2000-01-31 | 2003-07-24 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
US20030013649A1 (en) | 2000-01-31 | 2003-01-16 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
AU2001241541A1 (en) | 2000-02-17 | 2001-08-27 | Millennium Predictive Medicine, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer |
CN1169954C (zh) | 2000-03-09 | 2004-10-06 | 上海市肿瘤研究所 | 编码具有抑制癌细胞生长功能的人蛋白的多核苷酸 |
WO2001070979A2 (en) | 2000-03-21 | 2001-09-27 | Millennium Pharmaceuticals, Inc. | Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer |
US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
AU2001274888A1 (en) | 2000-05-19 | 2001-12-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
EP1358349A2 (en) | 2000-06-05 | 2003-11-05 | Avalon Pharmaceuticals | Cancer gene determination and therapeutic screening using signature gene sets |
WO2002010449A2 (en) | 2000-07-28 | 2002-02-07 | Compugen Inc. | Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome |
EP1325032A2 (en) | 2000-10-05 | 2003-07-09 | Immunex Corporation | Nectin polypeptides, polynucleotides, methods of making and use thereof |
AU3942202A (en) | 2000-11-30 | 2002-06-11 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
EP1361300B1 (en) * | 2000-12-20 | 2006-07-19 | Teijin Limited | Method for manufacturing polyester mixed fiber yarn |
EP1425302A2 (en) | 2001-01-24 | 2004-06-09 | Protein Design Labs | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
US20030073144A1 (en) | 2001-01-30 | 2003-04-17 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of pancreatic cancer |
US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
WO2002086084A2 (en) | 2001-04-04 | 2002-10-31 | Quark Biotech, Inc. | Sequence characteristics of bladder cancer |
AU2002309583A1 (en) | 2001-04-18 | 2002-11-05 | Protein Desing Labs, Inc. | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
US6794501B2 (en) | 2001-05-04 | 2004-09-21 | Ludwig Institute For Cancer Research | Colon cancer antigen panel |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
JP2004528046A (ja) | 2001-06-05 | 2004-09-16 | エクセリクシス・インコーポレイテッド | p53経路のモディファイヤーとしてのDGKsおよび使用方法 |
US7171311B2 (en) | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
EP1517998A2 (en) | 2001-06-18 | 2005-03-30 | EOS Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
US7189507B2 (en) | 2001-06-18 | 2007-03-13 | Pdl Biopharma, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
US20040076955A1 (en) | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
US20030099974A1 (en) | 2001-07-18 | 2003-05-29 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer |
KR101005130B1 (ko) | 2001-07-19 | 2011-01-04 | 니목스 코포레이션 | 종양 및 세포의 제거 또는 파괴를 필요로 하는 다른질환의 치료에 효과적인 펩티드 |
NZ573740A (en) | 2001-09-18 | 2010-07-30 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor, particularly kidney tumor - TAT184 |
WO2003040340A2 (en) * | 2001-11-07 | 2003-05-15 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer |
WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
US20030232350A1 (en) | 2001-11-13 | 2003-12-18 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
AU2003245488A1 (en) | 2002-06-13 | 2003-12-31 | Regulome Corporation | Functional sites |
DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
AU2008202217B2 (en) * | 2002-08-16 | 2012-07-26 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 191PAD12(b) useful in treatment and detection of cancer |
AU2003243151A1 (en) | 2002-08-16 | 2004-03-03 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
EP1585965A4 (en) | 2002-08-29 | 2009-05-13 | Univ Massachusetts | USE OF EMULSION RESTRICTING TECHNOLOGY FOR GENERATING OXIDATIVELY STABLE LIPID DELIVERY SYSTEMS |
AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
DK1725249T3 (en) | 2003-11-06 | 2014-03-17 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugating to ligands. |
WO2005092380A2 (en) | 2004-03-26 | 2005-10-06 | Pfizer Products Inc | Uses of anti-ctla-4 antibodies |
WO2005111076A1 (en) | 2004-05-12 | 2005-11-24 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nectin 4 (n4) as a marker for cancer prognosis |
RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
CA2603093A1 (en) | 2005-03-31 | 2006-10-05 | Agensys, Inc. | Antibodies and related molecules that bind to 161p2f10b proteins |
CN101500590A (zh) * | 2005-03-31 | 2009-08-05 | 阿根西斯公司 | 与161p2f10b蛋白结合的抗体和相关分子 |
EP2078732B1 (en) * | 2006-07-10 | 2015-09-16 | Fujita Health University | Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry |
CA2667019C (en) | 2006-10-27 | 2016-03-29 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
JP5394246B2 (ja) | 2007-03-30 | 2014-01-22 | ジェネンテック, インコーポレイテッド | 抗体及びイムノコンジュゲートとこれらの使用方法 |
CN101969970B (zh) * | 2007-10-12 | 2014-10-15 | 西雅图基因公司 | 用抗体-药物偶联物联合治疗 |
ES2874306T3 (es) * | 2010-09-29 | 2021-11-04 | Agensys Inc | Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12 |
-
2011
- 2011-09-29 ES ES18171803T patent/ES2874306T3/es active Active
- 2011-09-29 SI SI201131535T patent/SI2621526T1/sl unknown
- 2011-09-29 TW TW112112533A patent/TW202344270A/zh unknown
- 2011-09-29 TW TW109135992A patent/TWI764324B/zh active
- 2011-09-29 CN CN201510519846.0A patent/CN105567717B/zh active Active
- 2011-09-29 LT LTEP11831345.1T patent/LT2621526T/lt unknown
- 2011-09-29 CN CN201180056969.5A patent/CN103402538B/zh active Active
- 2011-09-29 JP JP2013531875A patent/JP6083871B2/ja active Active
- 2011-09-29 AU AU2011312417A patent/AU2011312417B2/en active Active
- 2011-09-29 DK DK11831345.1T patent/DK2621526T3/en active
- 2011-09-29 IL IL290591A patent/IL290591B1/en unknown
- 2011-09-29 TW TW107103146A patent/TWI674112B/zh active
- 2011-09-29 WO PCT/US2011/054054 patent/WO2012047724A1/en active Application Filing
- 2011-09-29 UA UAA201305358A patent/UA110495C2/uk unknown
- 2011-09-29 PL PL18171803T patent/PL3409287T3/pl unknown
- 2011-09-29 PT PT181718032T patent/PT3409287T/pt unknown
- 2011-09-29 KR KR1020217026806A patent/KR102353283B1/ko active IP Right Grant
- 2011-09-29 MX MX2016003743A patent/MX347954B/es unknown
- 2011-09-29 EP EP21166650.8A patent/EP3903812A1/en active Pending
- 2011-09-29 KR KR1020137011094A patent/KR20130130709A/ko active Application Filing
- 2011-09-29 PT PT118313451T patent/PT2621526T/pt unknown
- 2011-09-29 KR KR1020197004139A patent/KR102166408B1/ko active IP Right Grant
- 2011-09-29 KR KR1020227001399A patent/KR102504750B1/ko active IP Right Grant
- 2011-09-29 EA EA201790850A patent/EA201790850A1/ru unknown
- 2011-09-29 CA CA2811644A patent/CA2811644C/en active Active
- 2011-09-29 HU HUE18171803A patent/HUE054855T2/hu unknown
- 2011-09-29 RS RS20180854A patent/RS57483B1/sr unknown
- 2011-09-29 TW TW100135340A patent/TWI524901B/zh active
- 2011-09-29 MX MX2013003419A patent/MX337873B/es active IP Right Grant
- 2011-09-29 TW TW104140581A patent/TWI651096B/zh active
- 2011-09-29 KR KR1020237028203A patent/KR102627947B1/ko active IP Right Grant
- 2011-09-29 KR KR1020177031187A patent/KR101851746B1/ko active IP Right Grant
- 2011-09-29 SI SI201131986T patent/SI3409287T1/sl unknown
- 2011-09-29 KR KR1020247001866A patent/KR20240013851A/ko not_active Application Discontinuation
- 2011-09-29 EP EP11831345.1A patent/EP2621526B1/en active Active
- 2011-09-29 KR KR1020207028941A patent/KR102295534B1/ko active IP Right Grant
- 2011-09-29 TW TW107143990A patent/TWI720377B/zh active
- 2011-09-29 ES ES11831345.1T patent/ES2680624T3/es active Active
- 2011-09-29 IL IL311145A patent/IL311145A/en unknown
- 2011-09-29 DK DK18171803.2T patent/DK3409287T5/da active
- 2011-09-29 TW TW111117461A patent/TWI814373B/zh active
- 2011-09-29 EA EA201300411A patent/EA027887B1/ru unknown
- 2011-09-29 HU HUE11831345A patent/HUE038908T2/hu unknown
- 2011-09-29 PL PL11831345T patent/PL2621526T3/pl unknown
- 2011-09-29 US US13/249,111 patent/US8637642B2/en not_active Ceased
- 2011-09-29 BR BR112013007309-8A patent/BR112013007309B1/pt active IP Right Grant
- 2011-09-29 KR KR1020237006492A patent/KR102595129B1/ko active IP Right Grant
- 2011-09-29 EP EP18171803.2A patent/EP3409287B9/en active Active
- 2011-09-29 MX MX2017006479A patent/MX369679B/es unknown
-
2013
- 2013-03-14 US US13/830,899 patent/US9078931B2/en active Active
- 2013-03-22 MX MX2019013655A patent/MX2019013655A/es unknown
- 2013-03-24 IL IL225460A patent/IL225460B/en active IP Right Grant
-
2015
- 2015-07-13 US US14/798,302 patent/US9314538B2/en active Active
-
2016
- 2016-03-14 US US15/069,853 patent/US9962454B2/en active Active
- 2016-12-15 JP JP2016243252A patent/JP2017110002A/ja not_active Withdrawn
-
2017
- 2017-08-14 PH PH12017501461A patent/PH12017501461A1/en unknown
- 2017-09-06 US US15/697,146 patent/USRE48389E1/en active Active
-
2018
- 2018-04-02 US US15/943,527 patent/US10894090B2/en active Active
- 2018-07-23 HR HRP20181154TT patent/HRP20181154T8/hr unknown
- 2018-07-31 CY CY181100790T patent/CY1121023T1/el unknown
- 2018-10-02 IL IL262073A patent/IL262073B/en active IP Right Grant
- 2018-11-02 JP JP2018207044A patent/JP2019055958A/ja active Pending
- 2018-11-02 JP JP2018207426A patent/JP6726258B2/ja active Active
- 2018-11-02 JP JP2018207295A patent/JP2019031563A/ja active Pending
- 2018-12-14 HK HK18116104.9A patent/HK1256964A1/zh unknown
-
2020
- 2020-06-26 JP JP2020110083A patent/JP7042872B2/ja active Active
- 2020-11-13 IL IL278696A patent/IL278696B/en unknown
- 2020-12-15 US US17/122,786 patent/US11559582B2/en active Active
-
2021
- 2021-05-18 CY CY20211100429T patent/CY1124166T1/el unknown
-
2022
- 2022-03-15 JP JP2022039841A patent/JP7370405B2/ja active Active
- 2022-09-28 NL NL301198C patent/NL301198I2/nl unknown
- 2022-09-29 NO NO2022039C patent/NO2022039I1/no unknown
- 2022-10-04 HU HUS2200043C patent/HUS2200043I1/hu unknown
- 2022-10-05 LT LTPA2022012C patent/LTPA2022012I1/lt unknown
- 2022-10-05 FR FR22C1050C patent/FR22C1050I2/fr active Active
- 2022-12-14 US US18/066,156 patent/US20230346968A1/en active Pending
-
2023
- 2023-10-17 JP JP2023178591A patent/JP2023179713A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7370405B2 (ja) | 191p4d12タンパク質に結合する抗体薬物結合体(adc) | |
US8309093B2 (en) | Antibody drug conjugates (ADC) that bind to 24P4C12 proteins | |
TWI606063B (zh) | 結合至158p1d7蛋白之抗體藥物結合物(adc) | |
AU2020201153B2 (en) | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins |